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Summary			 The	diverse	outcomes	of	ubiquitination	primarily	relate	 to	 the	 flexibility	of	ubiquitin	 in	 forming	homo-	or	heterotypic	chains	on	each	of	 its	seven	 lysine	residues	which	in	turn	stimulate	distinct	downstream	signaling	pathways.	These	ubiquitin	 signals	 must	 be	 selectively	 initiated	 on	 the	 substrate	 protein	 and	subsequently	decoded	to	facilitate	the	desired	cellular	function.	These	initiation	and	decoding	steps	often	involve	additional	post-translational	modifications	and	ubiquitin	 receptor	proteins,	 but	 the	enzymes	and	ubiquitin	 chains	 involved	 for	many	ubiquitinated	substrates	are	not	clear.	Here,	I	have	explored	the	initiation	and	 decoding	 of	 ubiquitin	 signals,	 focusing	 on	 lysine-11	 (K11)	 linked	polyubiquitin	chains	and	their	role	in	protein	degradation.	I	established	 in	vitro	assays	to	understand	how	K11-chains	are	decoded	and	whether	these	chains	act	as	 a	 signal	 for	 proteasome-mediated	 degradation.	 Pure	 homotypic	 K11-chains	did	not	bind	the	proteasome	or	its	associated	ubiquitin	binding	proteins,	but	did	bind	to	the	mitophagy	ubiquitin	receptors,	MyosinVI	and	TAX1BP1.	Heterotypic	K11/K48	 linkages	 not	 only	 bound	 the	 proteasome	 but	 also	 stimulated	degradation	of	the	cell	cycle	substrate,	cyclin	B1.	To	further	explore	the	functions	of	 K11-chains	 I	 focused	 on	 the	 hypoxia	 inducible	 transcription	 factor	 (HIF)	pathway,	as	K11-ubiquitination	had	been	implicated	in	proteasome-independent	degradation	of	the	transcription	factor.	I	established	an	in	vitro	assay	to	initiate	HIF	ubiquitination,	via	prolyl	hydroxylation,	and	determine	the	type	of	ubiquitin	chains	 involved.	 Recombinant	 HIF	 isoforms	 were	 rapidly	 hydroxylated	 when	incubated	 with	 cell	 extracts.	 Moreover,	 the	 levels	 of	 iron	 and	 small	 molecule	metabolites	 within	 the	 lysates	 regulated	 HIF	 hydroxylation.	 However,	 this	hydroxylation	 was	 insufficient	 to	 reproducibly	 promote	 HIF	 ubiquitination	 or	determine	 the	ubiquitin	 chains	 involved.	While	 the	nature	of	 the	polyubiquitin	chains	 formed	 in	 the	HIF	 pathway	 remain	 elusive,	my	 studies	 identify	 distinct	roles	 for	 homotypic	 and	 heterotypic	 K11-polyubiquitination	 in	 proteasome-mediated	degradation.			
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 Chapter	1:	Introduction	
	 	
1.1	The	Ubiquitin	Proteasome	System	The	 ubiquitin	 proteasome	 system	 (UPS)	 is	 the	 major	 pathway	 for	regulating	the	breakdown	of	 intracellular	proteins,	 involving	the	conjugation	of	the	 small	 76	 amino	 acid	 polypeptide,	 ubiquitin,	 to	 a	 protein	 substrate,	 by	 a	carefully	controlled	enzymatic	cascade	(Hershko	and	Ciechanover,	1998;	Pickart,	2001).	However,	ubiquitination	 is	not	 just	a	signal	 for	protein	degradation,	but	also	acts	as	an	essential	post	translational	modification	required	for	most	cellular	processes,	 including	 cell	 signaling,	 cell	 cycle	 regulation,	 DNA	 repair,	 and	endosomal-lysosomal	 trafficking	 (Ikeda	 and	 Dikic,	 2008).	 A	 key	 feature	 of	ubiquitination	 that	 allows	 these	 diverse	 functions	 is	 the	 ability	 of	 ubiquitin	 to	form	chains	on	itself	via	one	of	its	seven	lysine	residues	(K6,	K11,	K27,	K29,	K33,	K48	and	K63)	or	 its	N-terminus	(Met-linked	or	 linear	chains)	 (Ikeda	and	Dikic,	2008;	 Kim	 et	 al.,	 2009).	 These	 chains	 may	 contain	 one	 type	 of	 linkage	(homotypic)	 or	 a	 mixture	 of	 different	 linkages	 (heterotypic)	 (Boname	 et	 al.,	2010).	 Consequently,	 the	 range	 of	 outcomes	 allowed	 by	 the	 possible	combinations	 of	 ubiquitin	 chains	 and	 their	 individual	 linkages	 are	 hugely	diverse.		
1.1.1	How	are	ubiquitin	chains	formed?	Ubiquitin	 conjugation	 is	 controlled	 by	 an	 enzymatic	 cascade	 involving	three	different	classes	of	enzymes:	(i)	the	E1	activating	enzyme,	which	catalyses	the	 activation	 of	 ubiquitin	 in	 an	 ATP-dependent	 step	 (Ema	 et	 al.),	 (ii)	 the	 E2	conjugating	enzymes	that	form	a	thioester	attachment	to	ubiquitin	and	catalyse	the	transfer	of	ubiquitin	 to	an	E3	 ligase,	and	(iii)	 the	E3	 ligases,	which	catalyse	the	 transfer	 and	 covalent	 attachment	 of	 ubiquitin	 to	 a	 lysine	 residue	 in	 the	protein	substrate	either	directly,	 in	the	case	of	the	Really	Interesting	New	Gene	(RING)	 E3	 ligases,	 or	 by	 forming	 a	 thioester	 intermediate,	 in	 the	 case	 of	 the	homologous	to	the	E6-associated	protein	C-terminus	(HECT)	E3	ligases	(Hershko	and	Ciechanover,	1998;	Pickart,	2001)	(Figure	1.1).	In	addition,	RING-Between-
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RING	E3	ligases,	such	as	Parkin	(Marin	et	al.,	2004),	share	features	of	both	HECT	and	 RING	 E3	 ligases,	 in	 which	 thioester-bound	 E2	 enzymes	 are	 bound	 to	 the	RING	while	ubiquitin	 is	transferred	to	a	catalytic	cysteine	of	a	separate	domain	(Spratt	 et	 al.,	 2014).	 There	 is	 one	 major	 E1	 enzyme,	 approximately	 50	 E2	enzymes	 and	 around	 700	 E3	 ligases.	 It	 has	 also	 been	 described	 that	 some	ubiquitin	 ligases	 may	 act	 as	 E4	 enzymes	 which	 modify	 substrates	 previously	ubiquitinated	by	an	E3	ligase	(Koegl	et	al.,	1999;	Richly	et	al.,	2005).		 	 		 	 		
	
Figure 1.1: The ubiquitin conjugation cascade. Schematic of the enzymes involved in the 
formation of ubiquitin chains, ubiquitin conjugation. The approximate number of mammalian 
ubiquitin enzymes involved in ubiquitin conjugation are indicated.  	 E3	 ligases	 are	 principally	 responsible	 for	 substrate	 specificity,	 as	 they	recruit	the	E2	enzyme	and	bind	to	the	protein	substrate.	However,	the	outcome	of	ubiquitination	is	dependent	on	the	type	of	linkage	formed	and	recognition	of	the	 ubiquitin	 signal	 by	 ubiquitin	 binding	 proteins	 (UBPs)	 (see	 1.1.3).	 In	 some	cases	ubiquitin	 linkages	are	determined	by	 the	E2	or	E3	enzyme	 involved.	The	E2,	Ubc13	(UBE2N),	only	forms	K63-linked	chains	(Hofmann	and	Pickart,	2001),	whereas	Ube2S	predominantly	 forms	K11-linked	chains	(Jin	et	al.,	2008;	Wu	et	al.,	2010).	However,	 the	abundant	UbcH5	(UBE2D)	 family	can	 form	all	 types	of	ubiquitin	 chains	 in	 vitro	 (Brzovic	 and	 Klevit,	 2006).	 E3	 ligases	 can	 also	 show	similar	 linkage	 specificity,	 as	 observed	 for	 the	 HECT	 ligases,	 such	 as	 Nedd4,	which	forms	K63-linked	chains,	and	E6AP,	which	forms	K48-linked	chains.	More	recently,	 linear	 ubiquitin	 chain	 formation	has	 been	 shown	 to	 be	 dependent	 on	the	 linear	 ubiquitin	 chain	 assembly	 complex	 (LUBAC)	 E3	 ligase	 complex	
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(Shimizu	et	al.,	2015).	 Indeed,	 it	 is	 likely	 that	most	E2	and	E3	 interactions	will	determine	the	nature	of	the	ubiquitin	chain	formed.		While	 the	number	of	E3	 ligases	 is	partly	 responsible	 for	diversity	 in	 the	ubiquitin	system,	it	is	important	to	note	that	ubiquitin	conjugation	is	reversible,	through	 cleavage	 of	 the	 isopeptide	 bond	 by	 deubiquitinating	 enzymes	 (DUBs)	(Reyes-Turcu	 and	 Wilkinson,	 2009)(See	 1.1.4).	 Therefore,	 DUBs	 increase	 the	complexity	 of	 the	 ubiquitin	 system	 through	 their	 ability	 to	 remove	 or	 edit	ubiquitin	linkages.		
1.1.2	Complexity	and	diversity	in	ubiquitination	While	 all	 linkages	 are	 known	 to	 exist	 in	 cells,	 the	 best	 characterised	 of	these	linkages	are	K48	and	K63-linked	polyubiquitin	chains.	K48-chains	are	the	canonical	signal	for	protein	degradation	by	the	26S	proteasome	(Thrower	et	al.,	2000),	 whereas	 K63-chains	 do	 not	 signal	 proteasomal	 degradation	 but	 are	involved	 in	 intracellular	 signalling	 or	 directing	 proteins	 to	 the	 endosomal	lysosomal	 pathway	 (Ikeda	 and	 Dikic,	 2008).	 The	 functions	 of	 the	 other	 chain	types,	which	all	exist	in	cells,	are	less	well	defined	(Xu	et	al.,	2009;	Yau	and	Rape,	2016).	Linear	chains	have	a	specific	role	in	immunity	and	are	required	for	NF-κB	activation	(Shimizu	et	al.,	2015).	These	chains	are	formed	by	the	LUBAC	E3	ligase	complex,	and	have	a	structure	very	similar	to	K63-linked	chains,	which	are	also	involved	 in	NF-κB	 signaling	 (Shimizu	 et	 al.,	 2015).	Of	 the	 other	 chain	 linkages,	K11	 are	 the	 next	most	 abundant	 (Xu	 et	 al.,	 2009)	 and	 have	 been	 shown	 to	 be	involved	in	cell	cycle	control	(Jin	et	al.,	2008),	regulation	of	the	hypoxia	response	(Bremm	 et	 al.,	 2014)	 and	 ER-associated	 degradation	 (ERAD)(Xu	 et	 al.,	 2009).	Interestingly,	K11-chains	may	 also	have	non-degradative	outcomes	 involved	 in	cell	 signaling,	 including	 haematopoiesis	 (Dao	 et	 al.,	 2012)	 and	 the	 immune	response	(Qin	et	al.,	2014).	How	K11-chains	are	recognised	in	cells	is	not	known.		K6,	 K27,	 K29	 and	 K33-chain	 linkages	 are	 all	 present	 in	 cells	 in	 low	concentrations,	however	their	abundance	increases	with	proteasomal	inhibition,	indicating	 they	may	 have	 a	 role	 in	 proteasomal	 degradation	 (Xu	 et	 al.,	 2009).	Whether	 they	 form	 homotypic	 linkages	 or	 mixed	 chains	 is	 not	 clear,	 but	 the	dimeric	structures	of	these	less	abundant	ubiquitin	linkages	have	been	resolved	
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and	they	do	have	distinct	conformations	(Castaneda	et	al.,	2016;	Kristariyanto	et	al.,	 2015;	 Michel	 et	 al.,	 2017),	 suggesting	 that	 they	 can	 act	 as	 specific	 signals	within	the	cell.	Indeed,	K6	and	K27	linkages	have	been	shown	to	be	involved	in	DNA	 replication	 and	 repair	 (Gatti	 et	 al.,	 2015;	Morris	 and	 Solomon,	 2004)	 and	K29	and	K33	 linkages	are	de-ubiquitinated	by	TRABID,	a	DUB	 involved	 in	Wnt	signaling	(Licchesi	et	al.,	2011).	In	 principle,	 the	 diversity	 of	 ubiquitin	 chains	 is	 increased	 by	 the	possibility	of	mixed	linkages	forming	heterotypic	chains,	which	may	be	encoded	within	 a	 single	 lysine	 chain	 or	 form	 branched	 structures.	 Initially,	 it	 was	observed	 that	 mixed	 ubiquitin	 linkages	 may	 actually	 protect	 ubiquitinated	proteins	from	degradation	(Kim	et	al.,	2007;	Kim	et	al.,	2009),	but	more	recently	Meyer	 and	 Rape	 (Meyer	 and	 Rape,	 2014)	 showed	 that	 heterotypic	 K48/K11-linked	 chains	 may	 be	 a	 superior	 proteasome	 degradation	 signal	 compared	 to	homotypic	K48-linked	chains.	Heterotypic	chains	may	also	have	non-degradative	roles,	such	as	the	identification	that	mixed	K63	and	K11-linkages	are	necessary	for	 the	 efficient	 internalization	 of	MHC	 Class	 I	molecules	 from	 the	 cell	 surface	(Boname	 et	 al.,	 2010).	 Therefore,	 it	 is	 possible	 that	 other	 forms	 of	 heterotypic	ubiquitin	 linkages	 will	 have	 specific	 cellular	 functions,	 but	 currently	 these	remain	to	be	determined.	Lastly,	the	presence	of	multiple	lysine	residues	within	a	substrate	allows	several	 sites	 of	 ubiquitination	 which	 maybe	 modified	 with	 multi-monoubiquitination,	 (Dimova	 et	 al.,	 2012;	 Kravtsova-Ivantsiv	 et	 al.,	 2009)	multiple	 chains	of	 the	 same	 linkage	 (Lu	 et	 al.,	 2015)	or	potentially	 of	 different	linkages,	 adding	 further	 complexity	 to	 the	 ubiquitin	 signal.	 One	 of	 the	 first	examples	relating	to	complex	ubiquitin	modifications	was	observed	in	studying	endocytosis,	where	multiple	monoubiquitination	of	receptor	tyrosine	kinases	led	to	 internalisation	 and	 lysosomal	 degradation	 (Haglund	 et	 al.,	 2003).	 More	recently,	Lu	et	al,	 suggest	 that	 the	number	of	polyubiquitin	chains	 formed	on	a	protein	substrate	can	influence	the	rate	of	protein	degradation	(Lu	et	al.,	2015).	
	
	
Introduction		
		 31	
1.1.3	Recognition	of	polyubiquitin	chains	by	ubiquitin	binding	proteins	The	 recognition	 of	 polyubiquitin	 chains	 by	 UBPs	 allows	 polyubiquitin	signals	to	be	decoded	and	facilitates	their	desired	outcome	(Hurley	et	al.,	2006).	UBPs	 contain	 ubiquitin	 binding	 domains	 (UBDs),	 a	 diverse	 group	 of	 protein	regions	that	can	bind	ubiquitin	either	in	mono	or	polyubiquitinated	form.		Most	UBDs	 are	 comprised	 of	 a	 single	 α-helix	 that	 binds	 to	 ubiquitin	 through	 a	hydrophobic	 region	 within	 the	 ubiquitin	 moiety	 at	 isoleucine	 44	 (I44	 patch)	(Table	1.1).	The	hydrophobic	interaction	between	monoubiquitin	and	UBDs	is	of	low	 affinity	 (mM	 range)	 but	 the	 formation	 of	 polyubiquitin	 chains	 or	 multi-monoubiquitins	 considerably	 increases	 the	 strength	 of	 this	 interaction	 (Table	
1.1).	Aside	from	chain	 length,	the	 lysine	 linkage	of	the	chains	can	also	alter	the	affinity	of	UBDs	for	ubiquitin.	The	second	UBA	(ubiquitin	associated)	domain	of	Rad23	binds	K48-linkages	with	higher	 affinity	 than	K63-chains	 (Elsasser	 et	 al.,	2004).	Furthermore,	UBPs	often	contain	several	UBDs,	which	increase	the	avidity	for	ubiquitin	and	may	alter	the	specificity	for	different	lysine	linked	chains.	For	example,	 the	 combined	 VHS	 and	 UIM	 domains	 of	 ESCRT0	 proteins,	 Hrs	 and	STAM1	have	a	higher	affinity	 for	K63-chains	compared	to	K48-chains	(Ren	and	Hurley,	2010).	The	Nathan	lab	recently	showed	that	the	Rad23	proteins,	hHR23A	and	B,	which	contain	two	UBA	domains,	bind	with	high	selectivity	to	K48-linked	chains,	whereas	 the	ESCRT0	proteins,	containing	VHS,	DUIM	and	UIM	domains,	bind	only	to	K63-linked	chains	(Nathan	et	al.,	2013).	Whether	K11-linked	chains	are	recognised	by	linkage-selective	UBPs	is	unknown.	
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Table 1.1: Structures and binding affinities of known UBDs. Adapted from Hurley et al, 
Biochemistry Journal, 2006. 
	
1.1.4	 Deubiquitinating	 enzymes	 and	 selective	 disassembly	 of	 ubiquitin	
chains.	Polyubiquitin	chains	can	be	disassembled	by	DUBs,	of	which	there	are	six	classes:	1,	ubiquitin	C-terminal	hydrolases,	2,	ubiquitin	specific	proteases	(USPs),	3,	 ovarian	 tumour	 proteases	 (OTUs),	 4,	 Josephins,	 5,	 MINDY	 (MIU-containing	novel	 DUB	 family),	 and	 6,	 the	 JAB1/MPN/MOV34	 metalloenzymes	 (JAMMs)	(Figure	 1.2).	 The	 first	 5	 DUB	 families	 are	 cysteine	 proteases,	 while	 JAMMs	require	zinc	for	their	catalytic	activity	(Komander	et	al.,	2009).	Most	DUBs	have	the	capacity	to	disassemble	ubiquitin	chains	irrespective	of	the	ubiquitin	linkage	
Name of UBD Source protein Affinity to Ub (Kd) Structure Binding to Ub 
UBA 
(ubiquitin associated) 
Dsk2 
 
hHR23A 
 
 
 
 
2nd UBA 8µM 
for K48Ub4 
and 28µM 
K63Ub4 
Compact 3α helical bundles with 
conserved hydrophobic patch on 
α1 and α3 helix 
Ile44 hydrophobic patch of Ub binds α1 and α3 conserved 
hydrophobic patch 
UIM 
(ubiquitin-interacting motif) 
Vps27 
S5a 100µM-2mM 
Single α-helix around conserved 
alanine residue Binds Ile
44 hydrophobic patch of Ub 
MIU 
(motif interacting with ubiquitin) 
 
Rabex-5 30µM α helical– around conserved alanine residue 
Binds Ile44 hydrophobic patch of Ub in opposite orientation to 
UIM 
DUIM 
(double-sided UIM) Hrs  
α helical– two UIM sequences are 
interlaid on a single helix Both faces are capable of binding Ile
44 hydrophobic patch of Ub 
CUE  
(coupling of ubiquitin conjugation to 
endoplasmic reticulum degradation) 
Vps9 
Cue2  3 α helical bundles  
Binds Ile44 hydrophobic patch of Ub via conserved hydrophobic 
residues in C-terminal of α helix 
GAT  
(GGA and TOM) 
GGA3 
TOM1 100µM 3 α helical bundles 
Binds Ile44 hydrophobic patch of Ub through two sites: high and 
low affinity 
NZF 
(Npl4 zinc finger) Npl4 100µM 
30 residue domains around a 
single zinc binding site 
Binds Ile44 hydrophobic patch of Ub through Thr-Phe pair of 1st 
‘zinc knuckle’ and hydrophobic residue of 2nd 
A20 ZnF 
(A20 zinc finger) Rabex-5 12-22µM  Binds a polar patch on Ub centred on Asp
58.  
UBP ZnF 
(ubiquitin-specific processing protease zinc 
finger) 
Isopeptidase T 3µM 
130 residue domain around single 
zinc-binding site in N-terminal half 
fused to an α/β fold 
Free C-terminal glycine residue of Ub binds within ‘tunnel’ of 
UBP ZnF. Also interaction with Ile36 region of Ub 
UBZ 
(ubiquitin-binding ZnF domain)   
30 residue domain assumed to 
bind a single zinc ion via its 
conserved cysteine and histidine 
residues 
 
Ubc 
(ubiquitin-conjugating enzyme- related 
domains) 
Ubcs are also known as E2 enzymes. 
UbcH5  150αα catalytic core with α/β fold Conserved cysteine forms thiolester with Ub C-terminus 
UEV 
(Ubc E2 variant domain) 
Vps23 
Tsg101 100µM Lacks catalytic cysteine of Ubcs Via Ile
44  patch and also hydrophilic Gln 62 site of Ub 
UBM 
(ubiquitin-binding motif)  180µM 
30 residues centred on invariant 
Leu-Pro pair Around Leu
8 of Ub, near but not overlapping with Ile 44 region 
GLUE 
(Gram-like ubiquitin binding in EAP45)   
Ubiquitin-binding plekstrin 
homology domain  
JAB1/MPN  380µM 
Metalloprotease motif JAMM 
(JAB1/MPN domain 
metalloenzyme) 
Thought to bind Ile44 based on mutational studies 
PFU 
(PLAA family ubiquitin binding domain) Doa1  
2° structure predictions suggest 
similar structure to UEV  !
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involved,	 as	 observed	 with	 the	 several	 USPs	 (Komander	 et	 al.,	 2009).	 USP5,	which	 cleaves	 free	 ubiquitin	 chains,	 recognizes	 the	 C-terminal	 diglycine	 motif	regardless	 of	 the	 ubiquitin	 linkage	 (Reyes-Turcu	 and	 Wilkinson,	 2009).		However,	chain	specific	DUBs	have	been	identified,	particularly	within	the	OTU	family,	 including	 the	 K11-specific	 DUB,	 Cezanne	 (Bremm	 et	 al.,	 2010)	 and	 the	predominantly	K29-specific	DUB,	TRABID	(Tran	et	al.,	2008;	Virdee	et	al.,	2010),	and	a	K63-specific	metalloprotease	DUB,	AMSH	(McCullough	et	al.,	2004).	What	determines	 the	 DUBs	 ability	 to	 discriminate	 between	 different	 chain	 types	 is	unclear	but	may	be	steric,	as	shown	by	the	structural	resolution	of	AMSH	bound	to	K63	dimers	(Sato	et	al.,	2008).		 	
		
				
Figure 1.2: Deubiquitination. Schematic of the removal of ubiquitin chains by 
deubiquitination. (A) Most DUBs remove chains in a processive manner, such the 
proteasome-associated DUB USP14. (B) Some DUBs can remove the whole ubiquitin chain, 
‘en-bloc’. A well validated example is the proteasome-associated DUB, Rpn11. The 
polyubiquitin chain is disassembled by DUBs that recognize the free C-terminus (e.g. USP5). 
The approximate number of mammalian DUBs are also indicated.  	
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1.2	The	Proteasome.	The	26S	proteasome	 is	 a	 large,	2.5MDa,	degradative	 complex	within	 the	cell,	 composed	 of	 the	 20S	 catalytic	 chamber	 and	 the	 19S	 regulatory	 particle	(Figure	1.3).	The	proteasome	recognizes	ubiquitinated	substrates,	which	bind	to	the	 19S	 regulatory	 particle	 (Peth	 et	 al.,	 2010).	 The	 ubiquitin	 chains	 are	 then	removed	 by	 proteasome-associated	 DUBs	 (Finley,	 2009),	 and	 the	 protein	unfolded	 in	 an	 ATP-dependent	 process,	 prior	 to	 opening	 of	 the	 20S	 gate,	 and	translocation	 into	 the	 20S	 catalytic	 chamber	 (Figure	 1.3)	 (Peth	 et	 al.,	 2010;	Smith	 et	 al.,	 2007;	 Smith	 et	 al.,	 2011),	 where	 proteolysis	 takes	 place.	 The	resulting	 polypeptides	 are	 released	 within	 the	 cell	 to	 be	 recycled,	 but	 an	additional	important	function	of	the	proteasome	is	to	provide	peptides	that	are	trimmed	to	9-13	amino	acids	in	length	and	loaded	onto	MHC	Class	I	molecules	to	be	presented	on	the	cell	surface	 for	 immune	surveillance	(Kisselev	et	al.,	1999;	Rock	et	al.,	2002).		
1.2.1	Proteasome	composition	The	proteasome	consists	of	a	20S	catalytic	subunit	and	a	regulatory	19S	cap	 (Figure	 1.3).	 There	 is	 a	 gate	 between	 the	 subunits,	 which	 allows	transmission	of	unfolded	substrates	into	the	20S	catalytic	chamber.	This	gate	is	in	a	closed	conformation	when	substrates	are	not	bound	to	the	19S,	and	is	only	opened	following	activation	of	the	AAA	ATPases	in	the	19S	ring.	In	addition,	the	proteasome	 binds	 several	 DUBs	 and	UBPs,	which	 can	modulate	 the	 binding	 of	ubiquitinated	substrates	and	disassembly	of	the	polyubiquitin	chains.										
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Figure 1.3: The 26S Proteasome. Ribbon cartoon structure of the 26S proteasome based on 
the S. Cerevisiae cryo-EM structure by Beck et al (Beck and Baumeister, 2016) of the 
removal of ubiquitin chains by deubiquitination. The proteasome comprises a 2.5MDa 
complex of the 19S regulatory particle (RP) and the 20S catalytic core particle (CP). Ubiquitin 
receptors are present in the RP lid. The ATPase subunits in the base control gate opening of 
the 20S α-ring. Peptidase activity occurs in the β-rings and is encoded in the three subunits 
(β1, β2, β5). The DUB Rpn11 forms part of the lid. Ubp6 (USP14) was not resolved in this 
structure. The other mammalian DUB, Uch37, is not present in yeast. 	
1.2.2	Functions	of	the	19S	regulatory	particle.	The	19S	cap	is	formed	of	a	base,	containing	the	ATPase	subunits,	and	the	lid,	which	binds	polyubiquitinated	substrates	via	two	ubiquitin	receptors,	Rpn10	and	Rpn	13	(Figure	1.3)	(Husnjak	et	al.,	2008;	Peth	et	al.,	2010;	Schreiner	et	al.,	2008).		The	19S	lid	is	composed	of	nine	subunits,	Rpn3,	5,	6,	7,	8,	9,	11,	12	and	15.	Rpn11	 is	 a	 JAMM	 metalloprotease	 which	 combines	 with	 Rpn8	 to	 form	 a	heterodimer	with	DUB	activity	(Pathare	et	al.,	2014;	Worden	et	al.,	2014)	and	is	responsible	 for	 deubiquitination	 of	 substrates.	 Rpn11	 is	 thought	 to	 cleave	polyubiquitin	 chains	 proximally	 from	 the	 ubiquitinated	 substrate	 prior	 to	unfolding	 and	 translocation	 to	 the	 20S,	 enabling	 rapid	 degradation	 of	 the	substrate	(Verma	et	al.,	2002;	Yao	and	Cohen,	2002).	
26 Proteasome 
RP 
RP 
CP 
Lid – containing Rpn11 and Ub receptors 
(Rpn10 and Rpn13) 
Base – containing ATPase ring 
α ring (forms gate to 20S core particle) 
β ring 
α ring 
β ring Catalytic subunits – β1, β2, β5 
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The	 19S	 base	 contains	 six	 AAA-ATPase	 subunits	 (termed	 Rpt1-6),	 two	scaffolding	proteins	(Rpn	1	and	2),	and	ubiquitin	binding	receptors	(Rpn10	and	Rpn	13)	(Figure	1.3).	Rpn10	was	the	first	ubiquitin	receptor	to	be	identified	in	the	26S	proteasome	(Deveraux	et	al.,	1994),	however	deletion	mutants	of	Rpn10	in	 yeast	 were	 still	 viable	 indicating	 that	 there	 were	 other	 ubiquitin	 receptors	within	 the	 proteasome	 (van	 Nocker	 et	 al.,	 1996).	 Subsequently,	 other	proteasome-associated	UBPs	were	identified	in	yeast,	including	Rpn13	(Husnjak	et	 al.,	 2008),	Rpt5	 (Lam	et	 al.,	 2002)	and	Sem1	 (Paraskevopoulos	et	 al.,	 2014).	Rpn1	 was	 also	 identified	 as	 being	 responsible	 for	 binding	 and	 recruitment	 of	ubiquitinated	 substrates	 (Elsasser	 et	 al.,	 2002),	 but	 it	 was	 only	 recently	demonstrated	that	Rpn1	not	only	binds	ubiquitin	via	its	UBD	but	also	binds	the	UBL	domain	of	a	DUB,	Ubp6	(USP14	in	mammals),	by	another	Rpn1	UBL-binding	site,	facilitating	substrate	deubiquitination	(Shi	et	al.,	2016).		The	ATPase	subunits	of	the	19S	base	catalyse	the	unfolding	of	the	protein	substrate,	 the	opening	of	 the	narrow	gate	 into	 the	20S	and	the	translocation	of	the	 unfolded	 substrate	 into	 the	 20S	 catalytic	 chamber	 in	 an	 ATP-dependent	process	(Smith	et	al.,	2005).	Up	 to	 three	DUBs	 are	 known	 to	 associate	with	 the	 proteasome:	 Rpn11,	USP14	(Ubp6	in	yeast),	and	Uch37.	Rpn11	forms	a	core	component	of	the	19S	as	discussed	above	(Figure	1.3).	The	functions	of	Uch37,	which	is	not	found	in	less	diverse	 organisms	 such	 as	 yeast,	 are	 obscure.	 USP14,	 which	 is	 always	 found	bound	to	proteasomes,	is	only	active	when	associated	with	the	complex	(Leggett	et	 al.,	 2002)	 and	 seems	 to	 be	 involved	 in	 the	 processive	 removal	 of	 ubiquitin	molecules	 from	 the	 distal	 end	 of	 chains.	 Whether	 USP14	 is	 rate-limiting	 for	proteasome-mediated	 degradation	 or	 promotes	 substrate	 degradation	 remains	unclear.	The	Finley	group	show	removal	of	USP14	increases	protein	degradation	of	Cyclin	B1	and	other	substrates,	and	that	an	USP14	inhibitor	can	promote	the	removal	of	aggregate	prone	proteins	(Lee	et	al.,	2016;	Lee	et	al.,	2011).	However,	Peth	et	al	showed	that	USP14	is	required	for	activation	of	the	AAA	ATPases	and	gate	 opening	 following	 deubiquitination	 of	 the	 protein	 substrate	 (Peth	 et	 al.,	2009).	 Thus,	 while	 USP14	 is	 clearly	 required	 for	 proteasome-mediated	degradation,	the	complex	nature	of	its	functions	remain	to	be	fully	determined.			
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1.2.3	Mechanisms	of	catalytic	action	within	the	20S	The	 20S	 core	 particle	 is	 responsible	 for	 the	 catalysis	 of	 proteins	 and	 is	composed	of	four	stacked	heptameric	rings	(Figure	1.3).	The	outer	rings	contain	the	 structural	 α-subunits	 which	 form	 a	 narrow	 entry	 channel	 which	 control	substrate	 entry	 into	 the	 catalytic	 core	 (Groll	 et	 al.,	 2000).	The	 requirement	 for	entry	 into	the	20S	 is	governed	by	the	gate,	and	only	de-ubiquitinated,	unfolded	polypeptides	 are	 able	 to	 pass	 into	 the	 catalytic	 chamber.	 The	 flux	 of	 small	fluorescent	 tri-peptides	 through	 the	gate	and	 their	 subsequent	cleavage	can	be	used	in	in	vitro	assays	as	a	measure	of	gate	opening	(Peth	et	al.,	2009).	The	 two	 inner	 rings	 contain	 the	 catalytic	 β-subunits	 (β1,	 β2	 and	 β5)	(Figure	1.3),	which	are	caspase,	 trypsin	and	chymotrypsin	 like	peptidases	that	degrade	 the	 substrate	 into	 small	 peptides.	 These	 peptides	 are	 then	 further	degraded	by	 intracellular	 proteases,	 or	 can	be	presented	 at	 the	 cell	 surface	 by	MHC	 Class	 I,	 enabling	 the	 immune	 system	 to	 survey	 the	 intracellular	 protein	content	of	cells	(Rock	et	al.,	1994).		
1.2.4	Recognition	of	ubiquitinated	proteins	by	the	26S	proteasome	It	 is	 well	 established	 that	 the	 canonical	 signal	 for	 proteasomal	degradation	is	K48-linked	polyubiquitin	chains	(Thrower	et	al.,	2000).	However,	the	 proteasome	 in	 isolation	 does	 not	 seem	 to	 have	 the	 ability	 to	 distinguish	between	different	polyubiquitin	linked	chains	(Hofmann	and	Pickart,	2001;	Kim	et	al.,	2007;	Saeki	et	al.,	2009).	Isolated	proteasomes	bind	to	K48	and	K63-linked	chains	in	vitro	and	degrade	the	substrates.	Thus	Rpn10	and	Rpn13	do	not	appear	to	 have	 any	 lysine	 linkage	 specificity.	However,	 in	 cells,	 K63-polyubiquitinated	conjugates	are	protected	from	proteasomal	degradation	by	K63-selective	UBPs,	such	 as	 the	 ESCRT0	 complex,	which	 bind	 strongly	 to	 the	 conjugates	 and	 block	their	binding	to	the	19S	(Nathan	et	al.,	2013).		Interestingly,	prior	to	my	studies,	it	 was	 not	 known	whether	 other	 ubiquitin	 lysine	 linkages,	 such	 as	 K11,	 could	bind	to	the	26S	proteasome.	Aside	 from	 specific	 recognition	 of	 ubiquitin	 chains,	 proteasome	associated	proteins	may	be	able	to	promote	ubiquitin	chain	formation	on	certain	substrates.	 In	 yeast,	 the	 proteasome-associated	 ubiquitin	 ligase,	 Hul5	
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(mammalian	 orthologue,	 UBE3C),	 can	 extend	 the	 ubiquitination	 of	 bound	ubiquitinated	 substrates	by	 acting	 as	 an	E4	 (Crosas	 et	 al.,	 2006).	 Furthermore,	Ubp6	(USP14	orthologue)	preferentially	deubiquitinates	substrates	modified	by	Hul5,	suggesting	that	Hul5	and	Ubp6	may	function	in	opposition	to	each	other	to	modify	 proteasome-associated	 degradation	 of	 certain	 substrates	 (Crosas	 et	 al.,	2006).		 	
1.2.5	 What	 are	 the	 minimal	 requirements	 to	 signal	 proteasome-mediated	
degradation?	Until	 recently,	 it	 is	was	 thought	 that	 a	 chain	 of	 four	 ubiquitins	was	 the	minimum	linkage	length	required	for	proteolysis	by	the	proteasome	(Thrower	et	al.,	 2000).	 However,	 this	 has	 recently	 been	 disputed,	 and	 may	 depend	 on	 the	nature	 of	 the	 substrate	 or	 the	 number	 of	 ubiquitin	 chains.	 The	 Ciechanover	group	 showed	 that	 a	 single	 ubiquitin	 moiety	 can	 facilitate	 the	 degradation	 of	several	 protein	 substrates	 in	 vitro	 (Shabek	 et	 al.,	 2012).	 Furthermore,	 recent	studies	have	shown	that	multiple	monoubiquitination	of	cyclin	B1	and	the	NF-κB	precursor,	p105	(Dimova	et	al.,	2012;	Kravtsova-Ivantsiv	et	al.,	2009)	can	trigger	proteasomal	degradation	or	proteasomal	processing.	Single	molecule	studies	(Lu	et	 al.,	 2015)	 confirm	 these	 findings	 and	 go	 on	 to	 explore	 the	 requirement	 of	several	 short	 polyubiquitin	 chains	 as	 a	 more	 efficient	 signal	 for	 proteasome-mediated	 degradation	 than	 a	 single	 tetraubiquitin	 chain.	 However,	 it	 is	important	 to	 note	 that	 multiple	 monoubiquitination	 of	 other	 cell	 cycle	substrates,	 securin	 and	 geminin,	 did	 not	 allow	 degradation	 (Lu	 et	 al.,	 2015)	suggesting	that	proteasome-mediated	degradation	is	not	solely	ubiquitin	linkage	specific	and	is	dependent	on	intrinsic	properties	of	the	protein	substrate.	The	Matouschek	lab	have	shown	that	an	ubiquitin	chain	is	not	sufficient	to	signal	 proteasome-mediated	 degradation	 without	 the	 presence	 of	 an	 unfolded	region	within	the	protein	substrate	(Prakash	et	al.,	2004;	Yu	et	al.,	2016).	Binding	of	the	ubiquitinated	substrate	occurs	via	the	ubiquitin	chain	but	the	proteasomal	degradation	 is	 initiated	at	 a	disorded	 region	within	 the	protein	 (Prakash	et	 al.,	2004;	Takeuchi	et	al.,	2007).	Interestingly,	proteins	with	UBL	domains	that	lack	initiation	 sites	 are	 spared	 degradation	 by	 the	 proteasome.	 For	 example,	 the	
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proteasome	 shuttling	 factor,	 Rad23,	 binds	 K48-linked	 ubiquitinated	 substrates	and	 shuttles	 them	 to	 the	 proteasome	 allowing	 the	 substrate	 to	 be	 degraded,	however	 Rad23	 is	 spared	 from	 degradation	 due	 to	 the	 lack	 of	 a	 sufficient	unstructured	region	to	act	as	an	initiation	site	(Fishbain	et	al.,	2011).		
1.3	Lysine-11	polyubiquitin	chains.	K11-linked	polyubiquitin	chains	are	of	interest	as	they	are	the	third	most	abundant	linkages	in	cells	(5-10%	in	humans,	20-30%	in	yeast)	(Jacobson	et	al.,	2009;	Xu	et	al.,	2009),	have	a	unique	structure	compared	to	K48,	K63	or	linear-linked	chains	(Castaneda	et	al.,	2013),	and	have	putative	roles	 in	many	cellular	pathways	(Figure	1.4).	The	best	characterized	role	for	K11-linkages	is	in	the	cell	cycle.	In	mitosis,	the	anaphase	promoting	complex/cyclosome	(APC/C)	E3	ligase	catalyses	 polyubiquitin	 chain	 formation	 on	 cell	 cycle	 proteins,	 cyclinB1	 and	securin,	signalling	the	degradation	of	these	mitotic	regulators	(Min	and	Lindon,	2012;	 Pines,	 2011).	 In	 addition	K11-chains	 have	 been	 shown	 to	 accumulate	 in	cells	released	from	mitotic	arrest,	when	the	APC/C	is	most	active	(Matsumoto	et	al.,	2010).	 In	vitro	studies	have	 identified	that	several	E2	enzymes	are	required	for	the	ubiquitination	of	APC/C	substrates.	Either	UbcH10	or	UbcH5	are	required	to	initiate	ubiquitination	of	CyclinB1,	and	the	polyubiquitin	chain	formed	is	then	extended	by	 the	K11-specific	E2	enzyme,	Ube2S	(Garnett	et	al.,	2009;	 Jin	et	al.,	2008).	Therefore,	 it	was	initially	thought	that	K11-chains	were	required	for	the	degradation	of	cell	cycle	checkpoint	proteins.	Interestingly	however,	knockdown	of	Ube2S	by	siRNA-depletion	in	HeLa	cells	only	delayed	exit	from	mitosis	when	drug-induced	 perturbations	 (e.g.	 monastrol)	 of	 the	 cell	 cycle	 were	 used,	 and	Ube2S	was	 not	 required	 for	 normal	mitosis	 (Garnett	 et	 al.,	 2009).	 In	 addition,	Ube2S	is	not	necessary	for	degradation	of	ubiquitinated	CyclinB1	in	Xenopus	cell	extracts,	as	multiple	monoubiquitination	of	CyclinB1	was	sufficient	to	initiate	its	proteasome-mediated	degradation	(Dimova	et	al.,	2012).	It	is	possible	that	K11-chains	are	required	for	degradation,	but	in	conjunction	with	K48-chains.	Recent	
in	 vitro	 studies	 showed	 that	 branched	 K11/K48-chains	 formed	 on	 cell	 cycle	substrates,	Nek2A	and	CyclinA,	 facilitated	proteasomal	degradation	(Meyer	and	Rape,	2014).		 	
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Figure 1.4: K11-polyubiquitin chains and their potential functions. Schematic of the 
potential outcomes of modifications with K11-linked ubiquitin chains. The position of K11 
within the ubiquitin molecule is shown. K11-linked ubiquitin may be involved in proteasome-
mediated degradation, proteasome-independent degradation, endocytosis or stabilisation of 
the protein substrate. 		In	contrast	with	the	presumed	proteasome-mediated	degradative	role	of	K11-linkages	in	the	cell	cycle,	K11-polyubiquitination	has	been	observed	in	other	cellular	processes,	including	ER-associated	degradation	(ERAD)	(Xu	et	al.,	2009),	the	hypoxia	response	(Bremm	et	al.,	2014),	and	even	stabilizing	proteins	such	as	
β-catenin	(Dao	et	al.,	2012).	Therefore,	it	is	important	to	establish	whether	K11-chains	are	a	signal	for	proteasomal	degradation,	and	if	not,	to	establish	how	K11-polyubiquitin	chains	mediate	cellular	outcomes.	 I	was	particularly	 interested	in	exploring	the	hypoxia	response	pathway,	as	this	was	a	major	focus	of	the	Nathan	lab.		
1.4	The	oxygen	sensing	pathway	Oxygen	 is	an	essential	molecule	 for	 life	and	 it	 is	 therefore	 important	 for	cells	to	be	able	to	respond	swiftly	to	changes	in	oxygen	availability.	 	Metazoans	have	 developed	 an	 evolutionary	 conserved	 mechanism	 to	 respond	 to	 oxygen	
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availability,	 dependent	 on	 the	 Hypoxia	 Inducible	 transcription	 Factors	 (HIFs)	which,	under	conditions	of	low	oxygen	tension	(hypoxia,)	activate	genes	involved	in	glucose	uptake,	angiogenesis,	and	redox	homeostasis	to	promote	cell	survival	(Benita	 et	 al.,	 2009;	 Manalo	 et	 al.,	 2005).	 Since	 the	 identification	 of	 these	transcription	 factors	nearly	 thirty	 years	 ago,	 it	 has	become	apparent	 that	HIFs	are	 not	 only	 involved	 in	 a	 physiological	 response	 to	 promote	 cell	 survival	 and	oxygen	 delivery	 to	 tissues,	 but	 are	 also	 implicated	 in	 hereditary	 cancer	syndromes,	tumorigenesis,	pulmonary	hypertension	and	modulation	of	immune	responses	(Kaelin,	2008;	Maxwell	and	Ratcliffe,	2002).	Moreover,	the	regulation	of	HIFs	in	aerobic	conditions	is	poorly	understood.	Consequently,	it	is	of	interest	to	understand	how	HIFs	are	tightly	regulated.		
1.4.1	Hypoxia	Inducible	transcription	Factors	upregulate	gene	expression	in	
hypoxia	HIFs	consist	of	a	basic	helix-loop-helix	motif	and	a	PER-ARNT-SIM	domain	(Wang	and	Semenza,	1995).	There	are	three	different	isomers	of	HIF:	HIF1,	HIF2	and	 HIF3.	 HIF1	 and	 HIF2	 have	 the	 same	 domain	 architectures,	 and	 are	 post	translationally	 regulated	 similarly,	 whereas	 HIF3	 encodes	 a	 truncated	 form	 of	the	transcriptional	activating	domains,	incapable	of	activating	genes	to	the	same	extent	 as	 the	 other	 isoforms	 (Figure	 1.5).	 HIF1	 is	 ubiquitously	 expressed,	whereas	 HIF2	 is	 more	 specific,	 being	 localized	 in	 blood	 vessels,	 lungs,	 liver,	kidneys,	 interstitial	cells	and	the	neural	crest	(Wiesener	et	al.,	2003).	However,	HIF1	and	HIF2	can	be	expressed	in	the	same	cells,	where	they	can	differentially	activate	target	genes.	The	mechanism	for	the	selective	activation	of	HIF2	target	genes	 is	 not	 known.	 HIF1	 was	 first	 implicated	 in	 the	 regulation	 of	 oxygen	responses,	when	 it	was	 identified	 as	 a	 transcription	 factor	which	bound	 to	 the	erythropoietin	 (EPO)	 gene	 promoter	 under	 hypoxic	 conditions,	 activating	 EPO	transcriptional	 activity	 (Semenza,	 1994).	 How	 HIF1	 activity	 was	 regulated	 by	oxygen,	at	that	time,	was	unclear.		
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Figure 1.5: The hypoxia inducible transcription factors. Schematic illustrating the domain 
architecture of the HIF subunits. HIF1α and HIF2α share a similar domain architecture with 
the bHLH-PAS domains (DNA binding), the ODD and the N- and C-activating domains (NAD 
and CAD). Both HIF1α and HIF2α form a heterodimer with HIFβ  (ARNT). The prolines 
hydroxylated by PHDs are indicated. FIH hydroxylates a conserved asparagine within the 
CAD (N803 and N847) to regulate transcriptional activity. HIF3α has many isoforms, which 
may encode the bHLH-PAS domains and a putative ODD. No CAD has been identified. It is 
postulated that P492 is hydroxylated by PHDs but this remains controversial.  	
	 The	 first	 purification	 of	 HIF	 identified	 two	 proteins	 of	 120	 and	 92kDa	corresponding	 to	 an	α	 and	β	 subunit,	 respectively	 (Wang	and	Semenza,	1995).		Later,	 it	 was	 discovered	 that	 HIFβ	 (aryl	 hydrocarbon	 receptor	 nuclear	translocator	(ARNT))	is	constitutively	expressed	in	normoxia	and	can	participate	in	other	 transcriptional	 responses,	whereas	HIFα	 (referring	 to	both	HIF1α	 and	HIF2α	isoforms)	forms	the	regulatory	component	(discussed	in	1.4.2	below).		During	 hypoxia,	 HIFα	 binds	 with	 HIFβ	 to	 form	 a	 heterodimer	 which	translocates	 to	 the	nucleus	 and	binds	 to	 a	HIF	Response	Element,	 a	 consensus	sequence	of	5’-RCGTG-3’	in	the	promoter	of	hypoxia-responsive	genes	(Benita	et	al.,	 2009).	Between	one	 and	 two	hundred	 genes	 are	upregulated	by	binding	of	the	HIF	heterodimer	to	the	HRE	in	target	genes,	including	those	responsible	for	
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stimulating	angiogenesis,	such	as	the	Vascular	Endothelial	Growth	Factor	(VEGF)	(Kelly	et	al.,	2003;	Pugh	and	Ratcliffe,	2003).	Studies	in	arterial	endothelial	cells	(ECs)	using	a	constitutively	active	form	of	HIF1α,	have	shown	that	targets	of	HIF	include	 transcription	 factors,	 cytokines,	 prostaglandins	 and	 collagens,	 enabling	tissue	reperfusion	when	oxygen	is	scarce	(Manalo	et	al.,	2005).	HIF1	also	acts	as	a	 metabolic	 regulator,	 coordinating	 a	 change	 from	 oxidative	 metabolism	 to	glycolysis	 by	 increasing	 expression	 of	 glucose	 transporters	 (GLUT1),	 glycolytic	enzymes,	 and	 enzymes	 associated	with	 the	 tricarboxylic	 acid	 (TCA)	 cycle	 (e.g.	Lactate	Dehydrogenase	(LDHA)	and	pyruvate	dehydrogenase	kinase)	(Semenza,	2012).		
	
1.4.2	Hypoxia	Inducible	transcription	Factors	are	regulated	by	hydroxylation	
and	ubiquitination	HIFs	 have	 been	 shown	 to	 be	 highly	 sensitive	 to	 oxygen	 concentration,	increasing	as	oxygen	concentrations	decrease	between	2	and	1%	and	reaching	a	peak	 at	 0.5%	 oxygen	 concentration	 (Jiang	 et	 al.,	 1996),	 and	 their	 cellular	abundance	is	controlled	by	post-translational	regulation	of	the	HIFα	subunit.	In	normoxia,	HIFα	is	degraded	in	a	two	stage	process	involving	the	prolyl	hydroxylation	 of	 two	 conserved	 proline	 residues	 in	 the	 oxygen	 degradation	domain	of	HIF1α	(Bruick	and	McKnight,	2001;	Epstein	et	al.,	2001)	which	allows	recognition	of	 these	hydroxylated	prolines	by	 the	Von	Hippel	 Lindau	E3	 ligase	complex,	 VHL	 (Maxwell	 et	 al.,	 1999)	 (Figure	 1.6).	 VHL	 subsequently	polyubiquitinates	 three	conserved	 lysine	residues	 in	 the	HIF1α	ODD	(Paltoglou	and	 Roberts,	 2007;	 Tanimoto	 et	 al.,	 2000),	 leading	 to	 proteasome-mediated	degradation	 of	 HIF1α	 and	 thereby	 preventing	 undesirable	 activation	 of	 the	hypoxic	response	during	conditions	of	normoxia.			
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Figure 1.6: Regulation of HIF stability by prolyl hydroxylation and ubiquitination. 
Schematic illustrating the regulation of the HIFα subunit by prolyl hydroxylation and 
ubiquitination. When oxygen is abundant HIFα undergoes prolyl hydroxylation by the PHDs. 
Prolyl hydroxylated HIFα is recognized by the VHL E3 ligase which ubiquitinates HIFα leading 
to its rapid proteasome-mediated degradation. When oxygen is scarce, PHDs are no longer 
active and HIFα is stabilized. HIFα then forms a heterodimer with HIFβ, translocates to the 
nucleus and activates genes containing HREs. PHD activity is not only dependent on oxygen, 
but also requires 2-OG, ferrous iron and ascorbate. It is also noteworthy that oxygen 
concentrations in tissues are much lower than atmospheric oxygen.  		Interestingly,	 the	ubiquitin	post-translational	modification	of	HIF1α	was	identified	 prior	 to	 the	 identification	 of	 HIF1α	 prolyl	 hydroxylation	 by	 PHD	enzymes.	 As	 discussed,	 HIF1α	 was	 first	 shown	 to	 be	 involved	 in	 the	transcriptional	 regulation	 genes	 by	 examining	 the	 hypoxic	 activation	 of	 EPO	(Semenza,	 1994)	 and	 	 p53	 (An	 et	 al.,	 1998).	 	 By	 expressing	 specific	 regions	 of	HIF1α	 in	HEK293	cells	and	measuring	degradation	by	pulse	chase,	Huang	et	al	were	 able	 to	 identify	 the	oxygen	 sensitive	 region	of	HIF1α,	 termed	 the	oxygen	dependent	degradation	domain	(Huang	et	al.,	1998).	They	identified	that	amino	acids	 401	 to	 603	 of	 HIF1α	 contained	 two	 PEST-like	 sequences	 (two	 proline,	glutamic	 acid,	 serine,	 threonine)	 that	 were	 required	 for	 proteasome-mediated	degradation	of	the	α	subunit	in	normoxia	(Huang	et	al.,	1998).		Subsequently,	 the	 E3	 ligase	 required	 for	 the	 ubiquitination	 and	degradation	of	HIF1α	was	identified	by	the	Ratcliffe	group,	as	the	product	of	the	
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Von	Hippel-Lindau	(VHL)	tumour	suppressor	gene,	pVHL	(Maxwell	et	al.,	1999).	VHL	 disease	 is	 a	 hereditary	 cancer	 syndrome	 characterised	 by	 angiogenic	tumours	which	 show	 features	 in	 common	with	 activation	 of	 hypoxia	 inducible	genes	(Iliopoulos	et	al.,	1995).	Maxwell	et	al	showed	that	renal	carcinoma	cells	deficient	in	the	VHL	gene	(RCC4	cells)	stabilized	HIF1α	and	this	was	reversed	by	expression	of	VHL	in	RCC4	cells.	Furthermore,	HIF1α	and	HIF2α	were	found	to	associate	 with	 VHL	 by	 immunoprecipitation,	 following	 treatment	 with	proteasome	 inhibitors	 or	 under	 hypoxic	 conditions	 (Maxwell	 et	 al.,	 1999),	suggesting	 that	 VHL	was	 required	 for	 the	 ubiquitination	 of	 HIFα.	 Biochemical	studies	by	the	Kaelin	and	Ratcliffe	groups	and	others	showed	that	VHL	associates	with	Elongins	A	and	B,	and	cullin-2	(Cul-2)	(Kamura	et	al.,	1999;	Maxwell	et	al.,	1999;	Pause	et	al.,	1997)	thereby	forming	an	SCF	(Skp-1-Cullin-F-box	protein)	E3	ligase	complex	(Hershko	and	Ciechanover,	1998).	The	E2	enzyme	used	in	these	studies	was	UbcH5,	however	the	E2	enzyme	required	for	VHL	ubiquitination	in	cells	is	not	known.		The	 first	 lysine	within	 the	HIF1α	 ODD	observed	 to	 be	modified	 by	VHL	was	 lysine	 532	 (K532)	 (using	 Flag-tagged	 HIFα	 mutants	 in	 HEK293	 cells)	(Tanimoto	et	al.,	2000).	Subsequently,	two	other	lysine	residues,	K538	and	K547,	were	 found	 to	 be	 modified	 by	 VHL	 (Paltoglou	 and	 Roberts,	 2007).	 Indeed,	 it	seems	 that	 all	 these	 lysines	 are	 required	 for	 efficient	 ubiquitination	 and	proteasome-mediated	degradation	of	HIF1α,	as	the	ODD	was	only	fully	stabilized	when	 point	 mutations	 were	 made	 in	 each	 of	 the	 three	 lysines	 (Paltoglou	 and	Roberts,	2007).	Interestingly,	Paltoglou	et	al	also	identified	an	ODD	degradation	product	 when	 VHL-mediated	 degradation	 was	 impaired	 suggesting	 that	 there	may	 be	 a	 VHL-independent	 mechanism	 of	 HIF1α	 degradation	 (Paltoglou	 and	Roberts,	2007).	It	was	noted	that	HIF	was	stabilised	not	only	by	hypoxia,	but	also	by	iron	chelation	and	cobalt	 ions,	 suggesting	 that	a	 ferro-protein	oxygen	sensor	maybe	involved	 in	HIF	 regulation.	 In	 addition,	 the	 inhibition	of	HIF	degradation	by	2-oxoglutarate	(2-OG,	also	known	as	α-ketoglutarate)-	analogues,	the	requirement	for	 oxygen,	 and	 the	 binding	 of	 VHL	 to	 an	 ODD	 domain	 containing	 proline	residues	(Ivan	et	al.,	2001;	Jaakkola	et	al.,	2001;	Masson	et	al.,	2001)	suggested	
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that	 prolyl	 hydroxylation	 by	 a	 2-oxoglutarate	 dependent	 dioxygenase	 maybe	required	for	HIF	regulation.	As	HIFs	are	 conserved	 in	all	metazoans,	 it	was	possible	 to	explore	 their	regulation	 in	 less	 diverse	 organisms,	 and	 rapidly	 identify	 the	 dioxygenases	required	for	HIFα	degradation.	A	database	analysis	in	Caenorhabditis	elegans	(C.	
elegans)	identified	a	conserved	2-oxoglutarate	dioxygenase	enzyme,	egg-laying-defective	9	(EGL-9,	EGLN),	whose	structural	predictions	suggested	that	 it	could	bind	2-OG	and	Fe2+	and	has	the	characteristic	β-barrel	jelly	roll	motif,	common	to	2-oxoglutarate	dioxygenases.	Worms	containing	inactivating	mutations	in	EGL-9	stabilised	HIF1.		In	addition,	recombinant	HIF1	incubated	with	lysates	containing	either	 overexpressed	 or	 recombinant	 EGL-9	 bound	VHL.	 These	 reactions	were	dependent	on	the	addition	of	Fe2+	and	2-OG,	and	inhibited	by	hypoxia	and	cobalt	(Epstein	et	al.,	2001).	Concurrently,	 studies	 in	 drosophila	 identified	 several	 2-oxoglutarate	dependent	dioxygenases	which	have	human	homologues.	Recombinant	proteins	of	 these	 five	 homologues	 were	 incubated	 with	 a	 biotinylated	 HIF1αODD556-574	peptide	in	the	presence	of	Fe2+,	ascorbate	and	2-OG,	and	one	homologue	bound	VHL	assessed	by	a	35S-VHL	pull	down	assay	(described	in	Chapter	5.1).	This	2-oxoglutarate	dependent	dioxygenase	was	named	HIF	prolyl	hydroxylase	(HPH-1,	later	named	prolyl	hydroxylase	domain-containing	enzyme	1	(PHD1))	and	found	to	have	two	related	paralogs,	HPH-2	and	3	(PHD2	and	PHD3),	which	bound	VHL	under	similar	conditions	(Bruick	and	McKnight,	2001).	When	recombinant	PHD	was	 incubated	with	 HIF1	 peptide,	 a	 16kDa	modification	 was	 produced,	 which	corresponded	 to	 the	 size	of	 the	hydroxylation	of	HIF1α	 by	mass	 spectrometry.	This	hydroxylation	reaction	was	enhanced	by	addition	of	Fe2+,	ascorbate	and	2-OG	 and	 inhibited	 by	 the	 hypoxia	 mimic,	 cobalt	 (Bruick	 and	 McKnight,	 2001),	consistent	with	the	known	cofactors	for	2-OG	dependent	dioxygenases.		In	combination,	these	studies	demonstrated	that	the	regulation	of	HIF1α	in	 normoxia	was	 dependent	 on	 prolyl	 hydroxylation	 of	 two	 conserved	 proline	residues,	Pro402	and	Pro564	(Figure	1.5),	enabling	binding	of	the	VHL	E3	ligase	complex	 and	 subsequent	 ubiquitination	 of	 one	 of	 three	 conserved	 lysine	residues,	K532,	K538	or	K547,	 leading	 to	proteasome-mediated	degradation	of	HIF1α.	
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1.4.3	The	Prolyl	Hydroxylase	Enzymes		While	 three	 PHDs	 have	 been	 identified	 in	 humans,	 PHD2	 is	 the	predominant	enzyme	involved	in	HIF1α	regulation.	RNAi-mediated	depletion	of	PHD2	 results	 in	 increased	 HIF1α	 protein	 expression	 and	 activation	 of	 HIF1α	target	genes	(Berra	et	al.,	2003).	Loss	of	PHD2	in	mice	 is	 lethal	due	to	heart	or	placental	defects,	but	PHD1	and	PHD3	null	mice	are	viable	(Takeda	et	al.,	2006).	Furthermore,	PHD2	is	ubiquitously	expressed	whereas	PHD1	and	3	expression	is	more	limited,	with	PHD1	being	predominantly	expressed	in	the	testes	and	PHD3	in	the	heart	(Appelhoff	et	al.,	2004;	Lieb	et	al.,	2002).	The	 structure	 of	 the	 PHD	 enzymes	 incorporates	 a	 two-histidine-one-carboxylate	motif	which	coordinates	a	catalytic	Fe2+	iron	in	its	centre	(Epstein	et	al.,	2001)	and	the	crystal	structure	of	PHD2	has	been	resolved	(McDonough	et	al.,	2006;	Wilkins	and	Abboud,	2016)	(Figure	1.7).	There	are	two	2-OG	binding	sites	and	 one	 O2	binding	 site	 (Kaelin	 and	 Ratcliffe,	 2008).	 The	 prolyl	 hydroxylation	reaction	 results	 in	 the	 splitting	 of	 O2,	 hydroxylation	 of	 HIF1α,	 oxidative	decarboxylation	of	2-OG	to	form	succinate,	and	the	release	CO2	(Figure	1.7).	The	importance	 of	 2-OG	 and	 Fe2+	 for	 PHD	 activity	 is	 demonstrated	 by	 the	 use	 of	competitive	 inhibitors	 for	 2-OG	 binding,	 such	 as	 the	 2-OG	 analogue	dimethyloxalylglycine	(DMOG),	and	the	use	of	the	iron	chelator,	desferrioxamine	(DFO).		
	 PHD	 mutations	 have	 been	 identified	 as	 a	 cause	 of	 human	 disease,	including	 familial	 erythrocytosis	 in	 which	 patients	 with	 a	 P317R	mutation	 on	PHD2	 have	 a	 substantial	 loss	 of	 function	 of	 the	 PHD2	 enzyme	 resulting	 in	 an	elevated	 haematocrit,	 but	 normal	 EPO,	 and	 requiring	 frequent	 venesection	(Percy	 et	 al.,	 2006).	 Interestingly,	 mutations	 in	 VHL	 are	 also	 linked	 to	erythrocytosis,	 in	 particular	 in	 the	 Chuvash	 population	 in	 Russia,	 but	 these	patients	have	high	EPO	levels	in	addition	to	a	high	haematocrit,	suggesting	that	the	mechanism	of	erythrocytosis	is	different	from	that	of	PHD2	mutations	(Percy	et	al.,	2003).	
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Figure 1.7: PHDs and their mechanism of action. (A) Ribbon structural diagram of PHD in 
complex with the ODD of HIF1α (P564 region peptide). Apo PHD2 is shown in green, PHD2 
in complex with ODD is shown in blue. The ODD peptide is shown in red. (Adapted from 
(Wilkins and Abboud, 2016)). (B) PHD Enzymatic reaction: (1) The ferrous iron (Fe2+) bound 
to PHD reacts with 2-oxoglutarate (2-KG). (2) oxygen reacts with the Fe2+ and HIF-1α, to form 
an iron-peroxyhemiketal bicyclic complex. (4) The oxygen is then cleaved, resulting in the 
hydroxylation of HIF1α. (5) Decarboxylation of 2-OG occurs and the prolyl hydroxylated HIFα 
is released. (6) carbon dioxide (CO2)  and  (7) succinate (from the decarboxylated 2-OG)  are 
then released. The PHD can then recycle and bind 2-OG again. (Adapted from (Peters et al., 
2015)).  	 PHD	 proteins	 are	 themselves	 regulated	 by	 SIAH	 (Seven	 In	 Absentia	Homolog),	a	RING	E3	ligase	(Nakayama	and	Ronai,	2004)	which	also	regulates	an	asparagine	hydroxylase	that	controls	HIF	activation,	Factor	Inhibiting	HIF	(FIH)	(Fukuba	et	al.,	2007).	However,	despite	the	ability	of	SIAH	ligases	to	mediate	the	proteasomal	 degradation	 of	 only	 PHD1	 and	 3,	 not	 PHD2,	 expression	 of	 SIAH2	leads	 to	HIF1α	 stabilisation	 in	U2OS	and	HEK293	 cells	 (Moller	 et	 al.,	 2009).	 In	
Multiple other interacting partners for the PHDs have been
described, including the tumour suppressor protein LIMD1
(LIM domain containing protein 1), which simultaneously binds
the PHDs and pVHL in a manner that promotes HIF-a degrada-
tion.[39] Many other interacting proteins have been reported to
be PHD substrates on the basis of antibody and/or proteomic
mass spectrometry analyses. The relevance of these interac-
tions to the hypoxic response remains to be validated, though
the findings do raise the possibility that competition for bind-
ing to the PHDs may be regulatory. Such competition is more
established for FIH, which we focus on in this review (see[40] for
a review of non-HIF PHD substrates).
2.3. HIF-a CAD interactions: FIH and CBP/p300
CBP/p300 interact with both the NAD and CAD in HIF-a,[41]
though only the latter of these interactions is known to be
regulated by oxygen-dependent hydroxylation and has been
structurally characterised.[17,42] NMR structures of the CH1 do-
mains of CBP and p300 in complex with HIF-1a CAD peptides
have been reported.[42] In both cases, the four alpha helices
that constitute the CH1 domain form a bundle that is stabi-
lised by coordination with three Zn2+ ions. The CAD folds
around the CH1 domain like a clamp, adopting two induced a-
helices that bind in an almost parallel arrangement on oppo-
site faces of the CH1 domain (Figure 4b). N803 in the HIF-1a
CAD is located on the N-terminal helix (Helix 1) and is buried
within the molecular interface. Hydroxylation at the pro-S posi-
tion of N803, which blocks HIF binding to CBP/p300, likely cre-
ates a direct steric clash with the backbone carbonyl of D799
in HIF-1a, so disrupting the formation of this helix (Fig-
ure 4b).[42,43] The tertiary structure of the HIF-1a CAD when
complexed with the CH1 domain of CBP/p300 is determined
almost exclusively by intermolecular contacts ; circular dichro-
ism analyses indicate that the isolated HIF-1a (and likely HIF-
2a) CAD is intrinsically disordered in solution.[42]
The available evidence indicates that FIH does not undergo
such major conformational changes as the PHDs on substrate
binding.[44] When bound to FIH, the HIF-1a CAD adopts an ex-
tended conformation that is less enclosed than that of CODD
binding to PHD2.[27,44] Multiple hydrogen bonds are involved in
binding the CAD to FIH, as well as hydrophobic interactions,
including with a valine residue present immediately N-terminal
to N803 in the HIF-1a CAD hydroxylation motif (CEVNAP); this
valine forms a hydrophobic interaction with W296 of FIH,
which is involved in an induced fit mechanism.[44] The primary
amide of N803 is positioned to form hydrogen bonds with
conserved residues in FIH, notably Q239. The interaction of
HIF-1a with FIH is likely more complex beyond the immediate
vicinity of the active site; a second binding site is observed in
which the HIF-a residues involved form an a-helix, as observed
for these same residues bound to the CH1 domain of CBP/
p300 Figure 4).[42,44]
Figure 3. HIF-1a CODD interactions with pVHL and PHD2. a) View from a crystal structure of pVHL in complex with a hydroxylated HIF-1a CODD peptide
(PDB ID: 1LQB[13]). b) Magnified view from a) showing the orientation of HyP564 and its hydrogen bond interactions with residues in pVHL. c) View from a crys-
tal structure of pVHL in complex with Ligand 51[36] (purple), an inhibitor of the pVHL:HIF-1a interaction. d) Superimposed views from X-ray crystal structures
of PHD2 alone (green, PDB ID: 2G1M[29]) and in complex with a HIF-1a CODD peptide (blue, PDB ID: 3HQR;[27] CODD peptide is shown in red). e) Binding
mode of a dihydropyrazole inhibitor (yellow) bound in the active site of PHD2 (PDB ID: 5A3U[37]).
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addition,	 a	 small	 protein	 inhibitor,	 derived	 from	 the	 Drosophila	 protein	Phyllopod	(PHYL),	has	been	shown	to	bind	SIAH	leading	to	reduced	degradation	of	 PHD3,	 increased	HIF1α	 stabilisation	 and	 reduced	HIF	 target	 gene	 activation	(Moller	et	al.,	2009).	
	
1.4.4	The	roles	of	HIFs	in	physiological	contexts	and	in	disease.	
	 The	 most	 well	 described	 functions	 of	 HIFs	 relate	 to	 their	 activation	 of	genes	 involved	 in	 metabolism,	 angiogenesis,	 redox	 homeostasis	 and	 pH	regulation	 (Benita	 et	 al.,	 2009;	 Manalo	 et	 al.,	 2005).	 However,	 they	 are	increasingly	 implicated	 in	 cell	 fate	 determination	 and	 regulation	 of	 immune	responses	(Maltepe	et	al.,	2005;	Mutoh	et	al.,	2012;	Palazon	et	al.,	2014).	While	a	detailed	analysis	of	all	the	physiological	functions	of	HIFs	is	beyond	the	scope	of	this	thesis,	it	is	of	relevance	to	discuss	the	role	of	HIFs	in	physiological	regulation	of	metabolism	and	the	role	of	HIFs	in	cancer.	In	 normoxic	 conditions,	 oxidative	 phosphorylation	 allows	 generation	 of	ATP	from	glucose	 in	the	mitochondria.	However,	when	oxygen	 is	reduced,	cells	switch	 to	 glycolysis	 (Semenza,	 2012)	 either	 in	 order	 to	 limit	 cellular	 damage	from	 reactive	 oxygen	 species	 	 (Zhang	 et	 al.,	 2008)	 or	 due	 to	 the	 decrease	 in	oxygen	availability.	This	physiological	response	to	hypoxia	is	necessary	to	enable	cell	 survival	 and	 a	 major	 function	 of	 HIFs	 is	 to	 upregulate	 genes	 involved	 in	glucose	uptake	and	redox	homeostasis,	allowing	this	switch	to	glycolysis	(Benita	et	al.,	2009;	Manalo	et	al.,	2005).	HIF1	mediates	the	upregulation	of:	(i)	glucose	transporters	(GLUT1)	and	glycolytic	enzymes	which	convert	glucose	to	pyruvate	(ii)	 pyruvate	 dehydrogenase	 kinase	 (PDHK),	 which	 prevents	 conversion	 of	pyruvate	 to	 Acetyl	 Coenzyme	 A	 (Acetyl	 CoA)	 by	 inhibition	 of	 pyruvate	dehydrogenase	(PDH)	thereby	preventing	entry	of	Acetyl	CoA	into	the	TCA	cycle	in	mitochondria,	and	(iii)	lactate	dehydrogenase	(LDH),	which	converts	pyruvate	to	 lactate	(Semenza,	2013).	HIF1	also	upregulates	genes	which	enable	selective	mitochondrial	 autophagy,	BNIP3	 (Zhang	et	 al.,	 2008)	and	BNIP3L	 (Bellot	 et	 al.,	2009),	 thereby	 reducing	 the	 availability	 of	 mitochondria	 for	 oxidative	phosphorylation.	 These	 HIF	 mediated	 modifications	 in	 energy	 metabolism	
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prevent	 the	 oxidation	 of	 proteins,	 lipids	 and	 nucleic	 acids	 by	 reactive	 oxygen	species	(ROS),	which	would	lead	to	cell	destruction	and,	ultimately	cell	death.	The	 first	 indication	 that	 HIFs	 were	 important	 in	 tumour	 formation,	related	to	the	identification	of	HIF	activation	in	renal	cell	carcinomas	(Kondo	et	al.,	2002)	(discussed	 in	1.4.7).	Indeed,	over	90%	of	renal	cell	carcinomas	have	mutations	 in	 VHL	 (Cowey	 and	 Rathmell,	 2009).	 Subsequent	 studies	 in	 other	hereditary	 tumour	 conditions	 also	 suggested	 that	 HIFs	 were	 important	 for	tumour	 formation,	 such	 as	 mutations	 in	 the	 TCA	 cycle	 enzymes	 succinate	dehydrogenase	 (SDH),	 fumarate	 hydratase	 (FH)	 and	 isocitrate	 dehydrogenase	(IDH)	(Hewitson	et	al.,	2007a),	primarily	through	metabolic	activation	of	HIF1α	(discussed	 in	1.4.6).	However,	 these	germline	mutations	may	also	affect	other	2-oxoglutarate	dependent	dioxygenases,	which	may	contribute	to	tumorigenesis	(discussed	 in	 1.4.5).	 Thus,	 whether	 HIFs	 can	 really	 be	 termed	 oncogenes	 is	debatable,	 as	 in	 some	 cases	 tumour	 suppressor	 functions	 have	 been	 observed,	whereby	deletion	of	HIF1α	lead	to	increased	tumour	growth	of	ES	cells	injected	into	mice	(Carmeliet	et	al.,	1998).		
	
1.4.5	PHDs	as	members	of	the	2-OG	dependent	dioxygenase	family		While	 PHDs	 are	mainly	 involved	 in	 HIF	 regulation,	 they	 form	 part	 of	 a	large	 group	 of	 2-OG	 dependent	 dioxygenases	 (2-OG-DDs)	 of	 which	 there	 are	more	 than	 60,	 which	 have	 diverse	 biological	 roles.	 	 All	 2-OG-DDs	 are	characterised	 by	 a	 double-stranded	 β	 helix	 fold	 (jelly	 roll)	 and	 a	 Fe2+	binding	motif,	 and	 their	 enzymatic	 activity	 relates	 to	 an	 oxygen-dependent	 reaction	 in	which	O2	is	split	into	two	atoms,	one	resulting	in	oxidation	of	a	substrate	and	the	other	 enabling	 oxidative	 decarboxylation	 of	 2-OG	 to	 form	 succinate	 and	 CO2	(Loenarz	and	Schofield,	2008).		The	 first	 2-OG-DD	 identified	 was	 collagen	 prolyl	 hydroxylase	 (CPH)	(Hutton	 et	 al.,	 1967).	 CPH	 catalyses	 prolyl-4-hydroxylation	 of	 specific	 proline-containing	motifs	in	collagen	which	leads	to	stabilisation	of	a	collagen	triple	helix	(Radmer	and	Klein,	2006).	Interestingly,	the	requirement	for	ascorbate	(vitamin	C)	as	a	cofactor	explains	the	 incidence	of	scurvy	 in	those	 lacking	vitamin	C	and	the	 resulting	 connective	 tissue	 damage.	 A	 further	 prolyl	 hydroxylase	 catalyses	
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prolyl-3-hydroxylation	of	 collagen	 causing	destabilisation	of	 the	 collagen	 triple	helix	(Myllyharju	and	Kivirikko,	2004).	More	recently,	 important	roles	 for	2-OG-DDs	have	been	 identified	 in	 the	epigenetic	 modification	 of	 genes	 by	 demethylation	 of	 histones.	 Histone	methylation,	by	histone	methyl	transferases,	mostly	occurs	on	lysine	residues	of	chromatin	 and	 results	 in	 transcriptional	 silencing	 or	 activation,	 thereby	modifying	gene	expression	(Klose	et	al.,	2006).	This	methylation	can	be	mono,	di	or	 tri-methylation.	 JumonjiC	 	 (JmjC)	 domain-containing	 histone	 demethylases	(JHDMs),	which	are	members	of	 the	2-OG-DD	 family,	 form	 the	 largest	group	of	histone	demethylases,	 catalysing	 the	removal	of	all	 three	states	of	methylation,	by	 binding	 Fe2+	 and	 2-OG	 and	 hydroxylating	 the	 methyl	 group	 on	 chromatin	which	is	released	as	formaldehyde	(Klose	et	al.,	2006).		FIH	 is	 a	 JmjC	 domain-containing	 protein	 which	 can	 hydroxylate	asparagine	 residues,	 including	 the	 HIF1α	 asparagine	 803	 (Lando	 et	 al.,	 2002).	This	 asparagine	 hydroxylation	 prevents	 HIF1α	 from	 binding	 the	 co-activators	p300	and	CREB	binding	protein	(CBP)	inhibiting	transcriptional	upregulation	of	HIF1	target	genes	(Loenarz	and	Schofield,	2008)	Further	evidence	of	the	importance	of	2-OG-DDs	is	evidenced	by	their	role	in	DNA	demethylation	 or	 repair.	 DNA	methyl	 transferases	 (DNMTs)	 covalently	modify	 the	 DNA	 base,	 cytosine,	 by	 forming	 5-methylcytosine	 (5mC).	 This	epigenetic	 modification	 results	 in	 a	 transcriptionally	 repressed	 state.	 Recent	work	has	 identified	 that	Ten-eleven	translocation	(TET)	enzymes	are	members	of	 the	 2-OG-DD	 family,	 capable	 of	 catalysing	 the	 oxidation	 of	 5mC	 to	 5-hydroxymethylcytosine	(5hmC).	Subsequent	oxidation	by	TET	enzymes	can	lead	to	 5-formyl	 cytosine	 (5fC)	 and	 5-	 carboxylcytosine	 (5caC),	 which	 may	 all	 be	recognised	by	different	DNA	binding	proteins	(Kohli	and	Zhang,	2013).		While	 TETs	 and	 JHDMs	 require	 oxygen	 for	 catalytic	 activity	 it	 has	 been	debated	 whether	 they	 respond	 to	 changes	 in	 oxygen	 availability	 in	 cells.	Originally,	 it	 was	 assumed	 that	 TETs	 and	 JHDMs	 functioned	 at	 lower	 oxygen	tensions	than	HIFs.	However,	recently	Thienpont	et	al,	have	shown	that	TETs	are	sensitive	to	oxygen	availability	and	that	decreased	availability	of	oxygen	leads	to	decreased	TET	 activity,	 independent	 of	 levels	 of	HIF	 or	 competing	metabolites	(Thienpont	et	al.,	2016).	
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1.4.6	Metabolic	regulation	of	PHDs	and	other	2-OG-dependent	dioxygenases	While	 the	 oxygen	 sensitivity	 of	 different	 2-OG-DDs	 is	 still	 debated,	 it	 is	increasingly	 evident	 that	 they	 are	 susceptible	 to	 changes	 in	 oxidative	phosphorylation	and	TCA	molecule	metabolites.	Oxidative	 phosphorylation	 occurs	 in	 mitochondria.	 Under	 aerobic	conditions,	 glucose	 is	 converted	 to	 pyruvate	 and	oxidatively	 decarboxylated	 to	form	Acetyl	CoA.	This	enters	 the	tricarboxylic	acid	(TCA)	cycle	 in	which	ATP	 is	generated	from	Acetyl	CoA	by	a	series	of	oxidation-reduction	reactions	(Figure	
1.8).	A	four	carbon	molecule,	oxaloacetate,	initiates	the	first	step	in	the	TCA	cycle	by	condensing	with	a	two	carbon	Acetyl	CoA	unit	to	 form	citrate.	The	6	carbon	citrate	is	oxidatively	decarboxylated	to	form	5	carbon	2-OG,	forming	NADH	and	releasing	CO2.	This	oxidative	decarboxylation	occurs	again	converting	5	carbon	2-OG	 to	 4	 carbon	 succinate,	 with	 the	 formation	 of	 NADH	 and	 release	 of	 CO2.	Oxaloacetate	is	regenerated	from	succinate	with	the	formation	of	NADH,	FADH2	and	 GTP.	 Electrons	 have	 therefore	 been	 removed	 from	 Acetyl	 CoA	 and	transferred	 to	 NADH	 and	 FADH2,	 these	 are	 then	 released	 by	 the	 electron	transport	chain	via	membrane	proteins	which	generate	a	proton	gradient	across	the	membrane	which	enables	formation	of	ATP	from	ADP	and	phosphate.														
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Figure 1.8: The TCA cycle. Schematic representation of the TCA cycle. Essentially, the 
oxidation of Acetyl-CoA drives NADH and small molecule metabolite precursors (e.g. 
succinate) for oxidative phosphorylation. NADH is produced by three enzymes within the TCA 
cycle: isocitrate dehydrogenase (IDH), the 2-oxoglutarate dehydrogenase complex (OGDHc), 
and malate dehydrogenase (MDH). NADH is also released by the pyruvate dehydrogenase 
complex (PDHc) with the conversion of pyruvate to acetyl-CoA. LDH=lactate dehydrogenase, 
FH=fumarate hydratase, SDH=succinate dehydrogenase.  
		 As	2-OG	 is	central	 to	 the	TCA	cycle,	 it	 is	possible	 that	alterations	 in	TCA	enzymes	change	the	cellular	abundance	of	2-OG	and	modulate	PHD	and	other	2-OG-DD	 activity.	 To	 explore	 this	 possibility,	 the	 Schofield	 group	 performed	biochemical	 experiments	 to	 investigate	whether	TCA	 intermediates	 are	 able	 to	bind	 to	 PHD2	 similarly	 to	 2-OG.	 TCA	 intermediates,	 including	 fumarate	 and	succinate,	 were	 incubated	 with	 recombinant	 PHD2181-426	 and	 Fe2+	 and	 the	complexes	formed	were	analysed	by	native	Electrospray	Ionisation	MS	(ESI-MS).	These	experiments	 showed	 that	 all	TCA	 intermediates	 except	oxaloacetate	 and	pyruvate	 were	 able	 to	 form	 a	 stable	 complex	 with	 the	 PHD2-HIF1αODD,.	However,	 when	 competition	 assays	 were	 performed	 in	 the	 presence	 of	 2-OG,	
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only	 fumarate	 and	 succinate	 could	 compete	with	 2-OG	 for	 active	 binding	 sites	(Hewitson	et	al.,	2007a).			In	 support	 of	 these	 biochemical	 findings,	 human	 germline	mutations	 in	TCA	 cycle	 enzymes,	 such	 as	 SDH,	 FH	 and	 IDH	 have	 been	 linked	 to	 tumour	formation,	potentially	through	their	metabolic	activation	of	HIFs	or	inhibition	of	other	 2-OG-DDs.	 Mutations	 in	 SDH	 are	 associated	 with	 development	 of	phaechromocytoma,	 paraganglionaoma	 (Eng	 et	 al.,	 2003;	 Pollard	 et	 al.,	 2005)	renal	 cell	 carcinoma	 and	 papillary	 thyroid	 cancer	 (Neumann	 et	 al.,	 2004).	Mutations	in	SDH,	which	catalyses	the	conversion	of	succinate	to	fumarate,	lead	to	 accumulation	 of	 succinate	 and	 subsequently	 HIF1	 stabilisation	 in	 normoxia	(Selak	 et	 al.,	 2005).	 Inhibition	 of	 SDH	 using	 SiRNA	 in	 HEK293T	 cells	 showed	stabilisation	 of	 HIF1α	 and	 activation	 of	 the	 HIF1α	 target	 gene	 BNIP3.	 In	 vitro	prolyl	 hydroxylation	 assays	 using	 recombinant	 HIF1αODD,	 cell	 extracts,	cofactors,	and	addition	of	either	succinate	or	the	iron	chelator,	DFO,	showed	by	immunoblot	 that	 increasing	 concentrations	 of	 succinate	 inhibited	 the	hydroxylation	 of	 HIF1α.	 Hence,	 SDH	 mutations	 lead	 to	 inhibition	 of	 PHD2,	causing	HIF1α	stabilization	thereby	enabling	angiogenesis	and	the	formation	of	angiogenic	tumours	(Selak	et	al.,	2005).		Mutations	 in	 FH,	which	 catalyses	 the	 conversion	 of	 fumarate	 to	malate,	are	 linked	to	 leiomyomatosis	and	renal	cell	carcinoma	(Pollard	et	al.,	2005).	As	fumarate	was	able	to	inhibit	PHD2	activity	in	2-OG	turnover	assays	(Hewitson	et	al.,	2007a),	it	was	possible	that	FH	mutations	lead	to	tumorigenesis	by	inhibition	of	PHD2	causing	HIF1α	stabilization,	similarly	to	succinate.	However,	the	Frezza	group	have	recently	shown	that	mutations	in	FH	lead	to	epigenetic	modification	involving	the	inhibition	of	TET-mediated	demethylation	of	the	regulatory	region	of	an	antimetastatic	mRNA,	thereby	increasing	cancer	metastasis,	independent	of	HIF1	(Sciacovelli	et	al.,	2016).	Mutations	in	IDH1	and	IDH2,	the	enzyme	which	catalyses	the	conversion	of	 isocitrate	 to	2-OG,	are	commonly	present	 in	gliomas	and	also	occur	 in	acute	myeloid	 leukaemia.	 IDH	 mutations	 have	 a	 reduced	 ability	 to	 catalyse	 the	conversion	of	isocitrate	to	2-OG,	thereby	decreasing	PHD	activity	and	stabilizing	HIF1α,	(Zhao	et	al.,	2009).	However,	Dang	et	al,	found	that	certain	glioblastoma	IDH	mutations	 (R132H)	 also	 led	 to	 the	 spurious	 formation	 of	 a	 metabolite	 of	
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unknown	physiological	 function,	 the	D	enantiomer	of	2-hydroxyglutarate	 (D-2-HG)	 (Dang	 et	 al.,	 2009).	 Paradoxically,	 this	 IDH1	 R132H	mutation	 resulted	 in	decreased	 levels	 of	HIF1α	 and	HIF2α	 (Koivunen	 et	 al.,	 2012),	 as	 the	 increased	levels	 of	 D-2-HG	 increased	 PHD2	 activity	 but	 inhibited	 other	 2-OG-DDs	(Koivunen	et	al.,	2012).		The	identification	of	D-2-HG	in	tumours	has	led	to	considerable	interest	in	enantiomers	of	this	metabolite.	2-hydroxyglutarate	(2-HG)	can	exist	in	both	the	L	and	D	 form	 in	metazoans.	 The	metabolite	 has	 traditionally	 been	 regarded	 as	 a	by-product	of	2-OG	metabolism	under	conditions	of	oxidative	damage,	as	human	germline	mutations	 in	 the	dehydrogenases	of	2-HG	(L-2-HGDH	and	D-2-HGDH)	cause	 inborn	 errors	 of	 metabolism	 characterized	 by	 neurological	 defects	 and	urinary	excretion	of	2-HG	(Oldham	et	al.,	2015).	Interestingly,	approximately	half	of	 all	 patients	 with	 D-2-HG	 aciduria	 have	 mutations	 in	 IDH2	 resulting	 in	 the	formation	of	D-2-HG	from	2-OG,	rather	than	mutations	in	D-2-HGDH	(Kranendijk	et	al.,	2012).	However	L-2-HG	aciduria	has	only	been	described	in	patients	with	mutations	in	L-2-HGDH.		Following	 the	 identification	 that	 D-2-HG	 can	 alter	 the	 activity	 of	 2-OG-DDs,	 biochemical	 studies	 on	 the	 enantiomeric	 forms	were	 undertaken.	 Studies	have	 shown	 that	 both	 D-2-HG	 and	 L-2-HG	 act	 as	 inhibitors	 of	 2-OG-DDs,	including	the	TET	methyl	cytosine	hydroxylases,	collagen	prolyl-4	hydroxylases	and	FIH	(Chowdhury	et	al.,	2011;	Figueroa	et	al.,	2010;	Xu	et	al.,	2011).	However,	the	2-HG	enantiomers	had	opposing	effects	on	PHD	enzymatic	function,	with	D-2-HG	increasing	PHD2	activity,	and	L-2-HG	marginally	decreasing	PHD2	function	(Koivunen	et	al.,	2012).		The	reasons	for	these	findings	are	not	fully	understood	but	 the	Schofield	group	have	suggested	 that	non-enzymatic	catalysis	of	D-2-HG	to	2-OG	may	occur	in	vitro	(mediated	by	ferrous-ferric	iron	and	reducing	agents	such	as	ascorbate)	promoting	PHD	function	(Tarhonskaya	et	al.,	2014).		Several	recent	cell	based	studies	confirmed	the	biochemical	observations	that	 L-2-HG	 could	 modulate	 the	 activity	 of	 some	 2-OG-DDs,	 and	 interestingly	identified	 a	 role	 for	 L-2-HG	 in	 hypoxia.	 Metabolomic	 analysis	 of	 pulmonary	arterial	and	smooth	muscle	cells	in	hypoxia	showed	an	increase	in	2-OG	and	L-2-HG	(Oldham	et	al.,	2015),	 and	 this	L-2-HG	accumulation	 in	hypoxia	was	due	 to	conversion	of	2-OG	to	L-2-HG	by	lactate	dehydrogenase	(Intlekofer	et	al.,	2015).	
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However,	neither	group	identified	a	role	for	L-2-HG	modulating	a	HIF	response	in	 cells,	 and	 prior	 to	 our	 studies,	 the	 role	 of	 the	 2-HG	 enantiomers	 in	 the	HIF	pathway	remained	controversial.			
1.4.7	Does	VHL	have	additional	functions	outside	of	the	HIF	pathway?	The	 efficient	 VHL-mediated	 degradation	 of	 HIF	 in	 normoxia	 is	 highly	important	 to	prevent	unwanted	activation	of	hypoxia-responsive	genes	 (Benita	et	 al.,	 2009;	 Berra	 et	 al.,	 2001).	 Moreover,	 the	 identification	 of	 germline	mutations	 in	VHL	and	cancer	somatic	mutations	highlight	 the	dominant	role	of	this	ligase	in	regulating	HIFs.		 Von	 Hippel-Lindau	 (VHL)	 disease	 is	 a	 dominantly	 inherited	 cancer	syndrome	characterised	by	angiogenic	tumours	including	renal	cell	carcinomas,	haemangioblastomas,	 phaeochromocytomas	 and	 pancreatic	 islet	 tumours	(Kaelin,	2008).	Hereditary	VHL	disease	 is	characterised	clinically	as	 type	1,	2A,	2B	and	2C,	where	type	1	patients	have	low	risk	of	phaechromocytoma	whereas	type	 2	 have	 high	 risk	 (Kaelin,	 2008).	 In	 addition,	 type	 2	 is	 subdivided	 into	 2A	with	 low	risk	of	 renal	 cell	 carcinoma	(RCC),	 type	2B	with	high	 risk	of	RCC	and	type	 2C	 with	 phaechromocytoma	 alone	 (Cowey	 and	 Rathmell,	 2009).	Interestingly,	 studies	 suggest	 that	 deregulation	 of	 HIF2α	 rather	 than	 HIF1α	 is	associated	with	VHL-null	RCC	tumorigenesis	(Kaelin,	2008),	as	tumour	formation	is	 suppressed	 in	 VHL-null	 RCCs	 depleted	 of	 HIF2α	 (Kondo	 et	 al.,	 2003).	Conversely,	overexpression	of	a	HIF2α	mutant	(P531A),	which	cannot	be	bound	by	 VHL,	 induced	 tumour	 formation	 in	 VHL	 reconstituted	 RCCs	 (Kondo	 et	 al.,	2002).	 However,	 in	 families	 with	 type	 2C	 VHL	 disease,	 characterised	 by	phaeochromocytoma	 alone,	 HIF	 regulation	 is	 unaffected	 (Clifford	 et	 al.,	 2001;	Hoffman	et	al.,	2001),	suggesting	that	VHL	may	have	additional	targets	to	HIFs.	Furthermore,	the	observations	that	PHD	mutations	activate	HIF	target	genes	but	do	 not	 lead	 to	 tumour	 formation	 supports	 the	 notion	 that	 VHL	 must	 have	additional	functions	aside	from	HIF	regulation.		Several	 studies	 have	 attempted	 to	 assign	 novel	 functions	 to	 VHL	 to	explain	 these	observations.	One	possible	mechanism	 is	 that	VHL	 is	 required	 to	inhibit	 Akt	 kinase	 activity.	 Akt	 is	 a	 serine-threonine	 kinase	 which	 promotes	
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cancer	survival	and	proliferation,	 including	in	renal	cell	carcinomas	where	VHL	is	 defective	 (Hager	 et	 al.,	 2009).	 Guo	 et	 al	 showed	 that	 Akt	 undergoes	 prolyl	hydroxylation	 by	 PHD	 and	 the	 subsequent	 binding	 of	 VHL	 inhibits	 Akt	 kinase	activity	(Guo	et	al.,	2016).	In	addition,	VHL	has	been	implicated	in	lactate	sensing	(Lee	et	al.,	2015).	Lee	et	al	have	shown	that	lactate,	an	anaerobic	metabolite,	can	promote	a	HIF-independent	hypoxic	response.	In	normoxia,	N-myc	downstream-regulated	 gene	 3	 protein	 (NDRG3)	 is	 hydroxylated	 and	ubiquitinated	 by	PHD2	and	VHL,	leading	to	its	proteasome-mediated	degradation.	However,	in	hypoxia,	lactate	 accumulates	 via	 anaerobic	 respiration	 and	 binds	NDRG3	 preventing	 its	degradation.	 NDRG3	 then	 binds	 c-Raf	 leading	 to	 activation	 of	 the	 Raf-ERK	pathway	thereby	triggering	angiogenesis	and	cell	growth	in	response	to	hypoxia	(Lee	 et	 al.,	 2015).	 It	 is	 still	 possible	 that	 VHL	 may	 have	 additional	 functions	outside	 of	 HIF	 and	 lactate	 signalling,	 relating	 to	 its	 ability	 to	 recognise	 prolyl-hydroxylated	motifs	in	proteins.		
	
1.4.8	Does	proteasome	independent	degradation	of	HIFα 	occur?	
	 The	 proteasomal	 degradation	 of	 HIF1α	 by	 VHL	 ubiquitination	 is	 well	characterised,	 however	 a	 longstanding,	 intriguing	 observation	 is	 that	 HIF1α	 is	stabilised	by	Bafilomycin	A	(Baf	A),	a	lysosomal	inhibitor	which	acts	by	inhibition	of	 the	 V-ATPase	 (Lim	 et	 al.,	 2006).	 It	 has	 been	 suggested	 that	 this	 HIF1α	stabilisation	 by	Baf	A	 is	mediated	 by	 the	V-ATPase	 binding	 to	VHL	 (Lim	 et	 al.,	2007),	mitochondrial	uncoupling	(Zhdanov	et	al.,	2012)	or	chaperone-mediated	autophagy	(Bremm	et	al.,	2014;	Ferreira	et	al.,	2015;	Hubbi	et	al.,	2014;	Hubbi	et	al.,	 2013;	 Selfridge	 et	 al.,	 2016).	 However,	 it	 is	 difficult	 to	 reconcile	 this	hypothesis	 with	 the	 observations	 that	 HIFα	 is	 completely	 stabilised	 by	proteasome	inhibition.		In	addition	to	the	proteasome-independent	degradation	of	HIFα,	there	is	evidence	that	VHL	may	not	be	the	only	ligase	implicated	in	regulation	of	the	HIF	response	as	Ferreira	et	al,	suggest	 that	HIF1	may	be	 lysosomally	degraded	 in	a	VHL-independent	 fashion	 by	 the	 E3	 ligase,	 CHIP	 (Stub1),	 leading	 to	 CMA	(Ferreira	et	al.,	2015).		This	observation	suggests	that	ubiquitinated	HIFα	may	be	prone	to	aggregrate	formation,	and	in	support	of	this	the	Deshaies	lab	observed	
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that	 P97,	 the	 AAA	 ATPase	 required	 for	 extracting	 ubiquitinated	 proteins	 from	membrane	or	complexes,	was	required	for	HIF1α	degradation	(Alexandru	et	al.,	2008).	It	is	therefore	plausible	that	HIF1α	is	not	only	degraded	in	a	proteasome-independent	 manner,	 but	 that	 many	 other	 ubiquitin	 enzymes	 may	 also	 be	involved	in	its	regulation.		
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1.5	Aims	of	this	thesis		 My	project	aims	were	to	determine	how	different	types	of	K11-polyubiquitin	conjugates	 interact	 with	 the	 26S	 proteasome,	 and	 to	 examine	 whether	 K11-linkages	are	recognised	by	specific	UBPs.	Furthermore,	 I	wanted	to	 identify	the	functional	 outcome	 of	 K11-chains	 by	 focussing	 on	 the	 hypoxia	 inducible	transcription	factor	(HIF)	pathway.	Specifically,	my	aims	were	to:	I) Establish	in	vitro	systems	to	generate	K11-polyubiquitin	chains.	II) Determine	 if	 K11-linked	 polyubiquitin	 chains	 are	 a	 signal	 for	proteasomal	degradation.	III) Elucidate	which	UBPs	bind	to	lysine-11	linked	polyubiquitin	chains.	IV) Establish	 in	 vitro	 assays	 to	 measure	 HIFα	 prolyl	 hydroxylation	 and	ubiquitination.	V) Determine	 which	 ubiquitin	 chain	 types	 were	 formed	 on	 HIF1α	 in	normoxia.					 	
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 Chapter	2:	Materials	and	Methods	
	
2.1	Antibodies	and	Reagents	The	 following	 primary	 antibodies	 were	 used:	 Mouse	 monoclonal	 to	 Ub	(P4D1,	Santa	Cruz);	mouse	monoclonal	to	proteasome	20S	α	subunits	(MCP231,	Enzo	 Life	 Sciences);	 mouse	monoclonal	 to	 cyclin	 B1	 (BD	 Pharmingen),	 mouse	monoclonal	 to	 cdc27	 (AF3.1,	 Santa	 Cruz);	 rabbit	 polyclonal	 to	 USP5	 (Bethyl	Laboratories),	mouse	monoclonal	to	Rpn10	(S5a-­18,	Enzo	Life	Sciences);	rabbit	monoclonal	 to	UBQLN1	(Cell	Signaling);	mouse	monoclonal	 to	ubiquitin	(P4D1,	sc-8017	 Santa	 Cruz	 Biotechnology);	 mouse	 monoclonal	 to	 ubiquitin	 (FK2,	 ST-1200	Calbiochem,);	affinity	purified	rabbit	polyclonal	antibodies	to	MyosinVI	and	Tax1BP1	(generated	by	the	Buss	laboratory	(Buss	et	al.,	1998;	Morriswood	et	al.,	2007;	 Sahlender	 et	 al.,	 2005));	 rabbit	 polyclonal	 to	 hydroxyl-proline	 HIF1α	(3434,	 Cell	 Signaling);	mouse	monoclonal	 to	HIF1α	 (610959,	 BD	Transduction	laboratories);	 rabbit	 polyclonal	 to	 HIF1α	 (sc-10790,	 Santa	 Cruz);	 rabbit	polyclonal	 to	 OGDH	 (HPA020347,	 Atlas);	 rabbit	 polyclonal	 to	 Lipoic	 acid	(437695,	 Calbiochem);	 mouse	 monoclonal	 to	 βactin	 (A228,	 Sigma);	 rabbit	polyclonal	to	PHD2	(NB100-137,	NovusBio);	rabbit	polyclonal	to	HIF2α	(ab199,	Abcam).	The	 following	 secondary	 antibodies	 were	 used:	 Goat	 anti-mouse	 HRP	(115-035-146,	Jackson);	goat	anti-rabbit	HRP	(111-035-045,	Jackson).			 The	 following	 reagents	were	 used:	 Ubiquitin	 (Boston	 Biochem);	Methyl	ubiquitin	 (Boston	 Biochem);	 MG132	 (Sigma	 Aldrich,);	 Bafilomycin	 A1	 (Alfa	Aesar,	 J61835);	 DMOG	 (Sigma-Aldrich,	 D6395);	 DFO	 (Sigma-Aldrich,	 D9533);	(D)-2-HG	 (Sigma-Aldrich,	 H8378);	 (L)-2-HG	 (Sigma-Aldrich,	 90790);	 α-ketoglutaric	 acid	 (Sigma-Aldrich,	 K1128);	 Sodium	 oxamate	 (Sigma-Aldrich,	O2751);	Iron	II	Choride	(Sigma-Aldrich,	372870).			 	
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2.2	Molecular	Biology	
2.2.1	Plasmids.			The	 following	 plasmids	 were	 kind	 gifts	 from	 Fred	 Goldberg:	pET26bHis10-UIM2-S5a	 (UIM	 of	 Rpn10/S5a),	 pDEST15-UBL-hHR23B,	 pGEX	GST-E6AP,	pGEX	GST-Nedd4,	pGEX4	T2	GST-RAD23B,	pET15b-E1,	pET15b-His-Ubch5b	(Besche	et	al.,	2009;	Nathan	et	al.,	2013).	pGEX-6P-1	GST-AMSH	(gift	from	Sylvie	Urbe),	pET28his-Ube2S	(gift	from	Mark	Kirschner),	 pET28a	HA-WT	Ncyclin	B1-6His	 pET28a	 and	HA-WT	Ncyclin	B1	 K64	 -6His	 (gifts	 from	 Randall	 King),	 pGEX	 PreScission	 (gift	 from	 Lauren	Jackson),	 pCDNA3	 HIF1α-HA	 (gift	 from	 Patrick	 Maxwell),	 and	 pHRSIN-pSFFV-HIF2α-Puro	(made	by	Peter	Bailey,	Nathan	lab).	pET47b	KanR	N	term	His	tag	3C		and	 pET49b	 KanR	 N	 term	 GST	 tag	 3C	 (gift	 from	 Vangelis	 Christodoulou	 and	Katrin	Rittinger).		
2.2.2	Plasmids	generated	using	standard	restriction	enzyme	cloning.			
pGEX-6P-1	 GST-Ube2SΔ.	 His-Ube2S	 was	 a	 gift	 from	 Marc	 Kirschner	(Harvard	 Medical	 School).	 GST-Ube2SΔ	 was	 formed	 by	 cloning	 DNA	 encoding	residues	1	to	196	of	Ube2S	into	the	bacterial	expression	vector	pGEX-6P-1,	using	the	following	primers:	Ube2S	BamH1	For	CGGGA	TCCAACTCCAACGTGGAGAACC	and	Ube2S	Not1	Rev	TTGCGGCCGCCTACTTGGCCATGGGACCCTCA.	All	PCRs	were	performed	according	to	the	manufacturer’s	protocols	using	Phusion	(NEB)	polymerase.	The	following	reactions	were	typically	used.		 	 	 	 	 	 	 		5X	Phusion	GC	buffer	 	 4µl	 	 1X	10mM	dNTPs		 	 	 0.4µl	 	 200µM	each	template	DNA	 	 	 0.5µl	Forward	primer	(10µM)	 	 1µl	 	 0.5µM	Reverse	primer		(10µM)	 	 1µl	 	 0.5µM	DMSO	 	 	 	 	 0.6µl	 	 3%	Phusion	DNA	polymerase	(NEB)	 0.2µl	 	 0.02U/µl	
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	 Correct	 insertions	 were	 identified	 by	 restriction	 digest	 and	 verified	 by	sequencing	(Source	Bioscience).	The	pCR	TOPO	vectors	were	then	digested	with	the	 respective	 restriction	 enzymes	 and	 the	 inserts	 ligated	 into	 the	 pGEX-6P-1	backbone	 (antarctic	 phosphatase	 treated)	 following	 gel	 purification	 using	 the	Roche	rapid	ligation	kit:			0.5µl	rapid	T4	ligase	5µl	2x	buffer	3.5µl	insert	1µl	vector		 	pGEX-6P-1	GST-Ube2SUBD	was	generated	by	James	Nathan	(Grice	et	al.,	2015)	using	the	UBD	from	USP5,	similarly	to	the	methods	described	by	Bremm	et	al	(Bremm	et	al.,	2010).		
		
GST-FAM115A	 or	 His-FAM115A	 constructs.	 FAM115A	 full	 length	 (FL),	the	 flavodoxin-like	 fold	 (FD)	 and	 putative	 protease	 domain	 (M60)	 were	amplified	by	PCR	 from	 the	 IMAGE	clone	 template	pOTB7	FAM115A	(IMAGE	 ID	3346754,	Source	Bioscience).	 	For	 the	GST-tagged	versions	 in	pGEX-6P-1	a	5’	BamHI	site	and	a	3’	NotI	site	were	 used.	 For	 the	 His-tagged	 versions	 in	 pET15b	 a	 5’	 NdeI	 site	 and	 a	 3’	BamHI	 site	 were	 used.	 The	 PCR	 products	 were	 ligated	 into	 pCR	 TOPO	 Blunt	(Invitrogen)	 as	 a	 subcloning	 and	 sequencing	 vector.	 Correct	 insertions	 were	identified	by	 restriction	digest	 and	verified	by	 sequencing	 (Source	Bioscience).	The	 pCR	 TOPO	 vectors	 were	 then	 digested	 with	 the	 respective	 restriction	enzymes	 and	 the	 inserts	 ligated	 into	 the	 pGEX-6P-1	 or	 PET15b	 backbone	(antarctic	phosphatase	treated)	following	gel	purification	using	the	Roche	rapid	ligation	kit.		
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2.2.3	Ligation	Independent	Cloning	(also	described	in	Chapter	5.2.1)	All	 the	 primers	 designed	 for	 Ligation	 Independent	 Cloning	 are	 listed	 in	
Appendix	1.	
GST	 or	 His	 tagged	 FAM115A.	 Primers	 were	 designed	 with	 extensions	homologous	to	the	LIC	vector,	pET47b	KanR	N	term	His	tag	3C	or	pET49b	KanR	pET49b	KanR	N	term	GST	tag	3C.	Forward	primer:	5’	CAG	GGA	CCC	CGT-specific	FAM115A	 sequence	 3’	 and	 reverse	 primer:	 5’	 GGC	 ACC	 AGA	 GCGTTA–specific	FAM115A	sequence	3’.	Primers	were	designed	to	two	regions	of	FAM115A:	the	FD-like	region	and	M60	region.	This	resulted	in	48	primer	pairs	for	each	region.	These	 were	 separated	 by	 1%	 agarose	 DNA	 gel	 electrophoresis	 at	 100V	 and	analysed	 by	 ChemiDoc.	 These	 primer	 pairs	were	 expanded	 by	 sequential	 PCR.		10μg	LIC	vector	was	 linearised	using	50U	KpnI	(NEB),	50U	SacI	(NEB),	1X	NEB	1.1	 buffer	 (NEB)	 in	 100μl	 reaction	 at	 37°C	 for	 3	 hr.	 Both	 LIC	 vector	 and	 PCR	products	 were	 PCR	 purified	 (Qiagen	 QIA	 Quick	 spin	 column	 kit)	 according	 to	manufacturer’s	instructions.	Both	the	linearised	vector	and	PCR	product	was	T4	DNA	polymerase	treated	as	follows:	0.01pmol	PCR	product	in	EB	buffer	(10mM	Tris-HCl	pH8.0),	 1X	T4	DNA	Polymerase	Buffer	 (NEB),	 6U	T4	DNA	Polymerase	(NEB)	and	2.5mM	dATP	(NEB)	was	incubated	at	22°C	30	min,	75°C	20	min	in	a	PCR	thermocycler;	1.5μg	linearised	vector,	1X	T4	DNA	Polymerase	buffer	(NEB),	3U	 T4	 DNA	 Polymerase	 (NEB)	 and	 2.5mM	 dTTP	 (NEB)	 was	 incubated	 as	described	 for	 PCR	 insert	 above.	 The	 LIC	 vector	 and	 PCR	 products	 were	 then	annealed	as	follows;	50ng	vector	was	added	to	0.02	pmol	insert	and	incubated	at	22°C	 for	 5	 min	 in	 a	 PCR	 thermocycler	 then	 6.2mM	 EDTA	 was	 added	 and	 the	mixture	 incubated	 for	 a	 further	 5min.	 As	 there	 were	 several	 inserts,	 this	 was	performed	 in	 a	 96	 well	 format.	 	 Annealed	 vector	 and	 insert	 were	 then	transformed	into	BL21	DE3*	Gold	E.	coli	as	described	below.	
	
His-HIF1αODD.	 His-HIF1αODD	 primers	 were	 designed	 with	 extensions	homologous	 to	 the	pET47b	LIC	 vector.	 Forward	primer:	 5’	 CAG	GGA	CCC	CGT-specific	HIF1α	sequence	3’	and	reverse	primer:	5’	GGC	ACC	AGA	GCGTTA-specific	HIF1α	 sequence	 3’.	 Primers	 were	 designed	 to	 include	 the	 Oxygen	 Dependent	Degradation	 domain	 and	 this	 resulted	 in	 8	 primer	 pairs.	 The	 vector	 was	
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linearised,	 vector	 and	 PCR	products	 purified,	 T4	DNA	polymerase	 treated,	 and	annealed	using	methods	described	above.	
	
GST-HIF1αODD.	Primers	were	designed	with	extensions	homologous	to	the	pET49b	 LIC	 vector.	 Forward	 primer:	 5’	 CAG	 GGA	 CCC	 CGT-specific	 HIF1α	sequence	 3’	 and	 reverse	 primer:	 5’	 GGC	 ACC	 AGA	 GCGTTA-specific	 HIF1α	sequence	 3’.	 Primers	 were	 designed	 to	 include	 the	 Oxygen	 Dependent	Degradation	 domain	 and	 this	 resulted	 in	 8	 primer	 pairs.	 The	 vector	 was	linearised,	vector	and	PCR	products	were	purified,	T4	DNA	polymerase	treated,	and	annealed	using	methods	described.		
His-HIF2αODD.	HIF2α	primers	were	designed	with	extensions	homologous	to	the	pET47b	LIC	vector.	Forward	primer:	5’	CAG	GGA	CCC	CGT-specific	HIF2α	sequence	 3’	 and	 reverse	 primer:	 5’	 GGC	 ACC	 AGA	 GCGTTA–specific	 HIF2α	sequence	 3’.	 Primers	 were	 designed	 to	 include	 the	 Oxygen	 Dependent	Degradation	 domain	 and	 this	 resulted	 in	 8	 primer	 pairs.	 The	 vector	 was	linearised,	vector	and	PCR	products	were	purified,	T4	DNA	polymerase	treated,	and	annealed	as	described.		
2.3		Biochemistry	
2.3.1	SDS-PAGE	and	immunoblotting		 Proteins	were	visualised	by	heating	with	6x	SDS	loading	buffer	at	90°C	for	5	min	and	separating	by	SDS-PAGE	electrophoresis	using	Tris	Glycine	buffer	at	200V.	 Total	 protein	 was	 analysed	 using	 Simply	 Safe	 Blue	 Coomassie	 Stain	(Thermofisher).		 Immunoblotting	was	 performed	by	 transferring	 protein	 from	 SDS-PAGE	gel	 to	 PVDF	 membrane	 at	 100V	 for	 1	 hr	 and	 visualising	 specific	 proteins	 by	incubation	with	primary	antibody	conjugated	to	Horse	Radish	Peroxidase	(HRP)	or	 subsequent	 incubation	 with	 secondary	 antibody	 conjugated	 to	 HRP	 as	specified	 in	the	text.	The	membrane	was	 incubated	with	SuperSignal	West	Pico	or	 Dura	 Enhanced	 Chemiluminescent	 Substrate	 (Thermofisher)	 for	 5	 min,	
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washed	 twice	with	 0.2%	 PBST	 for	 5	min	 and	 chemifluorescence	 visualised	 by	radiography	using	X-ray	film	(Fuji	Film).		
2.3.2	High	throughput	protein	expression	of	GST-FAM115A	in	E.	coli	using	LIC	
and	protein	purification	
GST-FAM115A.	pET47b	GST-FAM115A	was	transformed	into	BL21	DE3*	Gold	E.	coli	at	4°C	for	10min,	42°C	for	25	sec,	4°C	30	sec	and	then	SOC	medium	added	and	 the	culture	 incubated	37°C	 for	1	hr	 in	a	shaking	 incubator.	Cultures	were	 then	 plated	 onto	 warmed	 agar	 plates	 containing	 30μg/ml	 kanamycin	 at	37°C	 for	18	hr.	Two	 colonies	were	 grown	per	 construct	 in	deep	well	 blocks	 in	enriched	media	 (10mg/ml	N-Z-amine	AS,	 5mg/ml	 yeast	 extract,	 50mM	MgSO4,	50mM	 PO4,	 50mM	 NH4Cl,	 5mM	 Na2SO4,	 0.5%	 glycerol,	 0.05%	 glucose)	 and	protein	expression	was	 induced	using	0.5mM	IPTG	at	20°C	overnight.	 	Cultures	were	 lysed	 in	 situ	 using	 lysozyme	 and	 DNAaseI	 and	 lysates	 added	 to	 filter	columns	 capable	 of	 binding	 His,	 GST	 and	 Strep	 tags.	 Bound	 proteins	 were	washed	and	eluted	before	protein	concentration	was	assessed	by	SDS-PAGE	and	stained	with	Coomassie.	
2.3.3	Bacterial	protein	expression	and	purification.	
GST-E6AP.	 pGEX	 GST-E6AP	 was	 transformed	 into	 BL21	 DE3*	 E.	 coli	 as	described,	and	plated	onto	warmed	agar	plates	containing	100μg/ml	ampicillin	37°C	 incubator	 overnight.	 Two	 colonies	 were	 grown	 in	 5ml	 LB,	 100μg/ml	ampicillin	at	37°C	for	7	hr	in	shaking	incubator.	5	ml	culture	was	added	to	50	ml	LB,	100μg/ml	ampicillin	at	37°C	overnight	in	shaking	incubator.	10	ml	overnight	culture	was	 added	 to	 1l	 LB,	 100μg/ml	 ampicillin	 at	 37°C	 in	 shaking	 incubator	until	 OD	 0.4-0.6,	 measured	 by	 nanodrop.	 Protein	 synthesis	 was	 then	 induced	with	0.1mM	IPTG	16°C	overnight.	Cultures	were	centrifuged	4,500rpm	10	min	at	4°C	 and	 pellets	 washed	 in	 PBS,	 1mM	 DTT,	 transferred	 to	 50ml	 falcon	 and	centrifuged	 at	 3,750rpm	 at	 4°C	 for	 30min	 (Beckmann	 8:1000),	 before	 being	stored	at	-80°C.	The	cell	pellet	was	thawed	on	ice	and	resuspended	in	20ml	PBS,	1mM	DTT.	Cells	were	vortexed	to	ensure	they	were	fully	resuspended	and	30ml	PBS,	 1mM	 DTT	 added.	 50ml	 resuspended	 cells	 were	 lysed	 in	 cell	 disruptor	30,000	 PSI	 resulting	 in	 100ml	 final	 volume.	 Lysed	 cells	 were	 centrifuged	 at	
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30,000rpm	at	4°C	for	1	hr	(Beckmann	45Ti).	Supernatants	were	passed	through	a	 45μM	 filter	 and	 incubated	 with	 3ml	 equilibrated	 GSH	 Sepharose	 slurry	 (1:1	resin:	PBS,	1mM	DTT)	 for	2	hr	at	4°C	on	rotator.	Purification	was	continued	 in	4°C	cold	room	and	the	resin/	filtered	lysate	suspension	was	then	passed	over	a	20	ml	filter	column	(Biorad),	and	the	flow	through	(FT)	collected.	The	resin	was	washed	in	3	x	20ml	PBS	with	1mM	DTT,	followed	by	2	x	20ml	TBS	(1mM	DTT_.	Finally,	the	washed	resin	with	E6AP	bound	was	resuspended	in	3.5ml	TBS,	with		1mM	DTT,		and	10%	glycerol.	200l	aliquots	were	stored	at	-80°C.		
GST-Nedd4.	pGEX	GST-Nedd4	was	transformed,	expressed	and	purified	as	described	for	GST-E6AP	above.		
His-UbcH5b.	His-UbcH5b	 was	 transformed	 and	 expressed	 as	 described	for	 GST-E6AP	 to	 the	 point	 of	 cell	 lysis,	 with	 the	 following	 exception:	 protein	expression	was	induced	with	0.5mM	IPTG	for	3	hr	at	37°C	in	shaking	incubator.	Cell	 pellets	 were	 lysed	 in	 Binding	 Buffer	 (25mM	 Hepes	 pH	 7.5,	 500mM	 NaCl,	1mM	 DTT,	 20mM	 imidazole)	 in	 the	 cell	 disruptor	 as	 described	 for	 GST-E6AP.	Lysed	 cells	 were	 centrifuged	 at	 30,000rpm	 at	 4°C	 for	 1	 hr	 (Beckmann	 45Ti).	Supernatants	 were	 passed	 through	 a	 0.45μm	 filter	 and	 incubated	 with	 2ml	equilibrated	NiNTA	resin	 in	100ml	bottle	with	magnetic	 stirrer	at	4°C	 for	2	hr.	Purification	 was	 continued	 in	 4°C	 cold	 room.	 The	 resin/filtered	 lysate	suspension	was	passed	over	a	20ml	filter	column	(Biorad)	and	the	flow	through	(FT)	 collected.	 Resins	 were	washed	 in	 20ml	 Elution	 Buffer	 50mM	 (EB:	 25mM	Hepes	pH	7.5,	500mM	NaCl,	1mM	DTT,	0.025%	NP-40,	50mM	imidazole)	to	elute	bacterial	chaperones.	UbcH5b	was	eluted	in	12ml	EB	100mM	(25mM	Hepes	pH	7.5,	 500mM	 NaCl,	 1mM	 DTT,	 0.025%	 NP-40,	 100mM	 imidazole)	 and	 1ml	fractions	collected	in	1.5ml	eppendorfs	until	no	protein	was	no	longer	detected	in	the	eluate	(tested	by	Bradford	reagent	(Biorad)).	This	procedure	was	repeated	with	EB	200mM	(25mM	Hepes	pH	7.5,	500mM	NaCl,	1mM	DTT,	0.025%	NP-40,	200mM	imidazole)	and	1ml	fractions	collected	in	1.5ml	eppendorfs.	Finally,	the	resin	was	washed	in	EB	500mM	(25mM	Hepes	pH	7.5,	500mM	NaCl,	1mM	DTT,	0.025%	 NP-40,	 500mM	 imidazole)	 to	 remove	 all	 bound	 proteins.	 Protein	concentration	was	assessed	by	SDS-PAGE	and	 fractions	 containing	His-UbcH5b	
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at	 around	 17kDa	 were	 pooled	 in	 10,000MWCO	 Snakeskin	 dialysis	 membrane	(Pierce)	 and	 dialysed	 against	 1l	 HEPES	 buffer	 (20mM	 HEPES	 pH	 7.5,	 10%	glycerol,	 150mM	 NaCl,	 5mM	 MgCl2,	 1mM	 DTT)	 overnight	 4°C	 with	 magnetic	stirrer	and	repeated	for	2	hr	in	1l	fresh	HEPES	buffer	the	following	day.	Protein	purity	 was	 assessed	 by	 SDS-PAGE,	 protein	 concentration	 was	 assessed	 by	nanodrop,	and	aliquots	were	stored	at	-80°C.		
His-Ube2S.	 His-Ube2S	 was	 transformed,	 expressed	 and	 purified	 as	described	for	His-UbcH5b.		
GST-tagged	Ube2SΔ	and	Ube2SUBD.	A	truncation	mutant	of	Ube2S,	or	a	similar	truncation	fused	to	the	UBD	of	USP5	were	expressed	in	BL21	DE3*	E.	coli	and	induced	using	0.1mM	IPTG	16°C	O/N.	GST-Ube2SΔ	was	purified	as	for	GST-E6AP.	For	the	Ube2SUBD	protein,	the	cells	were	lysed	in	270mM	Sucrose,	50mM	Tris	 pH7.5,	 1mM	DTT	and	1	 tablet	Roche	EDTA	 free	protease	 cocktail	 in	 50ml	using	 a	 cell	 disruptor	 (30,000Psi	 lysis,	 15,000Psi	 washes),	 and	 centrifuged	 at	30,000rpm	 for	45	min	at	4°C.	The	 supernatants	were	 filtered	 through	a	0.2μm	filter	and	incubated	with	2	ml	equilibrated	GSH	Sepharose	resin	(GE	Healthcare)	2	hr	4°C.	The	resins	were	then	washed	with	100ml	high	salt	buffer	(500mM	NaCl,	25mM	 Tris-HCl	 pH7.5,	 1mM	 DTT)	 and	 100ml	 low	 salt	 buffer	 (150mM	 NaCl,	25mM	 Tris-HCl	 pH7.5,	 1mM	 DTT)	 and	 incubated	 with	 1.2mg/ml	 PreScission	protease	(GE	Healthcare)	on	rotator	4°C	overnight.	The	suspension	was	applied	to	a	20ml	Biorad	column	and	the	PreScission-cleaved	Ube2SUBD	was	collected.	The	resin	was	washed	with	5ml	low	salt	buffer	and	the	eluate	collected	until	no	further	protein	was	present	(assessed	by	Bradford	reagent	(Biorad)).	The	eluted	and	cleaved	Ube2SUBD	was	concentrated	to	half	original	volume	using	Vivaspin	10,000MWCO	column	and	assessed	by	nanodrop	and	SDS-PAGE.	Aliquots	were	stored	at	 -80°C.	This	 technique	was	modified	 from	Bremm	et	al,	 (Bremm	et	al.,	2010).		
GST-AMSH.	pGEX6P1-AMSH	was	a	kind	gift	from	Sylvie	Urbe	(University	of	 Liverpool).	The	protein	was	 expressed	and	purified	 as	 for	GST-Ube2SΔ,	 and	PreScission	protease	cleavage	was	used	to	cleave	the	N-terminal	GST	tag.	
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		 GST-CyB1-NTK64.	An	N-terminal	peptide	of	Cyclin	B1	with	a	single	 lysine	at	64	and	GST	tag	(CyB1-NTK64)	was	generated	from	the	CyB1-NTK64-His	tagged	vector,	which	was	a	gift	from	Randall	King	(Harvard	Medical	School)(Dimova	et	al.,	 2012).	 	 This	 construct	was	 transformed	 and	 expressed	 in	BL21	DE3*	E.	coli	and	the	cells	were	induced	using	0.5mM	IPTG	37°C	for	3hr.	The	cells	were	lysed	in	 25mM	 Hepes	 pH7.4,	 500mM	 NaCl,	 1mM	 DTT,	 0.025%	 NP40	 and	 20mM	imidazole	 using	 cell	 disruptor,	 (30,000Psi	 lysis,	 15,000Psi	 washes)	 and	centrifuged	 30,000rpm	 45min	 4°C.	 The	 supernatant	 was	 filtered	 through	 a	0.2μm	 filter	 and	 CyB1-NTK64	purified	 using	 a	 HT	 Trap	 crude	 3ml	 column	 (GE	Healthcare),	 at	 0.5ml/min	 into	 25mM	 Hepes	 pH7.4,	 500mM	 NaCl,	 1mM	 DTT,	0.025%	NP40	and	500mM	Imidazole.	0.5ml	fractions	were	collected	in	a	96	well	plate	and	protein	concentration	was	assessed	by	SDS-PAGE.	Fractions	containing	CyB1-NTK64	at	36kDa,	 were	 pooled	 and	 dialysed	 against	 20mM	 Hepes	 pH	 7.2,	10%	glycerol,	150mM	NaCl,	5mM	MgCl2	and	1mM	DTT	at	4°C	using	3,000MWCO	Snakeskin	dialysis	 tubing	(Pierce.)	CyB1-NTK64	was	concentrated	using	Vivaspin	15,000MWCO	 centrifugal	 filter	 columns	 (Millipore)	 until	 desired	 concentration	achieved	 and	 assessed	 by	 nanodrop	 and	 SDS-PAGE.	 Aliquots	 were	 stored	 at	 -80°C.	
	
GST-PreScission.		pGEX	PreScission		was	a	kind	gift	from	Lauren	Jackson	(University	of	Vanderbilt).	The	protein	was	transformed,	expressed	and	purified	as	described	for	GST-CyB1-NTK64	above.		
His-HIF1α	solubility	testing.	Two	colonies	were	grown	per	construct	 in	5ml	 LB	 broth	 with	 50μg/ml	 kanamycin	 and	 protein	 synthesis	 induced	 using	either	 0.5mM	 IPTG	 at	 37°C	 for	 3h	 or	 0.1mM	 IPTG	 at	 20°C	 overnight.	 Pre	 and	post-induction	cultures	were	centrifuged	and	cell	pellets	lysed	using	freeze/thaw	lysis	in	100μl	E.	coli	lysis	buffer	(20mM	Tris-HCl	pH8.0,	DNAaseI	(Sigma-Aldrich),	lysozyme	(Sigma-Aldrich).)	The	lysate	was	then	divided	in	two:	50μl	was	kept	as	the	whole	lysate	and	50μl	was	centrifuged	14,000rpm	5min	to	separate	soluble	and	 insoluble	 fractions.	 All	 samples	 were	 analysed	 by	 SDS-PAGE	 and	 stained	
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with	Coomassie	blue.	His-HIF1αODD530-652	was	chosen	for	large-scale	purification	due	to	its	solubility	and	size.			
His-HIF1αODD530-652.	 A	 His-tagged	 protein	 encoding	 residues	 530-652	 of	hHIF1α	was	expressed	in	BL21	DE3*	E.	coli	and	induced	using	0.5mM	IPTG	37°C	for	3hr.	Cells	were	lysed	in	TBS	(20mM	Tris-HCl	pH	7.4,	150mM	NaCl,	1mM	DTT)	in	 50ml	 using	 a	 cell	 disruptor,	 (30,000Psi	 lysis,	 15,000Psi	 washes)	 and	centrifuged	 at	 30,000	 rpm	 for	 45min	 at	 4°C.	 The	 supernatants	 were	 filtered	through	a	0.2μm	filter	and	 incubated	with	500μl	equilibrated	NiNTA	resin	2	hr	4°C	on	a	rotator.	The	suspension	was	applied	to	20ml	filter	column	(Biorad)	and	resins	were	washed	in	20	ml	TBS.	Protein	was	eluted	in	15ml	TBS	with	200mM	imidazole	 and	1ml	 fractions	were	 collected.	 	 Protein	was	 then	 eluted	 in	 15	ml	TBS	with	500mM	imidazole	and	the	eluate	collected	until	no	further	protein	was	present	(assessed	by	Bradford	reagent	(Biorad)).	Protein	purity	was	assessed	by	SDS-PAGE.	 Fractions	 containing	 His-HIF1αODD530-652	 at	between	 16	 and	 22kDa,	were	 pooled	 and	 dialysed	 against	 TBS	 at	 4°C	 using	 10,000MWCO	 Snakeskin	dialysis	 tubing	 (Pierce.)	 His-HIF1αODD530-652	 was	 concentrated	 using	 Vivaspin	15,000MWCO	 centrifugal	 filter	 columns	 (Millipore)	 until	 desired	 concentration	achieved	and	assessed	by	nanodrop	and	SDS-PAGE.	10%	glycerol	was	added	to	the	protein	before	aliquoting	and	storage	at	-80°C.	
	
GST-HIF1α	 solubility	 testing.	Two	 colonies	 were	 grown	 per	 construct,	expressed,	 lysed	 and	 analysed	 by	 SDS-PAGE	 as	 described	 for	 His-HIF1α	
solubility	 testing	 above.	 GST-HIF1αODD401-652	 was	 chosen	 for	 large-scale	purification	due	to	its	solubility	and	size.				 GST-HIF1αODD401-652.	A	GST-tagged	protein	encoding	residues	401-652	of	hHIF1α	 was	 expressed	 in	 BL21	 DE3*	 E.	 coli	 and	 induced	 using	 either	 0.1mM	IPTG	16°C	O/N	or	0.5mM	IPTG	37°C	for	3	hr.	Cells	were	lysed	in	PBS,	5mM	MgCl2,	1mM	DTT	in	cell	disruptor	and	centrifuged	as	described	above.	The	supernatant	was	 filtered	through	0.45μm	filter	and	GST-HIF1αODD401-652	purified	using	a	GST	column	 (GE	 Healthcare),	 at	 0.5ml/min	 into	 10mM	GSH,	 PBS,	 1mM	DTT.	 0.5ml	fractions	 were	 collected	 in	 a	 96	 well	 plate	 and	 protein	 concentration	 was	
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assessed	 by	 SDS-PAGE.	 Fractions	 containing	 GST-HIF1αODD401-652	at	between	 64	and	98kDa,	were	pooled	and	dialysed	against	20mM	Tris	pH	7.4,	10%	glycerol,	150mM	 NaCl,	 1mM	 DTT	 at	 4°C	 using	 10,000MWCO	 Snakeskin	 dialysis	 tubing	(Pierce.)	 GST-HIF1αODD401-652	 was	 measured,	 concentrated	 and	 stored	 as	described	for	His-HIF1αODD530-652	above.			 His-HIF2αODD381-655.	A	His-tagged	 protein	 encoding	 residues	 381-655	 of	human	 HIF2α	 was	 expressed	 and	 purified	 as	 described	 above	 for	His-HIF1α
ODD530-652	above.	
	
	 His-E1.	pET15b-E1,	a	kind	gift	from	Fred	Goldberg,	was	expressed,	lysed	and	centrifuged	in	TBS,	as	described	for	His-HIF1αODD530-652.	The	lysate	was	then	adjusted	 with	 a	 conjugation	 buffer	 (20mM	 Tris-HCl,	 20mM	 KCl,	 5mM	 MgCl2,	1mM	DTT,	5mM	ATP)	to	bind	to	1ml	equilibrated	Ub-agarose	(Sigma)	(30	min,	4°C	 on	 a	 rotator).	 The	 resin	 was	 washed	 with	 2.5ml	 50mM	 Tris,	 pH	 7.5,	 5ml	50mM	Tris,	 pH	7.5,	 250mM	KCl	 and	 then	2.5ml	50mM	Tris,	 pH	7.5,	 to	 remove	unbound	or	catalytically	inactive	E1.	To	elute	the	catalytically	active	E1,	the	resin	was	 incubated	 with	 3ml	 50mM	 Tris,	 2mM	 AMP,	 2mM	 PPi	 (disodium	pyrophosphate,	both	made	to	0.2M	stocks)	for	10min	on	column	and	the	eluate	collected.	This	was	repeated.	Finally,	the	resin	was	washed	in	2.5ml	50mM	Tris	followed	by	3ml	0.1M	Tris,	pH	9.0,	10mM	DTT	to	ensure	 full	elution	of	 the	E1.	Protein	was	analysed	by	SDS-PAGE	and	eluates	 containing	His-E1	were	pooled	and	 dialysed	 against	 500ml	 40mM	 Tris	 pH	 8.0,	 2mM	 DTT	 at	 4°C	 using	3,000MWCO	Snakeskin	dialysis	 tubing	(Pierce.)	overnight	and	then	repeated	 in	the	 morning.	 Concentration	 was	 assessed	 by	 nanodrop	 and	 SDS-PAGE.	 10%	glycerol	was	added	to	the	protein	before	aliquoting	and	storage	at	-80°C.				 The	 following	 proteins	 were	 expressed	 and	 purified	 by	 the	 Buss	 and	Kendrick-Jones’	labs:		
His-TAX1BP1.	 His-tagged	 hTAX1BP1	 (aa291-747)	 was	 expressed	 and	purified	as	described	previously	(Morriswood	et	al.,	2007).		
His-MyosinVI	CBD.	His-tagged	hMyosinVI	cargo	binding	domain	(CBD,	aa	1034-1253)	was	purified	as	described	previously	(Spudich	et	al.,	2007)	however	
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the	 NiNTA	 column	 was	 washed	 with	 PBS	 with	 100mM	 imidazole	 pH7.4	 and	eluted	in	PBS	with	300mM	imidazole	pH7.4.		
GST-MyosinVI	 CBD.	 GST-tagged	 hMyosinVI	 cargo	 binding	 domain	 (CBD,	aa	 1034-1253)	 was	 purified	 as	 described	 previously	 for	 GST-tagged	 Myosin	fusion	proteins	(Buss	et	al.,	1998)	and	purified	on	glutathione	sepharose	4B	(GE	Healthcare)	according	to	manufacturer’s	instructions.			 	
2.3.4	In	vitro	autoubiquitination	reaction	
E6AP	 autoubiquitination.	 GST-tagged	 E6AP	 was	 ubiquitinated	 using	ubiquitin	 (50μM),	 E1	 (100nM),	 UbcH5b	 (400nM),	 4mM	ATP	 and	 1mM	DTT	 in	TBS	 for	 1hr.	 The	 resins	were	washed	 5	 x	 1ml	 of	 TBS	 (50mM	 Tris-HCl,	 pH7.5,	150mM	NaCl	and	1mM	DTT).	The	reaction	was	stopped	with	sample	buffer	and	the	autoubiquitination	analysed	by	SDS-PAGE	and	immunoblotting.		
Ube2S	 autoubiquitination.GST-Ube2SΔ	 was	 ubiquitinated	 using	 50nM	E1,	4mM	ATP,	400nM	AMSH	and	50μM	Ub	in	conjugation	buffer	(150mM	NaCl,	50mM	 Tris	 pH	 7.4,	 1mM	 DTT,	 1mM	 MgCl2)	 for	 4hr	 or	 O/N.	 The	 resins	 were	washed	 5	 x	 1ml	 of	 TBS	 (50mM	Tris-HCl,	 pH7.5,	 150mM	NaCl	 and	 1mM	DTT.)		Ubiquitination	was	analysed	by	SDS-PAGE	and	immunoblotting.		
Cyclin	B1	ubiquitination.	GST-CyB1-NTK64	(3μM)	was	ubiquitinated	using	E1	 (300nM),	 Ube2C	 (2.5μM),	 Ube2S	 (0.9µM),	 ubiquitin	 (150μM),	 20μl	 APC/C	/cdc27	 beads,	 UBAB	 buffer	 (25mM	 Tris-HCl	 pH7.4,	 50mM	NaCl,	 10mM	MgCl2,	and	 100mM	DTT)	 and	 1.5μl	 energy	mix	 (375mM	 creatinine	 phosphate,	 50mM	ATP,	pH8,	50mM	MgCl2.)	The	ubiquitinated	GST-CyB1-NTK64	was	then	bound	to	glutathione	 Sepharose	 resin,	 washed	 and	 analysed	 by	 SDS-PAGE	 and	immunoblotting.	Alternatively,	5µM	GST-CyB1-NTK64	was	ubiquitinated	using	recombinant	APC/C	 	 (kind	 gift	 from	 David	 Barford,	 (Zhang	 et	 al.,	 2013))	 using	 a	 reaction	containing	the	following:	40mM	Tris	(pH	7.4),	10mM	MgCl2,	0.6mM	DTT,	250nM	E1,	125nM	to	1.25µM	Ube2C,	900nM	Ube2S,	40nM	APC/C,	2mM	Cdh1,	50µM	Ub,	5mM	ATP,	and	0.25mg/ml	BSA.	Reaction	mixtures	were	incubated	at	37°C	for	up	to	1	hr.	The	ubiquitinated	GST-CyB1-NTK64	was	then	bound	to	glutathione	resin,	
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washed,	 and	 analyzed	 by	 SDS-PAGE	 and	 western	 blotting.	 Ubiquitin	 linkages	formed	on	GST-CyB1-NTK64	were	measured	by	MS.									
2.3.5	 K11-polyubiquitin	 chain	 purification	 from	 Ube2SUBD	
autoubiquitination	reaction.	K11-polyubiquitin	 chains	 were	 purified	 from	 an	 Ube2SUBD	autoubiquitination	 reaction	 based	 on	 methods	 published	 by	 Bremm	 et	 al	(Bremm	et	al.,	2010)).	GST-Ube2SUBD	was	ubiquitinated	using	250nM	E1,	4.8μM	Ube2SUBD,	 3mM	Ub,	 400nM	AMSH	 and	 10mM	ATP	37°C	 for	 18hr.	 5ml	 of	 this	autoubiquitination	 reaction	 were	 incubated	 with	 60mM	 DTT	 10min	 on	 ice	 to	stop	the	ubiquitination	reaction	and	release	non-covalently	bound	polyubiquitin	chains	from	the	UBD.	70ml	50mM	NH4Ac	pH4.5	was	added	to	the	ubiquitination	reaction	 for	 30min	 on	 ice	 to	 precipitate	 all	 proteins	 except	 for	 ubiquitin.	Precipitates	 were	 removed	 by	 passing	 through	 a	 0.2μM	 filter	 and	 ubiquitin	chains	were	 separated	 using	 cation	 exchange	 chromatography	 using	 a	Mono-S	5/50	GL	column	 (GE	Healthcare),	 at	0.5ml/min	and	eluted	using	50mM	NH4Ac	pH4.5,	 1M	 NaCl	 at	 linear	 gradient	 in	 upflow	 0-60%	 Buffer	 B1	 (50mM	 NH4Ac	pH4.5,	1M	NaCl)	over	44	column	volumes.	0.5ml	fractions	were	collected	in	a	96	well	 plate.	 Polyubiquitin	 chains	 were	 assessed	 by	 SDS-PAGE	 and	 pooled	 Ub4	chains	 dialysed	 against	 20mM	 Tris-HCl	 pH7.4,	 1mM	 DTT	 at	 4°C	 using	3,000MWCO	 Snakeskin	 dialysis	 tubing	 (Pierce.)	 Ub4	 chains	 were	 concentrated	using	 Vivaspin	 15,000MWCO	 centrifugal	 filter	 columns	 (Millipore)	 500rpm	 at	4°C	 until	 desired	 concentration	 achieved	 and	 assessed	 by	 nanodrop	 and	 SDS-PAGE.		
2.3.6	Mammalian	26S	proteasome	purification			 Proteasome	 isolation.	 The	 hHR23B-Ubl	 method	 was	 used	 to	 extract	functional	 26S	 proteasomes	 from	 cells	 (Besche	 et	 al.,	 2009).	 2g	 rabbit	 skeletal	muscle	 were	 homogenised	 in	 20ml	 binding	 buffer	 (25mM	Hepes,	 5mM	MgCl2,	1mM	DTT,	1mM	ATP	10%	glycerol	and	150mM	NaCl),	and	the	insoluble	material	was	 removed	 by	 low	 speed	 centrifugation	 (15min.	 3000rpm	 at	 4°C.)	 The	
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supernatant	 was	 ultracentrifuged	 for	 1hr	 at	 36,000rpm	 at	 4°C	 to	 remove	 the	microsomal	fraction.	The	supernatant	was	filtered	through	0.45μm	filter	and	the	cleared	cell	lysate	supplemented	with	4mg	GST-Ubl	and	1ml	of	equilibrated	GSH	Sepharose	(GE	Healthcare.)	The	suspension	was	rotated	 for	2h	at	4°C	and	then	poured	 into	 a	 20ml	 Econo-Pac	 column	 (Biorad.)	 The	 Sepharose	 resin	 was	washed	with	3	x	25ml	of	binding	buffer.	To	elute	the	proteasomes,	the	resin	was	agitated	 in	500μl	 of	 2mg/ml	His-UIM	 in	 the	binding	buffer	 supplemented	with	1mM	ATP	and	incubated	for	15min.	The	eluate	was	collected	and	the	elution	step	repeated.	 To	 remove	 the	His-UIM	 the	 combined	 eluates	were	 incubated	 for	 20	min	 at	 4°C	 with	 equilibrated-NiNTA	 (Qiagen.)	 The	 NiNTA	 was	 removed	 by	spinning	 the	 eluate	 through	 a	 0.22μm	 centrifugal	 filter	 unit	 (Millipore)	 at	11,000rpm	1min.	The	eluate	containing	26S	proteasomes	were	stored	at	-80°C.		 Measurement	 of	 proteasome	 activity.	 Suc-LLVY-AMC	 was	 purchased	from	Bachem.	Purified	proteasomes	were	incubated	with	the	peptide	in	a	buffer	containing	50	mM	Tris	pH	7.4	with	40	mM	KCl,	5	mM	MgCl2,	1	mM	ATP,	and	1	mM	 DTT.	 Kinetic	 fluorescence	 was	measured	 in	 triplicate	 in	 a	 96-well	 format	(Molecular	Devices).	Proteasome	composition	was	assessed	by	analysis	of	20nM	26S	 proteasomes	 on	 native	 gels	 (NuPage,	 Invitrogen)	 in	 a	 buffer	 containing	50mM	Tris-HCl	pH8,	5mM	MgCl2,	1mM	ATP,	1mM	DTT	and	50μM	Suc-LLVY-amc,	incubating	 at	 37°C	 for	 30	min	 and	measuring	 LLVY-AMC	 in-gel	 cleavage	 using	Fuji	LAS	3000.		
2.3.7	Proteasome	binding	of	 ubiquitin	 conjugates	 and	measurement	 of	 26S	
activity	
		 The	 measurements	 of	 proteasomes	 bound	 to	 polyubiquitin	 conjugates	were	based	on	methods	described	by	 the	Nathan	 lab	and	others	(Nathan	et	al.,	2013).	 Rabbit	 26S	 proteasomes	 (10nM)	 were	 incubated	 with	 polyUb	 resin-bound	conjugates	(20nM)	in	the	presence	of	a	proteasome	binding	buffer	(50mM	Hepes-KOH	 pH8,	 250mM	 Potassium	 acetate,	 5mM	 MgCl2,	 0.1%	 TritonX-100,	2mM	 DTT,	 0.2mg/ml	 BSA	 and	 2mM	 ATP),	 and	 rotated	 for	 20	 min	 at	 4°C.	Unbound	26S	particles	were	removed	by	washing	with	400μl	binding	buffer	and	1ml	wash	buffer	(50mM	Tris/HCl	pH	7.5,	10mM	MgCl2,	1mM	DTT	and	1mM	ATP)	
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at	5,000rpm	for	1	at	min	4°C.	Proteasome	activity	was	measured	with	100µM	of	the	 fluorescent	 substrate	 LLVY-AMC	 (Bachem)	 in	 proteasome	 reaction	 buffer	(50mM	Tris/HCl	 pH	7.5,	 10mM	MgCl2,	 40mM	NaCl,	 1mM	DTT	 and	 1mM	ATP).	Cleavage	 of	 the	 peptide	 was	 monitored	 at	λex	 380nm,	λem	 460nm	 37°C	 for	60min	and	expressed	as	arbitrary	fluorescent	units	(AU).		
2.3.8	Competition	assay	to	measure	K48	or	K11	tetraubiquitin	binding	to	26S	
proteasomes.	
	Rabbit	 26S	 proteasomes	 (10nM)	 were	 incubated	 with	 polyUb	 resin-bound	 conjugates	 (20nM)	 and	 75nM,	 150nM	 or	 300nM	 K48	 or	 K11	tetraubiquitin	in	the	presence	of	binding	buffer	(50mM	Hepes-KOH	pH8,	250mM	Potassium	acetate,	5mM	MgCl2,	0.1%	TritonX-100,	2mM	DTT,	0.2mg/ml	BSA	and	2mM	ATP),	 and	 rotated	 for	 20	min	 at	 4°C.	 26S	 particles	 bound	 to	K48	 or	K11	tetraubiquitin	and	unbound	26S	particles	were	removed	by	washing	with	400μl	binding	 buffer	 (without	 BSA)	 and	 1ml	 wash	 buffer	 (50mM	 Tris/HCl	 pH	 7.5,	10mM	 MgCl2,	1mM	 DTT	 and	 1mM	 ATP)	as	 described	 previously	 .	 Proteasome	activity	was	measured	by	cleavage	of	the	fluorescent	substrate	LLVY-AMC.			
2.3.9	 Binding	 assay	 to	 measure	 lysine-63	 or	 lysine-11	 tetraubiquitin	
conjugate	binding	to	MyosinVI	CBD	or	Tax1BP1	His-Tax1BP1	 (500nM)	 or	 His-MyosinVI	 CBD	 (500nM)	 were	 incubated	with	 Ni-NTA	 agarose	 resin	 (Qiagen)	 in	 the	 presence	 of	 Tris	 binding	 buffer	(25mM	Tris-HCl	pH7.4,	250mM	NaCl,	0.1%	Triton,	1mM	DTT,	0.25mg/ml	BSA)	and	rotated	for	30min	at	4°C.	Increasing	concentrations	of	lysine-63	or	lysine-11	tetraubiquitin	conjugates	were	added	(25,	50	or	100nM)	and	incubated	at	4°C	for	30min	on	a	rotator.	Unbound	proteins	were	removed	by	washing	five	times	with	Tris	binding	buffer	and	proteins	visualised	by	Western	blotting.	
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2.3.10	 Competition	 assay	 to	 measure	 lysine-63	 tetraubiquitin	 conjugate	
binding	to	MyosinVI	CBD	or	Tax1BP1		GST-MyosinVI	 (300nM)	 was	 incubated	 with	 Glutathione	 Sepharose	 4B	(GE	 Healthcare)	 and	 lysine-63	 tetraubiquitin	 (150nM)	 in	 the	 presence	 of	 Tris	binding	buffer	and	rotated	 for	30min	at	4°C.	The	resins	were	 then	washed	 five	times	 before	 incubating	 with	 increasing	 concentrations	 of	 Tax1BP1	 (150nM,	300nM,	600nM,	1.2μM,	2.4μM)	in	the	presence	of	Tris	binding	buffer	and	rotated	for	30min	at	4°C.	The	resins	were	then	washed	five	times	and	proteins	visualised	by	Western	blotting.		
2.3.11	In	vitro	hydroxylation	assay	of	HIF1α	or	HIF2α	1μM	 HIF1αODD530-652	or	 100nM	 HIF2αODD381-655	was	 incubated	 with	 50μl	HeLa	cell	extract	(see	2.4)	in	Tris	Buffer	(20mM	Tris	(pH7.4),	5mM	KCl,	1.5mM	MgCl2,	1mM	DTT)	for	15	min	at	37°C.	The	reaction	was	stopped	by	the	addition	of	 SDS	 loading	 buffer	 and	 the	 proteins	 were	 separated	 by	 SDS-PAGE.	Hydroxylation	 was	 measured	 using	 the	 hydroxyl-proline	 specific	 antibody.	Measurements	 of	DMOG	or	 L-2-HG	were	performed	 similarly	 except	 the	 lysate	were	pre-incubated	with	 the	compounds	 for	10min	at	37°C	or	4°C	respectively	and	HeLa	lysates	pre-incubated	with	the	same	volume	of	reaction	buffer	(20mM	Hepes	(pH7.5),	5mM	KCl,	1.5mM	MgCl2)	for	10min	at	4°C.		
2.3.12	In	vitro	ubiquitination	assay	of	HIF1α	13.5μM	HIF1αODD401-652	was	incubated	with	500μl	washed	GSH	resin	(Tris	buffered	 saline	 (TBS):	 50mM	 Tris	 (pH7.5),	 150mM	 NaCl,	 1mM	 DTT)	 and	incubated	1	h	4°C	on	a	 rotator	 followed	by	 centrifuging	10,000rpm	1	min	4°C.	Supernatant	 was	 aspirated	 and	 sample	 taken.	 Resin	 was	 washed	 x5	 in	 TBS	500rcf	 2min	 4°C	 and	 resuspended	 in	 TBS	 to	 500μl	 final.	 200μl	 resin	 was	incubated	with	250μl	HeLa	lysate	and	TBS	added	to	1ml	final.	500μl	resin/lysate	mixture	was	taken	as	0	timepoint	and	500μl	was	incubated	for	18	h	at	37°C.	Each	resin/lysate	mixture	was	passed	over	a	10ml	filter	column	(Biorad)	to	separate	
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resin	from	flow	through	(FT),	and	the	FT	was	collected.	Resins	were	washed	x4	in	10ml	TBS,	0.5%	NP40	and	1	wash	TBS	without	detergent.	SDS-loading	buffer	was	added	to	FT	and	resins	samples,	and	proteins	were	separated	by	SDS-PAGE.	Ubiquitination	was	 visualised	 using	 a	 ubiquitin	 specific	 antibody.	 Experiments	using	 addition	 of	 ubiquitination	 machinery	 were	 performed	 similarly	 except	50nM	E1,	5μM	ubiquitin	or	ubiquitin	aldehyde,	4mM	ATP	with	or	without	2.5μM	UbcH5b	 were	 added	 to	 HIF1αODD401-652	 with	 HeLa	 lysate	 prior	 to	 incubation.	Experiments	using	proteasome	inhibition	were	performed	similarly	except	50μM	MG132	was	added	to	HeLa	lysate	prior	to	incubation	with	HIF1αODD401-652.		
2.4	Cell	Biology	
2.4.1	Cell	culture	HeLa	 cells	were	 grown	 in	DMEM	 (Sigma)	 supplemented	with	 10%	 fetal	calf	 serum	 (FCS,	 PAA),	 50	 IU/ml	 penicillin	 and	50μg/ml	 streptomycin	 (Sigma).	HeLa	cells	treated	with	proteasome	inhibitors	were	grown	similarly	except	with	addition	of	5μM	MG132,	4μM	lactacystin	or	20nM	Bortezomib/Velcade		for	18	hr.			
2.4.2	Cell	lysis	for	in	vitro	hydroxylation	and	ubiquitination	reactions	HeLa	 cell	 lysates	 were	 prepared	 for	 the	 in	 vitro	hydroxylation	 reaction	from	 1	 x	 108	 cells	 using	 two	 rounds	 of	 freeze/thaw	 lysis	 in	 2ml	 lysis	 buffer	(20mM	Hepes	(pH7.5),	5mM	KCl,	1.5mM	MgCl2).	Lysates	were	passed	through	a	21G	 needle	 eight	 times	 followed	 by	 two	 passes	 through	 a	 26G	 needle	 and	centrifuged	at	14,000rpm	for	30	min	at	4°C.	Supernatants	were	pooled,	aliquoted	and	 stored	 at	 -80°C.	 HeLa	 cell	 lysates	 were	 prepared	 for	 the	 in	 vitro	ubiquitination	 from	 1	 x	 108	 cells	 in	 2ml	 lysis	 buffer	 (50mM	 Tris-HCl	 pH7.4,	150mM	NaCl,	5mM	MgCl2,	0.5%	NP40,	PMSF,	Roche	cocktail),	 incubated	on	 ice	for	30	min	and	centrifuged	at	14,000rpm	for	30	min	at	4°C.	Supernatants	were	pooled,	aliquoted	and	stored	at	-80°C.		
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2.4.3	Immunoprecipitation	of	HIF1α	HIF1α	was	immunoprecipitated	from	1	x106	or	1	x	108	HeLa	cells	with	or	without	proteasome	inhibition	for	18	hr.	 	Cells	were	incubated	with	lysis	buffer	(LB:	 50mM	 Tris	 pH7.4,	 150mM	 NaCl,	 5mM	 MgCl2,	 1mM	 DTT,	 Benzonase,	 1%	NP40,	PMSF,	Roche)	for	30	min	at	4°C	on	a	rotator.	Lysed	cells	were	centrifuged	(4,000rpm	 15min	 4°C)	 and	 the	 cell	 pellet/debris	 removed.	 10%	 of	 the	supernatant	was	stored	as	 total	 cell	 lysate	 (TCL)	and	 the	 remaining	 lysate	was	pre-cleared	by	incubating	with	Protein	G	magnetic	dynabeads	(Thermo	Fisher),	equilibrated	in	LB	(30min	4°C	on	rotator).	Supernatants	were	separated	from	the	dynabeads	 using	 a	 magnet,	 and	 then	 incubated	 with	 Protein	 G	 dynabeads	conjugated	to	HIF1α	mouse	antibody	(3	hr	4°C	on	a	rotator).	The	protein	G	beads	were	 again	 immobilised	 using	 a	magnet	 and	washed	 x	 5	 in	 wash	 buffer	 (WB:	50mM	Tris	pH	7.4,	150mM	NaCl,	5mM	MgCl	2,	1mM	DTT,	0.1%	Triton	X)	and	1	wash	in	WB	without	detergent.	Immunoprecipitated	proteins	were	eluted	in	2X	SDS	 loading	 buffer.	 Proteins	 were	 separated	 by	 SDS-PAGE	 and	 HIF1α	stabilisation	was	measured	using	a	HIF1α	specific	antibody.		
2.5	Mass	Spectrometry		All	MS	was	performed	by	 the	CIMR	core	 facility	 (Robin	Antrobus)	or	by	Mike	Weekes	 (Steve	 Gygi	 lab,	 Harvard	Medical	 School/CIMR)	 according	 to	 the	following	protocols.		Proteins	 were	 resolved	 using	 a	 4-12%	 pre-cast	 polyacrylamide	 gel	 and	the	 lanes	were	cut	 into	equal	 size	chunks	with	proteins	reduced,	alkylated	and	digested	in-gel.	Tryptic	peptides	were	analysed	by	LC-MS/MS	using	a	Q	Exactive	coupled	to	an	RSLCnano	3000.	Peptides	were	resolved	and	sprayed	using	a	50cm	EASY	spray	 column	with	MSMS	acquired	by	 top	6	DDA.	Data	was	processed	 in	Proteome	 Discoverer	 1.4	 using	 the	 Sequest	 search	 engine.	 Searches	 were	performed	 against	 a	 Uniprot	 human	 database	 (20,176	 entries,	 downloaded	03/06/14)	with	Cam	C	as	a	fixed	modification,	oxidised	M,	GlyGly	K,	deamidated	N/Q	as	variable	modifications	and	a	maximum	of	2	missed	cleavages.	Peak	area	detection	was	 enabled	with	 peptides	 reporting	 average	 area	 of	 the	 three	most	abundant	 of	 each	 detected	 species.	 Peptides	 were	 filtered	 to	 0.01	 FDR	 and	
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identified	branch	sites	were	expressed	as	a	percentage	of	the	summed	intensity	of	all	quantified	ubiquitin	peptides.		
AQUA	mass	 spectrometry.	 The	 polyubiquitinated	Ube2SΔ	 gel	 piece	was	 sliced	into	3	parts	and	each	slice	was	destained	and	dehydrated	in	acetonitrile.	Proteins	were	 then	 digested	 in-gel	with	 Trypsin	 for	 3	 hr.	 Ubiquitin	 AQUA	 analysis	was	performed	 as	 previously	 described	 (Kirkpatrick	 et	 al.,	 2006).	 Briefly,	 peptides	were	 eluted,	 and	 peptide	 amount	 estimated.	 AQUA	 peptides	 were	 mixed	 at	600fmol	per	microgram	Ube2SΔ	peptide,	and	the	entire	samples	were	analysed	on	a	Q	Exactive	mass	spectrometer	equipped	with	an	Agilent	1100	binary	pump	and	a	Famos	microautosampler.	Peptides	were	separated	using	a	gradient	of	6	to	28%	 Acetonitrile	 in	 0.125%	 Formic	 acid	 over	 120	 minutes.	 Peptides	 were	detected	 in	 the	 Orbitrap	 by	 means	 of	 a	 data-	 dependent	 top-20	 method.	Extracted	 ion	 chromatograms	 were	 generated	 using	 Xcalibur	 v2.2	 software	(Thermo).	 Chromatographic	 co-elution	 of	 heavy	 and	 light	 peptide	 pairs	 and	accurate	 peak	 integration	 were	 manually	 confirmed.	 The	 abundance	 of	 each	peptide	was	determined	by	taking	the	ratio	of	the	integrated	areas	for	the	light	sample	peptide	versus	the	heavy	AQUA	internal	standard	peptide	(Kirkpatrick	et	al.,	2006).	The	percentage	K11-linkages	was	calculated	as	(fmol	K11)	/	(fmol	K6	+	K11	+	K27	+	K29	+	K33	+	K48	+	K63).		 	
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 Chapter	3:	Results	1,	K11-polyubiquitin	chains	as	a	
signal	for	proteasome-mediated	degradation.		
3.1	Introduction	K11-polyubiquitin	chains	are	the	third	most	abundant	linkage	within	the	cell	 and	 have	 been	 shown	 to	 be	 involved	 in	 cell	 cycle	 progression	 and	intracellular	 signaling	 (Jin	 et	 al.,	 2008;	Wickliffe	 et	 al.,	 2011;	Williamson	 et	 al.,	2009b).	 K11-chains	 are	 also	 thought	 to	 signal	 protein	 degradation	 by	 both	proteasome	and	proteasome-independent	means,	however	it	 is	not	known	how	these	 linkages	 are	 recognised	 by	 the	 26S.	 To	 understand	 how	 K11-ubiquitin	chains	 are	 recognized,	 and	 ultimately	 to	 determine	 their	 functions,	 it	 was	necessary	 to	 establish	 in	vitro	methods	 to	 form	both	 free	 and	 substrate-bound	K11-polyubiquitin	chains.				 To	allow	measurement	of	proteasome	binding	and	activity	in	vitro,	it	was	important	 to	 purify	 mammalian	 proteasomes	 and	 quantify	 their	 activity.	 The	Nathan	lab	has	developed	methods	to	quantitatively	measure	the	binding	of	pure	mammalian	proteasomes	 to	different	polyubiquitin	 chains	 types	 (Nathan	et	 al.,	2013).	This	approach	compares	the	binding	of	polyubiquitin	chains	on	substrate	proteins	 to	 isolated	mammalian	 26S	 proteasomes	 by	measuring	 the	 peptidase	activity	of	the	proteasomes	bound	to	the	chains.		I	chose	this	in	vitro	approach,	as	it	allowed	me	to	compare	differences	in	binding	 of	 different	 polyubiquitin	 chain	 types	 directly	 to	 the	 proteasome	independent	of	cellular	factors,	such	as	proteasome	shuttling	factors	or	ubiquitin	binding	 proteins,	 which	 may	 enhance	 or	 decrease	 this	 binding	 (Nathan	 et	 al.,	2013).	In	addition,	it	allowed	the	formation	of	chains	of	a	defined	length.				 In	 this	 Chapter,	 I	 outline	 the	 methods	 to	 generate	 K11	 and	 K48-linked	polyubiquitin	 chains	 and	 measure	 their	 binding	 to	 the	 proteasome.	 First,	 I	describe	 the	 formation	of	substrate-bound	homotypic	K11-linked	polyubiquitin	chains	on	the	E2	enzyme,	Ube2S,	and	K48-linked	chains	on	the	E3	ligase,	E6AP.	To	 enable	 direct	 comparison	 of	 free	 polyubiquitin	 chains	 of	 the	 same	 length,	 I	
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describe	 the	 formation	 of	 free	 homotypic	 K11-linked	 ubiquitin	 tetramers.	Subsequently,	 I	measure	 the	 binding	 of	 free	 and	 substrate-bound	K11	 or	K48-linked	polyubiquitin	chains	in	order	to	determine	which	chain	type	binds	more	strongly	to	the	proteasome.	Finally,	I	explore	whether	homotypic	or	heterotypic	K11-polyubiquitin	 chains	 formed	 on	 a	 physiological	 cell	 cycle	 substrate,	CyclinB1,	signal	proteasome-mediated	degradation.				 	
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3.2	Results.	
3.2.1	 Formation	 of	 homotypic	 lysine	 11-linked	 chains	 on	 the	 E2	 enzyme	
Ube2S.	To	measure	the	direct	binding	of	K11-chains	to	the	proteasome	and	other	interacting	 proteins,	 it	 was	 first	 necessary	 to	 generate	 pure	 K11-chains	 on	 a	single	 lysine	residue	on	a	substrate	protein.	Therefore,	 I	developed	a	system	to	form	K11-chains	on	the	E2	enzyme,	Ube2S.	This	E2	enzyme	is	unusual	in	that	it	can	autoubiquitinate	without	requiring	an	E3	ligase	(Wickliffe	et	al.,	2011;	Wu	et	al.,	 2010).	 To	 prevent	 the	 formation	 of	 multiple	 monoubiquitinated	 species,	 I	made	 a	 GST-tagged	 Ube2S	 mutant	 construct,	 in	 which	 the	 lysine	 rich	 tail	 had	been	 removed	 leaving	 a	 single	 terminal	 lysine,	 197.	 I	 transformed	 this	 GST-Ube2SΔ	into	DE3*	E.	coli	using	standard	methods	and	induced	protein	synthesis	with	0.5mM	IPTG	37°C	3	hr.	Analysis	of	pre	and	post-induction	samples	showed	a	 clear	 band	 at	 around	 50kDa	 in	 the	 post-induction	 samples	 (Figure	 3.1A),	indicating	expression	of	the	GST-Ube2SΔ	protein.	After	lysis	of	these	bacteria	and	removal	 of	 cell	 debris	 by	 centrifugation	 and	 filtration,	 I	 incubated	 the	 cleared	lysate	 with	 GSH	 Sepharose	 resin.	 I	 washed	 the	 resin	 to	 leave	 the	 resin-bound	GST-Ube2SΔ	 protein.	 Analysis	 by	 SDS-PAGE	 showed	 GST-Ube2SΔ	 migrated	 at	50kDa	with	 few	 other	 faster	migrating	 species,	 likely	 to	 be	 truncations	 of	 the	GST-Ube2SΔ	(Figure	3.1B).		
	
Figure 3.1: Expression and purification of GST-Ube2SΔ. GST-tagged Ube2SΔ was 
expressed in E. coli, purified on glutathione sepharose beads and separated by SDS-PAGE 
before staining with Coomassie blue.  (A) Coomassie stained gel of GST-Ube2SΔ induction. 
Numbers refer to 4 separate clones (10µl sample added) (B) Coomassie stained gel of GST-
Ube2SΔ purification. 20, 10, 5, 2.5 and 1.25µl samples added. 	
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		 Having	 purified	 the	 truncated	 GST-Ube2SΔ	 construct,	 I	 went	 on	 to	establish	 ubiquitination	 assays.	 I	 incubated	 the	 resin-bound	 GST-Ube2SΔ	 with	recombinant	 E1,	 ubiquitin,	 ATP,	 and	 AMSH	 at	 37°C	 overnight,	 enabling	polyubiquitin	chain	formation	on	the	GST-Ube2SΔ	(Figure	3.2A).	The	presence	of	 the	 de-ubiquitinating	 enzyme,	 AMSH,	 within	 the	 reaction	 should	 cleave	 the	K63	 chains	 that	 can	 be	 formed	 by	 Ube2S	 truncations	 (Bremm	 et	 al.,	 2010),	increasing	 the	 purity	 of	 K11-chain	 formation.	 Subsequent	 washing	 of	 the	ubiquitinated	resin	removed	unbound	components	of	the	reaction,	leaving	resin-bound	 polyubiquitinated	 GST-Ube2SΔ	 shown	 in	 the	 Coomassie	 stained	 gel	(Figure	 3.2B).	Mass	 spectrometry	 (MS)	 analysis	 of	 the	 polyubiquitinated	GST-Ube2SΔ	 (performed	 by	 Robin	 Antrobus)	 confirmed	 that	 these	 chains	 were	formed	 on	 the	 single	 terminal	 lysine	 197	 of	 GST-Ube2SΔ	 (Figure	 3.2C).	 To	further	exclude	the	possibility	of	multiple	monoubiquitination	on	GST-Ube2SΔ,	I	ubiquitinated	GST-Ube2SΔ	as	described,	but	used	methyl	ubiquitin	(UbMe,	Boston	Biochem),	 which	 prevents	 polyubiquitin	 chain	 formation.	 The	 reaction	 was	terminated	by	the	addition	of	SDS	loading	buffer,	and	the	ubiquitination	of	GST-Ube2SΔ	 measured	 by	 immunoblot.	 This	 showed	 a	 single	 ubiquitinated	 GST-Ube2SΔ	species	(Figure	3.2D)	confirming	that	only	a	single	lysine	residue	within	GST-Ube2SΔ	could	be	modified	by	ubiquitination.				 To	determine	the	ubiquitin	 linkage	purity	of	 the	polyubiquitin	chains	on	Ube2SΔ,	 we	 used	 Absolute	 Quantification	 (AQUA)	 mass	 spectrometry	 (MS),	which	 uses	 linkage	 specific	 ubiquitin	 standards	 (New	 England	 Biolabs)	 to	measure	 the	 levels	 of	 the	 different	 linkages	 within	 the	 polyubiquitin	 chains	formed	on	GST-Ube2SΔ.	Polyubiquitinated	GST-Ube2SΔ	was	formed	as	described	and	 analysed	 by	 MS	 AQUA	 (performed	 by	 Mike	 Weekes,	 Harvard	 Medical	School/CIMR).	This	showed	92%	purity	of	the	K11-polyubiquitin	chains	formed	(Figure	3.2E).	
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Figure 3.2: Formation of homotypic K11-linked polyubiquitin chains on Ube2SΔ. (A) 
Schematic of polyubiquitinated Ube2SΔ with K11-linked chains. (B) Polyubiquitination of 
Ube2SΔ. GST-Ube2SΔ resin was incubated with E1, ATP and ubiquitin overnight, the resin 
washed and ubiquitinated Ube2SΔ visualised by Coomassie staining. (C, D) K197 is the 
lysine modified by ubiquitination.  Polyubiquitinated GST-Ube2SΔ resin was separated by 
SDS-PAGE and analysed by MS/MS or immunoblot for ubiquitin. (E) K11-linked polyubiquitin 
chains are formed on Ube2SΔ. The ubiquitination reactions described were subjected to 
AQUA MS to analyse the different ubiquitin linkages (Mike Weekes, Harvard Medical 
School/CIMR). Ub=ubiquitin, UbMe=methyl ubiquitin. 		
3.2.2	Formation	of	K11-linked	tetraubiquitin	chains.		Although	 the	 GST-Ube2SΔ	 polyubiquitination	 reactions	 generated	 pure	K11-linked	 linkages,	 the	 chains	 were	 of	 undefined	 length.	 To	 compare	 the	binding	 of	 K11-polyubiquitin	 chains	 to	 other	 ubiquitin	 linkages	 (e.g.	 K48	 and	K63)	 it	was	necessary	to	generate	K11-linked	chains	of	a	 fixed	 length.	K48	and	K63-linked	tetraubiquitin	(Ub4)	chains	were	commercially	available,	but	this	was	not	the	case	for	K11-linkages.	I	therefore	generated	pure,	free	K11-linked	chains	
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based	 on	methods	 described	 by	Bremm	et	 al.	 (Bremm	et	 al.,	 2010).	 Free	K11-linked	 chains	 are	 formed	during	 the	 autoubiquitination	 reaction	of	Ube2S,	 and	the	 yield	 of	 these	 free	 chains	 can	 be	 increased	 by	 using	 a	 Ube2S	 fused	 to	 the	ubiquitin	 binding	 domain	 (UBD)	 of	 USP5	 (Bremm	 et	 al.,	 2010)	 (Figure	 3.3A).	Therefore,	 the	UBD	domain	of	USP5	was	 first	 cloned	 into	our	 truncated	Ube2S	construct	(by	James	Nathan)	and	I	transformed	this	GST-tagged	Ube2SUBD	into	BL21	DE3*	E.	coli	as	described.	Protein	synthesis	was	induced	with	0.1mM	IPTG	16°C	 overnight.	 Analysis	 of	 pre	 and	 post-induction	 samples	 showed	 a	 band	 at	around	 50kDa	 in	 the	 post-induction	 samples	 compared	 to	 the	 pre-induction	(Figure	3.3B),	indicating	expression	of	the	GST	Ube2SUBD	protein.	After	lysis	of	these	 bacteria,	 I	 incubated	 the	 cleared	 lysate	 with	 GSH	 Sepharose	 resin,	 then	washed	 the	 resin	 with	 a	 high	 salt	 buffer	 and	 then	 low	 salt	 buffer	 to	 remove	contaminants.	 Analysis	 by	 SDS-PAGE	 showed	 that	 GST-Ube2SUBD	migrated	 at	50kDa	(Figure	3.3C).	The	GST	tag	was	removed	by	 incubating	the	resin-bound	GST-Ube2SUBD	 with	 GST-PreScission	 (1.2mg/ml)	 and	 the	 soluble	 Ube2SUBD	eluted.	SDS-PAGE	analysis	of	the	resin	and	eluate	showed	cleaved	Ube2SUBD	at	36kDa	(Figure	3.3D).			 Next,	 soluble	K11-linked	ubiquitin	 chains	were	 generated	by	 incubating	the	Ube2SUBD	with	E1,	ubiquitin,	ATP	and	cleaved	AMSH	at	37°C	overnight	as	described	in	3.2.1.	The	autoubiquitination	reaction	was	terminated	by	addition	of	 60mM	DTT,	which	 helps	 release	 the	 non-covalently	 bound	K11-chains	 from	the	 active	 cysteine	 of	 the	 Ube2S	 and	 the	 UBD	 (Figure	 3.3E,	 lane	 2).	 	 The	Ube2SUBD	and	E1	were	precipitated	by	addition	of	50mM	NH4Ac	pH4.5,	and	the	K11-linked	 chains	 isolated	 using	 cation	 exchange	 chromatography.	 0.5ml	fractions	were	collected	and	analysed	by	SDS-PAGE.	The	fractionation	of	tri	and	tetra-ubiquitinated	 (Ub4)	 species	 is	 shown	 (Figure	 3.3F).	 Fractions	 from	 each	chain	 length	were	pooled	and	dialysed	 into	20mM	Tris	pH	7.4.	Finally,	 the	Ub4	chains	were	 concentrated	 and	 the	 chain	 length	 verified	 by	 Coomassie	 staining	(Figure	3.3G)	and	immunoblot	(Figure	3.3H)	compared	to	the	commercial	K48-linked	tetraubiquitin.	Having	generated	the	K11-linked	tetraubiquitin	(K11-Ub4)	it	was	 important	 to	 verify	 that	 these	 chains	 are	 linked	 though	K11.	 Therefore,	quantitative	 MS	 was	 performed	 (Robin	 Antrobus,	 CIMR),	 which	 showed	 K11-linkages	of	high	purity	(Figure	3.3I).	
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Figure 3.3: Formation of K11-tetraubiquitin chains using GST-Ube2SUBD. (A) Schematic 
of the ubiquitination reaction. (B) GST-Ube2SUBD induction in E. Coli. (C) GST-Ube2SUBD 
purification on GSH resin. (D) PreScission cleavage of GST-Ube2SUBD. The resin bound 
GST-Ube2SUBD was incubated with GST-PreScission and the free Ube2SUBD concentrated 
from the flow through. (E) Ube2SUBD autoubiquitination reaction illustrated in (A). (F) 
Fractions containing K11-Ub4 separated using cation chromotography.  (G-I) Analysis of the 
K11-Ub4. The K11-Ub4 was concentrated and compared to commercial K48-Ub4 using SDS-
PAGE and Coomassie staining (G) or immunoblot for ubiquitin (H). Chain linkage was 
analysed by quantitative MS using ion intensity (Robin Antrobus, CIMR) (I). 
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3.2.3	Do	homotypic	K11-linked	polyubiquitin	chains	bind	to	the	mammalian	
proteasome?		 Mammalian	 proteasomes	 were	 isolated	 from	 rabbit	 muscle	 using	 the	method	described	by	Besche	et	al.	(Besche	et	al.,	2009).	Briefly,	the	rabbit	muscle	was	homogenized	and	proteasomes	extracted	by	 incubating	the	 lysate	with	the	Ubl	 of	 hHR23B	 bound	 to	 GST	 (GST-hHR23B	 Ubl).	 This	 ubiquitin	 like	 (Ubl)	domain	binds	with	high	affinity	 to	 the	Rpn10	and	Rpn13	receptors	on	 the	19S.	The	 26S	 proteasomes	 were	 eluted	 with	 an	 excess	 of	 a	 His-tagged	 UBD,	 the	ubiquitin	interacting	motif	(UIM)	of	Rpn10.	This	UBD	was	subsequently	removed	with	 NiNTA	 resin,	 leaving	 pure	 26S	 proteasomes	 (Besche	 et	 al.,	 2009).	 I	confirmed	the	structural	integrity	of	the	purified	proteasomes	by	native	gel	with	fluorescent	 substrate	 overlay	 (LLVY-AMC)	 which	 showed	 clear	 bands	corresponding	to	doubly	and	singly-capped	26S	proteasome	(Figure	3.4A).	I	also	confirmed	the	functional	activity	of	the	26S	by	cleavage	of	the	chymotrypsin-like	fluorescent	substrate,	LLVY-AMC	(Figure	3.4B).		 Having	 purified	 the	 mammalian	 proteasome,	 I	 could	 then	 compare	 the	binding	of	homotypic	K11-linked	chains	to	K48-linked	polyubiquitin	chains,	the	canonical	 signal	 for	proteasomal	degradation.	 	K48-linked	polyubiquitin	 chains	were	 formed	 by	 incubating	 GST	 resin-bound	 E6AP	 with	 E1,	 the	 E2	 UbcH5b,	ubiquitin	and	ATP	(Figure	3.4C).	E6AP	is	a	HECT	E3	ligase	that	forms	pure	K48-linked	 polyubiquitin	 chains	 (Kim	 et	 al.,	 2007).	 The	 resin-bound	 K11	 or	 K48-linked	polyubiquitin	 chains	were	 incubated	with	20nM	proteasomes	 at	4°C	 for	30min,	washed	 to	 remove	 unbound	 proteasomes,	 and	 the	 proteasomes	 bound	measured	by	the	cleavage	of	the	fluorescent	proteasome	substrate	LLVY-AMC	at	37°C	(Peth	et	al.,	2010).	Surprisingly,	I	found	that	the	K11-linked	chains	formed	on	 Ube2SΔ	 did	 not	 bind	 to	 the	 proteasome	 in	 comparison	 to	 K48-linked	polyubiquitin	chains	(Figure	3.4D).			
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Figure 3.4: Homotypic K11-polyubiquitin chains on UBE2SΔ do not bind the 
proteasome. (A, B) Isolation of mammalian proteasomes from rabbit muscle. 26S 
proteasomes were isolated from muscle extracts using the GST-Ubl method and the purity 
and activity were measured by native gel electrophoresis (A) and LLVY-AMC cleavage (B). 
In-gel proteasome activity was measured by incubating the gels in a Tris buffer containing 1 
mM ATP, 5mM MgCl2, and 50µM Suc-LLVY-AMC at 37°C for 30 min (A). Peptidase activity of 
the proteasomes (26S) was measured by LLVY-AMC cleavage (black squares), and a 
standard curve generated (linear 26S prep). LLVY-AMC peptidase activity of the rabbit 
muscle lysate depleted of proteasomes (black triangles) was also measured to assess the 
efficiency of the proteasome purification (B). (C, D) binding to polyubiquitinated GST-Ube2SΔ 
or GST-E6AP. Coomassie stained gel of in vitro autoubiquitination reaction showing 
polyubiquitin chain formation on Ube2SΔ and E6AP (C). GST-bound K11-chains (Ubn2SΔ) or 
K48-chains (E6AP) were incubated with purified mammalian proteasomes and proteasomes 
bound were measured by LLVY-AMC cleavage (D). Mean±SEM, 3 experimental replicates. 		
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3.2.4	 K11-linked	 tetraubiquitin	 cannot	 displace	 K48-polyubiquitin	 chains	
binding	to	the	proteasome.	Although	 K11-linked	 chains	 on	 Ube2SΔ	 do	 not	 bind	 strongly	 to	 the	proteasome,	 this	 finding	 may	 be	 accounted	 for	 by	 the	 difference	 in	 substrate	used	to	generate	the	K11-	and	K48-linked	chains	or	a	difference	in	polyubiquitin	chain	length	formed	on	Ube2SΔ	and	E6AP.	Therefore,	I	compared	the	binding	of	K11-	 and	 K48-Ub4	 to	 the	 proteasome	 using	 a	 competition	 assay	 developed	 by	Peth	 et	 al	 (Figure	 3.5A)	 (Peth	 et	 al.,	 2010).	 I	 incubated	 resin-bound	ubiquitinated	 GST-E6AP	 (Figure	 3.5B)	with	 either	 proteasomes	 alone	 or	with	proteasomes	and	increasing	concentrations	of	K11-Ub4	or	K48-Ub4	at	4°C.	I	then	washed	 the	 resin-bound	 ubiquitin	 conjugates,	 and	 quantified	 the	 proteasomes	bound	by	cleavage	of	LLVY-AMC	fluorescent	substrate	(Figure	3.5C)	Increasing	concentrations	of	K48-Ub4	competed	with	the	resin-bound	K48-linked	chains	to	bind	 proteasomes,	 such	 that	 at	 300nM	 K48-Ub4,	 proteasomes	 bound	 to	polyubiquitinated	E6AP	were	reduced	by	about	70%.	(Figure	3.5C).	 	However,	K11-Ub4,	at	concentrations	up	to	300nM,	did	not	prevent	proteasomes	binding	to	polyubiquitinated	 E6AP	 (Figure	 3.5C).	 Thus,	 K11-linked	 chains	 bind	 more	weakly	than	K48-linked	chains	to	proteasomes.															
Chapter	3,	K11-polyubiquitin	chains	as	a	signal	for	proteasome-mediated	
degradation		
		 89	
			
Figure 3.5: Free K11-ubiquitin tetramers do not compete with K48-ubiquitin tetramers 
for binding to bind 26S proteasomes. (A) Schematic of 26S proteasome binding 
competition assay. Polyubiquitinated resin-bound GST-E6AP (B) were incubated with K11 or 
K48-Ub4, the resins washed and proteasomes bound to polyubiquitinated E6AP measured by 
LLVY-AMC cleavage (C). Means±SEM of 4 experiments.  
	
3.2.5	 Homotypic	 and	 heterotypic	 K11-linked	 polyubiquitin	 chains	 differ	 in	
their	ability	to	bind	to	the	proteasome.	While	 homotypic	 K11-linked	 polyubiquitin	 chains	 did	 not	 bind	 to	 the	proteasome,	it	was	important	to	determine	whether	this	was	true	for	other	K11-ubiquitinated	 substrates.	 In	addition,	K11-linked	polyubiquitin	 chains	of	mixed	(heterotypic)	linkages	exist	in	cells,	and	may	be	the	dominant	species	formed	by	the	APC/C	(Meyer	and	Rape,	2014).	Therefore,	I	wanted	to	establish	methods	to	generate	different	types	of	K11-linked	polyubiquitin	chains	on	the	physiological	substrate,	Cyclin	B1,	and	measure	their	ability	to	bind	to	the	proteasome.		
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(i)	 Formation	 of	 K11	 polyubiquitin	 chains	 on	 Cyclin	 B1	 using	
immunoprecipitated	APC/C.		I	 first	 attempted	 to	 form	 K11-chains	 on	 cyclin	 B1,	 using	 semi-purified	APC/C	 from	 HeLa	 cells	 arrested	 in	 mitosis,	 according	 to	 published	 methods	(Williamson	et	al.,	2009a).	I	used	a	Cyclin	B1	N-terminal	mutant	construct	(CyB1-NTK64,	a	kind	gift	 from	Randall	King)	 in	which	all	 lysines	have	been	mutated	 to	arginines	 except	 for	 lysine	 64,	 to	 prevent	 the	 formation	 of	 multiple	monoubiquitination	(Dimova	et	al.,	2012).		I	modified	this	construct	to	encode	a	GST	 tag	 at	 the	 N-terminus	 and	 a	 His	 tag	 at	 the	 C-terminus,	 for	 use	 in	 our	proteasome	 binding	 assays.	 I	 purified	 this	 protein	 as	 described	 (see	 methods	
2.2)	 and	 verified	 the	 purity	 of	 the	 protein	 SDS-PAGE	 and	 Coomassie	 staining	(Figure	5.6A).	Although	there	were	some	truncated	products	(Figure	5.6B),	the	purity	was	sufficient	for	my	subsequent	experiments.	
	
Figure 3.6: Expression and purification of GST-CyB1-NTK64. GST-tagged CyB1-NTK64 was 
expressed in E. coli, purified on glutathione sepharose beads and separated by SDS-PAGE 
before staining with Coomassie blue.  (A) Coomassie stained gel of GST-CyB1-NTK64 
induction. Numbers correspond to litres of culture. (B) Coomassie stained gel of GST-CyB1-
NTK64 purification. 	 The	 APC/C	 was	 immunoprecipitated	 according	 to	 published	 methods	from	HeLa-S	 cells	 released	 from	 a	 nocodazole	 arrest	 (cells	 prepared	 by	 James	Nathan)	(Williamson	et	al.,	2009a).	I	then	incubated	the	CyB1-NTK64	in	an	in	vitro	autoubiquitination	reaction	containing	E1,	ubiquitin,	Ube2C,	Ube2S,	resin-bound	semi-purified	 APC/C	 and	 ATP	 at	 37°C	 (Figure	 3.7A).	 To	 separate	 the	 resin-bound	 APC/C	 which	 may	 itself	 be	 ubiquitinated,	 I	 centrifuged	 the	 suspension	using	 a	 0.2μm	 filter	 column	 and	 collected	 the	 flow	 through	 (FT).	 This	 FT	was	then	 incubated	with	equilibrated	GSH	resin	 to	bind	 the	polyubiquitinated	GST-tagged	 K64	 CyclinB1	 (Figure	 3.7A)	 The	 suspended	 resin	 was	 analysed	 by	
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immunoblot	with	a	ubiquitin	antibody	to	assess	CyB1-NTK64	ubiquitination.	This	showed	polyubiquitination	of	CyB1-NTK64	Ube2C	(Figure	3.7B,	lane	2)	and	chain	elongation,	 presumably	 with	 K11-linkages,	 in	 the	 presence	 of	 Ube2S,	 (Figure	
3.7B,	lane	3).	
		
Figure 3.7: Polyubiquitination of GST-CyB1-NTK64 using immunoprecipitated APC/C 
from HeLa-S cells. (A) Schematic of ubiquitin chains formed on resin-bound cyclinB1K64. (B) 
Immunoblot of polyubiquitin chains formed on GST-CyB1-NTK64 with Ube2C and Ube2S. Two 
forms of cyclin B1 are observed, which does not seem to be dependent on ubiquitination. 	 Although	this	approach	was	successful	in	forming	polyubiquitin	chains	on	CyB1-NTK64,	 ubiquitination	 was	 very	 variable	 between	 experiments	 and	optimisation	 using	 different	 time	 points	 and	 temperatures	 showed	 that	 CyB1-NTK64	 was	 degraded	 during	 long	 incubations.	 Indeed,	 MS	 analysis	 of	 the	immunoprecipitated	 APC/C	 showed	 that	 it	 contained	 multiple	 E3s,	 DUBs	 and	proteasome	subunits	(data	not	shown).	The	variability	in	ubiquitination	of	CyB1-NTK64	 and	 complexity	 of	 the	 immunoprecipitated	 APC/C	 made	 this	 approach	
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difficult	to	interpret.	It	was	therefore	important	to	establish	a	cleaner	system	to	generate	 ubiquitinated	 CyB1-NTK64.	 This	 required	 human	 recombinant	 APC/C,	which	was	kindly	provided	by	David	Barford	(Laboratory	of	Molecular	Biology,	Cambridge)	(Zhang	et	al.,	2013).				
(ii)	 Formation	 of	 K11-polyubiquitin	 chains	 on	 Cyclin	 B1	 using	 human	
recombinant	APC/C.		Human	recombinant	APC/C	provided	the	opportunity	to	form	homotypic	K11,	heterotypic	K11/K48	or	homotypic	K48-chains	on	CyB1-NTK64	and	compare	the	 binding	 and	 degradation	 of	 these	 different	 chains	 by	 the	 proteasome.	Therefore,	GST	bound	CyB1-NTK64	was	ubiquitinated	using	human	recombinant	APC/C,	 E1,	 two	 E2s	 (Ube2C	 and	 Ube2S),	 and	 different	 ubiquitins	 	 (wildtype	ubiquitin,	 K48-only	 ubiquitin	 (UbK48),	 K11-only	 ubiquitin	 (UbK11)	 or	 	 methyl-ubiquitin	 (UbMe))	 to	 form	 homotypic	 K11	 or	 K48-linked	 chains,	 as	 well	 as	heterotypic	 polyubiquitin	 chains	 (experiments	 performed	 with	 James	 Nathan)	(Figure	3.8A).	The	resin-bound	polyubiquitinated	CyB1-NTK64	was	then	washed	and	 ubiquitination	 measured	 by	 immunoblot.	 	 Monoubiquitination	 of	 CyB1-NTK64	was	observed	with	UbMe	 (Figure	 3.8B)	 confirming	 that	a	 single	 lysine	of	CyB1-NTK64	is	modified.	Homotypic	K11-chains	were	formed	with	UbK11	(Figure	
3.8B)	 and	 homotypic	 K48-chains	 with	 UbK48	 (Figure	 3.8D,	 lane	 4).	 Low	concentrations	 of	 Ube2C	 (125nM)	 formed	 monoubiquitinated	 CyB1-NTK64		(Figure	3.8B),	but	these	chains	were	elongated	in	the	presence	of	Ube2S	(Figure	
3.8B).	 The	 polyubiquitin	 chains	 formed	 on	 CyB1-NTK64	 were	 analysed	 by	quantitative	 MS,	 and	 showed	 that	 low	 concentrations	 of	 Ube2C	 with	 Ube2S	formed	heterotypic	K11	and	K48-chains	whereas	high	concentration	Ube2C	with	Ube2S	 formed	 polyubiquitin	 chains	 forming	 several	 different	 linkages	 (Figure	
3.8C).	 Interestingly,	 the	homotypic	and	heterotypic	K11-chains	were	 similar	 in	length,	but	the	homotypic	K48-chains	were	a	little	shorter	(Figure	3.8D).				 Having	 established	 a	 system	 to	 form	 different	 polyubiquitin	 chains	 on	CyB1-NTK64,	 we	 could	 then	 measure	 the	 ability	 of	 these	 conjugates	 to	 bind	proteasomes.	 Resin-bound	 homotypic	K11,	 heterotypic	K11/K48	 or	 homotypic	K48-polyubiquitin	chains	were	incubated	with	purified	mammalian	proteasomes	at	4°C	for	30	min,	and	the	proteasomes	bound	measured	by	LLVY-AMC	cleavage.	
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Minimal	 binding	 of	 homotypic	 K11-chains	 to	 the	 proteasome	 was	 observed,	similarly	 to	 polyubiquitinated	Ube2SΔ	 (Figure	 3.4).	 In	 comparison,	 homotypic	K48-polyubiquitin	 chains	 bound	 strongly	 to	 the	 proteasome.	 The	 heterotypic	K11/K48-linked	 chains	 bound	 to	 the	 proteasomes,	 but	 less	 strongly	 than	 the	homotypic	K48-chains	(Figure	3.8E).	Thus,	while	homotypic	K11-chains	did	not	bind	to	proteasomes,	heterotypic	K11/K48-chains	could	associate	with	the	26S.	
	
Figure 3.8: Heterotypic K11-polyubiquitin chains on cyclin B1 bind to the proteasome.  
(A-C) Synthesis of homotypic and heterotypic K11/K48-polyUb chains on CyB1-NTK64 using 
human recombinant APC/C. Resin-bound CyB1-NTK64 was incubated with co-activated 
APC/C, Ub (Ub, UbMe and UbK11), and E2s (Ube2C and Ube2S) for 1 hr at 37°C, washed and 
ubiquitination of CyB1-NTK64 measured by immunoblot for cyclin B1 (B). Quantification of the 
Ub-linkages formed was measured by MS (C). (D, E) Heterotypic but not homotypic K11-
polyubiquitin chains bind to the proteasome. CyB1-NTK64 was ubiquitinated with UbK11 and 
UbK48 to form homotypic polyUb chains or ubiquitinated with wildtype ubiquitin, forming 
K11/K48 heterotypic polyubiquitin chains (D). These ubiquitin conjugates were incubated with 
purified proteasomes and 26S proteasomes bound to the chains measured by LLVY-AMC 
cleavage (E). Means±SEM of 3 experiments. Ct=control  
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3.2.6	 Heterotypic	 K11/K48-linked	 chains	 facilitate	 proteasome-mediated	
degradation	of	cyclin	B1.		I	had	 shown	 that	 the	proteasome	did	not	bind	 to	homotypic	K11-linked	chains	 but	 did	 bind	 to	 heterotypic	 K11/K48	 and	 homotypic	 K48-chains	 to	different	 extents.	 How	would	 this	 difference	 in	 binding	 affect	 the	 proteasomal	degradation	 of	 the	 ubiquitinated	 substrate?	 To	 measure	 the	 ability	 of	 the	proteasome	 to	 degrade	 polyubiquitinated	 CyB1-NTK64,	 the	 homotypic	 K11,	heterotypic	 K11/K48	 or	 homotypic	 K48-chains	 were	 incubated	 with	 purified	mammalian	26S	proteasomes	at	37°C	 for	 the	 indicated	 times	 (Figure	 3.9A,	 B)	(these	 experiments	 were	 conducted	 with	 James	 Nathan).	 CyB1-NTK64	degradation	was	visualized	by	 immunoblot	 (Figure	 3.9A,	 B)	 and	quantified	by	densitometry	(Figure	3.9C).		Analyses	of	4	experiments	showed	that	about	80%	of	 CyB1-NTK64	modified	 with	 homotypic	 K48-chains	 was	 degraded	 by	 90	 min,	whereas	 homotypic	 K11-chains	were	 only	weakly	 degraded	 (20%	by	 90	min).		CyB1-NTK64	modified	with	heterotypic	K11/K48-chains	was	degraded,	but	less	so	than	CyB1-NTK64	modified	with	homotypic	K48-chains	(60%	by	90	min)	(Figure	
3.9C).				 Interestingly,	 although	 the	 homotypic	 K11-chains	 did	 not	 stimulate	significant	 proteasomal	 degradation	 of	 CyB1-NTK64,	 the	 proteasome-associated	DUBs	 could	 still	 disassemble	 the	 polyubiquitin	 chains	 (Figure	 3.9A,	 B).	Homotypic	 K48	 and	 heterotypic	 K11/K48-chains	 are	 deubiquitinated	 to	 3	ubiquitins	 by	 the	 proteasome	 whereas	 homotypic	 K11-chains	 are	deubiquitinated	to	only	4	ubiquitins.			 To	 further	 examine	 the	 ability	 of	 the	 proteasome	 to	 disassemble	polyubiquitin	 chains,	 I	measured	 the	 cleavage	 of	 K11-Ub4	 and	 K48-Ub4	 by	 the	proteasome.	Equal	concentrations	of	either	K11-Ub4	or	K48-Ub4	were	incubated	with	 purified	 mammalian	 proteasomes	 for	 0,	 30	 or	 60	 min	 and	 the	deubiquitination	 analysed	 by	 immunoblot	 (Figure	 3.9D).	While	 both	 K48	 and	K11-Ub4	 were	 disassembled	 by	 the	 proteasome,	 the	 K48-chains	 were	 cleaved	more	 rapidly.	 Thus,	 while	 homotypic	 K11-chains	 did	 not	 bind	 strongly	 to	mammalian	proteasomes,	the	26S	associated	DUBs	could	still	disassemble	these	chains,	potentially	protecting	them	from	degradation.	Alternatively,	heterotypic	
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K11/K48-chains	were	 sufficient	 to	 promote	 the	degradation	 of	 a	 ubiquitinated	substrate.				
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Figure 3.9: Homotypic K11-polyubiquitin is not efficiently degraded by mammalian 
proteasomes. (A-C) HA-tagged CyB1-NTK64 was incubated with co-activated APC/C, E1, 
E2s (Ube2C and Ube2S) and Ub, forming homotypic K11- and K48-polyUb chains (using 
UbK11 and UbK48) or heterotypic K11/K48-polyUb chains (using wildtype Ub). 26S 
proteasomes were added to the reactions and the samples incubated at 37°C. The reactions 
were terminated by the addition of SDS loading buffer at 0, 30, 60 and 90 min/ ubiquitination 
and degradation of measured by Immunoblot for cyclin B1 were used to measure degradation 
of CyB1-NTK64  (A, B) and graphical presentation of the means ± SEM of densitometric 
evaluation of the immunoblots from 4 separate experiments are shown (C). Degradation of 
CyB1-NTK64 was measured from 30 min, as time was needed to allow for ubiquitination of 
cyclin B1.Densitometry of the the cumulative ubiquitinated and non-ubiquitinated species of 
cyclin B1 was used to measure the effect of adding the proteasome. Immunoblots for the 20S 
α-subunits and the APC/C subunit cdc27 were used as loading controls. (D) Homotypic K11- 
and K48-free polyUb chains are disassembled by proteasome associated DUBs. 150nM K11-
Ub4 and K48-Ub4 were incubated with 20nM proteasomes at 37°C. The reactions were 
terminated by the addition of SDS loading buffer at 0, 30, and 60 min, and disassembly of the 
chains visualised by immunoblot for Ub. Immunoblots for the 20S α-subunits served as 
loading controls. 						
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3.3	Discussion	By	examining	direct	binding	of	purified	mammalian	proteasomes	 I	have	shown	that	homotypic	K11-chains	bind	weakly	to	the	proteasome	in	comparison	with	 K48-chains.	 This	 represents	 a	 potentially	 novel	 mechanism	 of	 the	proteasome	itself	distinguishing	between	different	chain	types.		We	 also	 showed	 that	 the	 proteasome	 differentiates	 between	 homotypic	and	heterotypic	K11-polyubiquitin	chains.	Heterotypic	K11/K48-chains	not	only	bound	 to	 the	 proteasome	 but	 also	 resulted	 in	 a	 degradative	 outcome	 for	 the	polyubiquitinated	 substrate,	 cyclin	 B1.	 Therefore,	 it	 is	 possible	 that	 different	polyubiquitin	chain	conformations,	as	 illustrated	by	homotypic	and	heterotypic	K11-chains,	 increases	 the	 diversity	 of	 ubiquitin	 signals	 targeting	 substrates	 to	the	proteasome,	which	may	be	important	for	regulating	protein	breakdown.		
3.3.1	Does	 the	 topology	of	homotypic	chain	 linkages	account	 for	 their	weak	
proteasomal	binding?	The	finding	that	K11-polyubiquitin	chains	did	not	bind	to	proteasome	was	unexpected,	as	previous	studies	had	not	identified	any	chain	linkage	specificities	by	ubiquitin	receptions	with	the	19S.	To	ensure	that	my	initial	observations	were	not	due	to	the	conformations	of	K11-polyubiquitin	chains	on	Ube2S,	I	went	on	to	examine	 free	 K11-ubiquitin	 chains	 and	 K11-polyubiquitinated	 cyclin	 B1.		Together,	 these	 experiments	 clearly	 show	 that	 the	 proteasome	 ubiquitin	receptors	 do	 not	 bind	 strongly	 to	 K11-conjugates,	 which	 suggests	 that	 the	structural	conformations	of	K11-ubiquitin	linkages	are	distinct	from	that	of	K48-ubiquitin	 chains.	 Subsequently,	 another	 group	 has	 confirmed	 observed	 similar	findings	 for	 K11-polyubiquitin	 chains	 on	 GFP,	 supporting	 our	 findings	 that	homotypic	 K11-chains	 are	 not	 a	 signal	 for	 proteasome-mediated	 degradation	(Martinez-Fonts	and	Matouschek,	2016)		 The	 structure	 of	 K11-ubiquitin	 dimers	 has	 been	 resolved	 by	 several	groups,	 and	 while	 this	 clearly	 reveals	 a	 structure	 distinct	 from	 other	 known	
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ubiquitin	 linkages,	 such	 as	 K48	 and	 K63,	 there	 is	 lack	 of	 agreement	 as	 to	 the	position	of	the	hydrophobic	I44	binding	patch,	the	recognition	site	on	ubiquitin	for	UBPs.		Resolved	structures	of	K11-ubiquitin	dimers	have	different	ubiquitin-ubiquitin	 orientations,	 depending	 on	 the	 experimental	 methods	 used,	 and	crucially	that	the	hydrophobic	I44	binding	region	of	ubiquitin	is	exposed	in	one	crystal	structure	(Bremm	et	al.,	2010),	and	buried	in	another	(Matsumoto	et	al.,	2010).	Furthermore,	Nuclear	Magnetic	Resonance	 (NMR)	data	and	Small	Angle	Neutron-scattering	 (SANS)	 data	 shows	 that	 the	 structure	 of	 K11-dimers	 is	distinct	 from	 the	 crystal	 structures	 (Castaneda	 et	 al.,	 2013).	 In	 addition,	Castaneda	et	al	show	that	 increasing	salt	concentration	brings	the	hydrophobic	patches	of	the	two	ubiquitins	closer	to	each	other,	which	is	not	seen	with	K48	or	K63	 dimers	 (Castaneda	 et	 al.,	 2013).	 Interestingly,	 the	 Fushman	 and	 Glickman	groups	also	show	that	the	UBA2	domain	of	hHR23A	(which	is	thought	to	shuttle	ubiquitinated	 proteins	 to	 the	 proteasome	 for	 degradation)	 binds	 K48	 dimers	more	 strongly	 than	 K11	 ubiquitin	 dimers,	 as	 a	 single	molecule	 of	 UBA	 cannot	interact	with	both	hydrophobic	regions	of	the	K11	ubiquitin	dimers	at	the	same	time,	 which	 is	 the	 case	 for	 K48	 ubiquitin	 dimers	 (Mansour	 et	 al.,	 2014).	Therefore,	it	is	possible	that	the	compact	K11	dimer	formation	and	orientation	of	the	 two	 ubiquitin	 molecules	 may	 prevent	 the	 I44	 hydrophobic	 region	 being	available	 to	 proteasomal	 receptors.	 Whether	 K11-polyubiquitin	 conjugates	directly	associate	with	proteins	such	as	hHR23A	and	other	putative	‘proteasome	shuttling’	proteins	was	important	to	examine	(see	Chapter	4).			
3.3.2	Heterotypic	K11/K48-chains	allow	binding	and	substrate	degradation	
by	the	proteasome.	
		 The	presence	of	a	relatively	low	percentage	of	K48-polyubiquitin	linkages	within	the	K11-polyubiquitin	chains	allowed	proteasome	binding	and	substrate	degradation.	 Presumably,	 the	 presence	 of	 K48-linkages	 within	 the	 heterotypic	chains	may	open	this	chain	formation	exposing	the	hydrophobic	binding	surface	of	 ubiquitin	 to	 proteasome	 receptors	 and	 shuttling	 factors.	 Alternatively,	 it	 is	possible	 that	 short	 regions	 of	K48-ubiquitin	 linkages	within	 a	mixed	 chain	 are	sufficient	for	proteasome	binding.	So	far,	it	is	not	possible	to	distinguish	between	
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these	possibilities,	 as	 the	 structures	of	mixed	ubiquitin	 linkages	have	not	been	resolved.	However,	my	 findings	 are	 consistent	with	 the	 studies	 of	Meyer	 et	 al,	where	 they	 identified	 K11/K48-heterotypic	 chains	 on	 cell	 cycle	 substrates,	facilitating	 their	 proteasome-mediated	 degradation	 (Meyer	 and	 Rape,	 2014).	However,	one	important	difference	with	our	studies	is	that	Meyer	et	al	conclude	that	 K11/K48-polyubiquitin	 chains	 are	 superior	 signals	 for	 proteasome-mediated	degradation	compared	to	K48-linked	chains,	which	we	did	not	observe.			 It	 is	 likely	 that	 heterotypic	 K11-polyubiquitin	 chains	 have	 different	functions	depending	on	the	linkages	involved.	Heterotypic	K11/K63	chains	were	identified	 on	Major	Histocompatibility	 Complex	 (MHC)	Class	 I	molecules	when	they	 are	 polyubiquitinated	 by	 the	 Kaposi	 Sarcoma	 associated	 herpes	 virus	 E3	ligase,	 K5	 (Boname	 et	 al.,	 2010).	 These	 mixed	 chains	 resulted	 in	 the	internalisation	of	MHC	Class	I	 from	the	cell	surface,	rather	than	degradation	by	the	 proteasome	 (Boname	 et	 al.,	 2010).	 How	 the	 conformation	 and	 linkages	within	 K11-polyubiquitin	 chains	 alters	 the	 recognition	 and	 outcome	 for	 the	ubiquitinated	substrate	may	account	for	the	diversity	of	functional	outcomes	of	K11-linkages	in	different	pathways	(Bremm	et	al.,	2014;	Dao	et	al.,	2012;	Dynek	et	al.,	2010;	Qin	et	al.,	2014).	However,	further	studies	are	needed	to	determine	the	 structures	 of	 the	 K11-heterotypic	 chains,	 and	 it	 would	 be	 intriguing	 to	visualise	 the	 alteration	 that	 K48,	 or	 indeed	 other	 ubiquitin	 linkages	 within	 a	heterotypic	chain,	make	to	the	binding	surfaces	revealed	to	the	proteasome	and	UBPs	within	the	cell.			
3.3.3	 What	 is	 the	 optimal	 signal	 for	 proteasome-mediated	 degradation	 of	
cyclin	B1?	Until	 recently,	 it	 was	 widely	 accepted	 that	 the	 shortest	 polyubiquitin	chain	required	for	recognition	by	the	proteasome	and	to	signal	degradation	was	four	 ubiquitins,	 linked	 by	 lysine	 48	 linkages	 (Thrower	 et	 al.,	 2000)	 but	 our	studies	and	those	of	others	(Dimova	et	al.,	2012;	Kravtsova-Ivantsiv	et	al.,	2009;	Meyer	 and	 Rape,	 2014)	 raise	 the	 possibility	 that	 the	 ubiquitin	 signals	 for	proteasome	degradation	may	be	more	diverse.		
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Two	 labs	 have	 recently	 shown	 that	 multiple	 monoubiquitination	 may	signal	 proteasome	 degradation	 (Dimova	 et	 al.,	 2012;	 Kravtsova-Ivantsiv	 et	 al.,	2009).	The	Ciechanover	lab	shows	that	multiple	monoubiquitination	of	the	p105	NF-κB	 precursor	 may	 be	 sufficient	 to	 signal	 proteasomal	 degradation	(Kravtsova-Ivantsiv	et	al.,	2009).	NF-κB	activation	requires	partial	proteasomal	degradation	 of	 one	 of	 its	 precursors,	 p105,	 to	 form	 p50.	 This	 requires	phosphorylation	 of	 the	 p105	 protein	 by	 IκB	 kinase	 (Myllyharju	 and	Kivirikko)	which	 allows	 recognition	 and	polyubiquitination	 of	 p105	by	 the	 SCF	E3	 ligase,	βTrCP	and	 leads	 to	partial	 proteasomal	degradation	of	p105	 to	 leave	p50.	The	Ciechanover	 lab	 proposes	 a	 phosphorylation	 independent	 proteasomal	degradation	 mechanism	 using	 a	 S927A	 p105	 mutant	 in	 which	 the	 serine	phosphorylated	by	IKK	and	recognised	by	βTrCP	(Heissmeyer	et	al.,	2001;	Lang	et	al.,	2003;	Salmeron	et	al.,	2001)	is	mutated	to	an	alanine.	In	a	cell	free	system,	they	show	that	this	35S-labelled	mutant	is	degraded	to	form	p50	in	the	presence	of	E1,	E2,	WT	ubiquitin	and	a	crude	reticulocyte	fraction	that	lacks	ubiquitin,	and	this	degradation	 is	 impaired	 in	 the	presence	of	MG132.	 In	 addition,	 they	 show	that	 the	 S927A	 p105	mutant	 can	 be	 degraded	 to	 form	 p50	 in	 the	 presence	 of	ubiquitin	 mutants	 which	 cannot	 form	 polyubiquitin	 chains	 (methyl	 ubiquitin	(UbMe),	and	UbKO	(ubiquitin	 in	which	all	 lysine	residues	have	been	mutated))	or	an	ubiquitin	mutant	unable	to	form	K48-linked	chains	(UbK48R),	albeit	to	a	lesser	extent	 than	 with	 WT	 ubiquitin.	 This	 data	 does	 support	 the	 hypothesis	 that	multiple	 monoubiquitination	 of	 S927A	 p105	 mutant	 can	 signal	 proteasomal	degradation	to	p50,	although	chains	formed	with	WT	Ub	still	appear	to	be	a	more	efficient	 degradation	 signal.	 The	 Ciechanover	 lab	went	 on	 to	 show	 that	 S927A	p105	 mutant	 was	 degraded	 to	 form	 p50	 in	 a	 yeast	 system	 expressing	 UbKO	similarly	to	one	expressing	WT	Ub.	In	mammalian	HEK293T	cells	co-expressing	Flag	p105	 and	 either	WT	Ub	or	UbKO,	 p105	was	processed	 similarly.	However,	the	 polyubiquitin	 conjugates	 visualised	 in	 these	 cells	 were	 certainly	 of	 lower	molecular	weight	but	not	necessarily	monoubiquitinated	as	endogeous	ubiquitin	is	present	in	these	cells	in	addition	to	the	overexpressed	UbKO.	In	addition,	p105	is	expressed	not	the	S927A	p105	mutant,	therefore	the	ubiquitination	visualised	may	be	due	to	phosphorylation	and	βTrCP	catalysed	polyubiquitination	to	form	short	chains	and	was	able	to	bind	proteasomal	subunits	similarly.		
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The	King	 and	 Finley	 labs	 also	 suggest	 that	multiple	monoubiquitination	may	 be	 a	 proteasome	 degradation	 signal	 for	 Cyclin	 B1	 (Dimova	 et	 al.,	 2012).	Dimova	et	al	added	a	35S-labelled	N-terminal	 fragment	of	CyclinB1	(cyc-B1-NT)	to	mitotically-arrested	 Xenopus	 extracts	 treated	with	 ubiquitin	 vinyl	 sulphone	(UbVS,)	 an	 isopeptidase	 inhibitor	 which	 prevents	 ubiquitin	 recycling,	 and	showed	 that	 cyc-B1-NT	 degradation	 was	 reduced	 by	 90-95%.	 Addition	 of	wildtype	 ubiquitin	 restored	 cyc-B1-NT	 degradation	 however	 addition	 of	 K11,	K48	or	K63	mutants	and	methyl	ubiquitin	restored	the	degradation	of	cyc-B1-NT	to	a	lesser	extent.	Degradation	still	occurred,	indicating	that	polyubiquitin	chain	formation	 was	 not	 essential	 for	 cyc-B1-NT	 degradation.	 As	 the	 cyc-B1-NT	contained	 a	 limited	 number	 of	 lysines,	 the	 King	 lab	 went	 on	 to	 investigate	whether	the	number	of	lysines	available	for	ubiquitination	affected	the	enhanced	degradation	 seen	 with	 polyubiquitinated	 cyc-B1-NT	 versus	 the	monoubiquitinated	 substrate.	 Using	 the	 Xenopus	 system	 described	 above	 they	measured	 the	 degradation	 of	 full-length	 CyclinB1	 versus	 CyclinB1	mutants	 (in	which	one	or	more	of	 four	 lysines	had	been	mutated	to	arginine).	 Interestingly	full	 length	CyclinB1	was	degraded	similarly	with	the	addition	of	exogenous	WT	Ub,	Ub11R,	 UbtriR	or	UbMe	indicating	 that	monoubiquitinated	 CyclinB1	 supported	proteasomal	degradation.	However,	 the	CyclinB1K64only	mutant,	 in	which	only	 a	single	 lysine	 was	 available	 for	 ubiquitination,	 showed	 significantly	 reduced	degradation	with	the	addition	of	Ub11R,	UbtriR	or	UbMe	compared	with	WT	Ub.	This	data	 indicates	 that	when	 there	 is	multiple	monoubiquitination	of	CyclinB1	 this	may	act	as	a	proteasome	degradation	signal	and	raised	the	question	of	whether	polyubiquitin	 chain	 linkage	 determined	 degradation	 by	 the	 proteasome,	 or	whether	the	density	of	ubiquitin	on	the	19S	was	more	important.	To	 explore	 this	 further,	 the	 Kirschner	 and	 Finlay	 labs	 developed	 single	molecule	 assays	 that	 enabled	 comparison	 of	 the	 proteasomal	 degradation	 of	cyclin	B1	modified	with	a	single	ubiquitin	tetramer	versus	two	dimers	(Lu	et	al.,	2015).	 Lu	 et	 al	 used	 purified	 APC/C	 to	 conjugate	 pre-formed	 K48	 dimers	 or	tetramers	onto	an	N	terminal	fragment	of	CyclinB1	(CyclinB1Nterm)	and	separated	the	 di	 or	 tetraubiquitinated	 conjugates	 by	 electrophoresis.	 These	 conjugates	were	 incubated	 with	 purified	 proteasomes,	 which	 had	 been	 salt	 washed	 to	remove	 USP14,	 preventing	 deubiquitination	 of	 the	 tetramers	 to	 dimers.	
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Quantification	 of	 the	 rate	 of	 degradation	 of	 CyclinB1Nterm	 by	 autoradiography	showed	 that	 CyclinB1Nterm	 ubiquitinated	 with	 two	 K48	 dimers	 was	 degraded	more	 rapidly	 than	 one	 ubiquitinated	with	 a	 single	 K48	 tetramer,	 and	 this	was	superior	 to	 K11-ubiquitin	 chains.	 Interestingly,	 the	 Kirschner	 and	 Finley	 labs	also	 compared	 the	 proteasomal	 degradation	 of	 Securin	modified	 with	 K48	 or	K11-linked	dimers,	 and	showed	 that	K48-linked	dimers	 resulted	 in	more	 rapid	degradation	 than	 K11	 (Lu	 et	 al.,	 2015),	 agreeing	 with	 our	 findings	 that	 K11	ubiquitination	 is	 a	 weaker	 proteasomal	 degradation	 signal	 than	 K48.	 The	physiological	benefit	of	forming	non-proteasomally	degraded	K11-conjugates	on	cell	 cycle	substrates	 is	not	yet	clear,	but	 they	may	serve	 to	prime	cyclin	B1	 for	subsequent	K48	mediated	degradation.		 Whether	 the	 ubiquitin	 signal	 is	 the	 only	 requirement	 for	 degradation	 is	brought	 into	 question	 by	 the	 Matouschek	 lab	 who	 suggest	 that	 an	 unfolded	region	in	the	substrate	is	also	needed	and	that	proteins	can	be	degraded	either	from	C	to	N	or	from	N	to	C	terminus	(Prakash	et	al.,	2004).	While	they	have	not	directly	 examined	 cyclin	 B1,	 the	Matouschek	 lab	 formed	 a	model	 two	 domain	protein	 consisting	 of	 dihydrofolate	 reductase	 (DHFR)	 and	 the	 ribonuclease,	barnase.	 Incubation	 with	 purified	 proteasomes	 allowed	 quantification	 of	degradation	 of	 the	 two-domain	 protein	 by	 autoradiography,	 and	 interestingly,	the	 two-domain	 protein	 could	 be	 completely	 degraded	 regardless	 of	 which	protein	was	adjacent	to	the	ubiquitination	signal.	The	Matouschek	lab	went	on	to	design	 a	 protein	 lacking	 an	 unstructured	 region	 which	 consisted	 of	 a	 tetra-ubiquitin	 tag	 attached	 to	 the	 N-terminus	 of	 DHFR.	 This	 protein	was	 degraded	inefficiently	 by	 the	 proteasome.	 However,	 when	 an	 unstructured	 region	 was	attached	either	to	the	C-terminus	or	between	the	ubiquitin	tag	and	the	DHFR,	the	protein	was	rapidly	degraded,	providing	evidence	that	an	unstructured	region	of	20	amino	acids	was	sufficient	to	allow	degradation	of	the	DHFR	(Prakash	et	al.,	2004).	While	 unfolded	 regions	 of	 Cyclin	 B1	 have	 not	 been	 determined,	 the	 N-terminal	 region	of	Cyclin	B1	 (1-64)	 is	predicted	 to	be	disorded,	and	 is	also	 the	site	 of	 ubiquitination.	 It	 is	 therefore	 likely	 that	 disorder	 in	 the	 N-terminus	 of	cyclin	 B1	 contributes	 to	 its	 recognition	 by	 the	 proteasome,	 in	 addition	 to	modification	 by	 polyubiquitination.	 Moreover,	 my	 findings	 highlight	 that	 the	
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nature	 of	 the	 polyubiquitin	 chain	 can	 directly	 alter	 the	 affinity	 of	 the	polyubiquitin	chain	on	Cyclin	B1	for	the	proteasome	ubiquitin	receptors.			
	
3.4	Summary	In	 this	 chapter,	 I	 determined	 if	 K11-linked	 polyubiquitin	 chains	 were	recognised	 by	 the	 proteasome	 and	 whether	 they	 acted	 as	 a	 signal	 for	proteasomal	 degradation.	 I	 generated	 both	 free	 and	 substrate-bound	 K11	 and	K48-linked	 polyubiquitin	 chains	 using	 in	 vitro	 autoubiquitination	 of	 the	 E2	enzyme,	 Ube2S,	 and	 E3	 enzyme,	 E6AP,	 respectively,	 and	 purified	 mammalian	proteasome	 from	 rabbit	 muscle.	 Using	 an	 in	 vitro	 binding	 assay	 to	 compare	binding	of	 the	 substrate-bound	polyubiquitin	 chains	 to	purified	proteasomes,	 I	showed	 that	K11-linked	polyubiquitin	 conjugates	 did	 not	 bind	 the	 proteasome	compared	 to	 K48-linked	 chains.	 Furthermore,	 K11-linked	 ubiquitin	 tetramers	were	not	able	to	displace	K48-linked	polyubiquitin	conjugates	from	purified	26S	proteasomes,	 confirming	 that	 K11-linked	 chains	 bound	 more	 weakly	 to	 the	proteasome	than	K48-linked	polyubiquitin	chains.	To	determine	the	relevance	of	these	 findings	 to	 known	 K11-polyubiquitinated	 substrates,	 we	 compared	 the	ability	of	homotypic	versus	heterotypic	polyubiquitin	chains	on	Cyclin	B1	to	bind	the	proteasome.	Homotypic	K11-linked	chains	on	Cyclin	B1	were	unable	to	bind	the	 proteasome	 whereas	 heterotypic	 K11/K48-linked	 chains	 facilitated	proteasome-mediated	 degradation,	 albeit	 less	 efficiently	 than	 homotypic	 K48-linked	chains.	Thus,	while	homotypic	K11-linked	polyubiquitin	chains	are	not	a	signal	for	proteasome-mediated	degradation,	heterotypic	K11/K48-linked	chains	are	 recognised	 by	 the	 proteasome	 and	 enable	 degradation	 of	 the	polyubiquitinated	substrate,	Cyclin	B1.				 	
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 Chapter	4:	Results	2,	Identification	of	K11-ubiquitin	
binding	proteins.	
	
4.1	Introduction		
4.1.1	The	recognition	of	K11-linked	polyubiquitin	chains	by	ubiquitin	binding	
proteins	To	date,	no	specific	UBPs	have	been	identified	for	K11-ubiquitin	chains.	It	had	 been	 suggested	 that	 the	 Rad23	 protein,	 hHR23A	 binds	 to	 K11-polyubiquitinated	 Cyclin	B1	 and	 shuttle	 it	 to	 the	 proteasome	 (Jin	 et	 al.,	 2008).	However,	 these	 observations	 may	 relate	 to	 Rad23	 proteins	 associating	 with	heterotypic	 K11/K48-polyubiquitin	 chains	 on	 cyclin	 B1	 rather	 than	 homotypic	K11-linked	 polyubiquitin	 linkages.	 Therefore,	 it	 was	 of	 interest	 to	 explore	whether	 there	 were	 UBPs	 that	 bound	 specifically	 to	 K11-linked	 polyubiquitin	chains	 or	 whether	 there	 were	 proteasome-associated	 shuttling	 factors	 which	enabled	K11-linked	polyubiquitin	chain	binding	to	the	proteasome.		In	this	chapter,	I	first	examine	how	known	proteasomal	shuttling	proteins	bind	to	substrate-bound	K11-linked	polyubiquitin	chains,	before	describing	how	mass	 spectrometry	 analysis	 of	 K11-linked	 polyubiquitin	 chains	 incubated	with	cell	 lysates	 can	 be	 used	 to	 identify	 potential	 novel	 K11-specific	 UBPs.	 I	 then	investigate	 whether	 a	 novel	 protein,	 FAM115A	 (identified	 by	 mass	spectrometry),	 is	able	to	bind	directly	 to	K11-linked	polyubiquitin	chains	using	bacterial	 expression	of	 the	 recombinant	protein.	 	 Lastly,	 I	 focus	on	other	UBPs	found	 to	 bind	 to	 K11-linked	 polyubiquitin	 chains	 by	 mass	 spectrometry,	 and	determine	how	Tax1	Binding	Protein	1	 (TAX1BP1,	 also	known	as	T6BP1),	 and	myosin	VI	bind	to	K11	and	K63–linked	polyubiquitin	chains.			 	
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4.2	Results		
	
4.2.1	 Ubiquitin	 binding	 proteins	 involved	 in	 shuttling	 proteins	 to	 the	
proteasome	do	not	bind	K11-polyubiquitin	chains.	Rpn10	 and	 the	 Rad23	 proteins	 (hHR23A	 and	 hHR23B)	 are	 the	predominant	 UBPs	 thought	 to	 shuttle	 polyubiquitinated	 proteins	 to	 the	proteasomes	 (Elsasser	 et	 al.,	 2004;	 Husnjak	 et	 al.,	 2008;	 Peth	 et	 al.,	 2010;	Schreiner	 et	 al.,	 2008).	 To	 determine	 whether	 homotypic	 K11-chains	 are	directed	 to	 the	 proteasome	 by	 associating	 with	 these	 proteasome	 shuttling	factors,	I	measured	the	binding	of	polyubiquitinated	GST-Ube2SΔ	and	GST-E6AP	to	either	the	proteasomal	subunit	Rpn	10	or	purified	hHR23A.	The	polyubiquitin	conjugates	 were	 incubated	 with	 the	 His-tagged	 UIM	 of	 Rpn10	 or	 full-length	hHR23A	 for	 1	 hr	 at	 4°C,	 the	 resins	washed	 and	 the	 bound	UBPs	 visualized	 by	immunoblot	 (Figure	 4.1A).	 While	 His-UIM	 bound	 to	 polyubiquitinated	 E6AP,	minimal	 binding	 to	 the	 K11-conjugates	was	 observed.	 HHR23A	 only	 bound	 to	polyubiquitinated	 E6AP	 and	 not	 the	 K11-chains	 on	 Ube2SΔ.	 I	 repeated	 this	binding	experiment	using	recombinant	hHR23B	(Figure	 4.1B)	which,	 similarly	to	hHR23A,	only	bound	to	polyubiquitinated	E6AP.		Having	 used	 recombinant	 proteins	 to	 investigate	 polyubiquitin	 chain	binding,	I	went	on	to	investigate	whether	the	K11	and	K48-chains	associate	with	proteasome	 shuttling	 factors	 from	 cell	 lysates	 (Figure	 4.1C,	 D).	Polyubiquitinated	 GST-Ube2SΔ	 and	 GST-E6AP	 were	 incubated	 with	 HeLa	 cell	lysates	for	1hr	at	4°C,	the	resins	washed	and	proteins	bound	to	the	polyubiquitin	conjugates	 visualized	 by	 immunoblot	 (Figure	 4.1C,	 D).	 Rpn10,	 hHR23A	 and	B	bound	to	polyubiquitinated	E6AP	but	not	polyubiquitinated	Ube2SΔ,	 consistent	with	 the	 assays	 using	 the	 recombinant	 proteins.	 I	 also	 immunoblotted	 for	another	 proteasome	 shuttling	 factor,	 Ubiquilin	 (UBQLN1),	 which	 contains	 an	ubiquitin	like	domain	(Ubl)	and	a	ubiquitin	associated	domain	(Ko	et	al.,	2004).	Similarly	 to	 the	Rad23	proteins,	UBQLN1	only	 bound	 to	 the	K48-polyubiquitin	chains.	While	the	proteasome	shuttling	factors	demonstrated	clear	specificity	for	K48-linked	polyubiquitin	conjugates,	it	was	important	to	determine	whether	the	
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K11-chains	 could	bind	other	UBPs	 in	 cell	 lysates.	Therefore,	 I	probed	 the	blots	for	the	UBP,	USP5,	a	deubiquitinating	enzyme	that	can	bind	both	K48	and	K63-linked	chains	(Nathan	et	al.,	2013).	USP5	bound	to	both	polyubiquitinated	E6AP	and	Ube2SΔ,	confirming	that	the	K11-chains	can	be	recognized	by	other	UBPs.		Although	the	proteasome	shuttling	factors	did	not	bind	to	the	K11-chains,	it	remained	possible	that	the	Rad23	proteins,	in	complex	with	19S,	may	increase	the	binding	of	K11-chains	to	the	proteasome.	To	address	this,	I	used	K11-chains	formed	on	GST-Ube2SΔ	and	K48-chains	formed	on	GST-E6AP	in	the	proteasome	binding	 assay	 (Figure	 3.4),	 but	 now	 in	 the	 presence	 of	 recombinant	 hHR23A.	After	1hr	 incubation	at	4°C,	 I	washed	the	resins,	and	assessed	the	proteasomes	bound	 to	 the	 polyubiquitin	 chains	 by	 LLVY-AMC	 cleavage.	 Polyubiquitinated	E6AP	 bound	 strongly	 to	 the	 proteasome,	 and	 this	 binding	 is	 increased	 in	 the	presence	 of	 hHR23A	 (protein	 purified	 by	 James	 Nathan)	 (Figure	 4.1E),	 as	previously	 reported	 (Nathan	et	 al.,	 2013).	However,	hHR23A	did	not	 affect	 the	ability	 of	 K11-chains	 on	 Ube2SΔ	 to	 bind	 to	 proteasomes	 (Figure	 4.1E).	 Thus,	Rad23	 proteins,	 in	 complex	 with	 the	 26S	 proteasome,	 did	 not	 facilitate	 the	binding	of	K11-linked	polyubiquitin	conjugates	to	the	proteasome.			 Could	 there	be	 other	 factors	within	 cell	 lysate	 that	 affect	 the	binding	of	K11-chains	 to	 the	 proteasome?	 To	 examine	 this,	 I	 incubated	 the	 K11-chains	formed	 on	 GST-Ube2SΔ	 and	 K48-chains	 formed	 on	 GST-E6AP	 with	 Hela	 cell	lysates,	removed	unbound	proteins	by	sequential	wash	steps,	and	measured	the	binding	of	endogenous	proteasomes	within	the	cell	extract	to	the	polyubiquitin	chains.	 	 The	 K48-linked	 polyubiquitin	 conjugates	 bound	 strongly	 to	 the	endogenous	 proteasomes,	 however,	 the	 K11-chains	 only	 bound	 weakly	 to	proteasomes	 (Figure	 4.1F).	 Therefore,	 there	 did	 not	 seem	 to	 be	 other	 cellular	factors	 that	 facilitated	 the	 binding	 of	 K11-linked	 polyubiquitin	 chains	 to	 the	proteasome.	
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Figure 4.1: Proteasome-associated ubiquitin binding proteins preferentially bind K48-
chains compared to K11-polyubiquitin chains. (A, B) Polyubiquitinated-E6AP and 
Ube2SΔ were incubated with 100nM Rpn10-UIM, hHR23A (A) or hHR23B (B) for 30 min at 
4°C, washed and the bound proteins visualised by immunoblot for His (Rpn10) or hHR23A/B. 
Ubiquitination of E6AP and Ube2SΔ was confirmed by immunoblot for ubiquitin (A) or 
Coomassie (B). (C, D) Proteasome associated UBPs in cell extracts do not bind homotypic 
K11-chains. Polyubiquitinated-E6AP and Ube2SΔ were incubated with HeLa cell extracts for 
30min at 4°C, washed and the bound proteins visualised by immunoblot for hHR23A and B 
(C), or Rpn10, UBQLN1 and USP5 (D). Ubiquitination of E6AP and Ube2SΔ was confirmed 
by Coomassie (C) or immunoblot for ubiquitin (D). (E) Resin-bound polyUb-E6AP and 
Ube2SΔ were incubated with purified proteasomes, or with 26S particles and 300nM 
hHR23A. The bound proteasomes were measured by LLVY-AMC cleavage. (F) Proteasomes 
in cell lysates bind to K48-polyUb chains but not K11-chains. Resin-bound polyubiquitinated-
E6AP and Ube2SΔ, and non-modified controls were incubated with HeLa lysates for 30 min 
at 4°C and the bound proteasomes measured. Values are means ± SEM from three 
experimental replicates. 
	
4.2.2	 Mass	 spectrometry	 approach	 to	 identify	 proteins	 that	 associate	 with	
K11-linked	polyubiquitin	chains.		Although	 K11-chains	 do	 not	 seem	 to	 bind	 the	 proteasome-associated	UBPs	 or	 shuttling	 factors,	 they	must	 be	 recognized	 by	 other	 UBPs	 to	 facilitate	their	functional	outcomes	in	cells.	We	were	also	interested	to	determine	whether	there	are	UBPs	that	demonstrate	linkage	specificity	for	K11-chains,	as	has	been	shown	 for	 K48	 and	 K63-linkages	 (Nathan	 et	 al.,	 2013).	 Therefore,	 to	 identify	UBPs	that	bound	K11-chains,	we	incubated	polyubiquitinated	GST-Ube2SΔ	with	HeLa	 cell	 lysates	 for	 1hr	 at	 4°C,	 extensively	 washed	 the	 resins,	 separated	 the	proteins	bound	to	the	polyubiquitin	conjugates	by	SDS-PAGE	and	visualized	the	bound	proteins	by	Coomassie	staining	(these	experiments	were	conducted	with	James	 Nathan).	 The	 gels	 were	 then	 analysed	 by	 MS/MS	 (Table	 4.1).	Polyubiquitinated	E6AP	was	used	as	a	control	for	identifying	K48-selective	UBPs.			The	predominant	proteins	identified	to	be	K48-specific	were	components	of	 the	 26S	 proteasome	 and	 associated	 UBPs.	 No	 proteasome	 subunits	 were	observed	to	bind	to	the	K11-conjugates,	consistent	with	the	proteasome	binding	experiments	 (Chapter	 3).	 However,	 several	 proteins	 that	 bound	 to	 K11-ubiquitin	 linkages	 were	 identified.	 The	 most	 abundant	 protein	 by	 MS	 was	 an	uncharacterized	102kDa	protein,	FAM115A.	Other	proteins	 that	bound	 to	K11-linkages	 are	 shown	 in	Table	 4.1.	 These	 included	 proteins	 with	 known	 UBDs,	such	 as	 myosin	 VI,	 TAX1BP1	 and	 Epsin	 2;	 DUBs,	 including	 USP4,	 11,	 and	 15,	which	are	a	subgroup	of	USPs	that	contain	a	DUSP	(domain	present	in	ubiquitin-
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specific	proteases)	(Harper	et	al.,	2011).	Several	proteins	bound	to	both	K48	and	K11-linked	polyubiquitin	chains,	including	the	DUB	USP5,	which	I	had	previously	shown	bound	both	chain	types	(Figure	4.1D).		 As	 FAM115A	 was	 an	 uncharacterized	 protein,	 which	 potentially	 bound	selectively	 to	 K11-linked	 polyubiquitin	 chains,	 I	 was	 keen	 to	 explore	 whether	this	was	indeed	a	K11-specific	UBP.		
 K48 specific K11 specific Both K48 and K11 
UBPs 3 5 
(myosin VI, Epsin 2, 
Tax1BP, Tollip and 
UBXN1) 
2 
(WRNIP, TOM1L2) 
Ubl-UBA proteins 2 0 0 
E3 ligases 2 2  
(NCCRP1/f box, 
RNF126) 
2  
(HUWE1, UBR4) 
DUBs 3 4  
(USP15, USP4, 
USP11, USP19) 
2 
(USP5, USP13) 
26S components 14 0 2 
(Alpha 4 and Rpt1) 
P97 components 5 0 0 
Uncharacterised 3 4 
(FAM115A, 
ANKRD13A, 
PAIP1/PABC) 
0 
	
Table 4.1: Identification of ubiquitin binding proteins that bind to homotypic K11-linked 
ubiquitin chains.  Polyubiquitinated GST-E6AP (K48-chains) or GST-Ube2SΔ (K11-chains) 
were incubated with A431 cell extracts at 4°C for 2 hr, the resins washed and the proteins 
bound to the resins separated by SDS-PAGE and analysed by MS/MS. The table summarises 
the proteins identified with more than 2 peptides. 	
	
4.2.3	Is	FAM115A	a	novel	K11-selective	ubiquitin	binding	protein?	Bioinformatic	 analyses	 of	 FAM115A	 showed	 that	 it	 is	 predicted	 to	 be	 a	soluble	protein	that	 is	evolutionary	conserved	from	zebrafish	to	humans.	Using	the	 Phyre2	 structural	 prediction	 programme	 (Kelley	 et	 al.,	 2015),	 FAM115A	 is	predicted	 to	 encode	 a	 flavodoxin-like	 fold	 at	 its	 N-terminus,	 and	 a	 C-terminal	region	 that	 shows	 high	 structural	 homology	 to	 the	 aminopeptidase	 domain	 of	ERAP1	 (endoplasmic	 reticulum	 aminopeptidase	 1)	 (Figure	 4.2A,	 B),	 a	 single-pass	 type	 II	ER	membrane	 that	cleaves	 the	amino	 terminus	of	peptides	 to	 load	onto	MHC	Class	I	(Chang	et	al.,	2005).	This	ERAP1	like	domain	is	also	similar	to	a	peptidase	 domain	 initially	 identified	 in	 bacteria	 (M60	 domain)	 (Nakjang	 et	 al.,	
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2012)	 (Figure	 4.2B).	 However,	 FAM115A	 encodes	 an	 arginine	 instead	 of	 a	histidine	 in	 the	 predicted	 catalytic	 site	 that	 co-ordinates	 the	 zinc	 molecule	(Figure	4.2B),	and	therefore	may	be	catalytically	inactive	as	a	peptidase.		Initial	 experiments	 (conducted	 by	 James	 Nathan)	 suggested	 that	FAM115A	 may	 bind	 to	 K11-polyubiquitin	 conjugates,	 as	 A431	 cells	 stably	expressing	 HA-FAM115A	 bound	 polyubiquitinated	 GST-Ube2SΔ	 resins	 more	strongly	than	polyubiquitinated	GST-E6AP	(Figure	4.2C).	
	
Figure 4.2: FAM115, a putative K11-ubiquitin binding protein. (A) Schematic of FAM115A 
protein (human) indicating the flavodoxin like region (FD like) and the M60 peptidase domain 
(M60/ERAP1). (B) Schematic ribbon diagram of the predicted M60/ERAP1 (green) like 
structure compared to ERAP1 (blue). The catalytic histidine (Maltepe et al.) in ERAP1 is 
indicated (images prepared by Roger Dodd, CIMR).  (C) Association of HA-FAM115A from 
cell lysates with polyubiquitin conjugates (James Nathan, CIMR). HA-FAM115A was 
expressed in A431 cells, immunopurified and incubated with either ubiquitinated E6AP or 
Ube2S in vitro 1h 4° and the resins washed x4 TBS 1% NP40. 		
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	 	To	examine	whether	FAM115A	directly	bound	 to	 the	K11-polyubiquitin	conjugates,	 it	 was	 important	 to	 generate	 recombinant	 FAM115A.	 Therefore,	 I	made	 GST	 and	 His-tagged	 constructs	 of	 full-length	 FAM115A	 (FL),	 the	flavodoxin-like	 fold	 (FD)	 and	 putative	 protease	 domain	 (M60).	 I	 transformed	these	constructs	 into	DE3*	E.	coli	using	standard	methods	and	 induced	protein	synthesis	with	0.5mM	IPTG	37°C	3hr.	These	proteins	were	highly	expressed	 in	the	bacteria	but	unfortunately	were	not	 soluble.	 I	 tested	 several	His-	 and	GST-tagged	constructs,	different	E.	coli	strains	(BL21,	Rosetta,	C41	and	C43)	different	induction	 temperatures	 (16°C,	25°C,	37°C)	and	many	different	buffers	 for	 lysis,	but	 only	 low	 concentrations	 of	 proteins	 were	 achieved	 with	 a	 GST-tagged	construct	 of	 the	 M60	 domain,	 and	 this	 rapidly	 aggregated	 in	 solution	 or	remained	on	the	resin	after	GST-PreScission	cleavage	(Figure	4.3A-C).			 In	 a	 final	 attempt	 to	 purify	 FAM115A	 I	 used	 the	 Ligation	 Independent	Cloning	 (LIC)	 system	 established	 by	 Dr	 Katrin	 Rittinger’s	 group	 (National	Institute	 for	 Medical	 Research/Francis	 Crick	 Institute),	 as	 a	 high	 throughput	method	 to	 screen	 up	 to	 96	 different	 constructs	 at	 a	 time,	 testing	 for	 protein	expression	and	solubility	(Chapter	 2.3.1).	The	advantage	of	 this	system	is	 that	one	 can	make	multiple	 peptides	 for	 each	 protein	 of	 interest,	 which	may	 have	differently	 solubility	 characteristics	 depending	 on	 the	 amino	 acid	 sequence.	Therefore,	 working	with	 Vangelis	 Christodoulou	 in	 Dr	 Rittinger’s	 group	 at	 the	NIMR,	I	designed	primers	for	48	FAM115A	peptides,	amplified	the	DNA	by	PCR	and	 used	 LIC	 to	 insert	 the	 DNA	 into	 a	 LIC	 vector	 with	 an	 N-terminal	 His	 tag.	These	 vectors	 were	 then	 transformed	 into	 BL21DE3*	 Gold	 E.	 coli	 and	 protein	expression	 induced	with	0.5mM	 IPTG	overnight.	 Solubility	 of	 the	peptides	was	assessed	 by	 SDS-PAGE	 and	 Coomassie	 staining.	 Although	 all	 constructs	expressed	successfully	 in	E.	coli,	the	peptides	were	either	insoluble	or	migrated	at	 the	 incorrect	predicted	size	 (probably	 truncated).	Thus,	bacterial	expression	of	FAM115A	was	unsuccessful,	and	so	far	I	have	been	unable	to	test	whether	 it	directly	binds	to	K11-linked	polyubiquitin	chains.						
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Figure 4.3: Expression of GST-FAM115A M60 in E. Coli. (A-C) GST-tagged FAM115A 
M60 was induced in E. coli with 0.5mM IPTG and expression in the total cell extracts 
measured by Coomassie staining (A). The GST-FAM115A M60 protein was then purified on 
glutathione sepharose beads and separated by SDS-PAGE before staining with Coomassie 
blue (B). PreScission cleavage of GST-FAM115A M60 on GSH resin overnight, analysed with 
Coomassie blue staining (C). The total reaction, flow through (unbound GST-FAM115A) and 
resin bound (GST-FAM115A, cleaved FAM115A, and free GST) are indicated. 			 	
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4.2.4	 Do	 ubiquitin	 binding	 proteins	 involved	 in	 mitophagy,	 TAX1BP1	 and	
myosin	VI,	bind	to	K11	polyubiquitin	chains?	While	it	proved	difficult	to	examine	if	FAM115A	was	a	K11-specific	UBP,	several	other	proteins	that	were	enriched	for	K11-linked	polyubiquitin	conjugate	binding	 were	 of	 interest	 (Table	 4.1).	 The	 identification	 of	 the	 autophagy	receptors,	TAX1BP1	and	Myosin	VI,	as	putative	K11-linkage	selective	UBPs	from	our	mass	 spectrometry	 results	 (Table	 4.1)	were	 intriguing,	 and	 I	 studied	 this	further	as	part	of	a	collaboration	with	Folma	Buss’	group	(CIMR).		Prior	mass	spectrometry	based	studies	showed	that	K11-linked	ubiquitin	linkages	increased	during	mitophagy	(Cunningham	et	al.,	2015),	suggesting	that	K11-linked	polyubiquitination	is	involved	in	this	specialised	form	of	autophagy.	TAX1BP1	was	also	known	 to	be	 recruited	by	 the	ubiquitin	kinase	PINK1	when	mitophagy	 is	 induced	 (Lazarou	 et	 al.,	 2015).	 Furthermore,	 a	 ubiquitin	 binding	domain	in	myosin	VI	that	binds	to	K11,	K63	and	K29	dimers	had	been	identified	(He	et	al.,	2016).	Therefore,	using	recombinant	TAX1BP1	and	Myosin	VI	from	Dr	Buss	 and	 Dr	 Kendrick-Jones	 (Chapter	 2.3.2)	 I	 aimed	 to	 examine	 how	 these	proteins	bind	to	K11-polyubiquitin	chains	and	whether	K11-polyubiquitin	chains	have	a	functional	role	in	the	binding	of	TAX1BP1	to	myosin	VI.		
Do	 Myosin	 VI	 and	 TAX1BP1	 bind	 to	 K11	 and	 K63-linked	 ubiquitin	
tetramers	 in	 vitro?	 In	 order	 to	 measure	 whether	 K11	 or	 K63-linked	tetraubiquitin	conjugates	would	bind	to	myosin	VI	CBD	or	TAX1BP1,	it	was	first	necessary	 to	 generate	 an	 in	 vitro	 binding	 assay.	 I	 used	 homotypic	 K11-linked	tetramers	 that	 I	 had	 generated	 previously	 (Chapter	 3)	 and	 recombinant	 His-TAX1BP1	and	His-myosin	VI	cargo	binding	domain	(CBD),	containing	the	MyUb	ubiquitin	 binding	 site	 recently	 identified	 as	 a	 novel	 ubiquitin	 binding	 domain	which	 includes	 the	 RRL	 motif,	 responsible	 for	 binding	 autophagy	 receptors	including	TAX1BP1	(Morriswood	et	al.,	2007).	These	proteins	were	designed	and	purified	 by	Prof.	 John	Kendrick-Jones	 (LMB).	 First,	 equal	 concentrations	 of	 the	His-TAX1BP1	or	His-Myosin	VI	CBD	were	immobilised	on	NiNTA	agarose	resin	at	4°C	for	30min	on	a	rotator	in	the	presence	of	Tris	binding	buffer	(TBB)	and	then	the	resins	washed	to	remove	unbound	proteins.	The	resin-bound	His-TAX1BP1	or	 His-myosin	 VI	 CBD	 was	 then	 incubated	 alone	 or	 with	 increasing	
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concentrations	 of	 K11	 or	 K63-tetramers	 for	 30min	 at	 4°C	 on	 a	 rotator,	 and	unbound	 tetramers	 (Ub4)	 removed	 by	 washing	 in	 TBB.	 Bound	 proteins	 were	visualised	by	immunoblot	using	antibodies	to	TAX1BP1,	myosin	VI	or	ubiquitin	respectively	 (Figure	 4.4A-C).	 Interestingly,	 I	 found	 that	 His-TAX1BP1	 or	 His-myosin	 VI	 CBD	were	 able	 to	 bind	 both	 K11	 and	 K63-Ub4,	 however	 only	weak	binding	to	K11	Ub4	was	observed	(Figure	4.4A,	B).		
		
Figure 4.4: MyosinVI CBD and Tax1BP1 bind to K63 and K11 ubiquitin tetramers in 
vitro. (A, B) His-tagged MyosinVI cargo binding domain (CBD) (A) His-tagged Tax1BP1 (C-
terminal half) (B) were bound to NiNTA resin and incubated with increasing concentrations of 
K63 or K11 tetra-ubiquitin (Ub4) and then washed to remove unbound Ub4. Bound proteins 
were visualised by immunoblot using antibodies against ubiquitin (A, B) and MyosinVI (A) or 
TaxBP1 (B). (C) Equal amounts of K63 or K11 Ub4 were visualised by immunoblot using an 
antibody against ubiquitin (FK2). 		
	
Competition	assay	to	measure	K63	and	K11	tetraubiquitin	conjugate	
binding	 to	 Myosin	 VI	 CBD	 or	 TAX1BP1	 in	 vitro.	 Myosin	 VI	 not	 only	 binds	ubiquitin	but	can	also	bind	TAX1BP1	(Morriswood	et	al.,	2007;	Sahlender	et	al.,	2005).	 However,	 the	 myosin	 VI	 binding	 domains	 for	 ubiquitin	 and	 TAX1BP1	overlap	 (Tumbarello	 et	 al.,	 2015).	 Therefore,	 I	 wanted	 to	 determine	 whether	ubiquitin	 or	 TAX1BP1	 bound	 preferentially	 to	 myosin	 VI,	 or	 whether	 the	
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complex	of	TAX1BP1	with	Myosin	VI	had	a	high	affinity/avidity	for	K63	or	K11-polyubiquitin	chains.		Recombinant	 GST-myosin	 VI	 CBD	 was	 incubated	 with	 Glutathione	Sepharose	resin	with	either	K11	or	K63	ubiquitin	tetramers	for	30	min	at	4°C	on	a	rotator.	Unbound	proteins	were	removed	by	several	washes	in	TBB.	The	resin-bound	myosin	VI	and	ubiquitin	tetramers	were	then	incubated	with	or	without	increasing	concentrations	of	His-TAX1BP1,	and	bound	proteins	were	visualised	by	 immunoblot	 using	 antibodies	 to	 GST,	 ubiquitin	 or	 TAX1BP1	 respectively	(Figure	4.5).		Unfortunately,	minimal	binding	of	the	K11-polyubiquitin	chains	to	Myosin	VI	 was	 observed,	 and	 TAX1PB1	 did	 not	 alter	 the	 binding	 of	 Myosin	 VI	 to	 the	ubiquitin	 chains	 (data	 not	 shown).	 However,	 interestingly,	 while	 the	concentration	of	K63	Ub4	bound	to	myosin	VI	remained	the	same	with	increasing	concentrations	of	TAX1BP1	(Figure	4.5,	middle	panel),	more	TAX1BP1	bound	to	the	GST-Myosin	VI	CBD	when	K63	Ub4	was	added	(Figure	4.5,	 lower	panel).	Therefore,	TAX1BP1	bound	to	Myosin	VI	CBD	more	strongly	 in	 the	presence	of	K63-Ub4,	rather	than	displacing	the	ubiquitin	chains,	suggesting	that	a	Myosin	VI-K63Ub4-TAX1BP1	complex	was	formed.	I	 attempted	 to	 repeat	 these	 experiments	 with	 higher	 concentrations	 of	K11-Ub4,	but	it	was	not	possible	to	generate	sufficient	recombinant	K11-Ub4	for	the	 competition	 assay.	 Therefore,	 it	 is	 probable	 that	 K11-linked	 polyubiquitin	conjugates	have	a	 low	affinity	or	avidity	 for	the	Myosin	VI	UBD,	and	are	of	 less	importance	than	K63-ubiquitin	linkages	in	mitophagy.			
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Figure 4.5: K63 tetramers form a complex with MyosinVI CBD and TAX1BP1. GST-
tagged Myosin VII CBD (MyVI CBD, blue) and K63 tetra-ubiquitin (Ub4) chains (yellow) were 
incubated with glutathione sepharose resin (GSH, red). The resins were washed and then 
incubated with increasing amounts of His-tagged TAX1BP1 (C-terminal half, green). The 
samples were analysed by immunoblotting with antibodies against GST to detect Myosin VI, 
bound ubiquitin (P4D1), and bound His-TAX1BP1. As controls, GST-MyosinVI CBD, K63 Ub4, 
and His-TAX1BP1 were individually incubated with GSH sepharose to determine if there was 
any non-specific binding. GST-MyosinVI CBD and His-TAX1BP1 were also incubated 
together to demonstrate direct binding. Inputs of K63 Ub4 and His-TAX1BP1 are also shown 
(TAX1PB1 input). Representative of four independent experiments. 				 	
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4.3	Discussion		
4.3.1	Is	FAM115A	a	K11-linked	polyubiquitin	selective	UBP?	It	 is	 very	 likely	 that	 K11-selective	 UBPs	 exist,	 particularly	 as	 they	 are	required	 for	 other	 ubiquitin	 linkages	 in	 cells.	 The	 Rad23	 proteins	 have	 been	shown	 to	 bind	 K48-linked	 polyubiquitin	 chains	 and	 shuttle	 them	 to	 the	proteasome	 (Elsasser	 et	 al.,	 2004;	 Nathan	 et	 al.,	 2013),	 whereas	 the	 ESCRT0	proteins	Hrs	and	STAM1,	preferentially	bind	K63-linkages,	blocking	their	binding	to	the	proteasome	and	instead	diverting	them	to	the	ERAD	pathway	(Nathan	et	al.,	2013;	Ren	and	Hurley,	2010).	Our	mass	spectrometry	experiments	identified	several	 proteins	 that	 potentially	 bind	 selectively	 to	 K11-linked	 polyubiquitin	chains,	and	I	initially	focused	on	FAM115A,	as	it	was	an	uncharacterised	protein	that	 bound	 more	 strongly	 to	 K11-chains	 compared	 with	 K48-chains	 when	immunopurified	from	cell	lysates.	Unfortunately	these	studies	have	been	difficult	to	pursue,	as	 I	was	unable	to	purify	FAM115A	in	E.	coli	despite	many	attempts,	and	 therefore	 could	 not	 determine	 whether	 FAM115A	 bound	 K11-chains	directly.	 In	 addition,	 other	 members	 of	 the	 Nathan	 group	 attempted	 several	approaches	 to	 examine	 if	 FAM115A	 is	 important	 in	 cell	 cycle	 regulation,	 and	found	that	overexpression	or	depletion	of	FAM115A	had	no	effect	on	the	exit	of	cells	from	mitosis,	cyclin	B1	ubiquitination	or	proteasomal	degradation.			During	our	investigations,	FAM115A	was	reported	to	act	as	a	membrane	associated	protein	 for	 temperature	control	channels,	and	was	renamed	TCAF-1	(TRPM8	Channel	Associated	Factor	1)	(Gkika	et	al.,	2015).	TRPM8,	a	cold	sensor,	interacted	with	FAM115A	using	GST-pulldown	assays.	Cell	surface	biotinylation	experiments	 showed	 that	 over	 expression	 of	 TCAF-1	 resulted	 in	 increased	TRPM8	 levels	 at	 the	 cell	 surface,	 and	 siRNA-mediated	 depletion	 of	 TCAF-1	decreased	 conductance	 activity	 of	 the	 TRPM8	 channel.	 Although	 the	 studies	support	 the	 association	 of	 FAM115A/TCAF-1	with	 TRPM8,	 this	 study	 gives	 no	additional	 insights	 into	 its	 putative	 role	 as	 a	 K11-UBP.	 Further	 attempts	 of	purification	of	FAM115A	could	have	been	pursued,	such	as	using	a	baculovirus	expression	 system.	However,	 this	 process	would	 be	 a	 significant	 and	 high	 risk	undertaking,	given	that	the	interaction	we	observed	with	HA-FAM115A	and	K11-linked	chains	was	from	cell	lysate	and	maybe	indirect.		
Chapter	4,	Identification	of	K11-ubiquitin	binding	proteins		
		 118	
	
4.3.2	 Is	 the	 binding	 of	 K11-linked	 chains	 to	 TAX1BP1	 and	 myosin	 VI	 of	
importance	in	mitophagy?	Both	 TAX1BP1	 and	 myosin	 VI	 bound	 K11-linked	 chains,	 albeit	 weakly	when	 compared	 to	 K63-linked	 chains.	 These	 findings	 are	 consistent	 with	 the	work	of	 the	Polo	 lab,	who	show	that	Myosin	VI	can	bind	to	K11,	K63	and	K29-linked	di-ubiquitin	(He	et	al.,	2016).	However,	whether	binding	of	these	UBPs	to	K11-linked	ubiquitin	chains	is	a	biological	relevance	to	mitophagy	remains	to	be	determined.		Studies	from	the	Harper	group	suggest	that	only	K63	chains	are	essential	(Ordureau	 et	 al.,	 2015)	 and	 that	 ubiquitin	 density	 at	 the	 mitochondrial	membrane	 is	 likely	 to	 be	 important	 (Ordureau	 et	 al.,	 2014).	 By	 quantifying	ubiquitin	chains	formed	on	mitochondria	following	mitochondrial	depolarisation	(Ordureau	et	al.,	2014),	the	Harper	group	found	that	depolarisation	leads	to	the	formation	 of	 multiple	 different	 chain	 linkages	 (K6,	 K11,	 K48	 and	 K63)	 on	mitochondrial	outer	membrane	proteins	 (Ordureau	et	 al.,	 2014).	 Subsequently,	they	identified	that	mitochondria	isolated	from	UbK6R	or	UbK63R	replacement	cells	showed	 a	 reduction	 in	 mitophagy	 (Ordureau	 et	 al.,	 2015),	 indicating	 the	importance	 of	 K63-linkages.	 Although	 a	 decrease	 in	 mitophagy	 was	 observed	with	UbK11R,	the	difference	was	not	significant	(Ordureau	et	al.,	2015).	Therefore,	while	 it	 is	 also	possible	 that	K11-chains	have	a	 specific	 role	 in	mitophagy,	 it	 is	evident	 that	 K63-linkages	 are	 more	 important.	 This	 is	 also	 supported	 by	 my	findings	that	more	TAX1BP1	is	recruited	to	Myosin	VI	when	it	is	bound	to	K63-polyubiquitin	 conjugates	 (Figure	 4.5).	 However,	 it	 would	 be	 of	 interest	 to	examine	if	heterotypic	K11/K63-chains	are	involved	in	mitophagy	or	have	higher	affinity	or	avidity	for	TAX1BP1	or	myosin	VI.	Furthermore,	as	other	groups	have	shown	 an	 involvement	 of	 K11-linkages	 in	 Beclin-1	 degradation	 and	 autophagy	(Jin	et	al.,	2016),	it	will	be	important	to	determine	the	conformation	of	the	chains	involved.		
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4.3.3	Could	other	proteins	that	bound	to	polyubiquitinated	Ube2S	selectively	
bind	K11-chains?	Several	 of	 the	 proteins	 listed	 in	 Table	 4.1	 may	 be	 involved	 in	 the	recognition	 of	 polyubiquitin	 chains,	 and	 potentially	 may	 bind	 K11-conjugates.	For	 example,	Ankyrin	Repeat	Domain	13	 (ANKRD13)	 consists	 of	 three	 ankyrin	repeats	in	the	N-terminus	and	three	or	four	UIMs	in	the	C-terminus,	depending	on	the	isoform.	ANKRD13	has	been	identified	as	a	regulator	of	EGFR	endocytosis	from	 the	 plasma	 membrane	 via	 K63-polyubiquitination	 (Tanno	 et	 al.,	 2012).	HeLa	 cells	 stimulated	 with	 Epidermal	 Growth	 Factor	 (EGF)	 showed	 that	ANKRD13	A,	B	and	D	proteins	bound	K63-polyubiquitinated	EGFR	(Tanno	et	al.,	2012).	However,	the	role	of	K11-ubiquitination	was	not	explored.	In	addition,	the	Komada	lab	recently	identified	ANKRD13	as	a	novel	Valosine	Containing	Protein	(VCP)-interacting	protein	on	the	endosome,	which	binds	K63-polyubiquitinated	Cav-1,	 leading	to	 its	 lysosomal	trafficking	(Burana	et	al.,	2016).	 	As	three	of	the	proteins	 identified	 from	 our	mass	 spectrometry	 analysis	 have	 been	 associated	with	 both	 K63-	 and	 K11-chains	 (TAX1PB1,	 Myosin	 VI	 and	 ANKRD13),	 it	 is	possible	that	the	UBPs	we	identified	have	a	preference	for	heterotypic	K11/K63-linked	chains	on	Ube2S.	Indeed,	our	AQUA	experiments	showed	that	92%	of	the	linkages	 are	 lysine	 11	 but	 the	 remaining	 8%	 may	 form	 heterotypic	 chains	(Chapter	 3).	 	 One	mechanism	 to	 investigate	 this	 further	would	 be	 to	 vary	 the	concentrations	of	AMSH	in	the	ubiquitin	reaction	to	generate	K11-homotypic	or	K11/K63-heterotypic	 chains	 on	 Ube2S	 and	 compare	 whether	 this	 alters	 the	proteins	bound	to	the	polyubiquitin	conjugates.		
	
4.3.4	 What	 are	 the	 biological	 roles	 of	 K11-linked	 polyubiquitin	 chains	 in	
cells?	 Our	experiments	could	provide	a	rationale	for	the	observed	proteasome-dependent	 and	 independent	 outcomes	 of	 K11-linked	 polyubiquitination	 that	have	been	described.		Firstly,	 K11-linkages	 within	 a	 polyubiquitin	 chain	 may	 protect	 the	substrate	from	proteasome	mediated-degradation,	as	suggested	by	the	studies	of	the	Wnt/β-catenin	 pathway	 (Dao	 et	 al.,	 2012).	 The	 Druker	 and	 Bagby	 groups	
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(Dao	 et	 al.,	 2012)	 investigated	 whether	 the	 E3	 ligase	 Fanconi	 anaemia	complementation	 group	 L	 (FANCL),	 had	 an	 important	 role	 in	 maintaining	haematopoietic	 stem	 cells.	 They	 showed	 that	 cells	 overexpressing	 FANCL	ubiquitinated	 β-catenin,	 surprisingly	 lead	 to	 its	 stabilisation,	 not	 degradation.	Using	ubiquitin	mutants,	a	K11-only	mutant	ubiquitin	 lead	to	stabilisation	of	β-catenin,	almost	to	the	same	extent	as	wildtype	ubiquitin.	This	suggests	that	when	FANCL	ubiquitinates	β-catenin	with	K11-chains	the	protein	is	stabilised	(Dao	et	al.,	 2012),	 supporting	 our	 findings	 that	 K11-linked	 polyubiquitination	 of	 a	substrate	is	an	inefficient	signal	for	proteasomal	degradation.		The	 ability	 of	 K11-linked	 polyubiquitination	 to	 stabilise	 proteins	 is	 also	supported	by	Qin	et	al,	in	their	studies	on	MITA	(Mediator	of	IRF3	Activation),	a	protein	 involved	 in	 the	 innate	 interferon	 response	 to	viral	 infection	 (Qin	et	 al.,	2014).	The	E3	ligase,	Ring	Finger	protein	(RNF)	5,	ubiquitinates	MITA	with	K48-chains	signalling	its	proteasomal	degradation	(Zhong	et	al.,	2009),	whereas	K63-linked	polyubiquitination	of	MITA	by	TRIM56	and	TRIM32	positively	 regulates	type	IFN	induction	(Zhang	et	al.,	2012).	Recently,	however,	Qin	et	al	showed	that	an	 RNF26	 ubiquitinates	 MITA	 with	 K11-chains	 during	 viral	 infection,	 which	stabilises	MITA	(Qin	et	al.,	2014).	Interestingly,	overexpression	of	RNF26	within	cells	led	to	autophagy-mediated	degradation	of	MITA,	which	suggests	there	is	a	link	 between	 K11-linked	 polyubiquitination	 and	 proteasome-independent	degradation.		The	 involvement	 of	 the	 K11-specific	 DUB,	 Cezanne	 (also	 known	 as	OTUB7B)	in	the	non-proteasomal	degradation	of	HIF1α	(Bremm	et	al.,	2014)	also	supports	 a	 role	 for	 K11-chains	 in	 proteasome-independent	 degradation.	 The	Komander	group	showed	that	knockdown	of	Cezanne	decreased	HIF1α	levels	in	both	 normoxia	 and	 hypoxia.	 In	 addition,	 in	 cells	where	 Cezanne	was	 depleted,	the	 proportion	 of	 K11-ubiquitin	 linkages	 (assessed	 by	 linkage	 specific	antibodies)	on	HIF1α	 increased.	However,	 this	ubiquitinated	HIF1α	 in	Cezanne	deficient	 cells	 did	 not	 increase	 following	 proteasome	 inhibition	 (Bremm	 et	 al.,	2014).	 As	 the	 Nathan	 group	 has	 a	 particular	 interest	 in	 the	 hypoxia	 response	pathway,	 I	was	keen	 to	explore	 the	 role	of	K11-polyubiquitin	and	proteasome-independent	degradation	of	HIFα	further	(Chapter	5).			 	 	
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4.4	Summary			 In	 this	 chapter,	 I	 showed	 that	 the	 known	proteasomal	 shuttling	 factors,	Rpn10,	Rad23	A	and	B	and	UBQLN1,	were	unable	 to	bind	K11-linked	chains	 in	comparison	 to	K63-linked	 chains	using	 an	 in	vitro	binding	 assay.	However,	 the	non-specific	UBP,	USP5,	did	bind	both	K11	and	K63-Ub4.	Using	a	MS	approach,	we	identified	several	proteins	from	cell	lysates	that	putatively	bound	selectively	to	K11-linked	polyubiquitin	conjugates.	I	showed	that	the	top	candidate	protein,	FAM115A,	 was	 able	 to	 bind	 K11-linked	 polyubiquitin	 chains	 in	 cell	 extracts.	However,	it	was	not	possible	to	determine	whether	this	interaction	was	direct,	as	I	was	not	able	to	recombinantly	express	FAM115A.	Subsequently,	I	showed	that	two	mitophagy	receptors,	MyosinVI	and	TAX1BP1,	bound	K11-linked	chains,	but	more	weakly	than	K63-linked	chains.	In	addition,	I	found	that	K63-	but	not	K11-ubiquitin	 tetramers	formed	 a	 complex	with	MyosinVI	 and	 TAX1BP1.	 Together,	these	studies	demonstrate	that	K11-polyubiquitin	conjugates	can	be	recognised	by	UBPs,	but	a	K11-selective	UBP	remains	elusive.				 	
Chapter	5,	Mechanisms	of	HIFα	prolyl	hydroxylation		
		 122	
 Chapter	5:	Results	3,	Mechanisms	of	HIFα 	prolyl	
hydroxylation		
	
5.1	Introduction		 My	biochemical	 studies	 identified	 clear	differences	 in	 the	 recognition	of	homotypic	 and	 heterotypic	 K11-ubiquitin	 linkages	 by	 the	 proteasome.	 These	findings	were	surprising,	given	that	K11-chains	had	previously	been	thought	to	have	 a	 major	 role	 in	 the	 cell	 cycle.	 	 Furthermore,	 although	 my	 biochemical	studies	on	the	ubiquitin	receptors,	TAX1BP	and	Myosin	VI,	suggested	that	K11-linked	 chains	 may	 have	 a	 role	 in	 mitophagy,	 they	 demonstrated	 very	 weak	binding	 compared	 to	 K63-linked	 chains.	 Therefore,	 I	 wanted	 to	 explore	 the	functional	 outcome	 of	 K11-ubiquitin	 chains	 in	 other	 cellular	 responses	 and	focused	on	the	HIF	pathway.	Two	prior	studies	predicted	a	role	for	K11-linkages	in	HIF	regulation:	(i)	The	 K11-selective	 DUB	 Cezanne	 had	 been	 shown	 to	 be	 involved	 in	 the	 non-proteasomal	 degradation	 of	HIF	 (Bremm	et	 al.,	 2014),	 and	 the	K11	E2,	 Ube2S,	regulated	HIF	levels,	putatively	through	ubiquitination	of	the	VHL	E3	ligase	(Jung	et	al.,	2006).	A	further	reason	for	exploring	the	HIF	pathway	was	that	the	Nathan	group	 had	 recently	 uncovered	 novel	 metabolic	 mechanisms	 of	 HIF	 activation,	independent	 of	 oxygen	 availability	 and	 potentially	 also	 independent	 of	proteasome-mediated	degradation.	Stephen	Burr	(PhD	student,	Nathan	lab)	had	undertaken	 forward	genetic	 screens	 in	 aerobic	 conditions	 and	 identified	 genes	involved	in	the	TCA	cycle	(the	2-oxoglutarate	dehydrogenase	complex	(OGDHc))	(Figure	5.3)	and	vacuolar-ATPase	(V-ATPase)	(Figure	5.7)	that	increased	HIFα	stability,	but	the	mechanism	was	not	known	and	it	was	possible	that	K11-linked	polyubiquitin	chains	may	be	involved.	Therefore,	I	wanted	to	establish	an	in	vitro	system	to	explore	HIFα	ubiquitination.	As	 the	 constitutive	 turnover	 of	 HIFα	 requires	 a	 two-step	 process,	involving	 the	 initiation	 of	 ubiquitination	 via	 HIFα	 prolyl	 hydroxylation	 and	 its	subsequent	ubiquitination,	this	chapter	focuses	on	establishing	an	in	vitro	assay	
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of	HIFα	 prolyl	 hydroxylation,	while	 the	 ubiquitination	 of	HIFα	 is	 addressed	 in	
Chapter	6.			Previous	 assays	of	HIFα	prolyl	 hydroxylation	have	used	 either	direct	 or	indirect	measurements	of	PHD	activity,	typically	using	small	HIF	peptides,	radio-labelling	 and	 the	 addition	 of	 excess	 cofactors	 to	 stimulate	 HIF	 hydroxylation	(Hewitson	 et	 al.,	 2007b).	While	 these	 techniques	 inform	 on	 the	 specificity	 and	site	 of	HIF	prolyl	 hydroxylation,	 a	major	 limitation	 is	 that	 they	 are	not	 able	 to	determine	 how	 changes	 in	 the	 cell	 (i.e.	 metabolite	 levels)	 directly	 affect	 HIFα	hydroxylation.	 Therefore,	 I	 aimed	 to	 establish	 a	 novel	 assay	 that	 enabled	quantification	of	PHD	activity	on	the	HIFα	protein,	using	cell	lysates	without	the	addition	of	exogenous	co-factors,	providing	a	unique	tool	to	elucidate	the	prolyl	hydroxylation	and	subsequent	ubiquitination	of	HIFα.	Moreover,	I	wanted	to	use	this	 assay	 to	 help	 uncover	 how	 HIFs	 can	 be	 regulated	 by	 small	 molecule	metabolites.	Here,	 I	 first	 describe	 the	 generation	 of	 a	 recombinant	 HIF1α	 protein	followed	 by	 the	 development	 of	 an	 in	 vitro	 assay	 to	 measure	 the	 prolyl	hydroxylation	 of	 HIF1α	 under	 normoxic	 conditions,	 without	 the	 addition	 of	exogenous	 cofactors.	 I	 use	 this	 assay	 to	 determine	 the	 effect	 of	 changes	 in	cellular	 metabolites	 on	 HIF1α	 hydroxylation,	 and	 confirm	 that	 disrupting	 the	OGDHc,	prevents	HIF1α	 prolyl	hydroxylation.	 I	 also	 investigate	how	TCA	small	molecule	 metabolites	 can	 alter	 PHD	 activity.	 I	 subsequently	 use	 this	 assay	 to	determine	how	HIF1α	can	be	regulated	in	a	seemingly	proteasome-independent	manner,	and	demonstrate	that	prolyl	hydroxylation	may	be	altered	by	inhibiting	the	main	proton	pump	involved	in	lysosomal	degradation,	the	Vacuolar	ATPase	(V-ATPase).	 Lastly,	 I	 develop	 an	 in	 vitro	 assay	 for	 HIF2α	 prolyl	 hydroxylation,	and	compare	the	metabolic	regulation	of	prolyl	hydroxylation	between	the	two	HIFα	isoforms.			 	
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5.2	Results		
	
5.2.1	 Establishing	 an	 in	 vitro	 assay	 to	 determine	 hydroxylation	 of	 HIF1α:	
generation	of	a	HIF1α 	recombinant	protein.		To	measure	the	hydroxylation	and	ubiquitination	of	HIFα	 in	vitro,	 it	was	first	 necessary	 to	 generate	 a	 HIF1α	 recombinant	 protein	 that	 included	 the	Oxygen	Dependent	Degradation	Domain,	which	encodes	the	prolines	and	lysines	modified	 by	 hydroxylation	 and	 ubiquitination	 respectively.	 Previous	 studies	 of	HIFα	 prolyl	 hydroxylation	 had	 only	 used	 small	 peptides	 containing	 a	 single	prolyl	 hydroxylated	 residue,	 and	 it	 was	 therefore	 unclear	 whether	 the	 whole	ODD	 of	 HIF1α	 would	 be	 soluble	 in	 bacteria.	 	 To	 rapidly	 test	 the	 solubility	 of	different	HIF1α	 constructs	 I	used	a	Ligation	Independent	Cloning	(LIC)	system,	developed	 by	 Vangelis	 Christodoulou	 in	 Katrin	 Rittinger’s	 lab	 (Francis	 Crick	Institute)	(Figure	5.1A).	Eight	HIF1αODD	constructs	were	amplified	by	PCR	and,	using	 LIC,	 expressed	 in	 DE3*	 E.	 coli	 using	 standard	 methods	 (Figure	 5.1B,	
Appendix	1).	Protein	synthesis	was	induced	with	either	0.5mM	IPTG	37°C	3	hr	or	0.1mM	IPTG	25°C	overnight.	Pre	and	post-induction	samples	were	centrifuged	to	separate	soluble	from	insoluble	protein	and	analysis	by	SDS-PAGE	allowed	me	to	 identify	 which	 post-induction	 samples	 displayed	 clear	 bands	 indicating	expression	 of	 soluble	 His-tagged	 HIF1αODD	protein.	 The	 HIF1αODD530-652	protein	was	 the	 most	 suitable	 for	 the	 subsequent	 assays,	 due	 to	 its	 small	 size	 and	solubility	(Figure	5.1C).	However,	His-HIF1αODD530-652	migrated	between	16	and	22kDa	(Figure	5.1C),	which	is	slower	than	would	be	predicted	for	its	molecular	weight	of	14kDa.	I	therefore	analysed	the	pure	protein	by	MS	(Robin	Antrobus,	CIMR	 proteomics	 facility),	 and	 confirmed	 that	 it	 encoded	 the	 correct	 protein	sequence.		In	 order	 to	 generate	 biochemical	 amounts	 of	 the	 His-HIF1αODD530-652	protein,	 I	 grew	2l	of	DE3*	E.	coli	 expressing	 the	 construct	 and	 induced	protein	synthesis	with	0.5mM	IPTG	37°C	3	hr.	I	initially	attempted	purification	of	the	His-HIF1αODD530-652	 protein	 using	 Fast	 Protein	 Liquid	 Chromatography	 (FPLC),	however	the	protein	failed	to	bind	the	NiNTA	column	(data	not	shown).	This	was	possibly	 due	 to	 a	 partially	 exposed	 His	 tag	 within	 the	 folded	 protein.	 As	 an	
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alternative	approach,	I	incubated	the	bacterial	lysates	with	NiNTA	resin	for	2	hr,	hypothesizing	that	a	prolonged	incubation	step	would	allow	the	His-HIF1αODD530-652	 protein	 to	 bind	 to	 the	 resin.	 This	 method	 improved	 protein	 binding	 and	allowed	elution	of	 the	HIF1α	 protein	 from	 the	 resin	 (Figure	 5.1D),	 generating	pure	His-HIF1αODD530-652	protein	for	the	hydroxylation	and	ubiquitination	assays	(Figure	5.1D).								
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Figure 5.1: Generation of a HIF1α protein for use in the in vitro assay using ligation 
independent cloning. (A) Schematic of Ligation Independent Cloning technique (LIC) 
courtesy of Vangelis Christodoulou (Katrin Rittinger lab, Francis Crick Institute). (B) 
Schematic of LIC of the HIF1αODD. The two prolines that can be hydroxylated by the PHDs 
are highlighted. Eight constructs were amplified by LIC and cloned into a 6xHis expression 
vector. (C) Small-scale solubility assays were performed to identify the HIF1αODD protein best 
suited for the hydroxylation assay. Coomassie-stained gel shows solubility assay of 
HIF1αODD530-652 protein selected. W – whole sample, S- supernatant (soluble fraction), P- pellet 
(insoluble fraction). (D) Dilution series of the purified HIF1αODD protein selected, separated by 
SDS-PAGE and stained with Coomassie blue. 
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5.2.2	 The	 HIF1αODD	 protein	 is	 hydroxylated	 in	 vitro	 in	 a	 PHD2	 dependent	
manner	without	the	addition	of	exogenous	cofactors.	Prior	 studies	 typically	 used	 recombinant	 HIF1α	 peptides	 with	 the	addition	of	exogenous	co-factors,	but	I	wanted	to	establish	a	system	that	would	allow	 prolyl-hydroxylation,	 and	 ultimately	 ubiquitination,	 directly	 from	 a	 cell	lysate.	Therefore,	I	first	isolated	HeLa	cell	lysates	that	would	provide	a	source	of	the	 prolyl	 hydroxylase	 enzyme,	 PHD2,	 and	 the	 essential	 cofactors	 for	 HIF1α	hydroxylation,	Fe2+	and	2-OG.	Based	on	my	prior	 studies	using	 cell	 lysates	as	 a	source	 of	 the	 APC/C,	 I	 lysed	 1	 x	 108	HeLa	 cells	 using	 freeze/thaw	 lysis	 in	 a	hypotonic	 buffer,	 followed	 by	 mechanical	 needle	 lysis,	 separated	 the	supernatants	 using	 centrifugation	 and	 collected	 these	 supernatants.	 I	 also	obtained	lysates	from	HeLa	cells	that	had	been	depleted	of	PHD2	using	CRISPR	Cas9	genome	editing	(PHD2	null	cells	generated	by	Stephen	Burr).		The	 prolyl	 hydroxylation	 assay	 was	 performed	 by	 incubating	 the	 HeLa	lysates	with	100nM	of	the	His-HIF1αODD530-652	recombinant	protein	for	15	min	at	37°C	in	TBS	(Figure	5.2A),	and	the	samples	analysed	by	immunoblot	for	HIF1α,	PHD2,	 β-actin,	 and	 a	 hydroxyl-proline	 specific	 antibody	 (OH-HIF1α)	 (Figure	
5.2B).	 A	 single	 migrating	 species	 was	 identified	 by	 the	 HIF1α	 antibody,	corresponding	to	the	His-HIF1αODD530-652	protein.	However,	the	hydroxyl-proline	specific	antibody	(OH-HIF1α)	only	detected	the	HIF1α	protein	following	15	min	incubation	 with	 the	 HeLa	 cell	 lysate.	 Furthermore,	 the	 levels	 of	 the	 prolyl-hydroxylated	His-HIF1αODD530-652	were	reduced	in	the	PHD2-depleted	cell	extract,	consistent	 with	 the	 antibody	 specifically	 recognising	 the	 prolyl-hydroxylated	species	(Figure	5.2B).	These	experiments	confirmed	that	the	His-HIF1αODD530-652	protein	 could	 be	 prolyl-hydroxylated	 in	 vitro,	 in	 a	 PHD2	 dependent	 manner,	without	the	use	of	exogenous	cofactors.								
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Figure 5.2: The HIF1αODD protein is hydroxylated in vitro in a PHD2 dependent manner 
without the addition of exogenous cofactors.  (A) Schematic of the in vitro hydroxylation 
assay: 1 x 108 wildtype HeLa cells were lysed using freeze/thaw lysis in a hypotonic buffer. 
Lysates were also obtained from HeLa cells depleted of PHD2 using CRISPRCas9 genome 
editing (sgRNA). Supernatants were collected and incubated with the His-HIF1αODD 
recombinant protein for 15 min at 37°C. Prolyl-hydroxylation was detected using a hydroxyl-
proline specific antibody (OH-HIF1α). (B) Hydroxylation of the His-HIF1αODD530-652 using 
wildtype and PHD2 depleted HeLa cell lysates. Prolyl hydroxylation was measured by 
immunoblot and compared to total His-HIF1αODD levels. β-actin served as a loading control. 
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5.2.3	HIF1α	prolyl	hydroxylation	is	prevented	when	the	OGDHc	is	disrupted.	Next,	 I	wanted	 to	 explore	whether	 this	 hydroxylation	 reaction	 could	 be	used	 to	 elucidate	 how	 HIF1α	 can	 be	 stabilised	 in	 aerobic	 conditions.	 In	particular,	this	assay	could	help	to	explain	the	recent	finding	in	the	Nathan	group	that	HIF1α	was	stabilised	in	aerobic	conditions	when	the	OGDHc	was	disrupted.		Using	a	forward	genetic	screen	in	near-haploid	KBM7	cells,	Stephen	Burr	(Nathan	 lab)	 identified	 two	 mitochondrial	 genes,	 oxoglutarate	 dehydrogenase	(OGDH)	 and	 lipoic	 acid	 synthase	 (LIAS),	 whose	 deletion	 results	 in	 HIF1α	stabilisation	(Figure	5.3A)	(Burr	et	al.,	2016).		OGDH	is	a	core	component	of	the	oxoglutarate	dehydrogenase	 complex	 (OGDHc),	which	 catalyses	 the	 conversion	of	 2-OG	 to	 succinate	 in	 the	 TCA	 cycle	 (Figure	 5.3B,	 C).	 The	 OGDHc	 has	 three	subunits	 and	 one	 of	 these	 subunits	 (Dihydrolipoamide	 S-Succinyltransferase,	DLST)	 requires	 lipoylation	with	 lipoic	 acid	 for	 catalytic	 activity	 (Figure	 5.3C).		Therefore,	we	had	genetic	evidence	that	both	OGDH	and	LIAS	were	required	for	catalytic	activity	of	the	OGDHc,	which	Stephen	Burr	went	on	to	confirm	(Burr	et	al.,	 2016).	 However,	 the	mechanism	 for	HIF1α	 stabilisation	was	 not	 clear,	 and	whether	 this	 prevented	 HIF1α	 prolyl	 hydroxylation	 (Figure	 5.3D),	ubiquitination	or	proteasome-mediated	degradation	was	not	known.	
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Figure 5.3: A KBM7 forward genetic screen identifies OGDH and LIAS as regulators of 
HIF1α stability. (A) Schematic of KBM7 HIFα-GFP reporter construct and results of the 
genetic screen by Stephen Burr (Nathan lab). KBM7 HIFα-GFP reporter cells were 
transduced with a gene-trapping retrovirus. Mutagenised GFPHIGH cells were selected by 
FACS and the gene-trapping insertions mapped by Illumina HiSeq. The bubble plot of 
enriched genes in the GFPHIGH population compared to unsorted mutagenised control KBM7 
cells is shown. Bubble size is proportional to the number of independent inactivating gene-
trap integrations identified (shown in brackets). (B) Structure of the OGDHc, showing OGDH 
and the lipoylated DLST (lipoylated by LIAS). (C) TCA schematic highlighting the OGDHc. (D) 
HIFα prolyl hydroxylation reaction, which requires 2-OG for catalytic activity. A, B, adapted 
from (Burr et al., 2016). 		
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		To	test	 if	OGDH	or	LIAS	were	required	for	HIF1α	prolyl	hydroxylation,	 I	used	 HeLa	 cells	 from	 OGDH	 or	 LIAS	 CRISPR-Cas9	 knockout	 (KO)	 clones	(validated	 by	 Stephen	 Burr	 (Burr	 et	 al.,	 2016))	 and	 measured	 prolyl	hydroxylation	of	His-HIF1αODD530-652	(Figure	 5.4A).	HIF1α	 prolyl	 hydroxylation	was	observed	after	15	min	in	the	wildtype	HeLa	lysates	incubated	with	the	His-HIF1αODD530-652	 protein,	 similarly	 to	 my	 initial	 optimisation	 experiments.	Moreover,	 a	PHD2	null	 clone	 completely	prevented	prolyl	hydroxylation	of	 the	HIF1α	protein	(Figure	5.4B,	C),	confirming	that	PHD2	is	the	main	PHD	for	HIF1α	in	HeLa	cells.	 Incubating	 the	wildtype	HeLa	 lysate	with	 the	well-validated	PHD	inhibitor,	 Dimethyloxalolylglycine	 (DMOG,)	 for	 10	 min	 37°C	 prior	 to	 the	hydroxylation	 assay	 also	 prevented	 His-HIF1αODD530-652	 prolyl-hydroxylation	
(Figure	 5.4B),	 again	 confirming	 the	 specificity	 of	 my	 assay.	 	Two	 null	 OGDH	(Figure	5.4B)	and	LIAS	(Figure	5.4C)	clones	were	examined	respectively,	and	in	all	cases	demonstrated	decreased	levels	of	prolyl	hydroxylation	compared	to	the	wildtype	 cells.	 Indeed,	 in	 two	 of	 the	 clones	 prolyl	 hydroxylation	 was	 not	detected.	The	variability	in	levels	of	the	hydroxylated	HIF1α	protein	in	the	OGDH	and	 LIAS	 null	 clones	 suggests	 that	 they	 are	 not	 directly	 involved	 in	 catalytic	activity	 but	 alter	 the	 levels	 of	 metabolites,	 that	 may	 interfere	 with	 2-OG	dependent	dioxygenase	activity.	However,	it	was	clear	that	deletion	of	OGDH	or	LIAS	led	to	inhibition	of	the	prolyl	hydroxylation	of	HIF1α	in	vitro.													
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Figure 5.4: HeLa cells extracts depleted of mitochondrial enzymes OGDH or LIAS 
inhibit HIF1αODD prolyl hydroxylation. (A) Schematic showing the HIF1α hydroxylation 
assay with lysates from OGDH, LIAS or PHD2 knockout (KO) clones. (B, C) Immunoblots of 
prolyl hydroxylated and total His-HIF1αODD530-652 in WT, OGDH null (B), LIAS null (C) or PHD2 
null (B, C) lysates. OGDH or LIAS loss (lipoate antibody detects lipoyl moiety on OGDHc) 
was confirmed by immunoblot.  β-actin served as a loading control. 
	
5.2.4	 HIF1α	 prolyl	 hydroxylation	 is	 impaired	 by	 the	 small	 molecule	
metabolite,	L-2-hydroxyglutarate.	The	most	 likely	 explanation	 for	 the	 inhibition	 of	 PHD	 activity	 following	OGDH	or	LIAS	depletion	related	 to	changes	 in	small	molecule	metabolite	 levels	when	the	TCA	cycle	was	disrupted.	Several	TCA	metabolites,	 such	as	succinate,	are	known	to	inhibit	prolyl	hydroxylation	by	directly	competing	for	2-OG	binding	
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to	 PHDs	 (Selak	 et	 al.,	 2005).	 This	 oxygen-independent	 stabilisation	 of	 HIF1α	drives	a	transcriptional	HIF	response	and	promotes	tumour	metastases	(Kaelin,	2008;	Maxwell	and	Ratcliffe,	2002).	Whole	cell	metabolite	studies	(performed	by	Stephen	Burr,	Nathan	lab,	and	Sofia	Costa,	Frezza	lab)	showed	that	succinate	was	not	increased	in	the	LIAS	and	OGDH	null	cells,	and	in	fact	was	barely	detectable.			However,	 one	metabolite	 was	 markedly	 increased	 in	 the	 OGDH	 and	 LIAS	 null	clones,	2-hydroxyglutarate	(Burr	et	al.,	2016).		2-HG	is	a	chiral	compound	that	exists	in	both	L-2-HG	and	D-2-HG	forms	in	cells,	 previously	 implicated	 in	 altering	 the	 activity	 of	 2-OG	 dependent	dioxygenases.	However,	 it	was	 controversial	whether	both	 enantiomers	 inhibit	or	activate	the	PHD	enzymes,	or	whether	2-HG	can	accumulate	to	a	sufficiently	high	 level	 in	 cells	 to	 inhibit	 2-OG	 dependent	 dioxygenases	 (Chowdhury	 et	 al.,	2011;	Tarhonskaya	et	al.,	2014;	Xu	et	al.,	2011).		To	 investigate	whether	 the	 levels	 of	 small	molecule	metabolites	 altered	prolyl-hydroxylation	 in	my	 assay,	 I	 first	 determined	whether	 succinate,	 which	had	 previously	 been	 shown	 to	 inhibit	 PHD	 activity,	 prevented	 prolyl-hydroxylation.	 HeLa	 lysates	 were	 incubated	 with	 increasing	 concentrations	 of	succinate	 for	 10	 min	 at	 37°C,	 before	 incubating	 with	 the	 His-HIF1αODD530-652	peptide	 for	 15	 min	 at	 37°C	 (Figure	 5.5A),	 and	 analysis	 by	 immunoblot	 as	previously	described	(Results	5.2.2).	DMOG	was	used	as	a	control,	as	described	previously.	While	 total	 levels	of	HIF1αODD530-652	remained	constant	between	 the	samples,	 prolyl-hydroxylated	 His-HIF1αODD530-652	 decreased	 with	 increasing	concentrations	 of	 succinate,	 compared	 with	 WT	 HeLa	 lysate	 (Figure	 5.5A).	Interestingly,	 relatively	 high	 levels	 of	 succinate	 (5-10mM)	 were	 required	 to	inhibit	 the	 prolyl-hydroxylation.	 This	 compares	 similarly	 to	 the	 in	 vitro	 prolyl	hydroxylation	assay	performed	by	Selak	et	al,	 in	which	concentrations	of	5mM	succinate	were	shown	to	inhibit	hydroxylation	of	HIF1α	(Selak	et	al.,	2005).	Next,	 I	wanted	 to	 explore	whether	 the	 2-HG	 enantiomers	 altered	 prolyl	hydroxylation	 of	 the	 HIF1αODD530-652	 protein.	 HeLa	 cell	 lysates	 were	 pre-incubated	 with	 either	 L-2-HG	 or	 D-2-HG	 before	 adding	 to	 the	 HIF1αODD530-652	peptide	for	15	min	at	37°C	(DMOG	was	used	as	a	control	for	prolyl-hydroxylation	inhibition)	(Figure	5.5B,	C).	Increasing	concentrations	of	the	L-2-HG	enantiomer	reduced	 prolyl-hydroxylation	 of	 the	 HIF1αODD530-652	 peptide,	 similarly	 to	 the	
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addition	 of	 DMOG,	 however	 addition	 of	 the	 D-2HG	 enantiomer	 had	 no	 effect	(Figure	5.5B,	C).	Interestingly,	higher	levels	of	D-2-HG	actually	increased	prolyl	hydroxylation	 of	 HIF1αODD530-652	(Figure	 5.5B,	 right	 panel),	 consistent	 with	 a	prior	report	showing	that	D-2-HG	may	activate	the	HIF	response	(Koivunen	et	al.,	2012;	 Losman	 et	 al.,	 2013).	However,	 this	 did	 not	 reach	 statistical	 significance	when	examined	in	several	biological	replicates	(Figure	5.5C).	It	was	 noteworthy	 that	 inhibition	 of	 PHD	 activity	 occurred	 at	 relatively	low	levels	L-2-HG	(0.5-1mM),	making	this	a	plausible	inhibitor	of	PHDs	when	the	OGDHc	was	impaired.	In	fact,	subsequent	studies	by	Stephen	Burr	demonstrated	that	L-2-HG	can	accumulate	to	1mM	in	cells	when	OGDHc	activity	is	impaired,	in	support	of	this	in	vitro	assay	(Burr	et	al.,	2016).	
Chapter	5,	Mechanisms	of	HIFα	prolyl	hydroxylation		
		 135	
		
Figure 5.5: HIF1α hydroxylation is regulated by succinate and the 2-hydroxyglutarate 
enantiomers. (A) Prolyl hydroxylation of His-HIF1αODD530-652 in wildtype (WT) HeLa lysates 
with or without the addition of succinate or DMOG. The hydroxylation assay was performed 
as previously described. (B,C) Prolyl hydroxylation of His-HIF1αODD530-652 in HeLa cell lysates 
with the addition of either L-2-HG or D-2-HG. Representative immunoblots are shown (B). 
Quantification using ImageJ software of three replicates. Mean±SEM, *p<0.05. N.S. = not 
significant. 
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5.2.6	Addition	of	2-OG	inhibits	HIF1α	hydroxylation	and	cannot	restore	PHD2	
activity	when	the	OGDHc	is	disrupted.		In	 principle,	 small	 molecule	 metabolite	 inhibition	 of	 PHDs	 should	 be	reversible,	 following	 the	 addition	 of	 sufficient	 2-OG.	 Therefore,	 excess	 2-OG	should	 be	 able	 to	 restore	 HIF1α	 prolyl	 hydroxylation	 when	 L-2-HG	 has	accumulated	following	disruption	of	the	OGDHc	(Figure	5.6A).	Using	either	WT	HeLa	lysate	or	lysates	from	OGDH	or	PHD2	KO	null	clones,	I	first	confirmed	that	His-HIF1αODD530-652	prolyl	 hydroxylation	was	 reduced	 in	 the	OGDH	KO’s	Figure	
5.6B),	consistent	with	my	prior	findings.		Next,	I	examined	if	the	addition	of	2-OG	restored	 HIF1α	 hydroxylation	 in	 the	 OGDH	 null	 lysates	 (Figure	 5.6C,	 D).	Surprisingly,	WT	HeLa	lysate	showed	decreased	prolyl-hydroxylation	of	the	His-HIF1αODD530-652	 protein	 with	 pre-incubation	 of	 2-OG,	 similar	 to	 the	 inhibition	observed	with	DMOG	or	in	the	PHD2	KO	clone	(Figure	5.6C).	Furthermore,	the	addition	of	2-OG	 to	 the	OGDH	KO	clone	decreased	prolyl	hydroxylation	 further	after	15	min	 (Figure	 5.6D).	However,	 I	did	observe	some	restoration	of	prolyl	hydroxylation	 in	 the	OGDH	null	 lysates,	particularly	with	1	and	5	mM,	at	 the	0	min	 sample	 (Figure	 5.6D),	 suggesting	 that	 addition	 of	 2-OG	 may	 have	 very	transient	effects	on	restoring	prolyl	hydroxylation.		As	 2-OG	 is	 converted	 to	 L-2-HG	 in	 cells	 by	 the	 enzymes	 Lactate	Dehydrogenase	 (LDHA)	 and	 Malate	 Dehydrogenase	 1	 and	 2	 (MDH	 1/2)	(Intlekofer	et	al.,	2015;	Oldham	et	al.,	2015),	it	was	possible	that	the	inhibition	of	HIF1α	hydroxylation	by	2-OG	was	due	to	the	rapid	conversion	of	2-OG	to	L-2-HG	in	 the	 cell	 lysates.	 Indeed,	 in	 related	 studies,	 Stephen	 Burr	 had	 shown	 that	inhibition	 of	 LDHA	 with	 oxamate	 prevented	 the	 formation	 of	 L-2-HG	 when	OGDHc	 activity	 was	 impaired,	 and	 restored	 HIF1α	 degradation	 (Burr	 et	 al.,	2016).	 Furthermore,	 the	 conversion	 of	 2-OG	 to	 L-2-HG	 within	 the	 lysate	 may	explain	why	hydroxylation	was	observed	in	the	0	min	samples	in	the	OGDH	null	cells,	but	not	after	a	15	min	incubation	(Figure	5.6D).		Therefore,	I	examined	whether	the	addition	of	oxamate	to	the	OGDH	cell	lysate	 restored	 prolyl	 hydroxylation.	 However	 the	 addition	 of	 oxamate	 to	 cell	lysates	altered	the	pH	of	the	reaction	to	such	an	extent	(indicated	by	the	colour	change	on	the	loading	buffer)	that	proteins	precipitated	from	the	reaction	and	it	
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was	 not	 possible	 to	 determine	whether	 any	 inhibition	 of	 HIF1α	 hydroxylation	was	due	to	the	activity	of	oxamate	or	to	the	pH	change	and	protein	precipitation	in	 the	 reaction	 (data	 not	 shown).	 Thus,	 the	 reason	 for	 inhibition	 of	 prolyl	hydroxylation	following	2-OG	remains	unclear,	but	 it	may	be	due	to	conversion	to	L-2-HG.	
Figure 5.6: Addition of 2-OG inhibits HIF1αODD hydroxylation and cannot restore PHD2 
activity when the OGDH complex is disrupted. (A) Schematic of the experimental outline, 
showing HIF1α hydroxylation assay with the addition of 2-OG (0.5-10mM) in the OGDH KO 
clone. (B) Immunoblot of prolyl hydroxylated His-HIF1αODD530-652 in HeLa lysates from WT 
cells and an OGDH KO clone. (C, D) Immunoblot of prolyl hydroxylated and total His-
HIF1αODD530-652 with increasing concentrations of 2-OG in WT (C) or OGDH null (D) cells. 
PHD2 null cells or DMOG treated lysates were used as controls for inhibition of HIF1α prolyl-
hydroxylation. 
Chapter	5,	Mechanisms	of	HIFα	prolyl	hydroxylation		
		 138	
5.2.7		Inhibition	of	the	Vacuolar	H+ATPase	prevents	HIF1α	hydroxylation	via	
depletion	of	intracellular	iron.	Studies	 using	 disruption	 of	 the	 OGDHc	 highlighted	 the	 ability	 of	 the	 in	
vitro	 approach	 to	 directly	measure	 the	 effects	 of	metabolic	 changes	 on	 prolyl-hydroxylation	 and	 HIF1α	 stabilisation.	 However,	 I	 was	 also	 keen	 to	 explore	whether	 this	 assay	 could	 be	 informative	 in	 other	 situations	 where	 HIF1α	stabilisation	 has	 been	 observed	 but	 the	 mechanism	 was	 not	 known.	 An	interesting	 observation	 from	 the	 forward	 genetic	 screen	 in	 near-haploid	 cells	using	the	HIFα	fluorescent	reporter	was	that	gene-trap	mutations	in	the	vacuolar	ATPase	 (V-ATPase)	 stabilised	HIF1α,	 but	 this	was	not	dependent	on	 lysosomal	degradation	 (Burr	 et	 al.,	 2016;	 Miles	 et	 al.,	 2017)	 (Figure	 5.7).	 Indeed,	stabilisation	of	HIF1α	by	inhibition	of	the	V-ATPase	with	Bafilomycin	A	had	been	shown	 by	 several	 groups	 previously,	 although	 the	 mechanism	 was	 unclear	(Bremm	et	 al.,	 2014;	 Ferreira	 et	 al.,	 2015;	Hubbi	 et	 al.,	 2013;	 Lim	 et	 al.,	 2007;	Selfridge	 et	 al.,	 2016;	 Zhdanov	 et	 al.,	 2012).	 My	 in	 vitro	 assay	 provided	 an	opportunity	 not	 only	 to	 determine	 whether	 deletion	 of	 the	 V-ATPase	 subunit	genes	would	directly	inhibit	the	prolyl	hydroxylation	of	HIF1α	in	vitro,	but	also	to	assist	in	identifying	the	mechanism	by	which	this	inhibition	occurs.	
	
Figure 5.7: A KBM7 forward genetic screen identifies V-ATPase subunits as regulators 
of HIF1α stability. (A) Results of the genetic screen by Stephen Burr. KBM7 HIFα-GFP 
reporter cells were transduced with a gene-trapping retrovirus. Mutagenised GFPHIGH cells 
were selected by FACS and the gene-trapping insertions mapped by Illumina HiSeq. The 
bubble plot of enriched genes in the GFPHIGH population compared to unsorted mutagenised 
control KBM7 cells is shown. (B) Gene-ontology pathway analysis of genes most enriched for 
gene-trapping insertional mutations in the genetic screen. Adapted from (Miles et al., 2017). 
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	 To	investigate	how	inhibition	of	the	V-ATPase	may	alter	the	hydroxylation	of	 HIF1α	 I	 treated	 HeLa	 lysates	 with	 10nM	 Bafilomycin	 A	 (BafA)	 overnight,	harvested	the	cells,	 lysed	them	as	described	(Results	5.2.2),	and	compared	the	levels	 of	 His-HIF1αODD530-652	prolyl-hydroxylation	 in	 BafA	 treated	 or	 untreated	HeLa	lysates	(Figure	5.8A,	B).	The	levels	of	prolyl-hydroxylated	His-HIF1αODD530-652	were	markedly	reduced	 in	 the	BafA	treated	cell	extract,	 similar	 to	 the	 levels	observed	 when	 DMOG	 was	 added	 to	 the	 hydroxylation	 reaction.	 As	 a	 further	control,	 I	 treated	 cells	with	100µM	of	 the	 iron	 chelator	desferrioxamine	 (DFO)	overnight,	 which	 inhibited	 prolyl-hydroxylation	 similarly	 to	 the	 BafA	 treated	cells	 (Figure	 5.8C).	Thus,	 V-ATPase	 inhibition	decreases	 the	 activity	 of	 prolyl-hydroxylation	in	the	cell	extracts.		
	
Figure 5.8: Inhibition of the V-ATPase prevents the prolyl hydroxylation of the 
HIF1αODD. (A) Schematic showing the prolyl hydroxylation of the HIF1αODD with HeLa cell 
extracts, treated with either BafA or DFO prior to lysis. (B, C) Immunoblots of His-HIF1αODD530-
652 prolyl hydroxylation using cells treated with BafA (B) or DFO (C) prior to lysis. DMOG was 
added to the cell extracts during the hydroxylation reaction as a control. 	
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		As	there	was	no	change	in	the	overall	level	of	PHD2	in	Hela	cells	treated	with	 V-ATPase	 inhibitors	 (Anna	 Miles,	 PhD	 student,	 Nathan	 lab	 (Miles	 et	 al.,	2017)),	it	was	likely	that	changes	in	essential	cofactors	were	responsible	for	the	decreased	 PHD	 activity.	 No	 significant	 alterations	 in	 2-OG	 abundance	 were	observed	 (Stephen	 Burr,	 data	 not	 shown).	 Moreover,	 while	 the	 V-ATPase	 can	affect	pH,	the	assay	was	buffered	in	TBS	at	pH	7.4,	making	changes	in	pH	unlikely	to	account	for	the	PHD	inhibition	observed.	We	therefore	focused	on	iron	as	this	is	 an	 essential	 cofactor	 for	 PHDs,	 and	 several	 prior	 studies	 implicated	 the	 V-ATPase	 in	 iron	 metabolism:	 (1)	 Iron	 is	 taken	 up	 in	 its	 ferric	 form	 bound	 to	transferrin,	 and	 Kozik	 et	 al	 had	 previously	 shown	 that	 V-ATPase	 inhibition	impairs	 transferrin	 clathrin-mediated	 endocytosis	 (Kozik	 et	 al.,	 2013),	 (2)	acidification	of	endosomes	is	required	for	the	conversion	of	ferric	to	ferrous	iron	by	 ferroreductases	 (Dautry-Varsat	et	al.,	1983;	Straud	et	al.,	2010),	and	(3)	 the	release	 of	 iron	 from	 ferritin	 stores	 	 is	 dependent	 on	 a	 specialised	 form	 of	autophagy	 (ferritinophagy)	 which	 requires	 V-ATPase	 acidification	 of	 the	lysosome	(Mancias	et	al.,	2014).	Therefore,	I	examined	if	iron	supplementation	to	cell	extracts	treated	with	BafA	 prior	 to	 lysis	 restored	 prolyl-hydroxylation	 of	 the	 His-HIF1αODD530-652	protein		(Figure	5.9A).	FeCl2	was	first	prepared	in	hypoxic	conditions	to	prevent	oxidisation	 and	 then	 added	 to	 the	 WT,	 BafA	 or	 DFO	 cell	 lysates,	 and	 prolyl-hydroxylation	of	His-HIF1αODD530-652	measured	as	described.	 	While	the	addition	of	 ferrous	 iron	 had	 no	 effect	 on	 the	 hydroxylation	 of	 the	 His-HIF1αODD530-652	protein	 in	 the	 untreated	 lysates	 (Figure	 5.9B,	 C),	 it	 increased	 prolyl-hydroxylation	 of	 His-HIF1αODD530-652	 in	 the	 BafA	 treated	 lysate	 (Figure	 5.9B),	consistent	 with	 the	 restoration	 of	 PHD	 activity.	 To	 confirm	 that	 iron	supplementation	 could	 overcome	 intracellular	 iron	 depletion,	 I	 repeated	 the	experiments	 using	 cells	 treated	 with	 DFO	 prior	 to	 lysis.	 Similarly	 to	 the	 BafA	treated	 cells,	 ferrous	 iron	 supplementation	 could	 overcome	 the	 loss	 of	intracellular	 iron,	 and	 restored	 prolyl-hydroxylation	 of	 His-HIF1αODD530-652		(Figure	 5.9C),	 demonstrating	 that	 altering	 iron	 levels	 can	 directly	 affect	 PHD	activity	 in	 the	 in	 vitro	 assay.	 These	 findings	 were	 observed	 with	 several	
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experimental	replicates	(Figure	5.9D),	and	together,	these	results	show	that	V-ATPase	inhibition	prevents	prolyl-hydroxylation	by	depleting	cellular	iron	levels.																																
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Figure 5.9: Ferrous iron restores prolyl hydroxylation of the HIF1αODD following V-
ATPase inhibition with BafA. (A) Schematic showing the hydroxylation of HIF1αODD with 
HeLa cell lysates treated with either BafA or DFO, and iron supplementation (FeCl2). (B, C) 
Immunoblots of His-HIF1αODD530-652 prolyl hydroxylation using cells treated BafA (B) or DFO 
(C) with or without addition of ferrous iron. (D) Quantification of three experimental replicates 
of (B) using ImageJ. Mean±SEM, *p<0.05, **p<0.01 N.S. = not significant. 
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5.2.8	Establishing	an	in	vitro	assay	to	determine	hydroxylation	of	HIF2α.	Having	demonstrated	that	an	in	vitro	assay	of	HIF1α	prolyl	hydroxylation	could	be	used	to	explore	and	identify	new	mechanisms	for	HIF1	activation,	I	was	keen	to	see	if	similar	techniques	could	be	used	to	examine	hydroxylation	of	the	other	 main	 isoform,	 HIF2α.	 While	 HIF1α	 is	 ubiquitously	 expressed,	 HIF2α	 is	limited	to	certain	cell	 types	(eg.	renal	cells,	endothelial	cells)	(Ema	et	al.,	1997;	Flamme	 et	 al.,	 1997;	 Tian	 et	 al.,	 1997).	 However,	 little	 is	 known	 about	 the	regulation	of	HIF2α	under	normoxic	conditions.		I	first	generated	a	HIF2α	recombinant	protein	that	included	the	either	one	or	both	of	 the	proline	residues	that	have	been	 identified	as	being	hydroxylated	by	PHD2,	Pro405	and	Pro531,	by	sequence	similarity	to	HIF1α.	Eight	constructs	were	 generated	 using	 Ligation	 Independent	 Cloning	 (LIC)	 (Figure	 5.10A)	 and	the	protein	was	purified	as	described	previously	(Results	5.2.2.)	 I	chose	to	use	the	 His-	 HIF2α381-655	construct	 for	 the	 hydroxylation	 assay	 as	 this	 was	 soluble	(Figure	5.10B,	C)	and	included	both	proline	residues	known	to	be	hydroxylated	(Figure	5.10A).	
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Figure 5.10: Generation of a HIF2α protein for use in the in vitro assay using ligation 
independent cloning. (A) Schematic of LIC of the HIF2α ODD. The two prolines that can be 
hydroxylated by the PHDs are highlighted. Eight constructs were amplified by LIC and cloned 
into a 6xHis expression vector. (B) Small-scale solubility assays were performed to identify 
the HIF2αODD protein best suited for the hydroxylation assay. Coomassie-stained gel shows 
solubility assay of three HIF2αODD protein constructs. W – whole sample, S- supernatant 
(soluble fraction), P- pellet (insoluble fraction). (C) Dilution series of the purified His-
HIF2αODD381-655protein selected, separated by SDS-PAGE and stained with Coomassie blue.  
	
5.2.9	 The	 HIF2αODD	 protein	 is	 hydroxylated	 in	 vitro	 in	 a	 PHD2	 dependent	
manner.	A	 HIF2α	 specific	 hydroxyl-proline	 antibody	 was	 not	 commercially	available,	 but	 given	 the	 similarities	between	 the	HIFα	 isoforms	 it	was	possible	that	 the	 antibody	 would	 cross-react	 with	 the	 hydroxylated	 HIF2α	 peptide.	
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Therefore,	I	first	determined	if	the	His-HIF2α381-655	recombinant	protein	could	be	hydroxylated	in	the	presence	of	HeLa	cell	 lysates	in	a	PHD2	dependent	manner	(Figure	 5.11A),	 without	 the	 addition	 of	 cofactors	 as	 I	 had	 shown	 for	 HIF1α	(Results	 5.2.3).	 WT	 HeLa	 lysates	 were	 incubated	 with	 the	 His-HIF2α381-655	peptide	 for	 15	min	 at	 37°C	 and	 DMOG	was	 used	 as	 a	 control	 (Figure	 5.11B).	Samples	 were	 analysed	 by	 immunoblot	 for	 HIF2α,	 β-actin,	 and	 a	 hydroxyl-proline	 specific	 antibody	 (OH-HIFα)	 (Figure	 5.11B).	 A	 single	migrating	HIF2α	species	was	identified	by	immunoblot,	corresponding	to	His-HIF2α381-655	peptide	in	all	 samples	 (Figure	 5.11B).	Probing	with	 the	OH-HIFα	antibody	 identified	a	single	 band	 after	 15	 min	 incubation	 with	 WT	 lysate	 (Figure	 5.11B).	Furthermore,	no	hydroxylation	was	observed	at	the	0	time	points	or	after	15	min	incubation	with	DMOG.	Thus,	the	OH-HIFα	antibody	successfully	detected	HIF2α	prolyl-hydroxylation.			Next,	I	examined	whether	small	molecule	metabolites	could	impair	HIF2α	prolyl	 hydroxylation	 and	 focused	 first	 on	 succinate	 (Figure	 5.11C).	 Pre-incubation	 with	 high	 concentrations	 succinate	 (5	 to	 10	 mM)	 inhibited	 HIF2α	prolyl-hydroxylation	 (Figure	 5.11C),	 suggesting	 that	 succinate	 regulates	 both	HIF1α	and	HIF2α	hydroxylation	similarly.		
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Figure 5.11: The HIF2αODD protein is hydroxylated in vitro in a PHD dependent manner.  
(A) Schematic of the in vitro hydroxylation assay, illustrating the His-HIF2αODD381-655 protein. 
(B) Immunoblot of total or prolyl hydroxylated His-HIF2αODD381-655 using wildtype HeLa lysates 
with or without addition of DMOG to the reaction. (C) Prolyl hydroxylation of HIF2αODD381-655 
with wildtype HeLa lysates with or without increasing concentrations of succinate (0.5-10mM) 
or DMOG. β-actin served as a loading control. 
	
5.2.10	HIF2α	prolyl	hydroxylation	is	impaired	when	the	OGHDc	is	disrupted,	
and	by	the	accumulation	of	L-2-HG	
	 Having	established	an	in	vitro	assay	of	HIF2α	prolyl	hydroxylation,	which	robustly	 reproduced	 published	 findings,	 I	 tested	whether	HIF2α	 hydroxylation	was	 inhibited	by	deletions	of	OGDH	and	LIAS,	 or	by	 the	 addition	of	 L-2-HG,	 as	had	been	identified	for	HIF1α.		First,	 I	 performed	 the	HIF2α	 assay	 as	 described	 using	HeLa	 cell	 lysates	from	OGDH,	LIAS	or	PHD2	KO	clones	(Figure	5.12A,	B).	Prolyl	hydroxylation	of	the	 His-HIF2α381-655	 protein	 was	 observed	 after	 15	 min	 incubation	 with	 WT	lysate	(Figure	5.12A,	B),	but	to	a	lesser	extent	in	the	OGDH	(Figure	5.12A)	or	LIAS	(Figure	5.12B)	KO	lysates.	No	hydroxylation	was	detected	after	15	min	in	
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the	PHD2	null	lysate	(Figure	5.12A,	B).	While	these	findings	are	similar	to	those	observed	for	HIF1α	(Figure	5.4),	the	levels	of	prolyl	hydroxylation	were	slightly	higher	 in	 the	HIF2α	 assay,	 although	 it	 is	 not	 known	 if	 only	 one	 or	 both	 of	 the	prolyl	hydroxylation	sites	within	HIF2α	are	recognized	by	the	antibody.		 To	determine	the	effect	of	the	2-HG	enantiomers	on	HIF2α	hydroxylation	I	incubated	the	His-HIF2α381-655	peptide	with	Hela	lysates	treated	with	increasing	concentrations	 of	 L-2-HG	 or	 D-2-HG	 as	 described	 previously.	 His-HIF2α381-655	prolyl	 hydroxylation	 was	 inhibited	 with	 increasing	 concentrations	 of	 L-2-HG	(Figure	5.12C,	left	panel).	However,	L-2-HG	did	not	inhibit	HIF2α	hydroxylation	to	 the	 same	 level	 as	 observed	with	HIF1α,	 as	 even	10mM	L-2-HG	did	not	 fully	prevent	prolyl	hydroxylation.	 Interestingly,	 there	was	also	a	slight	 inhibition	of	His-HIF2α381-655	hydroxylation	with	increasing	concentrations	of	D-2-HG	(Figure	
5.12C,	right	panel),	which	had	not	been	observed	with	HIF1α	(Figure	5.5B,	C).	Thus,	while	 impaired	 OGDHc	 activity	 and	 L-2-HG	 accumulation	 inhibits	 HIF2α	prolyl-hydroxylation,	this	is	to	a	lesser	extent	than	HIF1α.	
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Figure 5.12: HIF2αODD prolyl hydroxylation is inhibited when the OGDHc is disrupted or 
following treatment with 2-HG.  (A, B) Immunoblot of prolyl hydroxylated and total 
HIF2αODD381-655  with lysates from OGDH (A), LIAS (B)  or PHD2 (A, B) KO clones. (C) 
Immunoblot of  prolyl hydroxylated and total HIF2αODD381-655   with HeLa cell lysates treated 
with increasing concentrations of L-2-HG (left) or D-2-HG (right) (0.5-10mM). The addition of 
DMOG served as a control for PHD inhibition. β-actin was used as a loading control. 
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5.2.11	 	 V-ATPase	 inhibition	 depletes	 intracellular	 iron	 and	 prevents	 HIF2α	
hydroxylation.		 Next,	 I	 examined	 whether	 HIF2α	 hydroxylation	 would	 be	 affected	 by	intracellular	iron	depletion,	similarly	to	HIF1α.	I	first	treated	HeLa	cells	with	or	without	DFO	(100µM)	overnight	and	then	incubated	the	cell	lysates	with	the	His-HIF2αODD381-655	 protein	 before	 measuring	 prolyl	 hydroxylation	 by	 immunoblot	(Figure	5.13A).	The	addition	of	DMOG	to	the	hydroxylation	reaction	served	as	a	control	for	PHD	activity.	The	DFO	treated	lysate	almost	completely	inhibited	His-HIF2αODD381-655	 prolyl	 hydroxylation	 in	 comparison	 with	 untreated	 HeLa	 cells	(Figure	5.13A).		Having	 demonstrated	 that	 the	 HIF2α	 prolyl	 hydroxylation	 was	susceptible	to	iron	chelation,	I	examined	if	V-ATPase	inhibition	prevented	HIF2α	prolyl	 hydroxylation	 and	 whether	 this	 could	 be	 reversed	 with	 ferrous	 iron	supplementation	(Figure	5.13B).	I	treated	HeLa	cells	with	BafA	(10nM)	or	DFO	(100µM)	overnight,	 lysed	 the	 cells,	 and	 incubated	 the	 extracts	with	or	without	iron	 chloride.	 While	 the	 addition	 of	 ferrous	 iron	 had	 little	 effect	 on	 the	hydroxylation	 of	 His-HIF2αODD381-655	 in	 the	 WT	 lysate,	 0.5nM	 FeCl2	 completely	restored	 prolyl	 hydroxylation	 in	 the	 BafA	 and	 DFO	 treated	 lysates	 (Figure	
5.13B),	 similar	 to	 the	 findings	 with	 HIF1α	 prolyl	 hydroxylation	 (Figure	 5.9).	Thus,	 inhibition	of	the	V-ATPase	depletes	cellular	 iron	and	decreases	the	prolyl	hydroxylation	of	HIF1α	and	HIF2α	similarly.																				
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Figure 5.13: Ferrous iron restores prolyl hydroxylation of the HIF2αODD following V-
ATPase inhibition with BafA. (A) Immunoblots of His-HIF2αODD381-655 prolyl hydroxylation 
using cells treated with or without DFO prior to lysis. DMOG was added to the reaction as a 
control for PHD activity. (B) HeLa cells were treated with or without BafA (10nM) or DFO 
(100µM) overnight and then lysed. The cell extracts were then incubated with His-
HIF2αODD381-655 with or without addition of increasing concentrations of ferrous iron (FeCl2) as 
shown.  
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5.3	Discussion			 The	 balance	 between	 HIF1α	 stabilisation	 and	 degradation	 provides	 an	intrinsic	mechanism	for	the	cellular	response	to	oxygen	and	nutrient	availability.	In	 normoxia,	 the	 rapid	 proteasomal	 degradation	 of	 HIFα	 prevents	 unwanted	activation	 of	 hypoxia-responsive	 genes.	 This	 degradation	 is	 mediated	 by	 HIF	prolyl	 hydroxylation	 and	 subsequent	 ubiquitination	 by	 the	 E3	 ligase	 complex,	VHL,	 leading	 to	 proteasome-mediated	 degradation.	 Ultimately,	 I	 aimed	 to	identify	 the	 ubiquitin	 chains	 and	 other	 enzymes	 involved	 in	 HIF	 degradation,	however	prolyl	hydroxylation	is	required	to	initiate	this	ubiquitination	and	I	was	keen	 to	 identify	 factors	 controlling	 this	 initiation	 step	 before	 proceeding	 to	evaluate	ubiquitination.		
5.3.1	In	vitro	prolyl	hydroxylation	of	HIFs	using	cell	extracts	Prior	 assays	 of	 HIFα	 prolyl	 hydroxylation	 have	 used	 both	 direct	 and	indirect	measurements	of	PHD	activity.	Epstein	et	al,	utilised	1-14C	to	radiolabel	2-OG	and	measure	14C-CO2	release	when	 incubated	with	a	small	HIF1α	peptide,	recombinant	 PHD2,	 exogenous	 Fe2+,	 ascorbate	 and	 DTT	 (Epstein	 et	 al.,	 2001).	Thus,	 measurement	 of	 14C-CO2	 allowed	 an	 indirect	 quantification	 of	 PHD2	activity.	With	modifications	to	this	assay,	the	hydroxylated	HIF1α	peptide	could	also	be	collected	and	analysed	by	LC/MS	(Hewitson	et	al.,	2007a;	McNeill	et	al.,	2005)	 allowing	 direct	 measurement	 of	 HIF1α	 hydroxylation.	 An	 alternative	approach	 is	 the	 pVHL	 capture	 assay	 (Tuckerman	 et	 al.,	 2004),	 in	 which	 the	binding	 of	 a	 radiolabelled-pVHL	 to	 the	 hydroxylated	 proline	 of	 a	 biotinylated	HIF1α	 peptide	 was	 measured.	 However,	 as	 all	 these	 approaches	 require	exogenous	 cofactors	 and	 PHD2,	 the	 effects	 of	 changes	 in	 whole	 cell	 lysates	affecting	metabolites	or	iron	levels	could	not	be	assessed.			The	 development	 of	 an	 in	 vitro	 hydroxylation	 reaction,	 using	 only	 a	recombinant	HIFα	 peptide	 and	whole	 cell	 lysates	 enables	 the	 quantification	 of	HIFα	prolyl	hydroxylation	without	the	need	for	addition	of	exogenous	cofactors	in	a	short,	15	min	reaction.	This	has	several	advantages	over	previous	assays,	as	radioactivity	 or	 purification	 of	 PHDs	 is	 not	 required.	 Moreover,	 as	 exogenous	
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cofactors	 are	 not	 added,	 the	 effect	 of	 changes	 in	 levels	 of	 cofactor	 or	 other	metabolites	 on	HIFα	hydroxylation	 can	be	determined.	A	 further	 benefit	 is	 the	use	 of	 HIFα	 itself	 as	 a	 measure	 of	 prolyl-hydroxylation,	 rather	 than	 indirect	readouts	such	as	VHL	binding.	There	 are	 several	 limitations	 to	my	approach.	 I	 used	a	hydroxyl-proline	specific	 antibody,	 which	 does	 not	 provide	 an	 absolute	 quantification	 of	 prolyl	hydroxylation,	 as	 it	 is	 dependent	 on	 the	 affinity	 of	 the	 antibody	 for	 the	 HIFα	protein.	 An	 alternative	 strategy	 would	 be	 to	 use	 the	 migration	 properties	 of	hydroxylated	HIFα	 following	 electrophoresis,	 as	 previously	 used	by	 Selak	 et	 al	(Selak	 et	 al.,	 2005).	 MS	 of	 the	 HIFα	 protein	 could	 be	 used	 to	 determine	 HIFα	hydroxylation,	 but	 this	 would	 have	 made	 the	 assay	 more	 laborious	 and	more	expensive.	In	addition,	the	HIF1αODD	protein	used	encoded	amino	acids	530-652	and	therefore	incorporated	only	one	of	the	prolines	(Pro564)	hydroxylated	by	PHDs.	However,	prior	studies	have	shown	that	both	prolyl	hydroxylation	sites,	Pro564	and	Pro402,	can	function	independently,	to	bind	VHL	and	undergo	ubiquitination	(Masson	et	al.,	2001),	although	most	assays	of	PHD	activity	have	typically	used	very	 small	HIF1α	peptides	 (10-12mer)	 encoding	 Pro564	 only	 (Hewitson	 et	 al.,	2007a).	 Therefore,	 it	 may	 be	 important	 to	 measure	 prolyl	 hydroxylation	 in	 a	HIF1α	 protein	 with	 both	 prolines,	 similarly	 to	 the	 HIF2α	 protein	 used	 in	 my	assays.	Indeed,	the	presence	of	two	prolines	in	the	HIF2α	ODD	may	explain	why	L-2-HG	inhibition	was	less	efficient	compared	to	HIF1α	prolyl	hydroxylation.		All	PHDs	may	be	involved	in	HIFα	hydroxylation	but	as	PHD2	is	the	major	enzyme	 implicated	 in	 the	 hydroxylation	 of	 HIF1α	 (Berra	 et	 al.,	 2003),	 prior	assays	 have	mainly	 focussed	 on	 this	 isoform.	Hela	 cells	 encode	 all	 three	 PHDs	(unpublished	data,	Nathan	lab),	and	it	was	therefore	interesting	that	depletion	of	PHD2	 alone	 was	 sufficient	 to	 prevent	 both	 HIF1α	 and	 HIF2α	 prolyl	hydroxylation.	These	findings	suggest	that	PHD1	and	PHD3	do	not	have	a	major	role	in	constitutive	HIFα	turnover,	and	it	will	be	of	interest	to	explore	the	specific	effects	of	their	loss	on	HIFα	prolyl	hydroxylation.		
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5.3.2	Inhibition	of	prolyl	hydroxylation	by	impaired	OGDHc	activity	and	L-2-
HG	formation	I	show	that	the	hydroxylation	of	HIF1α	under	aerobic	conditions	is	highly	regulated	by	the	availability	of	TCA	metabolites,	succinate,	2-OG	and	L-2-HG,	and	by	 two	mitochondrial	 enzymes	 OGDH	 and	 LIAS.	 Together	with	 Stephen	 Burr’s	cell	 biology	 studies,	 my	 in	 vitro	 assay	 allowed	 us	 to	 build	 a	 model	 whereby	disrupting	the	OGDHc	leads	to	the	reversible	stabilisation	of	HIF1α	through	the	accumulation	of	L-2-HG	and	inhibition	of	the	PHDs	(Figure	5.14).		In	cells,	depletion	or	inhibition	of	the	three	main	enzymes	involved	in	L-2-HG	 formation,	 LDHA,	 MDH1	 and	 MDH2,	 decreased	 L-2-HG	 formation	 and	promoted	HIF1α	turnover	(Burr	et	al.,	2016).	However,	in	vitro,	I	was	not	able	to	restore	 prolyl	 hydroxylation	 of	 HIF1α	 in	 the	 OGDH	 or	 LIAS	 null	 cells.	 Several	explanations	 may	 account	 for	 this	 discrepancy.	 It	 is	 possible	 that	 2-OG	 is	converted	 to	 L-2-HG	 within	 the	 lysate,	 during	 the	 incubation	 at	 37°C.	 My	attempts	 to	 prevent	 this	 by	 the	 addition	 of	 oxamate	 were	 not	 successful.	 An	alternative	 approach	 would	 be	 to	 use	 antibody-depletion	 to	 remove	 LDHA	 or	MDH	from	the	lysate,	thereby	preventing	L-2-HG	formation.		Alternatively,	L-2-HG	may	not	compete	directly	with	2-OG	for	binding	to	PHDs	 but	 instead	 function	 as	 an	 allosteric	 inhibitor	 of	 prolyl	 hydroxylation.	Intriguingly,	 the	 L-2-HG	 inhibits	 PHDs	 at	 relatively	 low	 concentrations	 (0.5-1mM)	 compared	 to	 the	 levels	 of	 2-OG	 in	 cells	 (>10mM).	 It	would	 therefore	 be	interesting	 to	 directly	 measure	 the	 ability	 of	 L-2-HG	 to	 bind	 and	 inhibit	 a	recombinant	PHD2	protein,	and	to	measure	 if	L-2-HG	can	dissociate	2-OG	from	the	enzyme.										
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Figure 5.14: Disrupting the OGDHc leads to the accumulation of L-2-HG and activation 
of the HIF response. Schematic of the proposed model leading to HIF activation when the 
OGDHc is disrupted. The accumulation of 2-OG is converted to L-2-HG (dependent on LHDA 
and MDH1/2). L-2-HG inhibits PHD activity even in the context of high 2-OG levels, leading to 
stabilisation of the HIFα subunit. The HIF heterodimeric complex can then form. Based on 
model detailed in (Burr et al., 2016). 	
5.3.3	Inhibition	of	prolyl	hydroxylation	by	intracellular	iron	depletion		I	 show	 that	 inhibition	 of	 the	 V-ATPase	 leads	 to	 HIF1α	 stabilisation	 by	inhibition	of	HIF1α	prolyl	hydroxylation	and	this	can	be	restored	by	the	addition	of	 Fe2+.	 Together	 with	 Annie	 Miles’	 (PhD	 student,	 Nathan	 lab)	 cell	 biology	studies,	my	 in	vitro	assay	allowed	us	 to	develop	a	model	 in	which	 inhibition	of	the	V-ATPase	 restricts	 iron	 uptake,	 reducing	 the	 free	 pool	 of	 intracellular	 iron	and	stabilizing	HIFα	by	inhibition	of	prolyl	hydroxylation	(Figure	5.15).								
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Figure 5.15: V-ATPase inhibition leads to intracellular iron depletion and activation of a 
HIF response. Schematic of the proposed model leading to HIF activation when the V-
ATPase is inhibited. Inhibition of the V-ATPase prevents acidification of the endosomes and 
lysosomes, which prevents the conversion of ferric to ferrous iron, and the release of iron 
stores by ferritinophagy. Prolonged V-ATPase inhibition also leads to cholesterol depletion 
and a decrease in clathrin-mediated endocytosis, thereby also contributing to intracellular iron 
depletion through decreased transferrin trafficking. Based on my studies and the work of 
Anna Miles and Stephen Burr  *(Miles et al., 2017) 		As	the	PHD2	enzyme	is	dependent	upon	Fe2+	for	its	activity	(Epstein	et	al.,	2001)	it	is	interesting	that	the	chelation	of	iron	from	cell	lysates	did	not	prevent	the	 re-activation	 of	 PHD2	 once	 Fe2+	 was	 restored.	 In	 addition,	 it	 has	 been	suggested	that	Fenton	chemistry	is	responsible	for	non-enzymatic	catalysis	of	D-2-HG	 to	 2OG	 in	 vitro	 promoting	 PHD	 function	 (Tarhonskaya	 et	 al.,	 2014)	however,	the	use	of	a	wildtype	lysate	control	shows	no	increase	in	hydroxylation	with	 increasing	 Fe2+	 indicating	 that	 Fenton	 chemistry	 is	 not	 occurring	 at	significant	levels	at	the	concentrations	of	Fe2+	used	in	these	reactions.	
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Finally,	 I	 observed	 that	 lysates	 treated	 with	 BafA	 lead	 to	 inhibition	 of	HIF2α	 hydroxylation	 which	 was	 restored	 by	 the	 addition	 of	 Fe2+.	 Similarly	 to	HIF1α,	the	reduction	of	Fe2+	caused	by	V-ATPase	inhibition	or	iron	chelation	lead	to	PHD2	inhibition	due	to	lack	of	the	co-factor.		As	the	hydroxylation	of	both	HIF1	and	HIF2α	is	catalyzed	by	PHD2,	the	findings	are	unsurprising	but	revealing	as	HIF2α	hydroxylation	had	not	been	previously	investigated	and	further	validates	the	 robustness	and	 reproducibility	of	 these	 in	vitro	assays,	which	 can	now	 test	hydroxylation	of	two	HIFα	isoforms.		
5.3.4	Comparison	of	HIF1α 	and	HIF2α 	prolyl	hydroxylation	The	 development	 of	 the	 HIF2α	 hydroxylation	 assay	 allowed	 me	 to	determine	whether	there	were	differences	in	the	hydroxylation	of	HIF1α	versus	HIF2α,	particularly	as	HIF2α	has	more	a	limited	range	of	tissue	expression,	and	little	 is	 known	 about	 the	 normoxic	 regulation	 of	 HIF2α.	 While	 overall,	 the	findings	were	 similar	 between	 the	HIF1α	 and	HIF2α	 assays,	 there	were	 a	 few	interesting	observations.		Lysates	 lacking	 either	 OGDH,	 LIAS	 or	 PHD2	 led	 to	 inhibition	 of	 HIF2α	hydroxylation,	as	did	the	TCA	metabolite	succinate	and	the	2-OG	derivative	L-2-HG.	However,	the	level	of	HIF2α	hydroxylation	remained	higher	in	the	OGDH	and	LIAS	 null	 cells,	 compared	 to	 the	 HIF1α	 peptide.	 While	 the	 presence	 of	 two	proline	residues	 in	 the	HIF2α	peptide	may	partially	explain	these	 findings,	 it	 is	possible	that	HIF2α	prolyl	hydroxylation	is	less	susceptible	to	L-2-HG	inhibition.	Physiologically,	this	may	be	important	for	differentially	regulating	the	stability	of	HIFα	subunits	to	fine-tune	the	HIF	response.			 Interestingly,	 lysates	 treated	with	 the	 2-HG	 enantiomer	 D-2-HG	 slightly	enhanced	hydroxylation	of	the	HIF1αODD	protein	whereas	similar	concentrations	led	to	a	slight	decrease	in	HIF2αODD	hydroxylation.	The	effect	of	D-2-HG	on	HIFα	hydroxylation	has	been	contentious	within	published	literature	(Koivunen	et	al.,	2012;	Tarhonskaya	et	al.,	2014)	and	the	 reason	for	 the	differences	observed	 in	these	assays	are	not	yet	clear	(see	also	Chapter	7).		 	
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5.4	Summary		 In	 this	 chapter,	 I	 focused	 on	 an	 alternative	 pathway	 where	 K11-linked	chains	 had	 been	 implicated,	 the	 HIF	 response.	 	 I	 established	 in	 vitro	assays	 to	measure	 the	 initiation	 step	 of	HIFα	 ubiquitination,	 prolyl	 hydroxylation.	 Using	cell	 extracts	 and	 recombinant	 HIFα	 proteins	 I	 demonstrated	 that	 HIFα	 prolyl	hydroxylation	 could	 be	 rapidly	 quantified,	 without	 the	 addition	 of	 exogenous	cofactors.	In	particular,	I	identified	that	the	TCA	metabolite,	L-2-HG,	was	able	to	inhibit	HIF1α	hydroxylation	and	that	deletion	of	the	mitochondrial	enzyme	genes	OGDH	and	LIAS	led	to	HIF1α	stabilisation	by	inhibiting	the	prolyl	hydroxylation	of	 the	 HIF1αODD.	 I	 also	 showed	 that	 inhibition	 of	 the	 V-ATPase	 lead	 to	 HIF1α	stabilisation	due	to	depletion	of	cellular	iron,	and	that	HIF1α	hydroxylation	was	restored	by	addition	of	the	Fe2+.	Development	of	a	HIF2α	 in	vitro	hydroxylation	assay	 showed	 that	 prolyl	 hydroxylation	 of	 the	 HIF2αODD	 was	 inhibited	 in	 a	similar	 manner	 to	 HIF1α.	 However,	 D-2-HG	 led	 to	 a	 slight	 increase	 of	 HIF1α	hydroxylation,	but	a	moderate	decrease	of	HIF2α	hydroxylation.	Together,	these	findings	demonstrate	 the	 initiation	 step	of	HIF	ubiquitination	 can	be	 regulated	by	 diverse	 cellular	 processes,	 and	 that	 endogenous	 levels	 of	 small	 molecule	metabolites	 are	 critical	 in	 regulating	 HIFα	 prolyl	 hydroxylation.	 Having	established	a	robust	method	to	prolyl	hydroxylate	HIFα,	I	now	aimed	to	use	this	approach	to	explore	the	ubiquitination	of	HIF1α.				 	
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 Chapter	6:	Results	4,	Can	HIF1α 	ubiquitination	be	
reconstituted	in	vitro?		
6.1	Introduction		HIF1α	 is	 one	 of	 the	most	 short-lived	 proteins	 in	 cells	 (approximately	 5	minutes)(Salceda	 and	 Caro,	 1997)	 and	 its	 rapid	 proteasome-mediated	degradation	 is	 dependent	 on	 its	 ubiquitination	 by	 the	 VHL	 E3	 ligase	 complex.	However,	it	is	intriguing	that	HIF1α	still	has	a	short	half-life	of	approximately	1	hr	 following	 VHL	 depletion	 (Maxwell	 et	 al.,	 1999)	 and	 is	 still	 ubiquitinated	(Cockman	et	al.,	2000),	suggesting	that	factors	aside	from	VHL	may	be	involved	in	its	ubiquitination	and/or	degradation.	Furthermore,	 it	 is	possible	that	HIF1α	is	 regulated	 by	 several	 different	 polyubiquitin	modifications,	 analogous	 to	 the	NFκB	pathway,	where	K63	or	linear	ubiquitin	linkages	mediate	NF-kB	signalling	(Deng	 et	 al.,	 2000;	 Shimizu	 et	 al.,	 2015)	 independently	 of	 degradation.	 Thus,	 I	was	keen	to	explore	if	I	could	identify	the	types	of	ubiquitin	linkages	formed	on	HIF1α,	 and	 whether	 this	 would	 give	 some	 insights	 into	 VHL	 or	 proteasome-independent	regulation	of	HIF1α	stability.			Prior	 studies	 of	 HIF1α	 ubiquitination	 typically	 used	 radiolabelling	 and	expression	of	a	small	HIF1α	peptide	(Cockman	et	al.,	2000).	These	studies	were	instrumental	 in	 identifying	 a	 role	 for	 VHL,	 but	 the	 types	 of	 ubiquitin	 chains	formed	 were	 not	 examined.	 Indeed,	 examining	 ubiquitin	 lysine	 linkages	 using	radiolabelling	techniques	is	challenging,	as	the	samples	are	not	suitable	for	mass	spectrometry	 analysis	 of	 the	 ubiquitin	 chains	 formed.	 Therefore,	 I	 wanted	 to	explore	if	I	could	adapt	the	hydroxylation	assay	to	measure	HIFα	ubiquitination,	and	use	this	system	to	determine	the	ubiquitin	 linkages	 formed,	particularly	as	generating	 biochemical	 quantities	 of	 ubiquitinated	 HIF1α	 had	 not	 been	previously	attempted.				 In	 this	 chapter,	 I	 have	 taken	 two	 approaches	 to	 investigate	 the	ubiquitination	of	HIF1α:	 	 (1)	by	using	 the	HIF1α	 prolyl	hydroxylation	assay	 to	initiate	 ubiquitination	 on	 the	 HIF1α	 ODD	 (HIF1αODD),	 and	 (2)	 by	
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immunoprecipitating	endogenous	HIF1α	in	an	attempt	to	identify	new	ubiquitin	enzymes	involved	in	HIFα	signalling.		 	 	
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6.2	Results		
6.2.1	Establishing	an	in	vitro	assay	to	determine	ubiquitination	of	HIF1α.			 The	 in	vitro	assay	 to	quantify	prolyl	hydroxylation	of	HIF1α	 had	proved	extremely	valuable	in	elucidating	mechanisms	of	HIF1α	stabilisation	(Burr	et	al.,	2016;	Miles	et	al.,	2017),	but	had	not	yet	identified	HIF1α	ubiquitination.	Indeed,	it	 was	 somewhat	 surprising	 that	 I	 had	 not	 observed	 any	 ubiquitination	 or	degradation	 of	 the	 His-HIF1αODD530-652	protein,	 given	 that	 it	 contains	 all	 three	lysines	known	to	be	ubiquitinated	by	VHL	(K532,	K537	and	K548)	(Paltoglou	and	Roberts,	2007;	Tanimoto	et	al.,	2000).	It	was	possible	that	a	15	min	reaction	was	of	insufficient	length	to	ubiquitinate	the	His-HIF1αODD530-652	protein.	 	However,	I	did	 not	 observe	 any	 ubiquitination	 or	 decreased	 protein	 levels	 using	 longer	reaction	times	(data	not	shown).	Prior	 studies	 showed	 that	 both	 proline	 residues	 and	 all	 three	 lysine	residues	 of	 HIF1α	 maybe	 required	 for	 efficient	 ubiquitination	 (Paltoglou	 and	Roberts,	 2007).	 As	 the	 His-HIF1αODD530-652	 protein	 lacked	 the	 initial	 prolyl	hydroxylation	site	(P402),	it	was	possible	that	a	HIF1αODD	construct	encoding	all	three	 lysine	 residues	 and	both	proline	 residues	would	be	 required	 to	 visualise	ubiquitination.	Therefore,	I	designed	a	construct	encoding	all	these	residues,	His-HIF1αODD380-652,	and	purified	the	recombinant	protein	(Figure	6.1A).	This	longer	HIF1αODD	 construct	 was	 rapidly	 hydroxylated	 (Figure	 6.1B),	 similarly	 to	 His-HIF1αODD530-652protein	(Figure	5.2).	As	 there	 is	 no	 antibody	 specific	 to	 ubiquitinated	 HIF1α	 available,	identification	 of	 ubiquitination	 on	 the	 HIF1αODD	would	 require	 isolation	 of	 the	recombinant	 ubiquitinated	 protein	 and	 identification	 of	 the	 ubiquitinated	residues	 and	 chains	 by	 probing	 with	 ubiquitin	 antibodies	 or	 using	 mass	spectrometry.	 His-tagged	 proteins	 require	 isolation	 using	 NiNTA	 resin,	 which	often	 undergoes	non-specific	 binding	 	 (Figure	 6.1B,	 *band).	 Therefore,	 I	 also	designed	 and	 generated	 a	 GST-tagged	 HIF1αODD	 that	 encoded	 the	 required	proline	 (P402,	 P654)	 and	 lysine	 (K532,	 K537	 and	 K548)	 residues	 (GST-HIF1αODD401-652)	that	bound	GSH	Sepharose	(Figure	6.1C),	without	the	problems	of	 non-specific	 binding.	 Importantly,	 GST-HIF1αODD401-652	 was	 hydroxylated	
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when	 incubated	 with	 HeLa	 cell	 extracts,	 similarly	 to	 the	 His-tagged	 construct	(Figure	6.1D).				
Figure 6.1: Generation of HIF1α recombinant proteins for an in vitro ubiquitination 
assay. (A) Dilution series of the His-tagged HIF1αODD380-652 protein, separated by SDS-
PAGE and stained with Coomassie blue. (B) Hydroxylation of the His-HIF1αODD380-652 using 
HeLa cell lysate and PHD2 depleted HeLa cell lysate (*non-specific band). (C) Dilution series 
of the GST-tagged HIF1αODD401-652 protein, separated by SDS-PAGE and stained with 
Coomassie blue. (D) Hydroxylation of the GST-HIF1αODD401-652 using HeLa cell lysates with 
or without DMOG treatment. 	 Having	 generated	 new	HIF1αODD	 constructs	 I	 could	 proceed	with	 the	 in	
vitro	 ubiquitination	 assay,	 as	 shown	 in	 Figure	 6.2.	 Briefly,	 100nM	 GST-HIF1αODD401-652	was	pre-incubated	with	GSH	Sepharose	resin	 for	30	min	at	4°C.	The	resins	were	then	washed	in	TBS	to	remove	unbound	protein	and	incubated	with	cell	 lysate	for	18	hr	at	37°C	in	a	shaking	incubator.	As	it	was	possible	that	the	lack	of	ubiquitination	seen	in	my	hydroxylation	assays	(Chapter	5)	may	have	
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been	 due	 to	 insufficient	 E1,	 E2,	 ubiquitin	 or	 ATP	 in	 the	 cell	 lysate,	 these	were	added	 to	 the	 overnight	 reaction	 (50nM	E1,	 2.5μM	UbcH5b,	 5μM	 ubiquitin	 and	4mM	ATP)	(Figure	6.2).	Samples	were	taken	at	the	start	of	the	reaction	or	after	18	 hr,	 and	 passed	 over	 a	 10ml	 Biorad	 column	 at	 4°C	 to	 separate	 resin	 bound	GST-HIF1αODD401-652	from	the	flow	through	(FT),	and	analysed	by	immunoblot	or	Coomassie	staining.				
		
Figure 6.2: The in vitro ubiquitination assay. Schematic of the in vitro prolyl-hydroxylation 
and ubiquitination assay. The proline (P) and lysine (K) residues predicted to be hydroxylated 
and ubiquitinated are shown. 			 		
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A	 single	 HIF1α	 species	 was	 identified	 using	 the	 HIF1α	 antibody	 in	 the	resin-bound	samples	at	just	above	64kDa,	corresponding	to	the	GST-HIF1αODD401-652	 peptide	 (Figure	 6.3A,	 top	 panel).	 However,	 this	 band	 was	 also	 clearly	identified	in	the	FT	samples,	indicating	that	not	all	GST-HIF1αODD401-652	remained	resin-bound	 once	 lysate	 was	 added	 (Figure	 6.3A,	 bottom	 panel).	 There	 was	also	 faint	 band	 (Figure	 6.3A,	 *band)	 present	 above	 the	 64kDa	 band	 in	 both	resin	and	flow	through	after	18	hr	(long	exposure),	which	was	not	present	at	the	start	 that	 may	 correspond	 to	 monoubiquitination	 of	 GST-HIF1αODD401-652.	Interestingly,	 when	 the	 resin-bound	 samples	 were	 probed	 with	 the	 ubiquitin	specific	antibody,	a	protein	smear	above	100	kDa	was	 identified	 (Figure	 6.3B,	
left	 panel),	which	was	only	present	after	18	hr	 incubation,	suggesting	 that	 the	GST-HIF1αODD401-652	protein	undergoes	polyubiquitination.	As	expected,	the	flow	through	 samples	 showed	 abundant	 ubiquitination	 at	 both	 0	 hr	 and	 18	 hr.	However,	 more	 ubiquitination	 was	 observed	 after	 18	 hr,	 suggesting	 that	 the	addition	of	E1,	E2,	ubiquitin	and	ATP	promoted	general	E2	and	E3	ligase	activity	in	the	cell	extract	(Figure	6.3B,	C,	right	panels).		Next,	I	attempted	to	visualise	whether	the	ubiquitinated	GST-HIF1αODD401-652	could	be	observed	by	Coomassie	Blue	staining	(Figure	6.3C).	The	resin-bound	GST-HIF1αODD401-652	was	clearly	observed	at	0	hr	but	barely	detectable	at	18	hr,	with	a	very	 faint	slower	migrating	ubiquitinated	species	observed	(Figure	 6.3,	
left	 panel).	 It	was	 possible	 that	 the	 level	 of	 ubiquitinated	 GST-HIF1αODD401-652	was	 below	 the	 detection	 limit	 for	 the	 Coomassie	 staining,	 or	 that	 GST-HIF1αODD401-652	 was	 degraded	 by	 endogenous	 proteasomes	 within	 the	 cell	extract.	To	test	this	latter	hypothesis,	I	repeated	the	18	hr	ubiquitination	reaction	in	the	presence	of	a	proteasome	inhibitor	(50μM	MG132),	however	no	increase	in	the	GST-HIF1αODD401-652	band	intensity	was	observed	(data	not	shown).		
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Figure 6.3: In vitro ubiquitination assay using the GST-tagged HIF1αODD401-652 
recombinant protein with the addition of E1, E2, Ub, ATP and HeLa lysates. (A, B) 
Immunoblots of resin-bound GST-HIF1αODD401-652 and flow through from the in vitro 
ubiquitination reaction using antibodies specific to HIF1α (A) and ubiquitin (B) *band may 
correspond to monoubiquitinated GST-HIF1αODD401-652, **band may correspond to dimerised 
GST-HIF1αODD401-652 or endogenous HIF1α. Long and short exposures of the HIF1α 
immunoblots are shown. (C) Coomassie-stained SDS-PAGE gels of resin-bound GST-
HIF1αODD401-652 and FT from the in vitro ubiquitination assay.  
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6.2.2	Are	ubiquitin	chains	formed	on	GST-HIF1αODD	rapidly	disassembled	by	
DUBs?	While	 these	 initial	 experiments	 were	 encouraging,	 the	 levels	 of	ubiquitinated	 HIF1α	 were	 barely	 detectable,	 and	 insufficient	 for	 mass	spectrometry	 analysis.	 Therefore,	 I	 sought	 alternative	 explanations	 for	 the	inefficient	 ubiquitination.	Within	 the	 cell	 extract,	 it	was	possible	 that	 ubiquitin	chains	 formed	 on	 GST-HIF1αODD401-652	 were	 formed	 but	 then	 rapidly	disassembled	by	DUBs.	Indeed,	a	prior	in	vitro	study	using	a	radiolabelled	HIF1α	peptide	required	the	addition	of	ubiquitin	aldehyde	(which	inhibits	isopeptidase	activity	 through	modification	of	 the	ubiquitin	c-terminal	carboxyl	residue	to	an	aldehyde)	to	visualise	HIF1α	ubiquitination	(Cockman	et	al.,	2000).	Therefore,	I	repeated	 the	 ubiquitination	 reaction	 with	 the	 addition	 of	 5µM	 ubiquitin	aldehyde.	 	 After	 18	 hr	 incubation	 at	 37°C,	 I	 observed	 higher	molecular	weight	species	of	GST-HIF1αODD401-652	using	the	HIF1α	antibody	with	addition	of	either	ubiquitin	or	ubiquitin	 aldehyde	 (Figure	 6.4,	 top	 right).	 Immunoblotting	using	the	 ubiquitin	 specific	 antibody	 showed	 an	 ubiquitin	 ladder	 was	 present	 only	when	 ubiquitin	 aldehyde	 was	 used	 (Figure	 6.4,	 bottom	 right)	 which	 would	correspond	 to	 GST-HIF1αODD401-652	 ubiquitination.	 However,	 this	 was	 not	reproducibly	visible	on	a	Commassie	gel	(data	not	shown)	and	was	not	suitable	for	mass	 spectrometry	analysis.	Thus,	while	 there	 is	 some	 improvement	 in	 the	ubiquitination	 with	 ubiquitin	 aldehyde,	 the	 assay	 was	 still	 not	 suitable	 to	examine	the	types	of	ubiquitin	chains	formed	on	the	HIF1αODD.												
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Figure 6.4: HIF1αODD in vitro ubiquitination assay with DUB inhibition. GST-HIF1αODD401-
652 was incubated with E1, E2 (Ubch5b), ATP, and ubiquitin (Ub) as previously described, with 
or without the addition of 5µM ubiquitin aldehyde (Ub Ald). Immunoblots of resin-bound GST-
HIF1αODD401-652 from the in vitro ubiquitination reaction using antibodies specific to HIF1α (top 
panels) and ubiquitin (bottom panels) are shown. *possible HIF1αODD dimerisation. 	
	
6.2.3	Identifying	ubiquitination	of	endogenous	HIF1α.	It	 had	proven	 challenging	 to	 reconstitute	HIF1αODD	 ubiquitination	 using	the	in	vitro	assay	of	HIFα	hydroxylation.	In	particular,	I	was	not	able	to	generate	sufficient	ubiquitinated	HIF1α	for	mass	spectrometry	analysis.	Furthermore,	the	initial	aim	of	this	experimental	approach	was	to	use	the	cell	extracts	without	the	addition	of	ubiquitin,	E1	or	E2	enzymes,	which	may	alter	the	ubiquitin	linkages	formed.	 Therefore,	 as	 an	 alternative	 strategy	 I	 examined	 if	 I	 could	 isolate	ubiquitinated	endogenous	HIF1α	directly	from	cells.		As	 HIF1α	 should	 be	 stabilised	 in	 cells	 during	 aerobic	 conditions	 by	proteasome	 inhibition,	 I	 examined	 if	 I	 could	 immunoprecipitate	 endogenous	
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HIF1α	in	cells	to	isolate	the	ubiquitinated	HIF1α,	with	the	ultimate	aim	of	using	mass	spectrometry	to	identify	the	ubiquitin	chains	formed.		To	test	the	efficiency	of	endogenous	HIF1α	stabilisation,	I	first	incubated	1	x	106	HeLa	cells	with	or	without	different	proteasome	inhibitors	(5μM	MG132,	4μM	 Lactacystin	 or	 20nM	 Velcade	 (Bortezomib))	 overnight,	 and	 measured	HIF1α	 stabilisation	 by	 immunoblot	 (Figure	 6.5A,	 B).	 Lactacystin	 is	 an	irreversible	 proteasome	 inhibitor,	 whereas	 MG132	 and	 Velcade	 are	 reversible	inhibitors	 that	 preferentially	 target	 the	 chymotrypsin-like	 activity	 of	 the	proteasome.	 HIF1α	 was	 stabilised	 following	 MG132	 treatment,	 with	 higher	molecular	 weight	 species	 possibly	 corresponding	 to	 HIF1α	 ubiquitination	(Figure	 6.5A,	 B).	 Surprisingly,	 other	 proteasome	 inhibitors	 at	 concentrations	known	to	inhibit	the	proteasome	(data	not	shown)	had	no	effect	on	HIF1α	levels	(Figure	6.5A)	and	it	may	be	of	interest	in	future	studies	to	explore	why	MG132	seems	to	preferentially	stabilise	the	protein.					Having	 verified	 that	 proteasome	 inhibition	 lead	 to	 the	 accumulation	 of	HIF1α,	 I	 examined	 if	 I	 could	 detect	 endogenous	 HIF1α	 ubiquitination	 by	immunoprecipitation	 (Figure	 6.5A,	 C).	 HIF1α	 was	 readily	 detected	 in	 the	 IP	samples	following	MG132	treatment,	and	a	higher	molecular	weight	ladder	was	visible,	 potentially	 consistent	 with	 ubiquitination	 (Figure	 6.5A,	 C).	 However	some	HIF1α	degradation	products	were	observed	(Figure	6.5C,	*bands)	and	no	polyubiquitination	was	detected	(Figure	 6.5C,	 lower	 right	 panel).	 I	 scaled	up	the	experiment	to	attempt	to	generate	sufficient	samples	for	mass	spectrometry	quantification,	using	1	 x	108	HeLa	 cells	with	or	without	5μM	MG132	 treatment	overnight.	 	While	HIF1α	 stabilisation	was	again	observed,	ubiquitinated	HIF1α	was	 barely	 detectable	 by	 Coomassie	 staining	 (data	 not	 shown),	 and	 when	subjected	to	mass	spectrometry,	the	HIF1α	protein	was	not	identified.								
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Figure 6.5: Immunoprecipitation of endogenous HIF1α following proteasome inhibition. 
(A-C) Immunoblots of total cell lysates and immunoprecipitated HIF1α. (A) 1x106 HeLa cells 
were treated with or without proteasome inhibitors overnight (MG132 (MG), 5µM, lactacystin 
(L), 4µM, or Velcade (V), 20nM). Cells were lysed in 1% NP40 and 10% of the reaction was 
taken for the total cell lysate (TCL). The rest of the sample was immunoprecipitated for 
HIF1α. (B) Immunoblot of HIF1α in HeLa cells with or without overnight treatment with 
MG132 (5µM). β-actin served as a loading control. (C) HIF1α was immunoprecipitated in 
HeLa cells treated with 5µM MG132 overnight and the immunoprecipitated samples were 
probed for HIF1α or ubiquitin. HC, heavy chain, LC, light chain. *HIF1α species that may 
represent ubiquitination. 	
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	The	 reasons	 for	 failing	 to	 detect	HIF1α	 by	mass	 spectrometry	were	not	clear.	It	is	possible	that	there	was	insufficient	protein	from	the	IP,	but	this	seems	unlikely	based	on	previous	sample	analysis	for	other	proteins	in	the	Nathan	lab.	It	 has	 also	 been	 reported	 previously	 that	 HIF1α	 is	 difficult	 to	 detect	 by	mass	spectrometry	 (Doreen	 Cantrell,	 personal	 communication),	 which	 concurs	 with	the	 Nathan	 lab’s	 experience.	 An	 alternative	 approach	 would	 be	 to	 use	overexpressed	 HIF1α,	 but	 we	 find	 that	 this	 leads	 to	 HIF1α	 stabilisation,	presumably	 by	 overcoming	 the	 cellular	 hydroxylation	 machinery,	 and	 it	 is	therefore	 unclear	 how	 informative	 this	 would	 be	 on	 understanding	 the	mechanisms	 of	 HIF1α	 ubiquitination.	 Therefore,	 I	 have	 decided	 not	 to	 pursue	these	 in	 vitro	 approaches	 further,	 and	 instead	will	 focus	my	 future	work	 on	 a	forward	genetic	screens	to	uncover	novel	ubiquitin	enzymes	involved	in	the	HIF	response	(Chapter	7,	future	directions).		 	
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6.3	Discussion			 Most	prior	studies	of	HIFα	ubiquitination	have	relied	on	reconstitution	of	with	 small	 HIFα	 peptides	 and	 radiolabelling.	 Here,	 I	 attempted	 to	 generate	biochemical	 amounts	 of	 polyubiquitinated	 HIF1α	 to	 explore	 the	 types	 of	ubiquitin	linkages	involved,	but	unfortunately	these	were	not	successful.	Indeed,	it	was	 surprising	 that	HIF1α	 ubiquitination	was	difficult	 to	 detect,	 given	 that	 I	had	successfully	generated	a	robust	assay	for	HIFα	prolyl	hydroxylation.			
6.3.1	Why	was	it	difficult	to	detect	HIF1α 	ubiquitination?	A	major	limitation	in	my	ubiquitin	assays	may	be	the	level	of	ubiquitin	E3	ligases	within	the	cell	extract.	An	intrinsic	feature	of	E3	ligases	is	their	ability	to	rapidly	autoubiquitinate,	which	usually	leads	to	their	degradation.	It	 is	possible	that	VHL	was	destabilized	by	the	 lysis	conditions	or	there	was	 insufficient	VHL	(or	other	E3	ligases)	within	the	cell	extracts	to	ubiquitinate	HIF1α.	For	example,	Kamura	et	al	observed	HIF1α	ubiquitination	in	vitro,	but	this	required	purifying	HIF1α	and	the	VHL	complex	from	baculovirus	and	incubating	with	recombinant	E1,	E2	(Ubc5a)	and	ubiquitin	(Kamura	et	al.,	2000).	However,	as	my	aim	was	to	identify	enzymes	and	ubiquitin	chains	involved	in	HIF1α,	I	required	a	system	in	which	VHL	was	not	added,	as	 this	may	dictate	 the	ubiquitin	chains	 formed	and	prevent	identification	of	other	enzymes.		Cockman	et	al	did	observe	ubiquitination	of	HIF1α	without	the	addition	of	E1	 or	 E2	 enzymes,	 by	 using	 radiolabelled	 HIF1α	 peptides	 purified	 from	reticulocyte	lysates	and	incubating	them	with	extracts	from	COS7	cells	or	RCC4	cell	 lysates	 (renal	 cell	 carcinoma	 with	 VHL	 mutation)	 with	 or	 without	 VHL	overexpression	 (Cockman	 et	 al.,	 2000).	 However	 ubiquitin	 aldehyde	 was	required	 to	 stabilise	 ubiquitinated	 HIF1α	 sufficiently	 to	 be	 visualised	 by	autoradiography,	 and	 radiolabelling	 precludes	 further	 ubiquitin	 chain	 analysis	by	mass	spectrometry.		It	is	possible	that	ubiquitinated	HIF1α	failed	to	bind	to	the	GSH-resins	or	HIF1α	 antibody,	 as	 I	 always	 detected	 ubiquitinated	 HIF1αODD	 in	 the	 unbound	resin	fraction	(flow	through)	(Figure	6.3A).	In	addition,	only	faint	higher	bands	
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were	visualised	in	comparison	with	the	intensity	of	the	main	HIF1αODD	migrating	species,	suggesting	that	ubiquitination	of	the	recombinant	protein	was	inefficient	despite	 the	 addition	 of	 exogenous	 E1,	 E2,	 ubiquitin	 and	 ATP.	 An	 alternative	approach	 to	 isolate	 the	 relatively	 low	 abundant	 pool	 of	 ubiquitinated	 HIF1α	would	 be	 to	 use	 the	 affinity	 of	 polyubiquitin	 for	 UBDs.	 For	 example,	 Tandem	Ubiquitin	 Binding	 Entities	 (TUBEs)	 have	 been	 developed	 that	 bind	 to	polyubiquitin	chains	(Hjerpe	et	al.,	2009),	and	it	would	be	of	interest	to	use	these	TUBEs	 to	 isolate	 polyubiquitinated	 HIF1α	 and	 analyse	 these	 chains	 by	 mass	spectrometry.		
6.3.2	Alternative	methods	to	identify	the	types	of	ubiquitin	linkages	involved	
in	the	regulation	of	HIF1α .	One	of	my	aims	in	designing	an	in	vitro	assay	of	HIF1α	ubiquitination	was	to	 determine	 whether	 K11-chains	 were	 formed	 on	 HIF1α	 and	 whether	 this	mediated	 non-proteasomal	 degradation	 (Bremm	 et	 al.,	 2014)	 in	 a	 non-VHL	dependent	manner.	 Initially,	 I	used	a	HIF1α	peptide	that	 incorporated	both	the	prolines	and	lysine	residues	modified	by	PHDs	and	VHL.	However,	this	assumes	that	other	E3	ligases	ubiquitinate	HIF1α	similarly	to	VHL.	Immunoprecipitation	of	 ubiquitinated	 endogenous	 HIF1α	 should	 enable	 determination	 of	 lysine	residues	modified	 and	 chain	 types	 formed	 in	 the	 presence	 or	 absence	 of	 VHL.	However,	despite	stabilization	of	ubiquitinated	HIF1α	by	proteasomal	inhibition,	ubiquitinated	HIF1α	peptides	could	not	be	identified	by	mass	spectrometry.	An	alternative	 strategy	 would	 be	 to	 generate	 cells	 expressing	 an	 endogenously	tagged	HIF1α	 (using	CRISPR/Cas9	knock-in),	which	may	improve	the	efficiency	of	 the	 HIF1α	 immunoprecipitation,	 allowing	 detection	 of	 the	 ubiquitinated	species.	A	 further	 complementary	 approach	 to	 identify	 ubiquitin	 linkages	would	be	 the	 Ubi-CREST	 system	 (Hospenthal	 et	 al.,	 2015).	 This	 system	 relies	 on	 the	ability	of	linkage	specific	DUBs,	which	cleave	specific	ubiquitin	lysine	linkages	to	identify	which	chain	 types	are	 formed	on	protein	substrates	(Hospenthal	et	al.,	2015).	 Lastly,	 it	 would	 be	 possible	 to	 express	 ubiquitin	 mutants	 in	 cells	 and	determine	 linkage	specificity	 in	 this	way.	However,	 there	are	 limitations	 to	 the	
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use	of	overexpression	as	this	may	alter	the	activity	of	the	ubiquitin	molecule	and	result	in	ubiquitination	of	proteins	not	normally	ubiquitinated	in	cells.		 			6.4	Summary			 In	 this	 chapter,	 having	 developed	 a	 robust	 assay	 of	 HIFα	 prolyl	hydroxylation,	I	examined	if	I	could	use	this	to	ubiquitinate	HIF1α	and	determine	the	 linkages	 involved.	 However,	 ubiquitination	 of	 HIF1α	 proved	 difficult	 to	identify,	 and	 while	 ubiquitinated	 HIF1α	 could	 be	 visualised	 in	 cells,	 the	quantities	 generated	 were	 insufficient	 for	 mass	 spectrometry	 analysis.	Therefore,	 the	 analysis	 of	 the	 ubiquitin-linked	 chains	 formed	 on	 HIF1α	 will	require	the	development	of	alternative	experimental	approaches.								 	
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 Chapter	7:	Summary	and	Discussion		
7.1	Summary	K11-linked	chains	are	 the	 third	most	abundant	ubiquitin	 linkage	 in	cells	but	 whether	 they	 functioned	 as	 signals	 for	 proteasome-mediated	 degradation	was	unclear.	Therefore,	I	sought	to	identify	how	K11-linked	polyubiquitin	chains	are	recognised	by	UBPs	and	if	they	bind	directly	to	the	proteasome.	I	found	that	the	 proteasome	 has	 a	 markedly	 different	 ability	 to	 recognise	 K11-chains	compared	 to	 K48-linked	 polyubiquitin	 chains,	 with	 homotypic	 K11-chains	binding	 weakly	 to	 the	 proteasome	 in	 comparison	 to	 K48-chains.	 However,	heterotypic	K11/K48-chains	 not	 only	 bound	 to	 the	 proteasome	but	 stimulated	the	degradation	of	cyclin	B1.	Therefore,	my	studies	uncovered	a	potentially	novel	mechanism	 for	 proteasome-mediated	 degradation,	 whereby	 the	 nature	 of	 the	K11-ubiquitin	 linkages	 directly	 governed	 association	 with	 the	 19S	 ubiquitin	receptors	 (Grice	 et	 al.,	 2015).	 Using	 enzymatically	 synthesised	 K11-linked	polyubiquitin	 conjugates	 I	 went	 on	 to	 examine	 how	 K11-chains	 may	 be	recognised	 by	 ubiquitin	 receptors	 and	 whether	 K11-selective	 UBPs	 could	 be	identified.	Several	UBPs	 that	bound	K11-linkages	were	 identified,	 including	 the	mitophagy	ubiquitin	 receptors,	TAX1BP1	and	Myosin	VI	 (Kruppa	et	al,	2018	 in	
press).	However,	whether	K11-specific	UBPs	 are	present	 in	 cells	 remains	 to	be	determined.		The	 functional	outcomes	of	homotypic	K11-chains	remained	elusive	and	to	investigate	this	I	focused	on	the	HIF	pathway,	as	K11-ubiquitination	had	been	implicated	in	HIF	non-proteasomal	degradation.	I	first	developed	in	vitro	assays	to	 determine	 how	 ubiquitination	 of	 HIFα	 may	 be	 initiated,	 through	 prolyl	hydroxylation.	 By	 recombinantly	 expressing	 the	 oxygen-sensitive	 domain	 of	HIF1α	 and	 HIF2α	 I	 established	 a	 robust	 assay	 of	 prolyl	 hydroxylation,	 which	gave	new	insights	into	the	metabolic	regulation	of	HIFα	stability.	In	particular,	I	demonstrated	 that	 TCA	 metabolites,	 succinate,	 2-OG	 and	 L-2-HG	 inhibit	 the	prolyl	hydroxylation	of	both	HIF1α	and	HIF2α,	and	showed	that	cells	deficient	in	OGDH	or	LIAS	have	a	decreased	capacity	to	directly	hydroxylate	HIF1α	or	HIF2α.	
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In	 addition,	 I	 found	 that	 inhibition	 of	 the	 V-ATPase	 leads	 to	 a	 reversible	reduction	in	prolyl	hydroxylation	of	both	HIF1α	and	HIF2α	due	to	 intracellular	iron	 depletion.	 However,	 while	 these	 studies	 successfully	 established	 new	methods	 for	 measuring	 HIFα	 prolyl	 hydroxylation,	 and	 lead	 to	 several	publications	 (Burr	 et	 al.,	 2016;	 Miles	 et	 al.,	 2017),	 generating	 an	 assay	 to	ubiquitinate	HIF1α	proved	extremely	challenging.					
7.2	K11-polyubiquitin	chains		
7.2.1	 What	 do	 my	 studies	 tell	 us	 about	 the	 biological	 roles	 of	 K11-linked	
polyubiquitin	chains?	Prior	 to	 the	 start	 of	 my	 studies	 the	 major	 function	 of	 K11-linked	polyubiquitination	was	 attributed	 to	 cell	 cycle	progression.	However,	 it	 is	 now	apparent	 that	 homotypic	 K11-ubiquitin	 conjugates	 do	 not	 signal	 proteasome-mediated	degradation	(Grice	et	al.,	2015).	 Indeed,	prior	to	my	studies	the	Rape	group	demonstrated	that	heterotypic	K11/K48-linked	polyubiquitin	chains	were	mainly	formed	by	the	APC/C	on	cell	cycle	substrates	such	as	cyclin	B1	(Jin	et	al.,	2008).	My	 experiments	 to	 some	 extent	 support	 these	 findings,	 but	 rather	 than	K48/K11-heterotypic	 chains	 acting	 as	 a	 more	 efficient	 signal	 than	 homotypic	K48-linkages,	my	 results	 suggest	 that	 the	 presence	 of	 K11-linkages	within	 the	heterotypic	chain	decrease	the	rate	of	proteasome-mediated	degradation.			 It	was	therefore	likely	that	K11-linked	polyubiquitin	chains	were	involved	in	proteasome-independent	pathways,	and	I	hypothesised	that	by	identifying	the	K11-selective	 UBPs	 I	 could	 determine	 these	 uncharacterised	 functions	 of	 K11-chains.	This	approach	was	partially	successful,	as	I	did	identify	a	number	of	UBPs	that	 could	 bind	 K11-linked	 polyubiquitin	 conjugates,	 including	 the	 mitophagy	related	 proteins,	 TAX1BP1	 and	 Myosin	 VI.	 However,	 the	 exact	 role	 of	 K11-linkages	in	this	context	remain	to	be	fully	determined,	as	we	and	others	observe	that	 K63-linkages	 bind	 more	 strongly	 to	 Myosin	 VI	 than	 K11-linked	 ubiquitin	chains	(He	et	al.,	2016).		
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7.2.2	How	important	are	different	ubiquitin	linkages	for	stimulating	protein	
degradation?	The	finding	that	homotypic	K11-linked	polyubiquitin	chains	did	not	signal	proteasome-mediated	 degradation	 was	 unexpected	 (Grice	 et	 al.,	 2015),	particularly	 as	 it	 was	 previously	 shown	 that	 ubiquitin	 receptors	 on	 the	 19S	showed	no	specificity	for	K48-	and	K63-polyubiquitin	lysine	linkages	(Kim	et	al.,	2007;	Nathan	et	al.,	2013;	Peth	et	al.,	2010).	Currently,	there	is	little	data	to	show	whether	K6,	K27,	K29	or	K33-linked	polyubiquitin	chains	are	recognised	by	the	proteasome,	as	atypical	chains	have	been	difficult	to	generate	in	sufficiently	large	amounts	for	in	vitro	experiments.	Recently,	however,	the	Matouschek	group	used	chain-specific	 E2	 enzymes	 and	 chain	 terminating	 ubiquitin	 mutations,	 to	generate	 GFP-tagged	 substrates	 with	 K48,	 K63	 and	 K11-linked	 tetra-ubiquitin	chains,	and	measured	their	ability	 to	bind	the	proteasome	(Martinez-Fonts	and	Matouschek,	 2016).	 Consistent	 with	 my	 findings,	 they	 observed	 minimal	proteasome-mediated	degradation	of	GFP-K11-Ub4.	While	these	studies	focussed	on	 the	 degradation	 of	 K48,	 K63	 and	 K11-linked	 chains,	 enzymatic	methods	 to	generate	K29	 and	K33-linked	 chains,	 using	HECT	E3	 ligases	 and	 chain-specific	DUBs	(Kristariyanto	et	al.,	2015;	Michel	et	al.,	2015),	have	now	been	developed	and	it	will	be	of	interest	to	explore	their	direct	binding	to	the	proteasome.		Other	 methods	 of	 generating	 atypical	 ubiquitin	 chains	 for	 proteasome-mediated	 degradation	 in	 vitro	 include	 chemical	 synthesis	 of	 polyubiquitin	linkages	(Hemantha	et	al.,	2014)	and	other	non-enzymatic	techniques	(relying	on	using	a	silver-mediated	condensation	reaction	between	the	C-terminal	thioester	of	 one	 ubiquitin	 and	 the	 amine	 of	 a	 specific	 lysine	 on	 the	 other	 ubiquitin)	(Castaneda	et	al.,	2011;	Faggiano	et	al.,	2016).	However,	there	are	limitations	to	these	 methods,	 as	 it	 is	 not	 clear	 that	 the	 structures	 of	 chemically	 formed	polyubiquitin	 chains	 are	 the	 same	 as	 those	 formed	 enzymatically.	 Moreover,	these	 pure	 in	 vitro	 techniques	 of	 proteasome	 degradation	 should	 not	 be	interpreted	 in	 isolation,	 as	 they	 may	 miss	 the	 requirement	 of	 chain-specific	ubiquitin	 binding	 proteins	 that	 facilitate	 binding	 to	 the	 proteasome	 in	 cells.	 In	
vivo,	 ubiquitin	 chains	may	 also	 form	branched	 chains	 involving	many	different	linkages.	 Until	 ubiquitin	 chains	 can	 be	 isolated	 from	 cells	 and	 chain	 structure	
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analysed	 in	 addition	 to	 chain	 linkage,	 it	 will	 be	 difficult	 to	 determine	 the	subtleties	of	ubiquitin	modifications	in	cells.	Lastly,	 post-translational	 modification	 of	 ubiquitin	 itself	 may	 be	important	in	modulating	the	binding	of	polyubiquitin	chains	to	the	proteasome.		Ubiquitin	is	phosphorylated	on	residue	Serine	65	(Ser65)	by	the	Ser/Thr	kinase,	PTEN-induced	putative	kinase	1	 (PINK1)	which	 leads	 to	allosteric	activation	of	the	E3	ligase,	Parkin	and	is	required	for	the	clearance	of	damaged	mitochondria	(Koyano	 et	 al.,	 2014).	 Interestingly,	 how	 these	 chains	 are	 disassembled	 or	degraded	is	not	clear,	as	polyubiquitin	chains	containing	Ser65-	phosphorylated	ubiquitin	 are	 less	 readily	 disassembled	 by	 DUBs	 than	 non-phosphorylated	ubiquitin	(Swaney	et	al.,	2015;	Wauer	et	al.,	2015).	Although	studies	have	shown	that	a	Ser65-	phosphorylated	ubiquitin	mimetic	mutant	binds	to	the	proteasome	shuttling	factor,	Rad23	(Swaney	et	al.,	2015),	whether	they	are	recognised	by	the	proteasome	is	not	clear.		
	
7.2.3	Are	there	K11-specific	ubiquitin	binding	proteins?	 	
	 A	K11-specific	UBP	has	yet	to	be	identified.	My	mass	spectrometry	studies	suggest	that	FAM115A	may	bind	K11-linked	polyubiquitin	conjugates,	but	as	this	has	 proved	 difficult	 to	 recombinantly	 express,	 we	 do	 not	 yet	 know	 if	 this	 is	direct.	Moreover,	 the	fact	that	no	K11-specific	UBPs	have	been	identified	raises	the	 question	 of	 whether	 homotypic	 K11-chains	 form	 in	 cells	 or	 whether	 they	exist	more	commonly	as	heterotypic	linkages.	Indeed,	several	studies	identifying	roles	for	K11-chains	in	cells	have	shown	them	to	be	of	mixed	linkage	rather	than	homotypic,	including	K11/K63	heterotypic	chains	in	MHC	Class	I	internalisation	(Boname	et	al.,	2010)	and	K11/K48-chains	in	cell	cycle	control	(Meyer	and	Rape,	2014).	 Furthermore,	 if	 the	 abundance	 of	 homotypic	 K11-chains	 is	 low	 in	 cells	and	 they	are	 transiently	 formed	 for	specific	 roles,	 identification	of	K11-specific	UBPs	will	be	difficult.		Despite	these	limitations	to	identifying	K11-specific	UBPs,	the	existence	of	a	K11-specific	DUB,	Cezanne,	suggests	that	K11-chains	are	recognised	distinctly	from	 other	 chain	 types	 (Bremm	 et	 al.,	 2010).	 The	 recent	 crystal	 structure	 of	Cezanne	 in	 complex	with	K11-dimers	 reveals	 that	binding	of	ubiquitin	 enables	
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conformational	changes	in	Cezanne,	but	only	K11-dimers	are	able	to	bind	across	the	 active	 site	 resulting	 in	 catalysis	 (Mevissen	 et	 al.,	 2016).	 If	 ubiquitin	 chain	conformation	 specificity	 occurs	 for	 DUBs,	 it	 is	 highly	 likely	 that	 similar	mechanisms	occur	for	UBPs.		How	 ubiquitin	 binding	 proteins	 selectively	 bind	 polyubiquitin	 chains	 of	distinct	lysine	linkages	is	still	unclear,	although	it	is	likely	that	this	relates	to	the	affinity	and	avidity	of	the	UBDs.	Different	lysine	linked	ubiquitin	chains	may	alter	the	conformation	of	UBDs	to	facilitate	their	binding,	as	observed	for	the	binding	of	Cezanne	to	K11-dimers	(Mevissen	et	al.,	2016),	or	alternatively,	the	presence	and	orientation	of	tandem	UBDs	within	a	UBP	can	alter	the	affinity	of	the	UBP	to	specific	 polyubiquitin	 chain	 linkages	 (Discussed	 1.1.3)	 (Elsasser	 et	 al.,	 2004;	Ren	 and	 Hurley,	 2010).	 Furthermore,	 endogenous	 modifications	 of	 UBDs	 can	alter	 their	 avidity	 for	 ubiquitin.	 Matsumoto	 et	 al	 have	 shown	 that	 the	phosphorylation	of	p62	UBA	domain	at	serine	403	results	in	an	increased	affinity	to	 polyubiquitin	 linkages	 (Matsumoto	 et	 al.,	 2011).	 Therefore,	 it	 will	 be	important	 to	 investigate	 the	 binding	 of	 homotypic	 and	 heterotypic	 K11-polyubiquitin	 chains	 not	 only	 in	 vitro	 but	 also	 in	 a	 cellular	 context,	 as	endogenous	modifications	of	UBPs	may	alter	their	binding	affinities.			
7.3	HIFα 	prolyl	hydroxylation	and	ubiquitination		
7.3.1	Metabolic	regulation	of	PHDs	and	therapeutic	implications	Prior	 assays	 of	 PHD	 activity	 have	 required	 the	 use	 of	 purified	 PHD	 and	addition	of	exogenous	cofactors.	This	has	not	allowed	these	assays	to	determine	the	effect	of	altered	levels	of	cofactors	and	small	molecule	metabolites	on	PHDs.	I	developed	 a	 novel	 in	 vitro	 assay	 that	 quantified	 the	 prolyl	 hydroxylation	 of	 a	recombinant	HIFα	peptide	using	cell	lysates.	Moreover,	our	studies	highlight	the	role	of	oxygen-independent	regulation	of	PHD	activity,	through	changes	in	small	molecule	metabolites	 or	 iron	 availability.	The	presence	of	 L-2-HG	 in	 cell	 lysate	clearly	overcomes	2-OG	levels	but	the	mechanism	of	PHD	inhibition	is	unclear.	If	
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L-2-HG	 inhibition	of	PHD2	 is	 allosteric,	 identifying	 its	 binding	 site	would	be	of	interest,	and	may	point	to	new	avenues	for	developing	PHD	inhibitors	as	drugs.	PHD	 inhibitors	 are	 currently	 being	 developed	 for	 the	 treatment	 of	anaemia	 in	 chronic	 kidney	 disease	 (Maxwell	 and	 Eckardt,	 2016).	 This	 form	 of	anaemia	primarily	results	from	low	erythropoietin	levels.	As	EPO	is	a	HIF	target	gene,	 predominantly	mediated	 by	 HIF2α	 (Gale	 et	 al.,	 2008;	 Scortegagna	 et	 al.,	2005),	 inhibition	 of	 HIF	 degradation	 using	 PHD	 inhibitors	 provides	 a	 novel	therapeutic	 strategy	 for	 the	 treatment	 of	 renal	 anaemia.	 However,	 HIF	upregulates	many	genes	other	than	EPO	and	this	may	result	 in	side	effects.	For	example,	 an	obvious	 concern	 is	 an	 increased	 risk	of	developing	clear	 cell	 renal	cell	 carcinoma,	 seen	 in	 patients	 with	 mutations	 in	 the	 VHL	 gene	 and	 also	associated	with	 activation	 of	HIF2α	 (Kondo	 et	 al.,	 2003;	 Raval	 et	 al.,	 2005).	 In	addition,	 PHD	 inhibitors	 may	 affect	 other	 2-OG-DDs,	 for	 example	 chromatin	modifiers,	resulting	in	off-target	effects.		Phase	 II	 clinical	 trials	 of	 PHD	 inhibitors	 are	 underway	 (Maxwell	 and	Eckardt,	 2016)	 and	 Roxadustat	 (FG-4592)	 has	 shown	 correction	 of	 renal	anaemia	 in	 trial	 patients	 and	 has	 entered	 phase	 III	 trails	 (Rabinowitz,	 2013).	Given	the	clear	requirement	for	an	effective	PHD	inhibitor,	it	would	be	of	interest	in	 future	 studies	 to	 identify	 the	 mechanism	 by	 which	 L-2-HG	 inhibits	 PHD2	activity	(see	Future	Directions).		
	
7.3.2	Non-canonical	ubiquitination	of	HIF1α 			 While	my	 assays	 to	measure	 HIF1α	 proved	 challenging,	 it	 is	 still	 likely	that	E3	enzymes	aside	from	VHL	are	involved	in	the	HIF	pathway,	particularly	as	VHL	 loss	 stabilises	 HIF1α,	 but	 it	 still	 has	 a	 half-life	 of	 approximately	 1	 hr	(Cockman	 et	 al.,	 2000).	 Several	 groups	 have	 identified	 potential	 E3s	 or	chaperones	 for	 VHL	 independent	 degradation,	 but	 as	 yet,	 none	 of	 these	 have	been	substantially	validated.	Firstly,	 it	 has	 been	 proposed	 that	 HIF1α	 is	 degraded	 by	 chaperone-mediated	 autophagy,	 based	 on	 the	 observations	 that	 V-ATPase	 inhibitors	stabilise	HIF1α	(Hubbi	et	al.,	2013).	However,	we	have	clearly	shown	that	this	is	
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not	 independent	 of	 the	 PHD	 axis,	 and	 in	 fact	 depends	 on	 intracellular	 iron	depletion.		Ubiquitin-independent	 proteasome-mediated	 degradation	 has	 also	 been	proposed.	Montagner	 et	 al	 suggest	 that	 SHARP1,	 a	 prognostic	marker	 in	 triple	negative	breast	cancer,	directly	mediates	the	proteasomal	degradation	of	HIF1α	by	 acting	 as	 a	 shuttling	 factor	 to	 the	 proteasome,	 increasing	 degradation	 of	HIF1α	independent	from	VHL,	ubiquitination	or	oxygen	(Montagner	et	al.,	2012).	However,	this	finding	has	never	been	reproduced	in	the	literature,	and	ubiquitin-independent	degradation	by	the	proteasome	is	highly	contentious.	Recently,	Parkin	was	identified	as	an	E3	ligase	capable	of	ubiquitination	of	HIF1α	 leading	 to	 its	 proteasomal	 degradation	 (Liu	 et	 al.,	 2017).	 HIF1α	ubiquitination	 by	 Parkin	 was	 determined	 using	 an	 in	 vitro	 ubiquitination	reaction	 with	 E1,	 E2	 (UbcH7),	 ubiquitin,	 purified	 GST-Parkin,	 recombinant	PINK1	 and	 purified	 His-Trx-HIF1α.	 Interestingly,	 they	 observed	 that	 Parkin	ubiquitinated	 HIF1α	 at	 K477,	 and	 not	 the	 three	 previously	 identified	 lysines	associated	 with	 VHL-mediated	 ubiquitination.	 Consistent	 with	 this	 finding,	Parkin-mediated	 ubiquitination	 occurs	 independently	 of	 VHL	 and	 oxygen.	Furthermore,	 efficient	 ubiquitination	may	 rely	 on	 phospho-ubiquitin	 as	 HIF1α	ubiquitination	 was	 reduced	 with	 a	 ubiquitin	 S65A	 mutant	 (Liu	 et	 al.,	 2017).	However,	 there	 are	 several	 limitations	 to	 this	 study,	most	 notably	 that	 prolyl-hydroxylation	of	HIF1α	was	not	measured.	Given	that	Parkin	has	a	clear	role	in	the	clearance	of	damaged	mitochondria,	it	is	possible	that	stabilisation	of	HIF1α,	when	 Parkin	 levels	 are	 reduced,	 is	 mediated	 by	 alterations	 in	 mitochondrial	metabolite	levels,	thereby	preventing	HIF1α	prolyl-hydroxylation.	Thus,	while	it	is	 likely	 that	 other	 E3	 ligases	 or	 degradative	 pathways	 are	 involved	 in	 HIF1α	stability,	 the	 mechanisms	 involved	 remain	 unclear.	 Therefore,	 in	 my	 future	studies,	 I	propose	 to	use	an	unbiased	 forward	genetic	approach	to	uncover	 the	ubiquitin	machinery	aside	from	VHL	in	HIF1α	degradation.				
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7.4	Future	directions.	
	 My	future	aims	are	to	develop	my	in	vitro	assays	for	metabolic	inhibition	of	PHDs,	and	 in	particular,	determine	 the	mechanism	by	which	L-2-HG	 inhibits	PHD2	 activity.	 Rather	 than	 focus	 solely	 on	 K11-polyubiquitination,	 I	 plan	 to	explore	the	VHL-independent	degradation	of	HIF1α	using	a	genetic	approach.			1)	 How	does	L-2-HG	inhibit	PHDs?	Having	demonstrated	that	relatively	low	concentrations	of	L-2-HG	inhibit	PHDs	in	a	cell	extract,	I	plan	to	determine	if	L-2-HG	 inhibits	 PHDs	 through	 competing	 for	 2-OG	 binding,	 or	 through	 allosteric	inhibition.	 These	 studies	 will	 involve	 the	 purification	 of	 a	 PHD2	 recombinant	protein	 and	 in	 vitro	 competition	 assays	 with	 2-OG.	 Furthermore,	 as	 there	 are	three	 PHD	 enzymes	 I	 also	 plan	 to	 explore	 if	 L-2-HG	 inhibits	 their	 activity	similarly.	 Initially,	 I	will	 generate	PHD1,	PHD2	and	PHD3	null	HeLa	 cells	using	CRISPR/Cas9	 for	 my	 established	 assay	 of	 HIFα	 prolyl-hydroxylation.	 Further	studies	 will	 be	 dependent	 on	 whether	 L-2-HG	 is	 a	 competitive	 or	 allosteric	inhibitor	of	PHDs.		2)		 CRISPR/Cas9	 forward	 genetic	 screens	 to	 uncover	 ubiquitin	 enzymes	
involved	in	HIF1α 	stability.	I	have	already	begun	to	establish	a	forward	genetic	screening	approach	to	identify	ubiquitin	enzymes	that	regulate	activation	of	our	HRE-HIF1αODD-GFP	reporter	(Burr	et	al.,	2016).	Using	a	focussed	 ‘ubiquitome’	specific	pooled	sgRNA	 library,	 I	am	exploring	whether	ubiquitin	enzymes	aside	from	VHL	regulate	HIF1α	levels.	These	screens	involve	using	a	stable	HeLa	clone	expressing	 the	 sensitive	 GFP-HIF1α	 reporter,	 and	 enriching	 for	 rare	 GFP	 high	cells	 (GFPHIGH)	 by	 sequential	 fluorescence-activated	 cell	 sorting	 (FACS).	 My	preliminary	 studies	have	validated	 this	 approach,	 and	 I	have	 several	 candidate	E3	 ligases	 that	 I	 would	 like	 to	 evaluate.	 If	 these	 enzymes	 validate,	 I	 plan	 to	elucidate	how	they	regulate	HIFα,	using	my	assays	of	prolyl-hydroxylation,	in	the	context	of	VHL	loss.	Ultimately,	I	hope	that	this	approach	will	help	elucidate	the	VHL-independent	mechanisms	of	HIFα	regulation.			
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FAM115A	
	
Primer	Name	 Sequence	(5’-3’)	FAM115A_85FW	 CAGGGACCCGGTTGCTCTTCCCCTGGGGCTCCC	FAM115A_88FW	 CAGGGACCCGGTCCTGGGGCTCCCATTGGTGTA	FAM115A_92FW	 CAGGGACCCGGTATTGGTGTACACCCATCCCTG	FAM115A_95FW	 CAGGGACCCGGTCACCCATCCCTGGCACCTTTG	FAM115A_99FW	 CAGGGACCCGGTGCACCTTTGGCCAAAATCCTC	FAM115A_102FW	 CAGGGACCCGGTGCCAAAATCCTCGAGGGCTCT	FAM115A_107FW	 CAGGGACCCGGTGGCTCTGGAGTGGATGCAAAG	FAM115A_112FW	 CAGGGACCCGGTGCAAAGGTTGAGCCAGAAGTG	FAM115A_259RV	 GGCACCAGAGCGTTACGCTATAACACAGCCATGGTA	FAM115A_264RV	 GGCACCAGAGCGTTAGCCATAGCGGGCAGCCGCTAT	FAM115A_268RV	 GGCACCAGAGCGTTACACCCGGCCCCGGCCATAGCG	FAM115A_273RV	 GGCACCAGAGCGTTAATGGCCAGTCACAACCACCCG	FAM115A_276RV	 GGCACCAGAGCGTTATAATACCTTATGGCCAGTCAC	FAM115A_279RV	 GGCACCAGAGCGTTAAACAGTGAATAATACCTTATG	FAM115A_282RV	 GGCACCAGAGCGTTACAGTTTACCAACAGTGAATAA	FAM115A_289RV	 GGCACCAGAGCGTTAAGCATTGAGCAGAAAGGGGCC	FAM115A_295RV	 GGCACCAGAGCGTTACCCATCCAGCCAGCGGACAGC	FAM115A_299RV	 GGCACCAGAGCGTTAGCCTCTGCGGCCCCCATCCAG	FAM115A_303RV	 GGCACCAGAGCGTTACACCACAATCTTGCCTCTGCG	
	
HIF1αODD	
	
Primer	Name	 Sequence	(5’-3’)	HIF	ODD380FW	 CAGGGACCCGGTTCAGAAGATACAAGTAGCCTC	HIF	ODD401FW	 CAGGGACCCGGTGCCCCAGCCGCTGGAGACACA	HIF	ODD403FW	 CAGGGACCCGGTGCCGCTGGAGACACAATCATA	HIF	ODD530FW	 CAGGGACCCGGTGAATTCAAGTTGGAATTGGTA	HIF	ODD603RV	 GGCACCAGAGCGTTACTGGAATACTGTAACTGTGCT	HIF	ODD652RV	 GGCACCAGAGCGTTAAGTAGTTTCTTTATGTATGTG	
	
HIF2αODD	
	
Primer	Name	 Sequence	(5’-3’)	HIF2Fw_377	 CAGGGACCCGGTCAAGAAGATTTACTTCGTCGA	HIF2Fw_381	 CAGGGACCCGGTCTTCGTCGATTCCCAGATCTT	HIF2Fw_495	 CAGGGACCCGGTACATTAATAAGTGCAGCCAGA	HIF2Rv_578	 GGCACCAGAGCGTTAAACAATGGCATCCTGGGCTTC	HIF2Rv_655	 GGCACCAGAGCGTTATACGTCATTAGGAATAAATGC	HIF2Rv_667	 GGCACCAGAGCGTTAAATGATGTGGAACATCTGTTT	
References	
	
	
	
 References		Alexandru,	G.,	Graumann,	J.,	Smith,	G.T.,	Kolawa,	N.J.,	Fang,	R.,	and	Deshaies,	R.J.	(2008).	UBXD7	binds	multiple	ubiquitin	ligases	and	implicates	p97	in	HIF1alpha	turnover.	Cell	134,	804-816.	An,	W.G.,	Kanekal,	M.,	Simon,	M.C.,	Maltepe,	E.,	Blagosklonny,	M.V.,	and	Neckers,	L.M.	(1998).	Stabilization	of	wild-type	p53	by	hypoxia-inducible	factor	1alpha.	Nature	392,	405-408.	Appelhoff,	R.J.,	Tian,	Y.M.,	Raval,	R.R.,	Turley,	H.,	Harris,	A.L.,	Pugh,	C.W.,	Ratcliffe,	P.J.,	and	Gleadle,	J.M.	(2004).	Differential	function	of	the	prolyl	hydroxylases	PHD1,	PHD2,	and	PHD3	in	the	regulation	of	hypoxia-inducible	factor.	The	Journal	of	biological	chemistry	279,	38458-38465.	Beck,	M.,	and	Baumeister,	W.	(2016).	Cryo-Electron	Tomography:	Can	it	Reveal	the	Molecular	Sociology	of	Cells	in	Atomic	Detail?	Trends	in	cell	biology	26,	825-837.	Bellot,	G.,	Garcia-Medina,	R.,	Gounon,	P.,	Chiche,	J.,	Roux,	D.,	Pouyssegur,	J.,	and	Mazure,	N.M.	(2009).	Hypoxia-induced	autophagy	is	mediated	through	hypoxia-inducible	factor	induction	of	BNIP3	and	BNIP3L	via	their	BH3	domains.	Molecular	and	cellular	biology	29,	2570-2581.	Benita,	Y.,	Kikuchi,	H.,	Smith,	A.D.,	Zhang,	M.Q.,	Chung,	D.C.,	and	Xavier,	R.J.	(2009).	An	integrative	genomics	approach	identifies	Hypoxia	Inducible	Factor-1	(HIF-1)-target	genes	that	form	the	core	response	to	hypoxia.	Nucleic	acids	research	37,	4587-4602.	Berra,	E.,	Benizri,	E.,	Ginouves,	A.,	Volmat,	V.,	Roux,	D.,	and	Pouyssegur,	J.	(2003).	HIF	prolyl-hydroxylase	2	is	the	key	oxygen	sensor	setting	low	steady-state	levels	of	HIF-1alpha	in	normoxia.	The	EMBO	journal	22,	4082-4090.	Berra,	E.,	Roux,	D.,	Richard,	D.E.,	and	Pouyssegur,	J.	(2001).	Hypoxia-inducible	factor-1	alpha	(HIF-1	alpha)	escapes	O(2)-driven	proteasomal	degradation	irrespective	of	its	subcellular	localization:	nucleus	or	cytoplasm.	EMBO	reports	2,	615-620.	Besche,	H.C.,	Haas,	W.,	Gygi,	S.P.,	and	Goldberg,	A.L.	(2009).	Isolation	of	mammalian	26S	proteasomes	and	p97/VCP	complexes	using	the	ubiquitin-like	domain	from	HHR23B	reveals	novel	proteasome-associated	proteins.	Biochemistry	48,	2538-2549.	Boname,	J.M.,	Thomas,	M.,	Stagg,	H.R.,	Xu,	P.,	Peng,	J.,	and	Lehner,	P.J.	(2010).	Efficient	internalization	of	MHC	I	requires	lysine-11	and	lysine-63	mixed	linkage	polyubiquitin	chains.	Traffic	11,	210-220.	
References		
		 183	
Bremm,	A.,	Freund,	S.M.,	and	Komander,	D.	(2010).	Lys11-linked	ubiquitin	chains	adopt	compact	conformations	and	are	preferentially	hydrolyzed	by	the	deubiquitinase	Cezanne.	Nature	structural	&	molecular	biology	17,	939-947.	Bremm,	A.,	Moniz,	S.,	Mader,	J.,	Rocha,	S.,	and	Komander,	D.	(2014).	Cezanne	(OTUD7B)	regulates	HIF-1alpha	homeostasis	in	a	proteasome-independent	manner.	EMBO	Rep	15,	1268-1277.	Bruick,	R.K.,	and	McKnight,	S.L.	(2001).	A	conserved	family	of	prolyl-4-hydroxylases	that	modify	HIF.	Science	(New	York,	NY)	294,	1337-1340.	Brzovic,	P.S.,	and	Klevit,	R.E.	(2006).	Ubiquitin	transfer	from	the	E2	perspective:	why	is	UbcH5	so	promiscuous?	Cell	cycle	(Georgetown,	Tex)	5,	2867-2873.	Burana,	D.,	Yoshihara,	H.,	Tanno,	H.,	Yamamoto,	A.,	Saeki,	Y.,	Tanaka,	K.,	and	Komada,	M.	(2016).	The	Ankrd13	Family	of	Ubiquitin-interacting	Motif-bearing	Proteins	Regulates	Valosin-containing	Protein/p97	Protein-mediated	Lysosomal	Trafficking	of	Caveolin	1.	The	Journal	of	biological	chemistry	291,	6218-6231.	Burr,	S.P.,	Costa,	A.S.,	Grice,	G.L.,	Timms,	R.T.,	Lobb,	I.T.,	Freisinger,	P.,	Dodd,	R.B.,	Dougan,	G.,	Lehner,	P.J.,	Frezza,	C.,	and	Nathan,	J.A.	(2016).	Mitochondrial	Protein	Lipoylation	and	the	2-Oxoglutarate	Dehydrogenase	Complex	Controls	HIF1alpha	Stability	in	Aerobic	Conditions.	Cell	metabolism	24,	740-752.	Buss,	F.,	Kendrick-Jones,	J.,	Lionne,	C.,	Knight,	A.E.,	Cote,	G.P.,	and	Paul	Luzio,	J.	(1998).	The	localization	of	myosin	VI	at	the	golgi	complex	and	leading	edge	of	fibroblasts	and	its	phosphorylation	and	recruitment	into	membrane	ruffles	of	A431	cells	after	growth	factor	stimulation.	The	Journal	of	cell	biology	143,	1535-1545.	Carmeliet,	P.,	Dor,	Y.,	Herbert,	J.M.,	Fukumura,	D.,	Brusselmans,	K.,	Dewerchin,	M.,	Neeman,	M.,	Bono,	F.,	Abramovitch,	R.,	Maxwell,	P.,	Koch,	C.J.,	Ratcliffe,	P.,	Moons,	L.,	Jain,	R.K.,	Collen,	D.,	and	Keshert,	E.	(1998).	Role	of	HIF-1alpha	in	hypoxia-mediated	apoptosis,	cell	proliferation	and	tumour	angiogenesis.	Nature	394,	485-490.	Castaneda,	C.A.,	Dixon,	E.K.,	Walker,	O.,	Chaturvedi,	A.,	Nakasone,	M.A.,	Curtis,	J.E.,	Reed,	M.R.,	Krueger,	S.,	Cropp,	T.A.,	and	Fushman,	D.	(2016).	Linkage	via	K27	Bestows	Ubiquitin	Chains	with	Unique	Properties	among	Polyubiquitins.	Structure	(London,	England	:	1993)	24,	423-436.	Castaneda,	C.A.,	Kashyap,	T.R.,	Nakasone,	M.A.,	Krueger,	S.,	and	Fushman,	D.	(2013).	Unique	structural,	dynamical,	and	functional	properties	of	k11-linked	polyubiquitin	chains.	Structure	21,	1168-1181.	Castaneda,	C.A.,	Liu,	J.,	Kashyap,	T.R.,	Singh,	R.K.,	Fushman,	D.,	and	Cropp,	T.A.	(2011).	Controlled	enzymatic	synthesis	of	natural-linkage,	defined-length	polyubiquitin	chains	using	lysines	with	removable	protecting	groups.	Chemical	communications	(Cambridge,	England)	47,	2026-2028.	
References		
		 184	
Chang,	S.C.,	Momburg,	F.,	Bhutani,	N.,	and	Goldberg,	A.L.	(2005).	The	ER	aminopeptidase,	ERAP1,	trims	precursors	to	lengths	of	MHC	class	I	peptides	by	a	"molecular	ruler"	mechanism.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	102,	17107-17112.	Chowdhury,	R.,	Yeoh,	K.K.,	Tian,	Y.M.,	Hillringhaus,	L.,	Bagg,	E.A.,	Rose,	N.R.,	Leung,	I.K.,	Li,	X.S.,	Woon,	E.C.,	Yang,	M.,	McDonough,	M.A.,	King,	O.N.,	Clifton,	I.J.,	Klose,	R.J.,	Claridge,	T.D.,	Ratcliffe,	P.J.,	Schofield,	C.J.,	and	Kawamura,	A.	(2011).	The	oncometabolite	2-hydroxyglutarate	inhibits	histone	lysine	demethylases.	EMBO	reports	12,	463-469.	Clifford,	S.C.,	Cockman,	M.E.,	Smallwood,	A.C.,	Mole,	D.R.,	Woodward,	E.R.,	Maxwell,	P.H.,	Ratcliffe,	P.J.,	and	Maher,	E.R.	(2001).	Contrasting	effects	on	HIF-1alpha	regulation	by	disease-causing	pVHL	mutations	correlate	with	patterns	of	tumourigenesis	in	von	Hippel-Lindau	disease.	Human	molecular	genetics	10,	1029-1038.	Cockman,	M.E.,	Masson,	N.,	Mole,	D.R.,	Jaakkola,	P.,	Chang,	G.W.,	Clifford,	S.C.,	Maher,	E.R.,	Pugh,	C.W.,	Ratcliffe,	P.J.,	and	Maxwell,	P.H.	(2000).	Hypoxia	inducible	factor-alpha	binding	and	ubiquitylation	by	the	von	Hippel-Lindau	tumor	suppressor	protein.	The	Journal	of	biological	chemistry	275,	25733-25741.	Cowey,	C.L.,	and	Rathmell,	W.K.	(2009).	VHL	gene	mutations	in	renal	cell	carcinoma:	role	as	a	biomarker	of	disease	outcome	and	drug	efficacy.	Current	oncology	reports	11,	94-101.	Crosas,	B.,	Hanna,	J.,	Kirkpatrick,	D.S.,	Zhang,	D.P.,	Tone,	Y.,	Hathaway,	N.A.,	Buecker,	C.,	Leggett,	D.S.,	Schmidt,	M.,	King,	R.W.,	Gygi,	S.P.,	and	Finley,	D.	(2006).	Ubiquitin	chains	are	remodeled	at	the	proteasome	by	opposing	ubiquitin	ligase	and	deubiquitinating	activities.	Cell	127,	1401-1413.	Cunningham,	C.N.,	Baughman,	J.M.,	Phu,	L.,	Tea,	J.S.,	Yu,	C.,	Coons,	M.,	Kirkpatrick,	D.S.,	Bingol,	B.,	and	Corn,	J.E.	(2015).	USP30	and	parkin	homeostatically	regulate	atypical	ubiquitin	chains	on	mitochondria.	Nature	cell	biology	17,	160-169.	Dang,	L.,	White,	D.W.,	Gross,	S.,	Bennett,	B.D.,	Bittinger,	M.A.,	Driggers,	E.M.,	Fantin,	V.R.,	Jang,	H.G.,	Jin,	S.,	Keenan,	M.C.,	Marks,	K.M.,	Prins,	R.M.,	Ward,	P.S.,	Yen,	K.E.,	Liau,	L.M.,	Rabinowitz,	J.D.,	Cantley,	L.C.,	Thompson,	C.B.,	Vander	Heiden,	M.G.,	and	Su,	S.M.	(2009).	Cancer-associated	IDH1	mutations	produce	2-hydroxyglutarate.	Nature	462,	739-744.	Dao,	K.H.,	Rotelli,	M.D.,	Petersen,	C.L.,	Kaech,	S.,	Nelson,	W.D.,	Yates,	J.E.,	Hanlon	Newell,	A.E.,	Olson,	S.B.,	Druker,	B.J.,	and	Bagby,	G.C.	(2012).	FANCL	ubiquitinates	beta-catenin	and	enhances	its	nuclear	function.	Blood	120,	323-334.	Dautry-Varsat,	A.,	Ciechanover,	A.,	and	Lodish,	H.F.	(1983).	pH	and	the	recycling	of	transferrin	during	receptor-mediated	endocytosis.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	80,	2258-2262.	
References		
		 185	
Deng,	L.,	Wang,	C.,	Spencer,	E.,	Yang,	L.,	Braun,	A.,	You,	J.,	Slaughter,	C.,	Pickart,	C.,	and	Chen,	Z.J.	(2000).	Activation	of	the	IkappaB	kinase	complex	by	TRAF6	requires	a	dimeric	ubiquitin-conjugating	enzyme	complex	and	a	unique	polyubiquitin	chain.	Cell	103,	351-361.	Deveraux,	Q.,	Ustrell,	V.,	Pickart,	C.,	and	Rechsteiner,	M.	(1994).	A	26	S	protease	subunit	that	binds	ubiquitin	conjugates.	The	Journal	of	biological	chemistry	269,	7059-7061.	Dimova,	N.V.,	Hathaway,	N.A.,	Lee,	B.H.,	Kirkpatrick,	D.S.,	Berkowitz,	M.L.,	Gygi,	S.P.,	Finley,	D.,	and	King,	R.W.	(2012).	APC/C-mediated	multiple	monoubiquitylation	provides	an	alternative	degradation	signal	for	cyclin	B1.	Nature	cell	biology	14,	168-176.	Dynek,	J.N.,	Goncharov,	T.,	Dueber,	E.C.,	Fedorova,	A.V.,	Izrael-Tomasevic,	A.,	Phu,	L.,	Helgason,	E.,	Fairbrother,	W.J.,	Deshayes,	K.,	Kirkpatrick,	D.S.,	and	Vucic,	D.	(2010).	c-IAP1	and	UbcH5	promote	K11-linked	polyubiquitination	of	RIP1	in	TNF	signalling.	The	EMBO	journal	29,	4198-4209.	Elsasser,	S.,	Chandler-Militello,	D.,	Muller,	B.,	Hanna,	J.,	and	Finley,	D.	(2004).	Rad23	and	Rpn10	serve	as	alternative	ubiquitin	receptors	for	the	proteasome.	The	Journal	of	biological	chemistry	279,	26817-26822.	Elsasser,	S.,	Gali,	R.R.,	Schwickart,	M.,	Larsen,	C.N.,	Leggett,	D.S.,	Muller,	B.,	Feng,	M.T.,	Tubing,	F.,	Dittmar,	G.A.,	and	Finley,	D.	(2002).	Proteasome	subunit	Rpn1	binds	ubiquitin-like	protein	domains.	Nature	cell	biology	4,	725-730.	Ema,	M.,	Taya,	S.,	Yokotani,	N.,	Sogawa,	K.,	Matsuda,	Y.,	and	Fujii-Kuriyama,	Y.	(1997).	A	novel	bHLH-PAS	factor	with	close	sequence	similarity	to	hypoxia-inducible	factor	1alpha	regulates	the	VEGF	expression	and	is	potentially	involved	in	lung	and	vascular	development.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	94,	4273-4278.	Eng,	C.,	Kiuru,	M.,	Fernandez,	M.J.,	and	Aaltonen,	L.A.	(2003).	A	role	for	mitochondrial	enzymes	in	inherited	neoplasia	and	beyond.	Nature	reviews	Cancer	3,	193-202.	Epstein,	A.C.,	Gleadle,	J.M.,	McNeill,	L.A.,	Hewitson,	K.S.,	O'Rourke,	J.,	Mole,	D.R.,	Mukherji,	M.,	Metzen,	E.,	Wilson,	M.I.,	Dhanda,	A.,	Tian,	Y.M.,	Masson,	N.,	Hamilton,	D.L.,	Jaakkola,	P.,	Barstead,	R.,	Hodgkin,	J.,	Maxwell,	P.H.,	Pugh,	C.W.,	Schofield,	C.J.,	and	Ratcliffe,	P.J.	(2001).	C.	elegans	EGL-9	and	mammalian	homologs	define	a	family	of	dioxygenases	that	regulate	HIF	by	prolyl	hydroxylation.	Cell	107,	43-54.	Faggiano,	S.,	Alfano,	C.,	and	Pastore,	A.	(2016).	The	missing	links	to	link	ubiquitin:	Methods	for	the	enzymatic	production	of	polyubiquitin	chains.	Analytical	biochemistry	492,	82-90.	Ferreira,	J.V.,	Soares,	A.R.,	Ramalho,	J.S.,	Pereira,	P.,	and	Girao,	H.	(2015).	K63	linked	ubiquitin	chain	formation	is	a	signal	for	HIF1A	degradation	by	Chaperone-Mediated	Autophagy.	Scientific	reports	5,	10210.	
References		
		 186	
Figueroa,	M.E.,	Abdel-Wahab,	O.,	Lu,	C.,	Ward,	P.S.,	Patel,	J.,	Shih,	A.,	Li,	Y.,	Bhagwat,	N.,	Vasanthakumar,	A.,	Fernandez,	H.F.,	Tallman,	M.S.,	Sun,	Z.,	Wolniak,	K.,	Peeters,	J.K.,	Liu,	W.,	Choe,	S.E.,	Fantin,	V.R.,	Paietta,	E.,	Lowenberg,	B.,	Licht,	J.D.,	et	al.	(2010).	Leukemic	IDH1	and	IDH2	mutations	result	in	a	hypermethylation	phenotype,	disrupt	TET2	function,	and	impair	hematopoietic	differentiation.	Cancer	cell	18,	553-567.	Finley,	D.	(2009).	Recognition	and	processing	of	ubiquitin-protein	conjugates	by	the	proteasome.	Annu	Rev	Biochem	78,	477-513.	Fishbain,	S.,	Prakash,	S.,	Herrig,	A.,	Elsasser,	S.,	and	Matouschek,	A.	(2011).	Rad23	escapes	degradation	because	it	lacks	a	proteasome	initiation	region.	Nature	communications	2,	192.	Flamme,	I.,	Frohlich,	T.,	von	Reutern,	M.,	Kappel,	A.,	Damert,	A.,	and	Risau,	W.	(1997).	HRF,	a	putative	basic	helix-loop-helix-PAS-domain	transcription	factor	is	closely	related	to	hypoxia-inducible	factor-1	alpha	and	developmentally	expressed	in	blood	vessels.	Mechanisms	of	development	63,	51-60.	Fukuba,	H.,	Yamashita,	H.,	Nagano,	Y.,	Jin,	H.G.,	Hiji,	M.,	Ohtsuki,	T.,	Takahashi,	T.,	Kohriyama,	T.,	and	Matsumoto,	M.	(2007).	Siah-1	facilitates	ubiquitination	and	degradation	of	factor	inhibiting	HIF-1alpha	(FIH).	Biochemical	and	biophysical	research	communications	353,	324-329.	Gale,	D.P.,	Harten,	S.K.,	Reid,	C.D.,	Tuddenham,	E.G.,	and	Maxwell,	P.H.	(2008).	Autosomal	dominant	erythrocytosis	and	pulmonary	arterial	hypertension	associated	with	an	activating	HIF2	alpha	mutation.	Blood	112,	919-921.	Garnett,	M.J.,	Mansfeld,	J.,	Godwin,	C.,	Matsusaka,	T.,	Wu,	J.,	Russell,	P.,	Pines,	J.,	and	Venkitaraman,	A.R.	(2009).	UBE2S	elongates	ubiquitin	chains	on	APC/C	substrates	to	promote	mitotic	exit.	Nature	cell	biology	11,	1363-1369.	Gatti,	M.,	Pinato,	S.,	Maiolica,	A.,	Rocchio,	F.,	Prato,	M.G.,	Aebersold,	R.,	and	Penengo,	L.	(2015).	RNF168	promotes	noncanonical	K27	ubiquitination	to	signal	DNA	damage.	Cell	reports	10,	226-238.	Gkika,	D.,	Lemonnier,	L.,	Shapovalov,	G.,	Gordienko,	D.,	Poux,	C.,	Bernardini,	M.,	Bokhobza,	A.,	Bidaux,	G.,	Degerny,	C.,	Verreman,	K.,	Guarmit,	B.,	Benahmed,	M.,	de	Launoit,	Y.,	Bindels,	R.J.,	Fiorio	Pla,	A.,	and	Prevarskaya,	N.	(2015).	TRP	channel-associated	factors	are	a	novel	protein	family	that	regulates	TRPM8	trafficking	and	activity.	The	Journal	of	cell	biology	208,	89-107.	Grice,	G.L.,	Lobb,	I.T.,	Weekes,	M.P.,	Gygi,	S.P.,	Antrobus,	R.,	and	Nathan,	J.A.	(2015).	The	Proteasome	Distinguishes	between	Heterotypic	and	Homotypic	Lysine-11-Linked	Polyubiquitin	Chains.	Cell	reports	12,	545-553.	Groll,	M.,	Bajorek,	M.,	Kohler,	A.,	Moroder,	L.,	Rubin,	D.M.,	Huber,	R.,	Glickman,	M.H.,	and	Finley,	D.	(2000).	A	gated	channel	into	the	proteasome	core	particle.	Nature	structural	biology	7,	1062-1067.	
References		
		 187	
Guo,	J.,	Chakraborty,	A.A.,	Liu,	P.,	Gan,	W.,	Zheng,	X.,	Inuzuka,	H.,	Wang,	B.,	Zhang,	J.,	Zhang,	L.,	Yuan,	M.,	Novak,	J.,	Cheng,	J.Q.,	Toker,	A.,	Signoretti,	S.,	Zhang,	Q.,	Asara,	J.M.,	Kaelin,	W.G.,	Jr.,	and	Wei,	W.	(2016).	pVHL	suppresses	kinase	activity	of	Akt	in	a	proline-hydroxylation-dependent	manner.	Science	(New	York,	NY)	
353,	929-932.	Hager,	M.,	Haufe,	H.,	Kemmerling,	R.,	Hitzl,	W.,	Mikuz,	G.,	Moser,	P.L.,	and	Kolbitsch,	C.	(2009).	Increased	activated	Akt	expression	in	renal	cell	carcinomas	and	prognosis.	Journal	of	cellular	and	molecular	medicine	13,	2181-2188.	Haglund,	K.,	Sigismund,	S.,	Polo,	S.,	Szymkiewicz,	I.,	Di	Fiore,	P.P.,	and	Dikic,	I.	(2003).	Multiple	monoubiquitination	of	RTKs	is	sufficient	for	their	endocytosis	and	degradation.	Nature	cell	biology	5,	461-466.	Harper,	S.,	Besong,	T.M.,	Emsley,	J.,	Scott,	D.J.,	and	Dreveny,	I.	(2011).	Structure	of	the	USP15	N-terminal	domains:	a	beta-hairpin	mediates	close	association	between	the	DUSP	and	UBL	domains.	Biochemistry	50,	7995-8004.	He,	F.,	Wollscheid,	H.P.,	Nowicka,	U.,	Biancospino,	M.,	Valentini,	E.,	Ehlinger,	A.,	Acconcia,	F.,	Magistrati,	E.,	Polo,	S.,	and	Walters,	K.J.	(2016).	Myosin	VI	Contains	a	Compact	Structural	Motif	that	Binds	to	Ubiquitin	Chains.	Cell	reports	14,	2683-2694.	Heissmeyer,	V.,	Krappmann,	D.,	Hatada,	E.N.,	and	Scheidereit,	C.	(2001).	Shared	pathways	of	IkappaB	kinase-induced	SCF(betaTrCP)-mediated	ubiquitination	and	degradation	for	the	NF-kappaB	precursor	p105	and	IkappaBalpha.	Molecular	and	cellular	biology	21,	1024-1035.	Hemantha,	H.P.,	Bavikar,	S.N.,	Herman-Bachinsky,	Y.,	Haj-Yahya,	N.,	Bondalapati,	S.,	Ciechanover,	A.,	and	Brik,	A.	(2014).	Nonenzymatic	polyubiquitination	of	expressed	proteins.	Journal	of	the	American	Chemical	Society	136,	2665-2673.	Hershko,	A.,	and	Ciechanover,	A.	(1998).	The	ubiquitin	system.	Annu	Rev	Biochem	67,	425-479.	Hewitson,	K.S.,	Lienard,	B.M.,	McDonough,	M.A.,	Clifton,	I.J.,	Butler,	D.,	Soares,	A.S.,	Oldham,	N.J.,	McNeill,	L.A.,	and	Schofield,	C.J.	(2007a).	Structural	and	mechanistic	studies	on	the	inhibition	of	the	hypoxia-inducible	transcription	factor	hydroxylases	by	tricarboxylic	acid	cycle	intermediates.	The	Journal	of	biological	chemistry	282,	3293-3301.	Hewitson,	K.S.,	Schofield,	C.J.,	and	Ratcliffe,	P.J.	(2007b).	Hypoxia-inducible	factor	prolyl-hydroxylase:	purification	and	assays	of	PHD2.	Methods	in	enzymology	
435,	25-42.	Hjerpe,	R.,	Aillet,	F.,	Lopitz-Otsoa,	F.,	Lang,	V.,	England,	P.,	and	Rodriguez,	M.S.	(2009).	Efficient	protection	and	isolation	of	ubiquitylated	proteins	using	tandem	ubiquitin-binding	entities.	EMBO	Rep	10,	1250-1258.	
References		
		 188	
Hoffman,	M.A.,	Ohh,	M.,	Yang,	H.,	Klco,	J.M.,	Ivan,	M.,	and	Kaelin,	W.G.,	Jr.	(2001).	von	Hippel-Lindau	protein	mutants	linked	to	type	2C	VHL	disease	preserve	the	ability	to	downregulate	HIF.	Human	molecular	genetics	10,	1019-1027.	Hofmann,	R.M.,	and	Pickart,	C.M.	(2001).	In	vitro	assembly	and	recognition	of	Lys-63	polyubiquitin	chains.	The	Journal	of	biological	chemistry	276,	27936-27943.	Hospenthal,	M.K.,	Mevissen,	T.E.T.,	and	Komander,	D.	(2015).	Deubiquitinase-based	analysis	of	ubiquitin	chain	architecture	using	Ubiquitin	Chain	Restriction	(UbiCRest).	Nature	protocols	10,	349-361.	Huang,	L.E.,	Gu,	J.,	Schau,	M.,	and	Bunn,	H.F.	(1998).	Regulation	of	hypoxia-inducible	factor	1alpha	is	mediated	by	an	O2-dependent	degradation	domain	via	the	ubiquitin-proteasome	pathway.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	95,	7987-7992.	Hubbi,	M.E.,	Gilkes,	D.M.,	Hu,	H.,	Kshitiz,	Ahmed,	I.,	and	Semenza,	G.L.	(2014).	Cyclin-dependent	kinases	regulate	lysosomal	degradation	of	hypoxia-inducible	factor	1alpha	to	promote	cell-cycle	progression.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	111,	E3325-3334.	Hubbi,	M.E.,	Hu,	H.,	Kshitiz,	Ahmed,	I.,	Levchenko,	A.,	and	Semenza,	G.L.	(2013).	Chaperone-mediated	autophagy	targets	hypoxia-inducible	factor-1alpha	(HIF-1alpha)	for	lysosomal	degradation.	The	Journal	of	biological	chemistry	288,	10703-10714.	Hurley,	J.H.,	Lee,	S.,	and	Prag,	G.	(2006).	Ubiquitin-binding	domains.	The	Biochemical	journal	399,	361-372.	Husnjak,	K.,	Elsasser,	S.,	Zhang,	N.,	Chen,	X.,	Randles,	L.,	Shi,	Y.,	Hofmann,	K.,	Walters,	K.J.,	Finley,	D.,	and	Dikic,	I.	(2008).	Proteasome	subunit	Rpn13	is	a	novel	ubiquitin	receptor.	Nature	453,	481-488.	Hutton,	J.J.,	Jr.,	Kaplan,	A.,	and	Udenfriend,	S.	(1967).	Conversion	of	the	amino	acid	sequence	gly-pro-pro	in	protein	to	gly-pro-hyp	by	collagen	proline	hydroxylase.	Archives	of	biochemistry	and	biophysics	121,	384-391.	Ikeda,	F.,	and	Dikic,	I.	(2008).	Atypical	ubiquitin	chains:	new	molecular	signals.	'Protein	Modifications:	Beyond	the	Usual	Suspects'	review	series.	EMBO	Rep	9,	536-542.	Iliopoulos,	O.,	Kibel,	A.,	Gray,	S.,	and	Kaelin,	W.G.,	Jr.	(1995).	Tumour	suppression	by	the	human	von	Hippel-Lindau	gene	product.	Nature	medicine	1,	822-826.	Intlekofer,	A.M.,	Dematteo,	R.G.,	Venneti,	S.,	Finley,	L.W.,	Lu,	C.,	Judkins,	A.R.,	Rustenburg,	A.S.,	Grinaway,	P.B.,	Chodera,	J.D.,	Cross,	J.R.,	and	Thompson,	C.B.	(2015).	Hypoxia	Induces	Production	of	L-2-Hydroxyglutarate.	Cell	metabolism	
22,	304-311.	
References		
		 189	
Ivan,	M.,	Kondo,	K.,	Yang,	H.,	Kim,	W.,	Valiando,	J.,	Ohh,	M.,	Salic,	A.,	Asara,	J.M.,	Lane,	W.S.,	and	Kaelin,	W.G.,	Jr.	(2001).	HIFalpha	targeted	for	VHL-mediated	destruction	by	proline	hydroxylation:	implications	for	O2	sensing.	Science	(New	York,	NY)	292,	464-468.	Jaakkola,	P.,	Mole,	D.R.,	Tian,	Y.M.,	Wilson,	M.I.,	Gielbert,	J.,	Gaskell,	S.J.,	von	Kriegsheim,	A.,	Hebestreit,	H.F.,	Mukherji,	M.,	Schofield,	C.J.,	Maxwell,	P.H.,	Pugh,	C.W.,	and	Ratcliffe,	P.J.	(2001).	Targeting	of	HIF-alpha	to	the	von	Hippel-Lindau	ubiquitylation	complex	by	O2-regulated	prolyl	hydroxylation.	Science	(New	York,	NY)	292,	468-472.	Jacobson,	A.D.,	Zhang,	N.Y.,	Xu,	P.,	Han,	K.J.,	Noone,	S.,	Peng,	J.,	and	Liu,	C.W.	(2009).	The	lysine	48	and	lysine	63	ubiquitin	conjugates	are	processed	differently	by	the	26	s	proteasome.	The	Journal	of	biological	chemistry	284,	35485-35494.	Jiang,	B.H.,	Semenza,	G.L.,	Bauer,	C.,	and	Marti,	H.H.	(1996).	Hypoxia-inducible	factor	1	levels	vary	exponentially	over	a	physiologically	relevant	range	of	O2	tension.	The	American	journal	of	physiology	271,	C1172-1180.	Jin,	L.,	Williamson,	A.,	Banerjee,	S.,	Philipp,	I.,	and	Rape,	M.	(2008).	Mechanism	of	ubiquitin-chain	formation	by	the	human	anaphase-promoting	complex.	Cell	133,	653-665.	Jin,	S.,	Tian,	S.,	Chen,	Y.,	Zhang,	C.,	Xie,	W.,	Xia,	X.,	Cui,	J.,	and	Wang,	R.F.	(2016).	USP19	modulates	autophagy	and	antiviral	immune	responses	by	deubiquitinating	Beclin-1.	The	EMBO	journal	35,	866-880.	Jung,	C.R.,	Hwang,	K.S.,	Yoo,	J.,	Cho,	W.K.,	Kim,	J.M.,	Kim,	W.H.,	and	Im,	D.S.	(2006).	E2-EPF	UCP	targets	pVHL	for	degradation	and	associates	with	tumor	growth	and	metastasis.	Nat	Med	12,	809-816.	Kaelin,	W.G.,	Jr.	(2008).	The	von	Hippel-Lindau	tumour	suppressor	protein:	O2	sensing	and	cancer.	Nature	reviews	Cancer	8,	865-873.	Kaelin,	W.G.,	Jr.,	and	Ratcliffe,	P.J.	(2008).	Oxygen	sensing	by	metazoans:	the	central	role	of	the	HIF	hydroxylase	pathway.	Molecular	cell	30,	393-402.	Kamura,	T.,	Koepp,	D.M.,	Conrad,	M.N.,	Skowyra,	D.,	Moreland,	R.J.,	Iliopoulos,	O.,	Lane,	W.S.,	Kaelin,	W.G.,	Jr.,	Elledge,	S.J.,	Conaway,	R.C.,	Harper,	J.W.,	and	Conaway,	J.W.	(1999).	Rbx1,	a	component	of	the	VHL	tumor	suppressor	complex	and	SCF	ubiquitin	ligase.	Science	(New	York,	NY)	284,	657-661.	Kamura,	T.,	Sato,	S.,	Iwai,	K.,	Czyzyk-Krzeska,	M.,	Conaway,	R.C.,	and	Conaway,	J.W.	(2000).	Activation	of	HIF1alpha	ubiquitination	by	a	reconstituted	von	Hippel-Lindau	(VHL)	tumor	suppressor	complex.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	97,	10430-10435.	Kelley,	L.A.,	Mezulis,	S.,	Yates,	C.M.,	Wass,	M.N.,	and	Sternberg,	M.J.	(2015).	The	Phyre2	web	portal	for	protein	modeling,	prediction	and	analysis.		10,	845-858.	
References		
		 190	
Kelly,	B.D.,	Hackett,	S.F.,	Hirota,	K.,	Oshima,	Y.,	Cai,	Z.,	Berg-Dixon,	S.,	Rowan,	A.,	Yan,	Z.,	Campochiaro,	P.A.,	and	Semenza,	G.L.	(2003).	Cell	type-specific	regulation	of	angiogenic	growth	factor	gene	expression	and	induction	of	angiogenesis	in	nonischemic	tissue	by	a	constitutively	active	form	of	hypoxia-inducible	factor	1.	Circulation	research	93,	1074-1081.	Kim,	H.T.,	Kim,	K.P.,	Lledias,	F.,	Kisselev,	A.F.,	Scaglione,	K.M.,	Skowyra,	D.,	Gygi,	S.P.,	and	Goldberg,	A.L.	(2007).	Certain	pairs	of	ubiquitin-conjugating	enzymes	(E2s)	and	ubiquitin-protein	ligases	(E3s)	synthesize	nondegradable	forked	ubiquitin	chains	containing	all	possible	isopeptide	linkages.	The	Journal	of	biological	chemistry	282,	17375-17386.	Kim,	H.T.,	Kim,	K.P.,	Uchiki,	T.,	Gygi,	S.P.,	and	Goldberg,	A.L.	(2009).	S5a	promotes	protein	degradation	by	blocking	synthesis	of	nondegradable	forked	ubiquitin	chains.	The	EMBO	journal	28,	1867-1877.	Kirkpatrick,	D.S.,	Hathaway,	N.A.,	Hanna,	J.,	Elsasser,	S.,	Rush,	J.,	Finley,	D.,	King,	R.W.,	and	Gygi,	S.P.	(2006).	Quantitative	analysis	of	in	vitro	ubiquitinated	cyclin	B1	reveals	complex	chain	topology.	Nature	cell	biology	8,	700-710.	Kisselev,	A.F.,	Akopian,	T.N.,	Woo,	K.M.,	and	Goldberg,	A.L.	(1999).	The	sizes	of	peptides	generated	from	protein	by	mammalian	26	and	20	S	proteasomes.	Implications	for	understanding	the	degradative	mechanism	and	antigen	presentation.	The	Journal	of	biological	chemistry	274,	3363-3371.	Klose,	R.J.,	Kallin,	E.M.,	and	Zhang,	Y.	(2006).	JmjC-domain-containing	proteins	and	histone	demethylation.	Nature	reviews	Genetics	7,	715-727.	Ko,	H.S.,	Uehara,	T.,	Tsuruma,	K.,	and	Nomura,	Y.	(2004).	Ubiquilin	interacts	with	ubiquitylated	proteins	and	proteasome	through	its	ubiquitin-associated	and	ubiquitin-like	domains.	FEBS	letters	566,	110-114.	Koegl,	M.,	Hoppe,	T.,	Schlenker,	S.,	Ulrich,	H.D.,	Mayer,	T.U.,	and	Jentsch,	S.	(1999).	A	novel	ubiquitination	factor,	E4,	is	involved	in	multiubiquitin	chain	assembly.	Cell	96,	635-644.	Kohli,	R.M.,	and	Zhang,	Y.	(2013).	TET	enzymes,	TDG	and	the	dynamics	of	DNA	demethylation.	Nature	502,	472-479.	Koivunen,	P.,	Lee,	S.,	Duncan,	C.G.,	Lopez,	G.,	Lu,	G.,	Ramkissoon,	S.,	Losman,	J.A.,	Joensuu,	P.,	Bergmann,	U.,	Gross,	S.,	Travins,	J.,	Weiss,	S.,	Looper,	R.,	Ligon,	K.L.,	Verhaak,	R.G.,	Yan,	H.,	and	Kaelin,	W.G.,	Jr.	(2012).	Transformation	by	the	(R)-enantiomer	of	2-hydroxyglutarate	linked	to	EGLN	activation.	Nature	483,	484-488.	Komander,	D.,	Clague,	M.J.,	and	Urbe,	S.	(2009).	Breaking	the	chains:	structure	and	function	of	the	deubiquitinases.	Nature	reviews	Molecular	cell	biology	10,	550-563.	
References		
		 191	
Kondo,	K.,	Kim,	W.Y.,	Lechpammer,	M.,	and	Kaelin,	W.G.,	Jr.	(2003).	Inhibition	of	HIF2alpha	is	sufficient	to	suppress	pVHL-defective	tumor	growth.	PLoS	biology	
1,	E83.	Kondo,	K.,	Klco,	J.,	Nakamura,	E.,	Lechpammer,	M.,	and	Kaelin,	W.G.,	Jr.	(2002).	Inhibition	of	HIF	is	necessary	for	tumor	suppression	by	the	von	Hippel-Lindau	protein.	Cancer	cell	1,	237-246.	Koyano,	F.,	Okatsu,	K.,	Kosako,	H.,	Tamura,	Y.,	Go,	E.,	Kimura,	M.,	Kimura,	Y.,	Tsuchiya,	H.,	Yoshihara,	H.,	Hirokawa,	T.,	Endo,	T.,	Fon,	E.A.,	Trempe,	J.F.,	Saeki,	Y.,	Tanaka,	K.,	and	Matsuda,	N.	(2014).	Ubiquitin	is	phosphorylated	by	PINK1	to	activate	parkin.	Nature	510,	162-166.	Kozik,	P.,	Hodson,	N.A.,	Sahlender,	D.A.,	Simecek,	N.,	Soromani,	C.,	Wu,	J.,	Collinson,	L.M.,	and	Robinson,	M.S.	(2013).	A	human	genome-wide	screen	for	regulators	of	clathrin-coated	vesicle	formation	reveals	an	unexpected	role	for	the	V-ATPase.	Nature	cell	biology	15,	50-60.	Kranendijk,	M.,	Struys,	E.A.,	Salomons,	G.S.,	Van	der	Knaap,	M.S.,	and	Jakobs,	C.	(2012).	Progress	in	understanding	2-hydroxyglutaric	acidurias.	Journal	of	inherited	metabolic	disease	35,	571-587.	Kravtsova-Ivantsiv,	Y.,	Cohen,	S.,	and	Ciechanover,	A.	(2009).	Modification	by	single	ubiquitin	moieties	rather	than	polyubiquitination	is	sufficient	for	proteasomal	processing	of	the	p105	NF-kappaB	precursor.	Molecular	cell	33,	496-504.	Kristariyanto,	Y.A.,	Choi,	S.Y.,	Rehman,	S.A.,	Ritorto,	M.S.,	Campbell,	D.G.,	Morrice,	N.A.,	Toth,	R.,	and	Kulathu,	Y.	(2015).	Assembly	and	structure	of	Lys33-linked	polyubiquitin	reveals	distinct	conformations.	The	Biochemical	journal	467,	345-352.	Lam,	Y.A.,	Lawson,	T.G.,	Velayutham,	M.,	Zweier,	J.L.,	and	Pickart,	C.M.	(2002).	A	proteasomal	ATPase	subunit	recognizes	the	polyubiquitin	degradation	signal.	Nature	416,	763-767.	Lando,	D.,	Peet,	D.J.,	Gorman,	J.J.,	Whelan,	D.A.,	Whitelaw,	M.L.,	and	Bruick,	R.K.	(2002).	FIH-1	is	an	asparaginyl	hydroxylase	enzyme	that	regulates	the	transcriptional	activity	of	hypoxia-inducible	factor.	Genes	&	development	16,	1466-1471.	Lang,	V.,	Janzen,	J.,	Fischer,	G.Z.,	Soneji,	Y.,	Beinke,	S.,	Salmeron,	A.,	Allen,	H.,	Hay,	R.T.,	Ben-Neriah,	Y.,	and	Ley,	S.C.	(2003).	betaTrCP-mediated	proteolysis	of	NF-kappaB1	p105	requires	phosphorylation	of	p105	serines	927	and	932.	Molecular	and	cellular	biology	23,	402-413.	Lazarou,	M.,	Sliter,	D.A.,	Kane,	L.A.,	Sarraf,	S.A.,	Wang,	C.,	Burman,	J.L.,	Sideris,	D.P.,	Fogel,	A.I.,	and	Youle,	R.J.	(2015).	The	ubiquitin	kinase	PINK1	recruits	autophagy	receptors	to	induce	mitophagy.	Nature	524,	309-314.	
References		
		 192	
Lee,	B.H.,	Lu,	Y.,	Prado,	M.A.,	Shi,	Y.,	Tian,	G.,	Sun,	S.,	Elsasser,	S.,	Gygi,	S.P.,	King,	R.W.,	and	Finley,	D.	(2016).	USP14	deubiquitinates	proteasome-bound	substrates	that	are	ubiquitinated	at	multiple	sites.	Nature	532,	398-401.	Lee,	D.C.,	Sohn,	H.A.,	Park,	Z.Y.,	Oh,	S.,	Kang,	Y.K.,	Lee,	K.M.,	Kang,	M.,	Jang,	Y.J.,	Yang,	S.J.,	Hong,	Y.K.,	Noh,	H.,	Kim,	J.A.,	Kim,	D.J.,	Bae,	K.H.,	Kim,	D.M.,	Chung,	S.J.,	Yoo,	H.S.,	Yu,	D.Y.,	Park,	K.C.,	and	Yeom,	Y.I.	(2015).	A	lactate-induced	response	to	hypoxia.	Cell	161,	595-609.	Lee,	M.J.,	Lee,	B.H.,	Hanna,	J.,	King,	R.W.,	and	Finley,	D.	(2011).	Trimming	of	ubiquitin	chains	by	proteasome-associated	deubiquitinating	enzymes.	Molecular	&	cellular	proteomics	:	MCP	10,	R110.003871.	Leggett,	D.S.,	Hanna,	J.,	Borodovsky,	A.,	Crosas,	B.,	Schmidt,	M.,	Baker,	R.T.,	Walz,	T.,	Ploegh,	H.,	and	Finley,	D.	(2002).	Multiple	associated	proteins	regulate	proteasome	structure	and	function.	Molecular	cell	10,	495-507.	Licchesi,	J.D.,	Mieszczanek,	J.,	Mevissen,	T.E.,	Rutherford,	T.J.,	Akutsu,	M.,	Virdee,	S.,	El	Oualid,	F.,	Chin,	J.W.,	Ovaa,	H.,	Bienz,	M.,	and	Komander,	D.	(2011).	An	ankyrin-repeat	ubiquitin-binding	domain	determines	TRABID's	specificity	for	atypical	ubiquitin	chains.	Nature	structural	&	molecular	biology	19,	62-71.	Lieb,	M.E.,	Menzies,	K.,	Moschella,	M.C.,	Ni,	R.,	and	Taubman,	M.B.	(2002).	Mammalian	EGLN	genes	have	distinct	patterns	of	mRNA	expression	and	regulation.	Biochemistry	and	cell	biology	=	Biochimie	et	biologie	cellulaire	80,	421-426.	Lim,	J.H.,	Park,	J.W.,	Kim,	M.S.,	Park,	S.K.,	Johnson,	R.S.,	and	Chun,	Y.S.	(2006).	Bafilomycin	induces	the	p21-mediated	growth	inhibition	of	cancer	cells	under	hypoxic	conditions	by	expressing	hypoxia-inducible	factor-1alpha.	Molecular	pharmacology	70,	1856-1865.	Lim,	J.H.,	Park,	J.W.,	Kim,	S.J.,	Kim,	M.S.,	Park,	S.K.,	Johnson,	R.S.,	and	Chun,	Y.S.	(2007).	ATP6V0C	competes	with	von	Hippel-Lindau	protein	in	hypoxia-inducible	factor	1alpha	(HIF-1alpha)	binding	and	mediates	HIF-1alpha	expression	by	bafilomycin	A1.	Molecular	pharmacology	71,	942-948.	Liu,	J.,	Zhang,	C.,	Zhao,	Y.,	Yue,	X.,	Wu,	H.,	Huang,	S.,	Chen,	J.,	Tomsky,	K.,	Xie,	H.,	Khella,	C.A.,	Gatza,	M.L.,	Xia,	D.,	Gao,	J.,	White,	E.,	Haffty,	B.G.,	Hu,	W.,	and	Feng,	Z.	(2017).	Parkin	targets	HIF-1alpha	for	ubiquitination	and	degradation	to	inhibit	breast	tumor	progression.	Nature	communications	8,	1823.	Loenarz,	C.,	and	Schofield,	C.J.	(2008).	Expanding	chemical	biology	of	2-oxoglutarate	oxygenases.	Nature	chemical	biology	4,	152-156.	Losman,	J.A.,	Looper,	R.E.,	Koivunen,	P.,	Lee,	S.,	Schneider,	R.K.,	McMahon,	C.,	Cowley,	G.S.,	Root,	D.E.,	Ebert,	B.L.,	and	Kaelin,	W.G.,	Jr.	(2013).	(R)-2-hydroxyglutarate	is	sufficient	to	promote	leukemogenesis	and	its	effects	are	reversible.	Science	(New	York,	NY)	339,	1621-1625.	
References		
		 193	
Lu,	Y.,	Lee,	B.H.,	King,	R.W.,	Finley,	D.,	and	Kirschner,	M.W.	(2015).	Substrate	degradation	by	the	proteasome:	a	single-molecule	kinetic	analysis.	Science	(New	York,	NY)	348,	1250834.	Maltepe,	E.,	Krampitz,	G.W.,	Okazaki,	K.M.,	Red-Horse,	K.,	Mak,	W.,	Simon,	M.C.,	and	Fisher,	S.J.	(2005).	Hypoxia-inducible	factor-dependent	histone	deacetylase	activity	determines	stem	cell	fate	in	the	placenta.	Development	(Cambridge,	England)	132,	3393-3403.	Manalo,	D.J.,	Rowan,	A.,	Lavoie,	T.,	Natarajan,	L.,	Kelly,	B.D.,	Ye,	S.Q.,	Garcia,	J.G.,	and	Semenza,	G.L.	(2005).	Transcriptional	regulation	of	vascular	endothelial	cell	responses	to	hypoxia	by	HIF-1.	Blood	105,	659-669.	Mancias,	J.D.,	Wang,	X.,	Gygi,	S.P.,	Harper,	J.W.,	and	Kimmelman,	A.C.	(2014).	Quantitative	proteomics	identifies	NCOA4	as	the	cargo	receptor	mediating	ferritinophagy.	Nature	509,	105-109.	Mansour,	W.,	Nakasone,	M.A.,	von	Delbrueck,	M.,	Yu,	Z.,	Krutauz,	D.,	Reis,	N.,	Kleifeld,	O.,	Sommer,	T.,	Fushman,	D.,	and	Glickman,	M.H.	(2014).	Disassembly	of	Lys11-	and	mixed-linkage	polyubiquitin	conjugates	provide	insights	into	function	of	proteasomal	deubiquitinases	Rpn11	and	Ubp6.	The	Journal	of	biological	chemistry.	Marin,	I.,	Lucas,	J.I.,	Gradilla,	A.C.,	and	Ferrus,	A.	(2004).	Parkin	and	relatives:	the	RBR	family	of	ubiquitin	ligases.	Physiological	genomics	17,	253-263.	Martinez-Fonts,	K.,	and	Matouschek,	A.	(2016).	A	Rapid	and	Versatile	Method	for	Generating	Proteins	with	Defined	Ubiquitin	Chains.	Biochemistry	55,	1898-1908.	Masson,	N.,	Willam,	C.,	Maxwell,	P.H.,	Pugh,	C.W.,	and	Ratcliffe,	P.J.	(2001).	Independent	function	of	two	destruction	domains	in	hypoxia-inducible	factor-alpha	chains	activated	by	prolyl	hydroxylation.	The	EMBO	journal	20,	5197-5206.	Matsumoto,	G.,	Wada,	K.,	Okuno,	M.,	Kurosawa,	M.,	and	Nukina,	N.	(2011).	Serine	403	phosphorylation	of	p62/SQSTM1	regulates	selective	autophagic	clearance	of	ubiquitinated	proteins.	Molecular	cell	44,	279-289.	Matsumoto,	M.L.,	Wickliffe,	K.E.,	Dong,	K.C.,	Yu,	C.,	Bosanac,	I.,	Bustos,	D.,	Phu,	L.,	Kirkpatrick,	D.S.,	Hymowitz,	S.G.,	Rape,	M.,	Kelley,	R.F.,	and	Dixit,	V.M.	(2010).	K11-linked	polyubiquitination	in	cell	cycle	control	revealed	by	a	K11	linkage-specific	antibody.	Molecular	cell	39,	477-484.	Maxwell,	P.H.,	and	Eckardt,	K.U.	(2016).	HIF	prolyl	hydroxylase	inhibitors	for	the	treatment	of	renal	anaemia	and	beyond.	Nature	reviews	Nephrology	12,	157-168.	Maxwell,	P.H.,	and	Ratcliffe,	P.J.	(2002).	Oxygen	sensors	and	angiogenesis.	Seminars	in	cell	&	developmental	biology	13,	29-37.	
References		
		 194	
Maxwell,	P.H.,	Wiesener,	M.S.,	Chang,	G.W.,	Clifford,	S.C.,	Vaux,	E.C.,	Cockman,	M.E.,	Wykoff,	C.C.,	Pugh,	C.W.,	Maher,	E.R.,	and	Ratcliffe,	P.J.	(1999).	The	tumour	suppressor	protein	VHL	targets	hypoxia-inducible	factors	for	oxygen-dependent	proteolysis.	Nature	399,	271-275.	McCullough,	J.,	Clague,	M.J.,	and	Urbe,	S.	(2004).	AMSH	is	an	endosome-associated	ubiquitin	isopeptidase.	The	Journal	of	cell	biology	166,	487-492.	McDonough,	M.A.,	Li,	V.,	Flashman,	E.,	Chowdhury,	R.,	Mohr,	C.,	Lienard,	B.M.,	Zondlo,	J.,	Oldham,	N.J.,	Clifton,	I.J.,	Lewis,	J.,	McNeill,	L.A.,	Kurzeja,	R.J.,	Hewitson,	K.S.,	Yang,	E.,	Jordan,	S.,	Syed,	R.S.,	and	Schofield,	C.J.	(2006).	Cellular	oxygen	sensing:	Crystal	structure	of	hypoxia-inducible	factor	prolyl	hydroxylase	(PHD2).	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	
103,	9814-9819.	McNeill,	L.A.,	Flashman,	E.,	Buck,	M.R.,	Hewitson,	K.S.,	Clifton,	I.J.,	Jeschke,	G.,	Claridge,	T.D.,	Ehrismann,	D.,	Oldham,	N.J.,	and	Schofield,	C.J.	(2005).	Hypoxia-inducible	factor	prolyl	hydroxylase	2	has	a	high	affinity	for	ferrous	iron	and	2-oxoglutarate.	Molecular	bioSystems	1,	321-324.	Mevissen,	T.E.T.,	Kulathu,	Y.,	Mulder,	M.P.C.,	Geurink,	P.P.,	Maslen,	S.L.,	Gersch,	M.,	Elliott,	P.R.,	Burke,	J.E.,	van	Tol,	B.D.M.,	Akutsu,	M.,	Oualid,	F.E.,	Kawasaki,	M.,	Freund,	S.M.V.,	Ovaa,	H.,	and	Komander,	D.	(2016).	Molecular	basis	of	Lys11-polyubiquitin	specificity	in	the	deubiquitinase	Cezanne.	Nature	538,	402-405.	Meyer,	H.J.,	and	Rape,	M.	(2014).	Enhanced	protein	degradation	by	branched	ubiquitin	chains.	Cell	157,	910-921.	Michel,	M.A.,	Elliott,	P.R.,	Swatek,	K.N.,	Simicek,	M.,	Pruneda,	J.N.,	Wagstaff,	J.L.,	Freund,	S.M.,	and	Komander,	D.	(2015).	Assembly	and	specific	recognition	of	k29-	and	k33-linked	polyubiquitin.	Molecular	cell	58,	95-109.	Michel,	M.A.,	Swatek,	K.N.,	Hospenthal,	M.K.,	and	Komander,	D.	(2017).	Ubiquitin	Linkage-Specific	Affimers	Reveal	Insights	into	K6-Linked	Ubiquitin	Signaling.	Molecular	cell	68,	233-246.e235.	Miles,	A.L.,	Burr,	S.P.,	Grice,	G.L.,	and	Nathan,	J.A.	(2017).	The	vacuolar-ATPase	complex	and	assembly	factors,	TMEM199	and	CCDC115,	control	HIF1alpha	prolyl	hydroxylation	by	regulating	cellular	iron	levels.		6.	Min,	M.,	and	Lindon,	C.	(2012).	Substrate	targeting	by	the	ubiquitin-proteasome	system	in	mitosis.	Seminars	in	cell	&	developmental	biology	23,	482-491.	Moller,	A.,	House,	C.M.,	Wong,	C.S.,	Scanlon,	D.B.,	Liu,	M.C.,	Ronai,	Z.,	and	Bowtell,	D.D.	(2009).	Inhibition	of	Siah	ubiquitin	ligase	function.	Oncogene	28,	289-296.	Montagner,	M.,	Enzo,	E.,	Forcato,	M.,	Zanconato,	F.,	Parenti,	A.,	Rampazzo,	E.,	Basso,	G.,	Leo,	G.,	Rosato,	A.,	Bicciato,	S.,	Cordenonsi,	M.,	and	Piccolo,	S.	(2012).	SHARP1	suppresses	breast	cancer	metastasis	by	promoting	degradation	of	hypoxia-inducible	factors.	Nature	487,	380-384.	
References		
		 195	
Morris,	J.R.,	and	Solomon,	E.	(2004).	BRCA1	:	BARD1	induces	the	formation	of	conjugated	ubiquitin	structures,	dependent	on	K6	of	ubiquitin,	in	cells	during	DNA	replication	and	repair.	Human	molecular	genetics	13,	807-817.	Morriswood,	B.,	Ryzhakov,	G.,	Puri,	C.,	Arden,	S.D.,	Roberts,	R.,	Dendrou,	C.,	Kendrick-Jones,	J.,	and	Buss,	F.	(2007).	T6BP	and	NDP52	are	myosin	VI	binding	partners	with	potential	roles	in	cytokine	signalling	and	cell	adhesion.	Journal	of	cell	science	120,	2574-2585.	Mutoh,	T.,	Sanosaka,	T.,	Ito,	K.,	and	Nakashima,	K.	(2012).	Oxygen	levels	epigenetically	regulate	fate	switching	of	neural	precursor	cells	via	hypoxia-inducible	factor	1alpha-notch	signal	interaction	in	the	developing	brain.	Stem	cells	(Dayton,	Ohio)	30,	561-569.	Myllyharju,	J.,	and	Kivirikko,	K.I.	(2004).	Collagens,	modifying	enzymes	and	their	mutations	in	humans,	flies	and	worms.	Trends	in	genetics	:	TIG	20,	33-43.	Nakayama,	K.,	and	Ronai,	Z.	(2004).	Siah:	new	players	in	the	cellular	response	to	hypoxia.	Cell	cycle	(Georgetown,	Tex)	3,	1345-1347.	Nakjang,	S.,	Ndeh,	D.A.,	Wipat,	A.,	Bolam,	D.N.,	and	Hirt,	R.P.	(2012).	A	novel	extracellular	metallopeptidase	domain	shared	by	animal	host-associated	mutualistic	and	pathogenic	microbes.	PloS	one	7,	e30287.	Nathan,	J.A.,	Kim,	H.T.,	Ting,	L.,	Gygi,	S.P.,	and	Goldberg,	A.L.	(2013).	Why	do	cellular	proteins	linked	to	K63-polyubiquitin	chains	not	associate	with	proteasomes?	The	EMBO	journal	32,	552-565.	Neumann,	H.P.,	Pawlu,	C.,	Peczkowska,	M.,	Bausch,	B.,	McWhinney,	S.R.,	Muresan,	M.,	Buchta,	M.,	Franke,	G.,	Klisch,	J.,	Bley,	T.A.,	Hoegerle,	S.,	Boedeker,	C.C.,	Opocher,	G.,	Schipper,	J.,	Januszewicz,	A.,	and	Eng,	C.	(2004).	Distinct	clinical	features	of	paraganglioma	syndromes	associated	with	SDHB	and	SDHD	gene	mutations.	Jama	292,	943-951.	Oldham,	W.M.,	Clish,	C.B.,	Yang,	Y.,	and	Loscalzo,	J.	(2015).	Hypoxia-Mediated	Increases	in	L-2-hydroxyglutarate	Coordinate	the	Metabolic	Response	to	Reductive	Stress.	Cell	metabolism	22,	291-303.	Ordureau,	A.,	Heo,	J.M.,	Duda,	D.M.,	Paulo,	J.A.,	Olszewski,	J.L.,	Yanishevski,	D.,	Rinehart,	J.,	Schulman,	B.A.,	and	Harper,	J.W.	(2015).	Defining	roles	of	PARKIN	and	ubiquitin	phosphorylation	by	PINK1	in	mitochondrial	quality	control	using	a	ubiquitin	replacement	strategy.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	112,	6637-6642.	Ordureau,	A.,	Sarraf,	S.A.,	Duda,	D.M.,	Heo,	J.M.,	Jedrychowski,	M.P.,	Sviderskiy,	V.O.,	Olszewski,	J.L.,	Koerber,	J.T.,	Xie,	T.,	Beausoleil,	S.A.,	Wells,	J.A.,	Gygi,	S.P.,	Schulman,	B.A.,	and	Harper,	J.W.	(2014).	Quantitative	proteomics	reveal	a	feedforward	mechanism	for	mitochondrial	PARKIN	translocation	and	ubiquitin	chain	synthesis.	Molecular	cell	56,	360-375.	
References		
		 196	
Palazon,	A.,	Goldrath,	A.W.,	Nizet,	V.,	and	Johnson,	R.S.	(2014).	HIF	transcription	factors,	inflammation,	and	immunity.	Immunity	41,	518-528.	Paltoglou,	S.,	and	Roberts,	B.J.	(2007).	HIF-1alpha	and	EPAS	ubiquitination	mediated	by	the	VHL	tumour	suppressor	involves	flexibility	in	the	ubiquitination	mechanism,	similar	to	other	RING	E3	ligases.	Oncogene	26,	604-609.	Paraskevopoulos,	K.,	Kriegenburg,	F.,	Tatham,	M.H.,	Rosner,	H.I.,	Medina,	B.,	Larsen,	I.B.,	Brandstrup,	R.,	Hardwick,	K.G.,	Hay,	R.T.,	Kragelund,	B.B.,	Hartmann-Petersen,	R.,	and	Gordon,	C.	(2014).	Dss1	is	a	26S	proteasome	ubiquitin	receptor.	Molecular	cell	56,	453-461.	Pathare,	G.R.,	Nagy,	I.,	Sledz,	P.,	Anderson,	D.J.,	Zhou,	H.J.,	Pardon,	E.,	Steyaert,	J.,	Forster,	F.,	Bracher,	A.,	and	Baumeister,	W.	(2014).	Crystal	structure	of	the	proteasomal	deubiquitylation	module	Rpn8-Rpn11.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	111,	2984-2989.	Pause,	A.,	Lee,	S.,	Worrell,	R.A.,	Chen,	D.Y.,	Burgess,	W.H.,	Linehan,	W.M.,	and	Klausner,	R.D.	(1997).	The	von	Hippel-Lindau	tumor-suppressor	gene	product	forms	a	stable	complex	with	human	CUL-2,	a	member	of	the	Cdc53	family	of	proteins.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	94,	2156-2161.	Percy,	M.J.,	McMullin,	M.F.,	Jowitt,	S.N.,	Potter,	M.,	Treacy,	M.,	Watson,	W.H.,	and	Lappin,	T.R.	(2003).	Chuvash-type	congenital	polycythemia	in	4	families	of	Asian	and	Western	European	ancestry.	Blood	102,	1097-1099.	Percy,	M.J.,	Zhao,	Q.,	Flores,	A.,	Harrison,	C.,	Lappin,	T.R.,	Maxwell,	P.H.,	McMullin,	M.F.,	and	Lee,	F.S.	(2006).	A	family	with	erythrocytosis	establishes	a	role	for	prolyl	hydroxylase	domain	protein	2	in	oxygen	homeostasis.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	103,	654-659.	Peters,	J.P.,	Her,	Y.F.,	and	Maher,	L.J.,	3rd	(2015).	Modeling	dioxygenase	enzyme	kinetics	in	familial	paraganglioma.	Biology	open	4,	1281-1289.	Peth,	A.,	Besche,	H.C.,	and	Goldberg,	A.L.	(2009).	Ubiquitinated	proteins	activate	the	proteasome	by	binding	to	Usp14/Ubp6,	which	causes	20S	gate	opening.	Molecular	cell	36,	794-804.	Peth,	A.,	Uchiki,	T.,	and	Goldberg,	A.L.	(2010).	ATP-dependent	steps	in	the	binding	of	ubiquitin	conjugates	to	the	26S	proteasome	that	commit	to	degradation.	Molecular	cell	40,	671-681.	Pickart,	C.M.	(2001).	Mechanisms	underlying	ubiquitination.	Annu	Rev	Biochem	
70,	503-533.	Pines,	J.	(2011).	Cubism	and	the	cell	cycle:	the	many	faces	of	the	APC/C.	Nature	reviews	Molecular	cell	biology	12,	427-438.	Pollard,	P.J.,	Briere,	J.J.,	Alam,	N.A.,	Barwell,	J.,	Barclay,	E.,	Wortham,	N.C.,	Hunt,	T.,	Mitchell,	M.,	Olpin,	S.,	Moat,	S.J.,	Hargreaves,	I.P.,	Heales,	S.J.,	Chung,	Y.L.,	Griffiths,	
References		
		 197	
J.R.,	Dalgleish,	A.,	McGrath,	J.A.,	Gleeson,	M.J.,	Hodgson,	S.V.,	Poulsom,	R.,	Rustin,	P.,	et	al.	(2005).	Accumulation	of	Krebs	cycle	intermediates	and	over-expression	of	HIF1alpha	in	tumours	which	result	from	germline	FH	and	SDH	mutations.	Human	molecular	genetics	14,	2231-2239.	Prakash,	S.,	Tian,	L.,	Ratliff,	K.S.,	Lehotzky,	R.E.,	and	Matouschek,	A.	(2004).	An	unstructured	initiation	site	is	required	for	efficient	proteasome-mediated	degradation.	Nature	structural	&	molecular	biology	11,	830-837.	Pugh,	C.W.,	and	Ratcliffe,	P.J.	(2003).	Regulation	of	angiogenesis	by	hypoxia:	role	of	the	HIF	system.	Nature	medicine	9,	677-684.	Qin,	Y.,	Zhou,	M.T.,	Hu,	M.M.,	Hu,	Y.H.,	Zhang,	J.,	Guo,	L.,	Zhong,	B.,	and	Shu,	H.B.	(2014).	RNF26	temporally	regulates	virus-triggered	type	I	interferon	induction	by	two	distinct	mechanisms.	PLoS	pathogens	10,	e1004358.	Rabinowitz,	M.H.	(2013).	Inhibition	of	hypoxia-inducible	factor	prolyl	hydroxylase	domain	oxygen	sensors:	tricking	the	body	into	mounting	orchestrated	survival	and	repair	responses.	Journal	of	medicinal	chemistry	56,	9369-9402.	Radmer,	R.J.,	and	Klein,	T.E.	(2006).	Triple	helical	structure	and	stabilization	of	collagen-like	molecules	with	4(R)-hydroxyproline	in	the	Xaa	position.	Biophysical	journal	90,	578-588.	Raval,	R.R.,	Lau,	K.W.,	Tran,	M.G.,	Sowter,	H.M.,	Mandriota,	S.J.,	Li,	J.L.,	Pugh,	C.W.,	Maxwell,	P.H.,	Harris,	A.L.,	and	Ratcliffe,	P.J.	(2005).	Contrasting	properties	of	hypoxia-inducible	factor	1	(HIF-1)	and	HIF-2	in	von	Hippel-Lindau-associated	renal	cell	carcinoma.	Molecular	and	cellular	biology	25,	5675-5686.	Ren,	X.,	and	Hurley,	J.H.	(2010).	VHS	domains	of	ESCRT-0	cooperate	in	high-avidity	binding	to	polyubiquitinated	cargo.	The	EMBO	journal	29,	1045-1054.	Reyes-Turcu,	F.E.,	and	Wilkinson,	K.D.	(2009).	Polyubiquitin	binding	and	disassembly	by	deubiquitinating	enzymes.	Chemical	reviews	109,	1495-1508.	Richly,	H.,	Rape,	M.,	Braun,	S.,	Rumpf,	S.,	Hoege,	C.,	and	Jentsch,	S.	(2005).	A	series	of	ubiquitin	binding	factors	connects	CDC48/p97	to	substrate	multiubiquitylation	and	proteasomal	targeting.	Cell	120,	73-84.	Rock,	K.L.,	Gramm,	C.,	Rothstein,	L.,	Clark,	K.,	Stein,	R.,	Dick,	L.,	Hwang,	D.,	and	Goldberg,	A.L.	(1994).	Inhibitors	of	the	proteasome	block	the	degradation	of	most	cell	proteins	and	the	generation	of	peptides	presented	on	MHC	class	I	molecules.	Cell	78,	761-771.	Rock,	K.L.,	York,	I.A.,	Saric,	T.,	and	Goldberg,	A.L.	(2002).	Protein	degradation	and	the	generation	of	MHC	class	I-presented	peptides.	Advances	in	immunology	80,	1-70.	
References		
		 198	
Saeki,	Y.,	Kudo,	T.,	Sone,	T.,	Kikuchi,	Y.,	Yokosawa,	H.,	Toh-e,	A.,	and	Tanaka,	K.	(2009).	Lysine	63-linked	polyubiquitin	chain	may	serve	as	a	targeting	signal	for	the	26S	proteasome.	The	EMBO	journal	28,	359-371.	Sahlender,	D.A.,	Roberts,	R.C.,	Arden,	S.D.,	Spudich,	G.,	Taylor,	M.J.,	Luzio,	J.P.,	Kendrick-Jones,	J.,	and	Buss,	F.	(2005).	Optineurin	links	myosin	VI	to	the	Golgi	complex	and	is	involved	in	Golgi	organization	and	exocytosis.	The	Journal	of	cell	biology	169,	285-295.	Salceda,	S.,	and	Caro,	J.	(1997).	Hypoxia-inducible	factor	1alpha	(HIF-1alpha)	protein	is	rapidly	degraded	by	the	ubiquitin-proteasome	system	under	normoxic	conditions.	Its	stabilization	by	hypoxia	depends	on	redox-induced	changes.	The	Journal	of	biological	chemistry	272,	22642-22647.	Salmeron,	A.,	Janzen,	J.,	Soneji,	Y.,	Bump,	N.,	Kamens,	J.,	Allen,	H.,	and	Ley,	S.C.	(2001).	Direct	phosphorylation	of	NF-kappaB1	p105	by	the	IkappaB	kinase	complex	on	serine	927	is	essential	for	signal-induced	p105	proteolysis.	The	Journal	of	biological	chemistry	276,	22215-22222.	Sato,	Y.,	Yoshikawa,	A.,	Yamagata,	A.,	Mimura,	H.,	Yamashita,	M.,	Ookata,	K.,	Nureki,	O.,	Iwai,	K.,	Komada,	M.,	and	Fukai,	S.	(2008).	Structural	basis	for	specific	cleavage	of	Lys	63-linked	polyubiquitin	chains.	Nature	455,	358-362.	Schreiner,	P.,	Chen,	X.,	Husnjak,	K.,	Randles,	L.,	Zhang,	N.,	Elsasser,	S.,	Finley,	D.,	Dikic,	I.,	Walters,	K.J.,	and	Groll,	M.	(2008).	Ubiquitin	docking	at	the	proteasome	through	a	novel	pleckstrin-homology	domain	interaction.	Nature	453,	548-552.	Sciacovelli,	M.,	Goncalves,	E.,	Johnson,	T.I.,	Zecchini,	V.R.,	da	Costa,	A.S.,	Gaude,	E.,	Drubbel,	A.V.,	Theobald,	S.J.,	Abbo,	S.R.,	Tran,	M.G.,	Rajeeve,	V.,	Cardaci,	S.,	Foster,	S.,	Yun,	H.,	Cutillas,	P.,	Warren,	A.,	Gnanapragasam,	V.,	Gottlieb,	E.,	Franze,	K.,	Huntly,	B.,	et	al.	(2016).	Fumarate	is	an	epigenetic	modifier	that	elicits	epithelial-to-mesenchymal	transition.	Nature	537,	544-547.	Scortegagna,	M.,	Ding,	K.,	Zhang,	Q.,	Oktay,	Y.,	Bennett,	M.J.,	Bennett,	M.,	Shelton,	J.M.,	Richardson,	J.A.,	Moe,	O.,	and	Garcia,	J.A.	(2005).	HIF-2alpha	regulates	murine	hematopoietic	development	in	an	erythropoietin-dependent	manner.	Blood	105,	3133-3140.	Selak,	M.A.,	Armour,	S.M.,	MacKenzie,	E.D.,	Boulahbel,	H.,	Watson,	D.G.,	Mansfield,	K.D.,	Pan,	Y.,	Simon,	M.C.,	Thompson,	C.B.,	and	Gottlieb,	E.	(2005).	Succinate	links	TCA	cycle	dysfunction	to	oncogenesis	by	inhibiting	HIF-alpha	prolyl	hydroxylase.	Cancer	cell	7,	77-85.	Selfridge,	A.C.,	Cavadas,	M.A.,	Scholz,	C.C.,	Campbell,	E.L.,	Welch,	L.C.,	Lecuona,	E.,	Colgan,	S.P.,	Barrett,	K.E.,	Sporn,	P.H.,	Sznajder,	J.I.,	Cummins,	E.P.,	and	Taylor,	C.T.	(2016).	Hypercapnia	Suppresses	the	HIF-dependent	Adaptive	Response	to	Hypoxia.	The	Journal	of	biological	chemistry	291,	11800-11808.	Semenza,	G.L.	(1994).	Regulation	of	erythropoietin	production.	New	insights	into	molecular	mechanisms	of	oxygen	homeostasis.	Hematology/oncology	clinics	of	North	America	8,	863-884.	
References		
		 199	
Semenza,	G.L.	(2012).	Hypoxia-inducible	factors	in	physiology	and	medicine.	Cell	
148,	399-408.	Semenza,	G.L.	(2013).	HIF-1	mediates	metabolic	responses	to	intratumoral	hypoxia	and	oncogenic	mutations.	The	Journal	of	clinical	investigation	123,	3664-3671.	Shabek,	N.,	Herman-Bachinsky,	Y.,	Buchsbaum,	S.,	Lewinson,	O.,	Haj-Yahya,	M.,	Hejjaoui,	M.,	Lashuel,	H.A.,	Sommer,	T.,	Brik,	A.,	and	Ciechanover,	A.	(2012).	The	size	of	the	proteasomal	substrate	determines	whether	its	degradation	will	be	mediated	by	mono-	or	polyubiquitylation.	Molecular	cell	48,	87-97.	Shi,	Y.,	Chen,	X.,	Elsasser,	S.,	Stocks,	B.B.,	Tian,	G.,	Lee,	B.H.,	Shi,	Y.,	Zhang,	N.,	de	Poot,	S.A.,	Tuebing,	F.,	Sun,	S.,	Vannoy,	J.,	Tarasov,	S.G.,	Engen,	J.R.,	Finley,	D.,	and	Walters,	K.J.	(2016).	Rpn1	provides	adjacent	receptor	sites	for	substrate	binding	and	deubiquitination	by	the	proteasome.	Science	(New	York,	NY)	351.	Shimizu,	Y.,	Taraborrelli,	L.,	and	Walczak,	H.	(2015).	Linear	ubiquitination	in	immunity.	Immunological	reviews	266,	190-207.	Smith,	D.M.,	Chang,	S.C.,	Park,	S.,	Finley,	D.,	Cheng,	Y.,	and	Goldberg,	A.L.	(2007).	Docking	of	the	proteasomal	ATPases'	carboxyl	termini	in	the	20S	proteasome's	alpha	ring	opens	the	gate	for	substrate	entry.	Molecular	cell	27,	731-744.	Smith,	D.M.,	Fraga,	H.,	Reis,	C.,	Kafri,	G.,	and	Goldberg,	A.L.	(2011).	ATP	binds	to	proteasomal	ATPases	in	pairs	with	distinct	functional	effects,	implying	an	ordered	reaction	cycle.	Cell	144,	526-538.	Smith,	D.M.,	Kafri,	G.,	Cheng,	Y.,	Ng,	D.,	Walz,	T.,	and	Goldberg,	A.L.	(2005).	ATP	binding	to	PAN	or	the	26S	ATPases	causes	association	with	the	20S	proteasome,	gate	opening,	and	translocation	of	unfolded	proteins.	Molecular	cell	20,	687-698.	Spratt,	D.E.,	Walden,	H.,	and	Shaw,	G.S.	(2014).	RBR	E3	ubiquitin	ligases:	new	structures,	new	insights,	new	questions.	The	Biochemical	journal	458,	421-437.	Spudich,	G.,	Chibalina,	M.V.,	Au,	J.S.,	Arden,	S.D.,	Buss,	F.,	and	Kendrick-Jones,	J.	(2007).	Myosin	VI	targeting	to	clathrin-coated	structures	and	dimerization	is	mediated	by	binding	to	Disabled-2	and	PtdIns(4,5)P2.	Nature	cell	biology	9,	176-183.	Straud,	S.,	Zubovych,	I.,	De	Brabander,	J.K.,	and	Roth,	M.G.	(2010).	Inhibition	of	iron	uptake	is	responsible	for	differential	sensitivity	to	V-ATPase	inhibitors	in	several	cancer	cell	lines.	PloS	one	5,	e11629.	Swaney,	D.L.,	Rodriguez-Mias,	R.A.,	and	Villen,	J.	(2015).	Phosphorylation	of	ubiquitin	at	Ser65	affects	its	polymerization,	targets,	and	proteome-wide	turnover.	EMBO	reports	16,	1131-1144.	Takeda,	K.,	Ho,	V.C.,	Takeda,	H.,	Duan,	L.J.,	Nagy,	A.,	and	Fong,	G.H.	(2006).	Placental	but	not	heart	defects	are	associated	with	elevated	hypoxia-inducible	
References		
		 200	
factor	alpha	levels	in	mice	lacking	prolyl	hydroxylase	domain	protein	2.	Molecular	and	cellular	biology	26,	8336-8346.	Takeuchi,	J.,	Chen,	H.,	and	Coffino,	P.	(2007).	Proteasome	substrate	degradation	requires	association	plus	extended	peptide.	The	EMBO	journal	26,	123-131.	Tanimoto,	K.,	Makino,	Y.,	Pereira,	T.,	and	Poellinger,	L.	(2000).	Mechanism	of	regulation	of	the	hypoxia-inducible	factor-1	alpha	by	the	von	Hippel-Lindau	tumor	suppressor	protein.	The	EMBO	journal	19,	4298-4309.	Tanno,	H.,	Yamaguchi,	T.,	Goto,	E.,	Ishido,	S.,	and	Komada,	M.	(2012).	The	Ankrd	13	family	of	UIM-bearing	proteins	regulates	EGF	receptor	endocytosis	from	the	plasma	membrane.	Molecular	biology	of	the	cell	23,	1343-1353.	Tarhonskaya,	H.,	Rydzik,	A.M.,	Leung,	I.K.,	Loik,	N.D.,	Chan,	M.C.,	Kawamura,	A.,	McCullagh,	J.S.,	Claridge,	T.D.,	Flashman,	E.,	and	Schofield,	C.J.	(2014).	Non-enzymatic	chemistry	enables	2-hydroxyglutarate-mediated	activation	of	2-oxoglutarate	oxygenases.	Nature	communications	5,	3423.	Thienpont,	B.,	Steinbacher,	J.,	Zhao,	H.,	D'Anna,	F.,	Kuchnio,	A.,	Ploumakis,	A.,	Ghesquiere,	B.,	Van	Dyck,	L.,	Boeckx,	B.,	Schoonjans,	L.,	Hermans,	E.,	Amant,	F.,	Kristensen,	V.N.,	Peng	Koh,	K.,	Mazzone,	M.,	Coleman,	M.,	Carell,	T.,	Carmeliet,	P.,	and	Lambrechts,	D.	(2016).	Tumour	hypoxia	causes	DNA	hypermethylation	by	reducing	TET	activity.	Nature	537,	63-68.	Thrower,	J.S.,	Hoffman,	L.,	Rechsteiner,	M.,	and	Pickart,	C.M.	(2000).	Recognition	of	the	polyubiquitin	proteolytic	signal.	The	EMBO	journal	19,	94-102.	Tian,	H.,	McKnight,	S.L.,	and	Russell,	D.W.	(1997).	Endothelial	PAS	domain	protein	1	(EPAS1),	a	transcription	factor	selectively	expressed	in	endothelial	cells.	Genes	&	development	11,	72-82.	Tran,	H.,	Hamada,	F.,	Schwarz-Romond,	T.,	and	Bienz,	M.	(2008).	Trabid,	a	new	positive	regulator	of	Wnt-induced	transcription	with	preference	for	binding	and	cleaving	K63-linked	ubiquitin	chains.	Genes	&	development	22,	528-542.	Tuckerman,	J.R.,	Zhao,	Y.,	Hewitson,	K.S.,	Tian,	Y.M.,	Pugh,	C.W.,	Ratcliffe,	P.J.,	and	Mole,	D.R.	(2004).	Determination	and	comparison	of	specific	activity	of	the	HIF-prolyl	hydroxylases.	FEBS	letters	576,	145-150.	Tumbarello,	D.A.,	Manna,	P.T.,	Allen,	M.,	Bycroft,	M.,	Arden,	S.D.,	Kendrick-Jones,	J.,	and	Buss,	F.	(2015).	The	Autophagy	Receptor	TAX1BP1	and	the	Molecular	Motor	Myosin	VI	Are	Required	for	Clearance	of	Salmonella	Typhimurium	by	Autophagy.	PLoS	pathogens	11,	e1005174.	van	Nocker,	S.,	Sadis,	S.,	Rubin,	D.M.,	Glickman,	M.,	Fu,	H.,	Coux,	O.,	Wefes,	I.,	Finley,	D.,	and	Vierstra,	R.D.	(1996).	The	multiubiquitin-chain-binding	protein	Mcb1	is	a	component	of	the	26S	proteasome	in	Saccharomyces	cerevisiae	and	plays	a	nonessential,	substrate-specific	role	in	protein	turnover.	Molecular	and	cellular	biology	16,	6020-6028.	
References		
		 201	
Verma,	R.,	Aravind,	L.,	Oania,	R.,	McDonald,	W.H.,	Yates,	J.R.,	3rd,	Koonin,	E.V.,	and	Deshaies,	R.J.	(2002).	Role	of	Rpn11	metalloprotease	in	deubiquitination	and	degradation	by	the	26S	proteasome.	Science	(New	York,	NY)	298,	611-615.	Virdee,	S.,	Ye,	Y.,	Nguyen,	D.P.,	Komander,	D.,	and	Chin,	J.W.	(2010).	Engineered	diubiquitin	synthesis	reveals	Lys29-isopeptide	specificity	of	an	OTU	deubiquitinase.	Nature	chemical	biology	6,	750-757.	Wang,	G.L.,	and	Semenza,	G.L.	(1995).	Purification	and	characterization	of	hypoxia-inducible	factor	1.	The	Journal	of	biological	chemistry	270,	1230-1237.	Wauer,	T.,	Swatek,	K.N.,	Wagstaff,	J.L.,	Gladkova,	C.,	Pruneda,	J.N.,	Michel,	M.A.,	Gersch,	M.,	Johnson,	C.M.,	Freund,	S.M.,	and	Komander,	D.	(2015).	Ubiquitin	Ser65	phosphorylation	affects	ubiquitin	structure,	chain	assembly	and	hydrolysis.	The	EMBO	journal	34,	307-325.	Wickliffe,	K.E.,	Lorenz,	S.,	Wemmer,	D.E.,	Kuriyan,	J.,	and	Rape,	M.	(2011).	The	mechanism	of	linkage-specific	ubiquitin	chain	elongation	by	a	single-subunit	E2.	Cell	144,	769-781.	Wiesener,	M.S.,	Jurgensen,	J.S.,	Rosenberger,	C.,	Scholze,	C.K.,	Horstrup,	J.H.,	Warnecke,	C.,	Mandriota,	S.,	Bechmann,	I.,	Frei,	U.A.,	Pugh,	C.W.,	Ratcliffe,	P.J.,	Bachmann,	S.,	Maxwell,	P.H.,	and	Eckardt,	K.U.	(2003).	Widespread	hypoxia-inducible	expression	of	HIF-2alpha	in	distinct	cell	populations	of	different	organs.	FASEB	journal	:	official	publication	of	the	Federation	of	American	Societies	for	Experimental	Biology	17,	271-273.	Wilkins,	S.E.,	and	Abboud,	M.I.	(2016).	Targeting	Protein-Protein	Interactions	in	the	HIF	System.		11,	773-786.	Williamson,	A.,	Jin,	L.,	and	Rape,	M.	(2009a).	Preparation	of	synchronized	human	cell	extracts	to	study	ubiquitination	and	degradation.	Methods	in	molecular	biology	545,	301-312.	Williamson,	A.,	Wickliffe,	K.E.,	Mellone,	B.G.,	Song,	L.,	Karpen,	G.H.,	and	Rape,	M.	(2009b).	Identification	of	a	physiological	E2	module	for	the	human	anaphase-promoting	complex.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	106,	18213-18218.	Worden,	E.J.,	Padovani,	C.,	and	Martin,	A.	(2014).	Structure	of	the	Rpn11-Rpn8	dimer	reveals	mechanisms	of	substrate	deubiquitination	during	proteasomal	degradation.	Nature	structural	&	molecular	biology	21,	220-227.	Wu,	T.,	Merbl,	Y.,	Huo,	Y.,	Gallop,	J.L.,	Tzur,	A.,	and	Kirschner,	M.W.	(2010).	UBE2S	drives	elongation	of	K11-linked	ubiquitin	chains	by	the	anaphase-promoting	complex.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	107,	1355-1360.	Xu,	P.,	Duong,	D.M.,	Seyfried,	N.T.,	Cheng,	D.,	Xie,	Y.,	Robert,	J.,	Rush,	J.,	Hochstrasser,	M.,	Finley,	D.,	and	Peng,	J.	(2009).	Quantitative	proteomics	reveals	
References		
		 202	
the	function	of	unconventional	ubiquitin	chains	in	proteasomal	degradation.	Cell	
137,	133-145.	Xu,	W.,	Yang,	H.,	Liu,	Y.,	Yang,	Y.,	Wang,	P.,	Kim,	S.H.,	Ito,	S.,	Yang,	C.,	Wang,	P.,	Xiao,	M.T.,	Liu,	L.X.,	Jiang,	W.Q.,	Liu,	J.,	Zhang,	J.Y.,	Wang,	B.,	Frye,	S.,	Zhang,	Y.,	Xu,	Y.H.,	Lei,	Q.Y.,	Guan,	K.L.,	et	al.	(2011).	Oncometabolite	2-hydroxyglutarate	is	a	competitive	inhibitor	of	alpha-ketoglutarate-dependent	dioxygenases.	Cancer	cell	19,	17-30.	Yao,	T.,	and	Cohen,	R.E.	(2002).	A	cryptic	protease	couples	deubiquitination	and	degradation	by	the	proteasome.	Nature	419,	403-407.	Yau,	R.,	and	Rape,	M.	(2016).	The	increasing	complexity	of	the	ubiquitin	code.	Nature	cell	biology	18,	579-586.	Yu,	H.,	Kago,	G.,	Yellman,	C.M.,	and	Matouschek,	A.	(2016).	Ubiquitin-like	domains	can	target	to	the	proteasome	but	proteolysis	requires	a	disordered	region.		35,	1522-1536.	Zhang,	H.,	Bosch-Marce,	M.,	Shimoda,	L.A.,	Tan,	Y.S.,	Baek,	J.H.,	Wesley,	J.B.,	Gonzalez,	F.J.,	and	Semenza,	G.L.	(2008).	Mitochondrial	autophagy	is	an	HIF-1-dependent	adaptive	metabolic	response	to	hypoxia.	The	Journal	of	biological	chemistry	283,	10892-10903.	Zhang,	J.,	Hu,	M.M.,	Wang,	Y.Y.,	and	Shu,	H.B.	(2012).	TRIM32	protein	modulates	type	I	interferon	induction	and	cellular	antiviral	response	by	targeting	MITA/STING	protein	for	K63-linked	ubiquitination.	The	Journal	of	biological	chemistry	287,	28646-28655.	Zhang,	Z.,	Yang,	J.,	Kong,	E.H.,	Chao,	W.C.,	Morris,	E.P.,	da	Fonseca,	P.C.,	and	Barford,	D.	(2013).	Recombinant	expression,	reconstitution	and	structure	of	human	anaphase-promoting	complex	(APC/C).	The	Biochemical	journal	449,	365-371.	Zhao,	S.,	Lin,	Y.,	Xu,	W.,	Jiang,	W.,	Zha,	Z.,	Wang,	P.,	Yu,	W.,	Li,	Z.,	Gong,	L.,	Peng,	Y.,	Ding,	J.,	Lei,	Q.,	Guan,	K.L.,	and	Xiong,	Y.	(2009).	Glioma-derived	mutations	in	IDH1	dominantly	inhibit	IDH1	catalytic	activity	and	induce	HIF-1alpha.	Science	(New	York,	NY)	324,	261-265.	Zhdanov,	A.V.,	Dmitriev,	R.I.,	and	Papkovsky,	D.B.	(2012).	Bafilomycin	A1	activates	HIF-dependent	signalling	in	human	colon	cancer	cells	via	mitochondrial	uncoupling.	Bioscience	reports	32,	587-595.	Zhong,	B.,	Zhang,	L.,	Lei,	C.,	Li,	Y.,	Mao,	A.P.,	Yang,	Y.,	Wang,	Y.Y.,	Zhang,	X.L.,	and	Shu,	H.B.	(2009).	The	ubiquitin	ligase	RNF5	regulates	antiviral	responses	by	mediating	degradation	of	the	adaptor	protein	MITA.	Immunity	30,	397-407.		
